8701013_0|s|Famotidine-associated delirium.
8701013_0	22	30	delirium	Disease	D003693
8701013_0	0	10	Famotidine	Chemical	D015738
8701013_0	CID	D015738	D003693

8701013_2|s|Famotidine is a histamine H2-receptor antagonist used in inpatient settings for prevention of stress ulcers and is showing increasing popularity because of its low cost.
8701013_2	101	107	ulcers	Disease	D014456
8701013_2	0	10	Famotidine	Chemical	D015738

8701013_3|s|Although all of the currently available H2-receptor antagonists have shown the propensity to cause delirium, only two previously reported cases have been associated with famotidine.
8701013_3	99	107	delirium	Disease	D003693
8701013_3	170	180	famotidine	Chemical	D015738
8701013_3	CID	D015738	D003693

8701013_4|s|The authors report on six cases of famotidine-associated delirium in hospitalized patients who cleared completely upon removal of famotidine.
8701013_4	57	65	delirium	Disease	D003693
8701013_4	35	45	famotidine	Chemical	D015738
8701013_4	130	140	famotidine	Chemical	D015738
8701013_4	CID	D015738	D003693

439781_0|s|Indomethacin induced hypotension in sodium and volume depleted rats.
439781_0	21	32	hypotension	Disease	D007022
439781_0	0	12	Indomethacin	Chemical	D007213
439781_0	36	42	sodium	Chemical	D012964
439781_0	CID	D007213	D007022

22836123_0|s|Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report.
22836123_0	11	35	scleroderma renal crisis	Disease	D007674
22836123_0	47	57	tacrolimus	Chemical	D016559
22836123_0	62	74	prednisolone	Chemical	D011239

22836123_2|s|Moderate to high dose corticosteroid use is recognized as a major risk factor for SRC.
22836123_2	82	85	SRC	Disease	D007674
22836123_2	22	36	corticosteroid	Chemical	D000305

22836123_3|s|Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc.
22836123_3	40	66	thrombotic microangiopathy	Disease	D057049
22836123_3	113	116	SSc	Disease	D012595
22836123_3	83	95	cyclosporine	Chemical	D016572
22836123_3	CID	D016572	D057049

22836123_4|s|In this article, we report a patient with SRC induced by tacrolimus and corticosteroids.
22836123_4	42	45	SRC	Disease	D007674
22836123_4	57	67	tacrolimus	Chemical	D016559
22836123_4	72	87	corticosteroids	Chemical	D000305

22836123_5|s|The aim of this work is to call attention to the risk of tacrolimus use in patients with SSc.
22836123_5	89	92	SSc	Disease	D012595
22836123_5	57	67	tacrolimus	Chemical	D016559
22836123_5	CID	D016559	D012595

23433219_0|s|The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia.
23433219_0	51	60	psychosis	Disease	D011605
23433219_0	35	50	methamphetamine	Chemical	D008694
23433219_0	64	79	methamphetamine	Chemical	D008694
23433219_0	CID	D008694	D011605

23433219_1|s|OBJECTIVE: The objective of this study was to determine the risk of lifetime and current methamphetamine-induced psychosis in patients with methamphetamine dependence.
23433219_1	113	122	psychosis	Disease	D011605
23433219_1	89	104	methamphetamine	Chemical	D008694
23433219_1	140	155	methamphetamine	Chemical	D008694
23433219_1	CID	D008694	D011605

23433219_2|s|The association between psychiatric co-morbidity and methamphetamine-induced psychosis was also studied.
23433219_2	77	86	psychosis	Disease	D011605
23433219_2	53	68	methamphetamine	Chemical	D008694
23433219_2	CID	D008694	D011605

23433219_4|s|Patients with the diagnosis of methamphetamine based on DSM-IV were interviewed using the Mini International Neuropsychiatric Interview (M.I.N.I.) for methamphetamine-induced psychosis and other Axis I psychiatric disorders.
23433219_4	175	184	psychosis	Disease	D011605
23433219_4	202	223	psychiatric disorders	Disease	D001523
23433219_4	31	46	methamphetamine	Chemical	D008694
23433219_4	151	166	methamphetamine	Chemical	D008694
23433219_4	CID	D008694	D011605

23433219_7|s|Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.
23433219_7	16	35	depressive disorder	Disease	D003866
23433219_7	67	83	bipolar disorder	Disease	D001714
23433219_7	117	148	antisocial personality disorder	Disease	D000987
23433219_7	280	289	psychosis	Disease	D011605
23433219_7	191	206	methamphetamine	Chemical	D008694
23433219_7	256	271	methamphetamine	Chemical	D008694
23433219_7	CID	D008694	D011605
23433219_7	CID	D008694	D001714
23433219_7	CID	D008694	D000987

23433219_9|s|CONCLUSION: There was a high risk of psychosis in patients with methamphetamine dependence.
23433219_9	37	46	psychosis	Disease	D011605
23433219_9	64	79	methamphetamine	Chemical	D008694
23433219_9	CID	D008694	D011605

23433219_10|s|It was associated with co-morbid affective disorder, antisocial personality, and heavy methamphetamine use.
23433219_10	33	51	affective disorder	Disease	D019964
23433219_10	53	75	antisocial personality	Disease	D000987
23433219_10	87	102	methamphetamine	Chemical	D008694
23433219_10	CID	D008694	D000987

23433219_11|s|It is recommended that all cases of methamphetamine dependence should be screened for psychotic symptoms.
23433219_11	86	104	psychotic symptoms	Disease	D011605
23433219_11	36	51	methamphetamine	Chemical	D008694
23433219_11	CID	D008694	D011605

23535177_1|s|The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and levodopa-induced dyskinesias (LIDs) is severely impaired.
23535177_1	61	80	Parkinson's disease	Disease	D010300
23535177_1	82	84	PD	Disease	D010300
23535177_1	107	118	dyskinesias	Disease	D004409
23535177_1	120	124	LIDs	Disease	D004409
23535177_1	90	98	levodopa	Chemical	D007980
23535177_1	CID	D007980	D004409

23666265_0|s|The function of P2X3 receptor and NK1 receptor antagonists on cyclophosphamide-induced cystitis in rats.
23666265_0	87	95	cystitis	Disease	D003556
23666265_0	62	78	cyclophosphamide	Chemical	D003520
23666265_0	CID	D003520	D003556

23666265_1|s|PURPOSE: The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on cyclophosphamide (CYP)-induced cystitis in rats.
23666265_1	133	141	cystitis	Disease	D003556
23666265_1	102	118	cyclophosphamide	Chemical	D003520
23666265_1	120	123	CYP	Chemical	D003520
23666265_1	CID	D003520	D003556

23666265_4|s|Spontaneous pain behaviors following the administration of CYP were observed.
23666265_4	12	16	pain	Disease	D010146
23666265_4	59	62	CYP	Chemical	D003520
23666265_4	CID	D003520	D010146

23666265_8|s|RESULTS: Cyclophosphamide treatment increased the spontaneous pain behaviors scores.
23666265_8	62	66	pain	Disease	D010146
23666265_8	9	25	Cyclophosphamide	Chemical	D003520
23666265_8	CID	D003520	D010146

23666265_13|s|CONCLUSIONS: In CYP-induced cystitis, the expression of P2X3 and NK1 receptors increased in urothelium and/or suburothelium.
23666265_13	28	36	cystitis	Disease	D003556
23666265_13	16	19	CYP	Chemical	D003520
23666265_13	CID	D003520	D003556

23846525_0|s|Acute hepatitis associated with clopidogrel: a case report and review of the literature.
23846525_0	6	15	hepatitis	Disease	D056486
23846525_0	32	43	clopidogrel	Chemical	C055162
23846525_0	CID	C055162	D056486

23846525_2|s|We describe a case of clopidogrel-related acute hepatitis.
23846525_2	48	57	hepatitis	Disease	D056486
23846525_2	22	33	clopidogrel	Chemical	C055162
23846525_2	CID	C055162	D056486

23846525_4|s|Reports about cases of hepatotoxicity due to clopidogrel are increasing in the last few years, after the increased use of this drug.
23846525_4	23	37	hepatotoxicity	Disease	D056486
23846525_4	45	56	clopidogrel	Chemical	C055162
23846525_4	CID	C055162	D056486

23846525_5|s|In conclusion, we believe that physicians should carefully consider the risk of drug-induced hepatic injury when clopidogrel is prescribed.
23846525_5	93	107	hepatic injury	Disease	D056486
23846525_5	113	124	clopidogrel	Chemical	C055162
23846525_5	CID	C055162	D056486

23864035_0|s|Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
23864035_0	85	101	multiple myeloma	Disease	D009101
23864035_0	0	10	Bortezomib	Chemical	C400082
23864035_0	15	28	dexamethasone	Chemical	D003907

23864035_1|s|Bortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).
23864035_1	92	108	multiple myeloma	Disease	D009101
23864035_1	110	112	MM	Disease	D009101
23864035_1	0	10	Bortezomib	Chemical	C400082
23864035_1	12	16	bort	Chemical	C400082
23864035_1	18	31	dexamethasone	Chemical	D003907
23864035_1	33	36	dex	Chemical	D003907

23864035_2|s|This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy.
23864035_2	212	214	MM	Disease	D009101
23864035_2	57	61	bort	Chemical	C400082
23864035_2	118	121	dex	Chemical	D003907
23864035_2	161	165	bort	Chemical	C400082

23864035_11|s|Bort-dex was an effective salvage treatment for MM patients, particularly for those in first relapse.
23864035_11	48	50	MM	Disease	D009101
23864035_11	0	4	Bort	Chemical	C400082
23864035_11	5	8	dex	Chemical	D003907

23871786_0|s|Pubertal exposure to Bisphenol A increases anxiety-like behavior and decreases acetylcholinesterase activity of hippocampus in adult male mice.
23871786_0	43	50	anxiety	Disease	D001008
23871786_0	21	32	Bisphenol A	Chemical	C006780
23871786_0	CID	C006780	D001008

23871786_7|s|Results from our behavioral phenotyping indicated that anxiety-like behavior was increased in mice exposed to BPA.
23871786_7	55	62	anxiety	Disease	D001008
23871786_7	110	113	BPA	Chemical	C006780
23871786_7	CID	C006780	D001008

23871786_9|s|Our findings showed that pubertal BPA exposure increased anxiety-like behavior, which may be associated with decreased AChE activity of the hippocampus in adult male mice.
23871786_9	57	64	anxiety	Disease	D001008
23871786_9	34	37	BPA	Chemical	C006780
23871786_9	CID	C006780	D001008

23872883_2|s|The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats.
23872883_2	129	143	cardiotoxicity	Disease	D066126
23872883_2	107	120	isoproterenol	Chemical	D007545
23872883_2	CID	D007545	D066126

23892921_0|s|"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
23892921_0	116	132	multiple myeloma	Disease	D009101
23892921_0	216	223	Myeloma	Disease	D009101
23892921_0	48	60	lenalidomide	Chemical	C467567
23892921_0	65	78	dexamethasone	Chemical	D003907

23892921_1|s|Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition.
23892921_1	82	98	multiple myeloma	Disease	D009101
23892921_1	100	104	RRMM	Disease	D009101
23892921_1	0	12	Lenalidomide	Chemical	C467567
23892921_1	17	30	dexamethasone	Chemical	D003907
23892921_1	32	34	RD	Chemical	C467567|D003907

23892921_2|s|We studied 212 RRMM patients who received RD in RW.
23892921_2	15	19	RRMM	Disease	D009101
23892921_2	42	44	RD	Chemical	C467567|D003907

23892921_15|s|Our study confirms that RD is effective and safe in RRMM in the RW; it produces durable responses especially in patients who continue on treatment till progression and improves humoral immunity even in patients with stable disease.
23892921_15	52	56	RRMM	Disease	D009101
23892921_15	24	26	RD	Chemical	C467567|D003907

23949582_8|s|Mesna significantly reduces IFO's genotoxicity, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.
23949582_8	34	46	genotoxicity	Disease	D030342
23949582_8	0	5	Mesna	Chemical	D015080
23949582_8	28	31	IFO	Chemical	D007069
23949582_8	95	97	it	Chemical	D015080

23952588_0|s|Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
23952588_0	48	58	dyskinesia	Disease	D004409
23952588_0	93	112	Parkinson's disease	Disease	D010300
23952588_0	31	39	levodopa	Chemical	D007980
23952588_0	CID	D007980	D004409

23952588_1|s|Chronic pulsatile levodopa therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and dyskinesia.
23952588_1	39	58	Parkinson's disease	Disease	D010300
23952588_1	60	62	PD	Disease	D010300
23952588_1	115	125	dyskinesia	Disease	D004409
23952588_1	18	26	levodopa	Chemical	D007980
23952588_1	CID	D007980	D004409

23952588_2|s|We studied the prevalence and predictors of levodopa-induced dyskinesia among multiethnic Malaysian patients with PD.
23952588_2	61	71	dyskinesia	Disease	D004409
23952588_2	114	116	PD	Disease	D010300
23952588_2	44	52	levodopa	Chemical	D007980
23952588_2	CID	D007980	D004409

23952588_3|s|METHODS: This is a cross-sectional study involving 95 patients with PD on uninterrupted levodopa therapy for at least 6 months.
23952588_3	68	70	PD	Disease	D010300
23952588_3	88	96	levodopa	Chemical	D007980

23952588_9|s|Dyskinesia was present in 44% (n = 42) with median levodopa therapy of 3 years.
23952588_9	0	10	Dyskinesia	Disease	D004409
23952588_9	51	59	levodopa	Chemical	D007980
23952588_9	CID	D007980	D004409

23952588_12|s|Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily levodopa dose ( p < 0.001), and higher total UPDRS scores ( p = 0.005) than patients without dyskinesia.
23952588_12	14	24	dyskinesia	Disease	D004409
23952588_12	259	269	dyskinesia	Disease	D004409
23952588_12	78	86	levodopa	Chemical	D007980
23952588_12	166	174	levodopa	Chemical	D007980
23952588_12	CID	D007980	D004409

23952588_13|s|The three significant predictors of dyskinesia were duration of levodopa therapy, onset age, and total daily levodopa dose.
23952588_13	36	46	dyskinesia	Disease	D004409
23952588_13	64	72	levodopa	Chemical	D007980
23952588_13	109	117	levodopa	Chemical	D007980
23952588_13	CID	D007980	D004409

23952588_14|s|CONCLUSIONS: The prevalence of levodopa-induced dyskinesia in our patients was 44%.
23952588_14	48	58	dyskinesia	Disease	D004409
23952588_14	31	39	levodopa	Chemical	D007980
23952588_14	CID	D007980	D004409

24040781_0|s|An unexpected diagnosis in a renal-transplant patient with proteinuria treated with everolimus: AL amyloidosis.
24040781_0	59	70	proteinuria	Disease	D011507
24040781_0	96	98	AL	Disease	D000686
24040781_0	99	110	amyloidosis	Disease	D000686
24040781_0	84	94	everolimus	Chemical	C107135
24040781_0	CID	C107135	D000686
24040781_0	CID	C107135	D011507

24040781_1|s|Proteinuria is an expected complication in transplant patients treated with mammalian target of rapamycin inhibitors (mTOR-i).
24040781_1	0	11	Proteinuria	Disease	D011507
24040781_1	96	105	rapamycin	Chemical	D020123

24040781_3|s|In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.
24040781_3	51	62	amyloidosis	Disease	D000686
24040781_3	178	189	proteinuria	Disease	D011507
24040781_3	212	222	tacrolimus	Chemical	D016559
24040781_3	226	236	everolimus	Chemical	C107135
24040781_3	CID	C107135	D000686
24040781_3	CID	C107135	D011507

24067251_0|s|An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database).
24067251_0	35	48	kidney injury	Disease	D007674
24067251_0	84	113	tenofovir disoproxil fumarate	Chemical	C418563

24067251_5|s|Of the 407 Yellow Card records analysed, 106 satisfied criteria for TDF-related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome.
24067251_5	80	94	kidney disease	Disease	D007674
24067251_5	130	156	kidney tubular dysfunction	Disease	D007674
24067251_5	198	220	glomerular dysfunction	Disease	D007674
24067251_5	238	254	Fanconi syndrome	Disease	D005198
24067251_5	68	71	TDF	Chemical	C418563
24067251_5	CID	C418563	D005198

24067251_7|s|The incidence of hospitalisation for TDF kidney adverse effects was high, particularly amongst patients with features of Fanconi syndrome.
24067251_7	121	137	Fanconi syndrome	Disease	D005198
24067251_7	37	40	TDF	Chemical	C418563
24067251_7	CID	C418563	D005198

24068571_9|s|The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02).
24068571_9	87	95	delirium	Disease	D003693
24068571_9	11	22	thiopentone	Chemical	D013874
24068571_9	108	116	propofol	Chemical	D015742
24068571_9	CID	D013874	D003693

24072398_0|s|A single neurotoxic dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.
24072398_0	9	19	neurotoxic	Disease	D020258
24072398_0	67	77	depressive	Disease	D003866
24072398_0	28	43	methamphetamine	Chemical	D008694
24072398_0	CID	D008694	D003866

24072398_1|s|Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal.
24072398_1	133	152	depressive symptoms	Disease	D003866
24072398_1	0	15	Methamphetamine	Chemical	D008694
24072398_1	17	21	METH	Chemical	D008694
24072398_1	77	81	METH	Chemical	D008694
24072398_1	CID	D008694	D003866

24072398_2|s|However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits.
24072398_2	94	104	depressive	Disease	D003866
24072398_2	62	66	METH	Chemical	D008694
24072398_2	CID	D008694	D003866

24072398_3|s|Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.).
24072398_3	26	36	depressive	Disease	D003866
24072398_3	115	119	METH	Chemical	D008694
24072398_3	CID	D008694	D003866

24072398_6|s|This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.
24072398_6	5	15	depressive	Disease	D003866
24072398_6	40	44	METH	Chemical	D008694
24072398_6	192	200	dopamine	Chemical	D004298
24072398_6	202	207	DOPAC	Chemical	D015102
24072398_6	212	215	HVA	Chemical	D006719
24072398_6	217	225	tyrosine	Chemical	D014443
24072398_6	242	251	serotonin	Chemical	D012701
24072398_6	CID	D008694	D003866

24072398_8|s|These findings demonstrate for the first time that a single high dose of METH induces long-lasting depressive-like behaviour in mice associated with a persistent disruption of frontostriatal dopaminergic and serotonergic homoeostasis.
24072398_8	99	109	depressive	Disease	D003866
24072398_8	73	77	METH	Chemical	D008694
24072398_8	CID	D008694	D003866

24088636_0|s|Linezolid-induced optic neuropathy.
24088636_0	18	34	optic neuropathy	Disease	D009901
24088636_0	0	9	Linezolid	Chemical	C098010
24088636_0	CID	C098010	D009901

24088636_3|s|We describe a case of progressive loss of vision associated with linezolid therapy.
24088636_3	34	48	loss of vision	Disease	D014786
24088636_3	65	74	linezolid	Chemical	C098010

24088636_4|s|A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.
24088636_4	136	175	extensively drug-resistant tuberculosis	Disease	D054908
24088636_4	177	183	XDR-TB	Disease	D054908
24088636_4	227	241	loss of vision	Disease	D014786
24088636_4	107	116	linezolid	Chemical	C098010
24088636_4	121	131	ethambutol	Chemical	D004977

24088636_6|s|Ethambutol-induced toxic optic neuropathy was suspected and tablet ethambutol was withdrawn.
24088636_6	19	41	toxic optic neuropathy	Disease	D009901
24088636_6	0	10	Ethambutol	Chemical	D004977
24088636_6	67	77	ethambutol	Chemical	D004977

24088636_7|s|Deterioration of vision occurred despite withdrawal of ethambutol.
24088636_7	0	23	Deterioration of vision	Disease	D015354
24088636_7	55	65	ethambutol	Chemical	D004977

24091473_0|s|Resuscitation with lipid, epinephrine, or both in levobupivacaine-induced cardiac toxicity in newborn piglets.
24091473_0	74	90	cardiac toxicity	Disease	D066126
24091473_0	26	37	epinephrine	Chemical	D004837
24091473_0	50	65	levobupivacaine	Chemical	C476513

24091473_1|s|BACKGROUND: The optimal dosing regimens of lipid emulsion, epinephrine, or both are not yet determined in neonates in cases of local anaesthetic systemic toxicity (LAST).
24091473_1	154	162	toxicity	Disease	D064420
24091473_1	59	70	epinephrine	Chemical	D004837

24091473_2|s|METHODS: Newborn piglets received levobupivacaine until cardiovascular collapse occurred.
24091473_2	56	79	cardiovascular collapse	Disease	D002318
24091473_2	34	49	levobupivacaine	Chemical	C476513
24091473_2	CID	C476513	D002318

24100055_0|s|Incidence of heparin-induced thrombocytopenia type II and postoperative recovery of platelet count in liver graft recipients: a retrospective cohort analysis.
24100055_0	29	53	thrombocytopenia type II	Disease	D013921
24100055_0	13	20	heparin	Chemical	D006493
24100055_0	CID	D006493	D013921

24100055_2|s|The impact of immune-mediated heparin-induced thrombocytopenia type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results.
24100055_2	46	70	thrombocytopenia type II	Disease	D013921
24100055_2	72	83	HIT type II	Disease	D013921
24100055_2	99	115	thrombocytopenia	Disease	D013921
24100055_2	30	37	heparin	Chemical	D006493
24100055_2	CID	D006493	D013921

24100055_10|s|For further reduction of HIT type II, the use of intravenous heparin should be avoided and the prophylactic anticoagulation should be performed with low-molecular-weight heparin after normalization of platelet count.
24100055_10	25	36	HIT type II	Disease	D013921
24100055_10	29	36	type II	Disease	D013921
24100055_10	61	68	heparin	Chemical	D006493
24100055_10	170	177	heparin	Chemical	D006493
24100055_10	CID	D006493	D013921

24100257_0|s|Takotsubo syndrome (or apical ballooning syndrome) secondary to Zolmitriptan.
24100257_0	0	18	Takotsubo syndrome	Disease	D054549
24100257_0	23	49	apical ballooning syndrome	Disease	D054549
24100257_0	64	76	Zolmitriptan	Chemical	C089750
24100257_0	CID	C089750	D054549

24100257_4|s|Detailed history obtained retrospectively revealed that the patient took zolmitriptan sparingly only when she had migraines.
24100257_4	114	123	migraines	Disease	D008881
24100257_4	73	85	zolmitriptan	Chemical	C089750

24100257_5|s|But before this event, she was taking zolmitriptan 2-3 times daily for several days because of a persistent migraine headache.
24100257_5	108	125	migraine headache	Disease	D008881
24100257_5	38	50	zolmitriptan	Chemical	C089750

24100257_8|s|Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to zolmitriptan, but none of the cases were associated with TS.
24100257_8	55	80	coronary artery vasospasm	Disease	D003329
24100257_8	151	153	TS	Disease	D054549
24100257_8	94	106	zolmitriptan	Chemical	C089750
24100257_8	CID	C089750	D003329
24100257_8	CID	C089750	D054549

24114426_0|s|Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
24114426_0	0	10	Depression	Disease	D003866
24114426_0	12	25	impulsiveness	Disease	D010554
24114426_0	83	116	3,4-methylenedioxymethamphetamine	Chemical	D018817
24114426_0	118	122	MDMA	Chemical	D018817
24114426_0	124	131	ecstasy	Chemical	D018817
24114426_0	CID	D018817	D010554
24114426_0	CID	D018817	D003866

24114426_9|s|CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.
24114426_9	34	49	impaired memory	Disease	D008569
24114426_9	87	97	depression	Disease	D003866
24114426_9	99	112	impulsiveness	Disease	D010554
24114426_9	118	135	sleep disturbance	Disease	D020920
24114426_9	181	188	ecstasy	Chemical	D018817
24114426_9	CID	D018817	D020920
24114426_9	CID	D018817	D010554
24114426_9	CID	D018817	D003866

24126708_0|s|Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients.
24126708_0	87	106	Parkinson's disease	Disease	D010300
24126708_0	59	67	levodopa	Chemical	D007980

24126708_1|s|Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.
24126708_1	55	74	Parkinson's disease	Disease	D010300
24126708_1	164	174	dyskinesia	Disease	D004409
24126708_1	179	200	visual hallucinations	Disease	D006212
24126708_1	0	8	Levodopa	Chemical	D007980
24126708_1	CID	D007980	D006212
24126708_1	CID	D007980	D004409

24132704_12|s|Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript.
24132704_12	65	77	hyperlipemia	Disease	D006949
24132704_12	0	6	Crocin	Chemical	C029036
24132704_12	48	56	diazinon	Chemical	D003976
24132704_12	CID	D003976	D006949

24132704_13|s|CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.
24132704_13	86	98	hyperlipemia	Disease	D006949
24132704_13	13	19	Crocin	Chemical	C029036
24132704_13	69	77	diazinon	Chemical	D003976
24132704_13	CID	D003976	D006949

24158386_0|s|GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.
24158386_0	58	74	Hodgkin lymphoma	Disease	D006689
24158386_0	0	3	GEM	Chemical	C056507

24158386_4|s|Gemcitabine and cisplatin have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting.
24158386_4	43	45	HL	Disease	D006689
24158386_4	63	71	toxicity	Disease	D064420
24158386_4	0	11	Gemcitabine	Chemical	C056507
24158386_4	16	25	cisplatin	Chemical	D002945

24158386_5|s|In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included.
24158386_5	83	85	HL	Disease	D006689
24158386_5	99	110	gemcitabine	Chemical	C056507
24158386_5	147	165	methylprednisolone	Chemical	D008775
24158386_5	185	194	cisplatin	Chemical	D002945
24158386_5	227	230	GEM	Chemical	C056507

24158386_15|s|GEM-P is a salvage chemotherapy with relatively high response rates, leading to successful transplantation in appropriate patients, in the treatment of relapsed or refractory HL.
24158386_15	175	177	HL	Disease	D006689
24158386_15	0	3	GEM	Chemical	C056507

24190587_1|s|RATIONALE: Ecstasy (MDMA) is a psychostimulant drug which is increasingly associated with psychobiological dysfunction.
24190587_1	90	118	psychobiological dysfunction	Disease	D008107
24190587_1	11	18	Ecstasy	Chemical	D018817
24190587_1	20	24	MDMA	Chemical	D018817

24190587_10|s|CONCLUSIONS: The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users.
24190587_10	30	37	anxiety	Disease	D001008
24190587_10	42	52	depression	Disease	D003866
24190587_10	108	115	ecstasy	Chemical	D018817
24190587_10	CID	D018817	D003866

24209900_0|s|Ifosfamide related encephalopathy: the need for a timely EEG evaluation.
24209900_0	19	33	encephalopathy	Disease	D001927
24209900_0	0	10	Ifosfamide	Chemical	D007069

24209900_1|s|BACKGROUND: Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, lymphoma, gynecologic and testicular cancers.
24209900_1	89	96	cancers	Disease	D009369
24209900_1	107	115	sarcomas	Disease	D012509
24209900_1	117	125	lymphoma	Disease	D008223
24209900_1	127	161	gynecologic and testicular cancers	Disease	D009369
24209900_1	12	22	Ifosfamide	Chemical	D007069

24209900_2|s|Encephalopathy has been reported in 10-40% of patients receiving high-dose IV ifosfamide.
24209900_2	0	14	Encephalopathy	Disease	D001927
24209900_2	78	88	ifosfamide	Chemical	D007069

24209900_3|s|OBJECTIVE: To highlight the role of electroencephalogram (EEG) in the early detection and management of ifosfamide related encephalopathy.
24209900_3	123	137	encephalopathy	Disease	D001927
24209900_3	104	114	ifosfamide	Chemical	D007069

24209900_4|s|METHODS: Retrospective chart review including clinical data and EEG recordings was done on five patients, admitted to MD Anderson Cancer Center between years 2009 and 2012, who developed ifosfamide related acute encephalopathy.
24209900_4	130	136	Cancer	Disease	D009369
24209900_4	212	226	encephalopathy	Disease	D001927
24209900_4	187	197	ifosfamide	Chemical	D007069

24209900_5|s|RESULTS: All five patients experienced symptoms of encephalopathy soon after (within 12 h-2 days) receiving ifosfamide.
24209900_5	51	65	encephalopathy	Disease	D001927
24209900_5	108	118	ifosfamide	Chemical	D007069

24209900_10|s|CONCLUSIONS: Severity of ifosfamide related encephalopathy correlates with EEG changes.
24209900_10	44	58	encephalopathy	Disease	D001927
24209900_10	25	35	ifosfamide	Chemical	D007069

24209900_11|s|We suggest a timely EEG evaluation for patients receiving ifosfamide who develop features of encephalopathy.
24209900_11	93	107	encephalopathy	Disease	D001927
24209900_11	58	68	ifosfamide	Chemical	D007069

24220752_0|s|Incidence of contrast-induced nephropathy in hospitalised patients with cancer.
24220752_0	30	41	nephropathy	Disease	D007674
24220752_0	72	78	cancer	Disease	D009369
24220752_0	13	21	contrast	Chemical	D003287
24220752_0	CID	D003287	D007674

24220752_1|s|OBJECTIVES: To determine the frequency of and possible factors related to contrast-induced nephropathy (CIN) in hospitalised patients with cancer.
24220752_1	91	102	nephropathy	Disease	D007674
24220752_1	139	145	cancer	Disease	D009369
24220752_1	74	82	contrast	Chemical	D003287
24220752_1	CID	D003287	D007674

24220752_10|s|CIN was significantly more after treatment with bevacizumab/irinotecan (P = 0.021) and in patients with hypertension (P = 0.044).
24220752_10	104	116	hypertension	Disease	D006973
24220752_10	48	59	bevacizumab	Chemical	-1
24220752_10	60	70	irinotecan	Chemical	C051890

24220752_13|s|Hypertension and the combination of bevacizumab/irinotecan may be additional risk factors for CIN development.
24220752_13	0	12	Hypertension	Disease	D006973
24220752_13	36	47	bevacizumab	Chemical	-1
24220752_13	48	58	irinotecan	Chemical	C051890

24220752_15|s|Contrast-induced nephropathy (CIN) is a concern for oncological patients undergoing CT. .
24220752_15	17	28	nephropathy	Disease	D007674
24220752_15	0	8	Contrast	Chemical	D003287
24220752_15	CID	D003287	D007674

24220752_17|s|Hypertension and treatment with bevacizumab appear to be additional risk factors.
24220752_17	0	12	Hypertension	Disease	D006973
24220752_17	32	43	bevacizumab	Chemical	-1

24234943_0|s|Syndrome of inappropriate antidiuretic hormone secretion associated with desvenlafaxine.
24234943_0	0	46	Syndrome of inappropriate antidiuretic hormone	Disease	D007177
24234943_0	73	87	desvenlafaxine	Chemical	C086816
24234943_0	CID	C086816	D007177

24234943_1|s|OBJECTIVE: To report a case of syndrome of inappropriate anti-diuretic hormone (SIADH) secretion associated with desvenlafaxine.
24234943_1	31	78	syndrome of inappropriate anti-diuretic hormone	Disease	D007177
24234943_1	80	85	SIADH	Disease	D007177
24234943_1	113	127	desvenlafaxine	Chemical	C086816
24234943_1	CID	C086816	D007177

24234943_3|s|Her medications included desvenlafaxine, and symptoms included nausea, anxiety and confusion.
24234943_3	63	69	nausea	Disease	D009325
24234943_3	71	78	anxiety	Disease	D001008
24234943_3	83	92	confusion	Disease	D003221
24234943_3	25	39	desvenlafaxine	Chemical	C086816
24234943_3	CID	C086816	D001008
24234943_3	CID	C086816	D003221
24234943_3	CID	C086816	D009325

24234943_4|s|The serum sodium at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH.
24234943_4	172	177	SIADH	Disease	D007177
24234943_4	10	16	sodium	Chemical	D012964
24234943_4	123	129	sodium	Chemical	D012964

24234943_9|s|This case report suggests that desvenlafaxine might cause clinically significant hyponatremia.
24234943_9	81	93	hyponatremia	Disease	D007010
24234943_9	31	45	desvenlafaxine	Chemical	C086816
24234943_9	CID	C086816	D007010

24275640_0|s|Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin.
24275640_0	20	34	cardiotoxicity	Disease	D066126
24275640_0	85	96	doxorubicin	Chemical	D004317
24275640_0	CID	D004317	D066126

24275640_1|s|The mechanism of doxorubicin (DOX)-induced cardiotoxicity remains controversial.
24275640_1	43	57	cardiotoxicity	Disease	D066126
24275640_1	17	28	doxorubicin	Chemical	D004317
24275640_1	30	33	DOX	Chemical	D004317
24275640_1	CID	D004317	D066126

24275640_5|s|Single dose of DOX was associated with increased cardiac disarrangement, necrosis, and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP.
24275640_5	49	71	cardiac disarrangement	Disease	D006331
24275640_5	73	81	necrosis	Disease	D009336
24275640_5	15	18	DOX	Chemical	D004317
24275640_5	CID	D004317	D009336

24275640_8|s|Our results suggest that oxidative damage is associated with acute cardiotoxicity induced by a single dose of DOX only.
24275640_8	67	81	cardiotoxicity	Disease	D066126
24275640_8	110	113	DOX	Chemical	D004317
24275640_8	CID	D004317	D066126

24283660_0|s|Tacrolimus-related seizure after pediatric liver transplantation--a single-center experience.
24283660_0	19	26	seizure	Disease	D012640
24283660_0	0	10	Tacrolimus	Chemical	D016559
24283660_0	CID	D016559	D012640

24283660_7|s|Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.
24283660_7	65	73	seizures	Disease	D012640
24283660_7	120	143	end-stage liver disease	Disease	D058625
24283660_7	211	220	bilirubin	Chemical	D001663
24283660_7	247	250	TAC	Chemical	D016559
24283660_7	CID	D016559	D012640

24283660_8|s|Multivariate analysis showed that trough TAC level was the only independent risk factor associated with the seizures.
24283660_8	108	116	seizures	Disease	D012640
24283660_8	104	116	the seizures	Disease	D004830
24283660_8	41	44	TAC	Chemical	D016559
24283660_8	CID	D016559	D012640

24283660_10|s|High trough TAC level was the predominant factor that contributed to seizures in the early post-operative period after pediatric LT.
24283660_10	69	77	seizures	Disease	D012640
24283660_10	12	15	TAC	Chemical	D016559
24283660_10	CID	D016559	D012640

24283660_11|s|High PELD and Child-Pugh scores before LT and high post-operative serum Tbil may be contributory risk factors for TAC-related seizures.
24283660_11	126	134	seizures	Disease	D012640
24283660_11	114	117	TAC	Chemical	D016559
24283660_11	CID	D016559	D012640

24284476_3|s|Furthermore, apigenin did not prevent the amnesia induced by scopolamine (1mg/kg, i.p., 30 min before the acquisition).
24284476_3	42	49	amnesia	Disease	D000647
24284476_3	13	21	apigenin	Chemical	D047310
24284476_3	61	72	scopolamine	Chemical	D012601
24284476_3	CID	D012601	D000647

24309294_2|s|We have previously reported that CCK-8 significantly alleviated morphine-induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.
24309294_2	81	88	amnesia	Disease	D000647
24309294_2	33	38	CCK-8	Chemical	D012844
24309294_2	64	72	morphine	Chemical	D009020
24309294_2	166	174	morphine	Chemical	D009020
24309294_2	CID	D009020	D000647

24309294_8|s|The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced memory impairment.
24309294_8	185	202	memory impairment	Disease	D008569
24309294_8	37	42	CCK-8	Chemical	D012844
24309294_8	68	76	morphine	Chemical	D009020
24309294_8	159	164	CCK-8	Chemical	D012844
24309294_8	168	176	morphine	Chemical	D009020

24333387_0|s|Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats.
24333387_0	35	48	neurotoxicity	Disease	D020258
24333387_0	97	114	memory impairment	Disease	D008569
24333387_0	68	82	Streptozotocin	Chemical	D013311
24333387_0	CID	D013311	D008569

24333387_1|s|In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (STZ) induced memory impaired rats was explored.
24333387_1	68	76	toxicity	Disease	D064420
24333387_1	113	128	memory impaired	Disease	D008569
24333387_1	84	98	Streptozotocin	Chemical	D013311
24333387_1	100	103	STZ	Chemical	D013311
24333387_1	CID	D013311	D008569

24333387_2|s|In experiment set up 1: Memory deficit was found in Morris water maze test on 14-16 days after STZ (ICV; 3mg/Kg) administration.
24333387_2	24	38	Memory deficit	Disease	D008569
24333387_2	95	98	STZ	Chemical	D013311
24333387_2	CID	D013311	D008569

24333387_3|s|STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation.
24333387_3	89	106	neuroinflammation	Disease	D007249
24333387_3	0	3	STZ	Chemical	D013311
24333387_3	CID	D013311	D007249

24333387_4|s|STZ also significantly increased the level of ROS, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.
24333387_4	175	189	excitotoxicity	Disease	D064420
24333387_4	0	3	STZ	Chemical	D013311
24333387_4	51	58	nitrite	Chemical	D009573
24333387_4	60	62	Ca	Chemical	D002118

24333387_6|s|STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.
24333387_6	209	222	neurotoxicity	Disease	D020258
24333387_6	0	3	STZ	Chemical	D013311

24333387_7|s|Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.
24333387_7	163	176	neurotoxicity	Disease	D020258
24333387_7	20	29	Memantine	Chemical	D008559
24333387_7	44	53	Ibuprofen	Chemical	D007052
24333387_7	94	97	STZ	Chemical	D013311

24333387_12|s|Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in STZ induced memory impairment and neuronal cell death.
24333387_12	71	84	neurotoxicity	Disease	D020258
24333387_12	120	137	memory impairment	Disease	D008569
24333387_12	108	111	STZ	Chemical	D013311
24333387_12	CID	D013311	D008569

24341598_0|s|Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy.
24341598_0	99	110	nephropathy	Disease	D007674
24341598_0	34	49	sodium chloride	Chemical	D012965
24341598_0	55	64	diltiazem	Chemical	D004110
24341598_0	82	90	contrast	Chemical	D003287

24341598_1|s|INTRODUCTION AND OBJECTIVE: Contrast-induced nephropathy (CIN) significantly increases the morbidity and mortality of patients.
24341598_1	45	56	nephropathy	Disease	D007674
24341598_1	28	36	Contrast	Chemical	D003287

24341598_9|s|Among a total of 60 patients included in the study, 16 patients developed acute renal failure (ARF) on the second day after contrast material was injected (26.6%).
24341598_9	74	93	acute renal failure	Disease	D058186
24341598_9	95	98	ARF	Disease	D058186
24341598_9	124	132	contrast	Chemical	D003287
24341598_9	CID	D003287	D058186

24345882_0|s|Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence?
24345882_0	171	199	acute lymphoblastic leukemia	Disease	D054198
24345882_0	224	236	methotrexate	Chemical	D008727

24345882_2|s|Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.
24345882_2	44	57	neurotoxicity	Disease	D020258
24345882_2	202	230	acute lymphoblastic leukemia	Disease	D054198
24345882_2	25	37	methotrexate	Chemical	D008727
24345882_2	39	42	MTX	Chemical	D008727
24345882_2	166	169	MTX	Chemical	D008727

24434397_0|s|Tranexamic acid overdosage-induced generalized seizure in renal failure.
24434397_0	47	54	seizure	Disease	D012640
24434397_0	58	71	renal failure	Disease	D051437
24434397_0	0	15	Tranexamic acid	Chemical	D014148

24434397_4|s|Tranexamic acid (TNA) 1 g 8-hourly was administered to her to control bleeding per vaginum.
24434397_4	70	78	bleeding	Disease	D006470
24434397_4	0	15	Tranexamic acid	Chemical	D014148
24434397_4	17	20	TNA	Chemical	D014148

24434397_5|s|Two hours after the sixth dose of TNA, she had an episode of generalized tonic clonic convulsions.
24434397_5	73	97	tonic clonic convulsions	Disease	D004830
24434397_5	34	37	TNA	Chemical	D014148
24434397_5	CID	D014148	D004830

24434397_10|s|Thus, the precipitating cause of convulsions was believed to be an overdose of TNA.
24434397_10	33	44	convulsions	Disease	D012640
24434397_10	67	75	overdose	Disease	D062787
24434397_10	79	82	TNA	Chemical	D014148

24438483_0|s|Pre-treatment of bupivacaine-induced cardiovascular depression using different lipid formulations of propofol.
24438483_0	37	62	cardiovascular depression	Disease	D002318
24438483_0	17	28	bupivacaine	Chemical	D002045
24438483_0	101	109	propofol	Chemical	D015742

24438483_1|s|BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.
24438483_1	171	185	cardiotoxicity	Disease	D066126
24438483_1	90	101	bupivacaine	Chemical	D002045
24438483_1	128	136	propofol	Chemical	D015742
24438483_1	151	162	bupivacaine	Chemical	D002045
24438483_1	CID	D002045	D066126

24438483_2|s|The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity.
24438483_2	125	139	cardiotoxicity	Disease	D066126
24438483_2	55	63	propofol	Chemical	D015742
24438483_2	105	116	bupivacaine	Chemical	D002045
24438483_2	CID	D002045	D066126

24438483_5|s|We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption.
24438483_5	26	37	dysrhythmia	Disease	D001145
24438483_5	155	163	asystole	Disease	D006323
24438483_5	184	195	bupivacaine	Chemical	D002045
24438483_5	CID	D002045	D006323

24438483_11|s|CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.
24438483_11	161	172	cardiotoxic	Disease	D066126
24438483_11	48	56	propofol	Chemical	D015742
24438483_11	86	94	propofol	Chemical	D015742
24438483_11	141	152	bupivacaine	Chemical	D002045
24438483_11	207	218	bupivacaine	Chemical	D002045
24438483_11	CID	D002045	D066126

24451297_0|s|Drug-Induced Acute Liver Injury Within 12 Hours After Fluvastatin Therapy.
24451297_0	0	31	Drug-Induced Acute Liver Injury	Disease	D056486
24451297_0	54	65	Fluvastatin	Chemical	C065180
24451297_0	CID	C065180	D056486

24451297_1|s|Although statins are generally well-tolerated drugs, recent cases of drug-induced liver injury associated with their use have been reported.
24451297_1	69	94	drug-induced liver injury	Disease	D056486
24451297_1	9	16	statins	Chemical	D019161

24451297_2|s|A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with fluvastatin.
24451297_2	40	52	liver damage	Disease	D056486
24451297_2	109	120	fluvastatin	Chemical	C065180
24451297_2	CID	C065180	D056486

24459006_0|s|Fluconazole associated agranulocytosis and thrombocytopenia.
24459006_0	23	38	agranulocytosis	Disease	D000380
24459006_0	43	59	thrombocytopenia	Disease	D013921
24459006_0	0	11	Fluconazole	Chemical	D015725
24459006_0	CID	D015725	D000380
24459006_0	CID	D015725	D013921

24459006_1|s|CASE: We describe a second case of fluconazole associated agranulocytosis with thrombocytopenia and recovery upon discontinuation of therapy.
24459006_1	58	73	agranulocytosis	Disease	D000380
24459006_1	79	95	thrombocytopenia	Disease	D013921
24459006_1	35	46	fluconazole	Chemical	D015725
24459006_1	CID	D015725	D000380
24459006_1	CID	D015725	D013921

24459006_4|s|CONCLUSION: According to Naranjo's algorithm the likelihood that our patient's agranulocytosis and thrombocytopenia occurred as a result of therapy with fluconazole is probable, with a total of six points.
24459006_4	79	94	agranulocytosis	Disease	D000380
24459006_4	99	115	thrombocytopenia	Disease	D013921
24459006_4	153	164	fluconazole	Chemical	D015725
24459006_4	CID	D015725	D000380
24459006_4	CID	D015725	D013921

24459006_6|s|In particular the temporal relationship of bone marrow suppression to the initiation of fluconazole and the abatement of symptoms that rapidly reversed immediately following discontinuation.
24459006_6	43	66	bone marrow suppression	Disease	D001855
24459006_6	88	99	fluconazole	Chemical	D015725

24464946_0|s|Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.
24464946_0	135	149	cardiotoxicity	Disease	D066126
24464946_0	157	168	epirubicine	Chemical	D015251
24464946_0	CID	D015251	D066126

24464946_1|s|AIMS: To investigate whether alterations of myocardial strain and high-sensitive cardiac troponin T (cTnT) could predict future cardiac dysfunction in patients after epirubicin exposure.
24464946_1	44	61	myocardial strain	Disease	D009202
24464946_1	128	147	cardiac dysfunction	Disease	D006331
24464946_1	166	176	epirubicin	Chemical	D015251

24464946_2|s|METHODS: Seventy-five patients with non-Hodgkin lymphoma treated with epirubicin were studied.
24464946_2	36	56	non-Hodgkin lymphoma	Disease	D008228
24464946_2	70	80	epirubicin	Chemical	D015251

24464946_12|s|CONCLUSIONS: GLS combined with cTnT may provide a reliable and non-invasive method to predict cardiac dysfunction in patients receiving anthracycline-based chemotherapy.
24464946_12	94	113	cardiac dysfunction	Disease	D006331
24464946_12	136	149	anthracycline	Chemical	D018943

24535067_0|s|Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination?
24535067_0	32	41	myoclonus	Disease	D009207
24535067_0	14	23	etomidate	Chemical	D005045
24535067_0	62	70	Fentanyl	Chemical	D005283
24535067_0	72	81	midazolam	Chemical	D008874
24535067_0	CID	D005045	D009207

24535067_2|s|BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.
24535067_2	188	197	myoclonus	Disease	D009207
24535067_2	94	102	fentanyl	Chemical	D005283
24535067_2	104	113	midazolam	Chemical	D008874
24535067_2	136	144	fentanyl	Chemical	D005283
24535067_2	149	158	midazolam	Chemical	D008874
24535067_2	170	179	etomidate	Chemical	D005045
24535067_2	CID	D005045	D009207

24535067_6|s|Myoclonic movements are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection.
24535067_6	0	19	Myoclonic movements	Disease	D009069
24535067_6	124	133	etomidate	Chemical	D005045

24535067_7|s|The severity of pain due to etomidate injection, mean arterial pressure, heart rate, and adverse effects were also evaluated.
24535067_7	16	20	pain	Disease	D010146
24535067_7	28	37	etomidate	Chemical	D005045

24535067_9|s|CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.
24535067_9	144	153	myoclonus	Disease	D009207
24535067_9	48	56	fentanyl	Chemical	D005283
24535067_9	75	83	fentanyl	Chemical	D005283
24535067_9	88	97	midazolam	Chemical	D008874
24535067_9	126	135	etomidate	Chemical	D005045
24535067_9	CID	D005045	D009207

24554916_0|s|Cholestatic presentation of yellow phosphorus poisoning.
24554916_0	0	11	Cholestatic	Disease	D002779
24554916_0	46	55	poisoning	Disease	D011041
24554916_0	35	45	phosphorus	Chemical	D010758
24554916_0	CID	D010758	D002779

24554916_1|s|Yellow phosphorus, a component of certain pesticide pastes and fireworks, is well known to cause hepatotoxicity.
24554916_1	97	111	hepatotoxicity	Disease	D056486
24554916_1	7	17	phosphorus	Chemical	D010758

24554916_2|s|Poisoning with yellow phosphorus classically manifests with acute hepatitis leading to acute liver failure which may need liver transplantation.
24554916_2	0	9	Poisoning	Disease	D011041
24554916_2	60	75	acute hepatitis	Disease	D006505
24554916_2	87	106	acute liver failure	Disease	D017114
24554916_2	22	32	phosphorus	Chemical	D010758
24554916_2	CID	D010758	D006505
24554916_2	CID	D010758	D017114

24554916_3|s|We present a case of yellow phosphorus poisoning in which a patient presented with florid clinical features of cholestasis highlighting the fact that cholestasis can rarely be a presenting feature of yellow phosphorus hepatotoxicity.
24554916_3	39	48	poisoning	Disease	D011041
24554916_3	111	122	cholestasis	Disease	D002779
24554916_3	150	161	cholestasis	Disease	D002779
24554916_3	218	232	hepatotoxicity	Disease	D056486
24554916_3	28	38	phosphorus	Chemical	D010758
24554916_3	207	217	phosphorus	Chemical	D010758
24554916_3	CID	D010758	D002779

24571687_0|s|Vasovagal syncope and severe bradycardia following intranasal dexmedetomidine for pediatric procedural sedation.
24571687_0	0	17	Vasovagal syncope	Disease	D019462
24571687_0	29	40	bradycardia	Disease	D001919
24571687_0	62	77	dexmedetomidine	Chemical	D020927
24571687_0	CID	D020927	D001919
24571687_0	CID	D020927	D019462

24571687_1|s|We report syncope and bradycardia in an 11-year-old girl following administration of intranasal dexmedetomidine for sedation for a voiding cystourethrogram.
24571687_1	10	17	syncope	Disease	D013575
24571687_1	22	33	bradycardia	Disease	D001919
24571687_1	96	111	dexmedetomidine	Chemical	D020927
24571687_1	CID	D020927	D001919

24582773_0|s|Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder.
24582773_0	19	28	agitation	Disease	D011595
24582773_0	72	97	schizo-affective disorder	Disease	D011618
24582773_0	58	68	quetiapine	Chemical	C069541
24582773_0	CID	C069541	D011595

24582773_1|s|We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l).
24582773_1	59	84	schizo-affective disorder	Disease	D011618
24582773_1	173	187	zuclopenthixol	Chemical	D003006
24582773_1	205	212	lithium	Chemical	D008094
24582773_1	234	241	lithium	Chemical	D008094

24582773_3|s|Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder.
24582773_3	114	123	agitation	Disease	D011595
24582773_3	207	221	aggressiveness	Disease	D010554
24582773_3	225	245	personality disorder	Disease	D010554
24582773_3	54	64	quetiapine	Chemical	C069541
24582773_3	CID	C069541	D011595

24582773_5|s|The withdrawal and the gradual reintroduction of quetiapine 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to quetiapine.
24582773_5	103	112	agitation	Disease	D011595
24582773_5	142	151	agitation	Disease	D011595
24582773_5	49	59	quetiapine	Chemical	C069541
24582773_5	168	178	quetiapine	Chemical	C069541
24582773_5	CID	C069541	D011595

24587916_0|s|Antioxidant effects of bovine lactoferrin on dexamethasone-induced hypertension in rat.
24587916_0	67	79	hypertension	Disease	D006973
24587916_0	45	58	dexamethasone	Chemical	D003907
24587916_0	CID	D003907	D006973

24587916_1|s|Dexamethasone- (Dex-) induced hypertension is associated with enhanced oxidative stress.
24587916_1	30	42	hypertension	Disease	D006973
24587916_1	0	13	Dexamethasone	Chemical	D003907
24587916_1	16	19	Dex	Chemical	D003907
24587916_1	CID	D003907	D006973

24587916_3|s|In this study, we investigated the effect of chronic administration of LF on oxidative stress and hypertension upon Dex administration.
24587916_3	98	110	hypertension	Disease	D006973
24587916_3	116	119	Dex	Chemical	D003907
24587916_3	CID	D003907	D006973

24587916_11|s|LF lowered (P < 0.01) and dose dependently prevented (P < 0.001) Dex-induced hypertension.
24587916_11	77	89	hypertension	Disease	D006973
24587916_11	65	68	Dex	Chemical	D003907
24587916_11	CID	D003907	D006973

24587916_12|s|LF prevented body weight loss and significantly reduced the elevated plasma H2O2 and increased FRAP values.
24587916_12	18	29	weight loss	Disease	D015431
24587916_12	76	80	H2O2	Chemical	D006861

24587916_13|s|Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.
24587916_13	136	148	hypertension	Disease	D006973
24587916_13	124	127	Dex	Chemical	D003907
24587916_13	CID	D003907	D006973

24588023_0|s|The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients.
24588023_0	44	54	convulsive	Disease	D012640
24588023_0	55	63	seizures	Disease	D012640
24588023_0	24	39	tranexamic acid	Chemical	D014148
24588023_0	CID	D014148	D012640

24588023_8|s|Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.
24588023_8	40	48	seizures	Disease	D012640
24588023_8	131	155	congestive heart failure	Disease	D006333
24588023_8	162	173	hypothermic	Disease	D007035
24588023_8	229	244	tranexamic acid	Chemical	D014148
24588023_8	CID	D014148	D012640

24588023_9|s|When tested in a multivariate regression analysis, tranexamic acid was a strong independent predictor of seizures (OR 14.3, 95% CI 5.5-36.7; p < 0.001).
24588023_9	105	113	seizures	Disease	D012640
24588023_9	51	66	tranexamic acid	Chemical	D014148
24588023_9	CID	D014148	D012640

24588023_13|s|As tranexamic acid is the only modifiable factor, its administration, particularly in doses exceeding 80 mg.kg(-1), should be weighed against the risk of postoperative seizures.
24588023_13	168	176	seizures	Disease	D012640
24588023_13	3	18	tranexamic acid	Chemical	D014148
24588023_13	CID	D014148	D012640

24595967_0|s|Dysfunctional overnight memory consolidation in ecstasy users.
24595967_0	0	30	Dysfunctional overnight memory	Disease	D008569
24595967_0	48	55	ecstasy	Chemical	D018817
24595967_0	CID	D018817	D008569

24595967_2|s|Previous studies indicate that ecstasy users have marked and persistent neurocognitive and sleep-related impairments.
24595967_2	91	116	sleep-related impairments	Disease	D012893
24595967_2	31	38	ecstasy	Chemical	D018817
24595967_2	CID	D018817	D012893

24595967_6|s|Ecstasy users demonstrated impaired overnight memory consolidation, a finding that was more pronounced following associative interference.
24595967_6	27	52	impaired overnight memory	Disease	D008569
24595967_6	0	7	Ecstasy	Chemical	D018817
24595967_6	CID	D018817	D008569

24595967_8|s|We suggest that ecstasy-associated dysfunction in fronto-temporal circuitry may underlie overnight consolidation memory impairments in regular ecstasy users.
24595967_8	113	131	memory impairments	Disease	D008569
24595967_8	16	23	ecstasy	Chemical	D018817
24595967_8	143	150	ecstasy	Chemical	D018817
24595967_8	CID	D018817	D008569

24614773_0|s|Normoammonemic encephalopathy: solely valproate induced or multiple mechanisms?
24614773_0	15	29	encephalopathy	Disease	D001927
24614773_0	38	47	valproate	Chemical	D014635

24614773_2|s|In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine.
24614773_2	90	101	hemiparesis	Disease	D010291
24614773_2	168	187	hemiplegic migraine	Disease	D020325
24614773_2	145	154	valproate	Chemical	D014635

24614773_5|s|EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre N-methyl-D-aspartate (NMDA) receptor antibodies were present in this patient.
24614773_5	68	82	encephalopathy	Disease	D001927
24614773_5	98	118	N-methyl-D-aspartate	Chemical	D016202
24614773_5	120	124	NMDA	Chemical	D016202

24614773_6|s|The possible aetiologies of valproate-induced encephalopathy and NMDA receptor-associated encephalitis present a diagnostic dilemma.
24614773_6	46	60	encephalopathy	Disease	D001927
24614773_6	90	102	encephalitis	Disease	D004660
24614773_6	28	37	valproate	Chemical	D014635
24614773_6	65	69	NMDA	Chemical	D016202

24618873_0|s|Cerebellar and oculomotor dysfunction induced by rapid infusion of pethidine.
24618873_0	0	37	Cerebellar and oculomotor dysfunction	Disease	D002526|D005128
24618873_0	67	76	pethidine	Chemical	D008614

24618873_1|s|Pethidine is an opioid that gains its popularity for the effective pain control through acting on the opioid-receptors.
24618873_1	67	71	pain	Disease	D010146
24618873_1	0	9	Pethidine	Chemical	D008614
24618873_1	34	37	its	Chemical	D008614

24618873_2|s|However, rapid pain relief sometimes brings about unfavourable side effects that largely limit its clinical utility.
24618873_2	15	19	pain	Disease	D010146
24618873_2	95	98	its	Chemical	D008614

24618873_4|s|In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
24618873_4	17	50	impaired renal and liver function	Disease	D051437|D017093
24618873_4	81	85	pain	Disease	D010146
24618873_4	175	185	neurotoxic	Disease	D020258
24618873_4	225	237	irritability	Disease	D001523
24618873_4	242	249	seizure	Disease	D012640
24618873_4	95	104	pethidine	Chemical	D008614
24618873_4	198	210	norpethidine	Chemical	C002752
24618873_4	CID	C002752	D012640

24618873_6|s|In this case report, we highlight opioid's inhibitory side effects on the cerebellar structure that causes dysmetria, dysarthria, reduced smooth pursuit gain and decreased saccadic velocity.
24618873_6	107	116	dysmetria	Disease	D002524
24618873_6	118	128	dysarthria	Disease	D004401
24618873_6	34	42	opioid's	Chemical	D008614
24618873_6	CID	D008614	D002524
24618873_6	CID	D008614	D004401

24641119_0|s|Baboon syndrome induced by ketoconazole.
24641119_0	0	15	Baboon syndrome	Disease	-1
24641119_0	27	39	ketoconazole	Chemical	D007654

24641119_1|s|A 27-year-old male patient presented with a maculopapular eruption on the flexural areas and buttocks after using oral ketoconazole.
24641119_1	44	66	maculopapular eruption	Disease	D003875
24641119_1	119	131	ketoconazole	Chemical	D007654
24641119_1	CID	D007654	D003875

24641119_2|s|The patient was diagnosed with drug-induced baboon syndrome based on his history, which included prior sensitivity to topical ketoconazole, a physical examination, and histopathological findings.
24641119_2	44	59	baboon syndrome	Disease	-1
24641119_2	126	138	ketoconazole	Chemical	D007654

24641119_4|s|To the best of our knowledge, this is the first reported case of ketoconazole-induced baboon syndrome in the English literature.
24641119_4	86	101	baboon syndrome	Disease	-1
24641119_4	65	77	ketoconazole	Chemical	D007654

24653743_0|s|A Case of Sudden Cardiac Death due to Pilsicainide-Induced Torsades de Pointes.
24653743_0	10	30	Sudden Cardiac Death	Disease	D016757
24653743_0	59	78	Torsades de Pointes	Disease	D016171
24653743_0	38	50	Pilsicainide	Chemical	C042288
24653743_0	CID	C042288	D016171
24653743_0	CID	C042288	D016757

24653743_1|s|An 84-year-old male received oral pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed sudden cardiac death two days later.
24653743_1	133	152	atrial fibrillation	Disease	D001281
24653743_1	194	214	sudden cardiac death	Disease	D016757
24653743_1	34	46	pilsicainide	Chemical	C042288
24653743_1	55	61	sodium	Chemical	D012964
24653743_1	CID	C042288	D016757

24653743_4|s|Although the patient's renal function was not highly impaired and the dose of pilsicainide was low, the plasma concentration of pilsicainide may have been high, which can produce torsades de pointes in the octogenarian.
24653743_4	179	198	torsades de pointes	Disease	D016171
24653743_4	78	90	pilsicainide	Chemical	C042288
24653743_4	128	140	pilsicainide	Chemical	C042288
24653743_4	CID	C042288	D016171

24653743_5|s|Although the oral administration of class IC drugs, including pilsicainide, is effective to terminate atrial fibrillation, careful consideration must be taken before giving these drugs to octogenarians.
24653743_5	102	121	atrial fibrillation	Disease	D001281
24653743_5	62	74	pilsicainide	Chemical	C042288

24658375_0|s|All-trans retinoic acid-induced inflammatory myositis in a patient with acute promyelocytic leukemia.
24658375_0	45	53	myositis	Disease	D009220
24658375_0	72	100	acute promyelocytic leukemia	Disease	D015473
24658375_0	0	23	All-trans retinoic acid	Chemical	D014212
24658375_0	CID	D014212	D009220

24658375_1|s|All-trans retinoic acid (ATRA), a component of standard therapy for acute promyelocytic leukemia (APL), is associated with potentially serious but treatable adverse effects involving numerous organ systems, including rare skeletal muscle involvement.
24658375_1	68	96	acute promyelocytic leukemia	Disease	D015473
24658375_1	98	101	APL	Disease	D015473
24658375_1	0	23	All-trans retinoic acid	Chemical	D014212
24658375_1	25	29	ATRA	Chemical	D014212

24658375_2|s|Only a handful of cases of ATRA-induced myositis in children have been reported, and none in the radiology literature.
24658375_2	40	48	myositis	Disease	D009220
24658375_2	27	31	ATRA	Chemical	D014212
24658375_2	CID	D014212	D009220

24659727_0|s|Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.
24659727_0	76	84	lymphoma	Disease	D008223
24659727_0	16	25	lomustine	Chemical	D008130
24659727_0	46	62	cyclophosphamide	Chemical	D003520

24659727_1|s|This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.
24659727_1	35	43	toxicity	Disease	D064420
24659727_1	131	139	lymphoma	Disease	D008223
24659727_1	74	83	lomustine	Chemical	D008130
24659727_1	85	89	CCNU	Chemical	D008130
24659727_1	95	111	cyclophosphamide	Chemical	D003520
24659727_1	113	116	CTX	Chemical	D003520

24659727_4|s|Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19-43%).
24659727_4	0	11	Neutropenia	Disease	D009503
24659727_4	81	92	neutropenia	Disease	D009503
24659727_4	122	126	CCNU	Chemical	D008130
24659727_4	127	130	CTX	Chemical	D003520
24659727_4	CID	D003520	D009503
24659727_4	CID	D008130	D009503

24659727_9|s|On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs.
24659727_9	153	158	tumor	Disease	D009369
24659727_9	70	74	CCNU	Chemical	D008130
24659727_9	104	107	CTX	Chemical	D003520

24664478_0|s|Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature.
24664478_0	11	24	neurotoxicity	Disease	D020258
24664478_0	0	10	Nelarabine	Chemical	C104457

24664478_1|s|Severe nelarabine neurotoxicity in a patient who received concurrent intrathecal (IT) chemotherapy is reported.
24664478_1	18	31	neurotoxicity	Disease	D020258
24664478_1	7	17	nelarabine	Chemical	C104457

24664478_13|s|Her neuropathy stabilized and showed slight improvement and ultimately received an unrelated, reduced-intensity allogeneic transplant while in complete remission, but relapsed disease 10 weeks later.
24664478_13	4	14	neuropathy	Disease	D009422
24664478_13	0	3	Her	Chemical	C104457

24664478_15|s|To our knowledge, this is the first published case report of severe neurotoxicity caused by nelarabine in a patient who received concurrent IT chemotherapy.
24664478_15	68	81	neurotoxicity	Disease	D020258
24664478_15	92	102	nelarabine	Chemical	C104457

24665854_0|s|Valproate-induced hyperammonemic encephalopathy in a renal transplanted patient.
24665854_0	18	32	hyperammonemic	Disease	D022124
24665854_0	33	47	encephalopathy	Disease	D001927
24665854_0	0	9	Valproate	Chemical	D014635
24665854_0	CID	D014635	D022124

24665854_3|s|Valproate-induced hyperammonemic encephalopathy is an uncommon but serious effect of valproate treatment.
24665854_3	18	32	hyperammonemic	Disease	D022124
24665854_3	33	47	encephalopathy	Disease	D001927
24665854_3	0	9	Valproate	Chemical	D014635
24665854_3	85	94	valproate	Chemical	D014635
24665854_3	CID	D014635	D022124

24665854_4|s|Here, we describe the case of a 15-year-old girl who was on a long-term therapy with valproate due to epilepsy and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation.
24665854_4	102	110	epilepsy	Disease	D004827
24665854_4	124	146	impaired consciousness	Disease	D003244
24665854_4	152	166	hyperammonemia	Disease	D022124
24665854_4	85	94	valproate	Chemical	D014635
24665854_4	CID	D014635	D003244
24665854_4	CID	D014635	D022124

24671324_0|s|Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.
24671324_0	0	21	Necrotising fasciitis	Disease	D019115
24671324_0	101	131	Waldenstrom macroglobulinaemia	Disease	D008258
24671324_0	28	38	bortezomib	Chemical	C400082
24671324_0	43	56	dexamethasone	Chemical	D003907
24671324_0	CID	D003907	D019115
24671324_0	CID	C400082	D019115

24671324_1|s|Bortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies.
24671324_1	116	136	bacterial infections	Disease	D001424
24671324_1	161	173	malignancies	Disease	D009369
24671324_1	0	10	Bortezomib	Chemical	C400082
24671324_1	25	38	dexamethasone	Chemical	D003907

24671324_3|s|We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.
24671324_3	43	73	Waldenstrom macroglobulinaemia	Disease	D008258
24671324_3	87	108	necrotising fasciitis	Disease	D019115
24671324_3	117	128	neutropenia	Disease	D009503
24671324_3	166	176	bortezomib	Chemical	C400082
24671324_3	188	201	dexamethasone	Chemical	D003907
24671324_3	CID	D003907	D019115
24671324_3	CID	C400082	D019115

24671324_5|s|Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation.
24671324_5	53	73	bacterial infections	Disease	D001424
24671324_5	85	95	bortezomib	Chemical	C400082
24671324_5	111	124	dexamethasone	Chemical	D003907

24675088_0|s|An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity.
24675088_0	106	120	cardiotoxicity	Disease	D066126
24675088_0	86	97	doxorubicin	Chemical	D004317

24675088_2|s|In this study, we have utilized a rat model of progressive doxorubicin (DOX)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity.
24675088_2	85	99	cardiomyopathy	Disease	D009202
24675088_2	328	336	toxicity	Disease	D064420
24675088_2	59	70	doxorubicin	Chemical	D004317
24675088_2	72	75	DOX	Chemical	D004317
24675088_2	CID	D004317	D009202

24675088_9|s|Troponin I levels positively correlated with delayed and peak gadolinium contrast enhancement, histopathological grading, and diastolic dysfunction.
24675088_9	126	147	diastolic dysfunction	Disease	D018754
24675088_9	62	72	gadolinium	Chemical	D005682

24684312_0|s|Intradermal glutamate and capsaicin injections: intra- and interindividual variability of provoked hyperalgesia and allodynia.
24684312_0	99	111	hyperalgesia	Disease	D006930
24684312_0	116	125	allodynia	Disease	D006930
24684312_0	12	21	glutamate	Chemical	D018698
24684312_0	26	35	capsaicin	Chemical	D002211
24684312_0	CID	D002211	D006930

24684312_1|s|Intradermal injections of glutamate and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders.
24684312_1	94	98	pain	Disease	D010146
24684312_1	114	126	hyperalgesia	Disease	D006930
24684312_1	131	140	allodynia	Disease	D006930
24684312_1	176	190	pain disorders	Disease	D013001
24684312_1	26	35	glutamate	Chemical	D018698
24684312_1	40	49	capsaicin	Chemical	D002211
24684312_1	CID	D002211	D006930

24684312_8|s|Secondary pinprick hyperalgesia was observed as a marked increase in the visual analogue scale (VAS) response to von Frey gauges 60 and 100 g (P < 0.001) after glutamate injection.
24684312_8	19	31	hyperalgesia	Disease	D006930
24684312_8	160	169	glutamate	Chemical	D018698

24684312_9|s|For capsaicin, secondary pinprick hyperalgesia was detected with all von Frey gauges (P < 0.001).
24684312_9	34	46	hyperalgesia	Disease	D006930
24684312_9	4	13	capsaicin	Chemical	D002211
24684312_9	CID	D002211	D006930

24684312_11|s|Capsaicin injection was reproducible for secondary hyperalgesia (ICC > 0.70) and allodynia (ICC > 0.71).
24684312_11	41	63	secondary hyperalgesia	Disease	D006930
24684312_11	81	90	allodynia	Disease	D006930
24684312_11	0	9	Capsaicin	Chemical	D002211
24684312_11	CID	D002211	D006930

24684312_13|s|In conclusion, glutamate and capsaicin yield reproducible hyperalgesic and allodynic responses, and the present model is well suited for basic research, as well as for assessing the modulation of central phenomena.
24684312_13	58	70	hyperalgesic	Disease	D006930
24684312_13	75	84	allodynic	Disease	D006930
24684312_13	15	24	glutamate	Chemical	D018698
24684312_13	29	38	capsaicin	Chemical	D002211
24684312_13	CID	D002211	D006930

24691439_5|s|Treatment of WT mice with topical ocular 0.1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients.
24691439_5	142	158	retinal ganglion	Disease	D012173
24691439_5	170	189	axonal degeneration	Disease	D009410
24691439_5	225	233	glaucoma	Disease	D005901
24691439_5	46	59	dexamethasone	Chemical	D003907
24691439_5	CID	D003907	D005901
24691439_5	CID	D003907	D009410

24691439_6|s|Furthermore, dexamethasone-induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork (TM).
24691439_6	35	54	ocular hypertension	Disease	D009798
24691439_6	13	26	dexamethasone	Chemical	D003907
24691439_6	CID	D003907	D009798

24691439_8|s|Dexamethasone induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented dexamethasone-induced ocular hypertension.
24691439_8	209	228	ocular hypertension	Disease	D009798
24691439_8	0	13	Dexamethasone	Chemical	D003907
24691439_8	187	200	dexamethasone	Chemical	D003907
24691439_8	CID	D003907	D009798

24691439_9|s|Furthermore, reduction of ER stress in the TM with sodium 4-phenylbutyrate prevented dexamethasone-induced ocular hypertension in WT mice.
24691439_9	107	126	ocular hypertension	Disease	D009798
24691439_9	51	74	sodium 4-phenylbutyrate	Chemical	C075773
24691439_9	85	98	dexamethasone	Chemical	D003907
24691439_9	CID	D003907	D009798

24709919_0|s|Effects of ginsenosides on opioid-induced hyperalgesia in mice.
24709919_0	42	54	hyperalgesia	Disease	D006930
24709919_0	11	23	ginsenosides	Chemical	D036145

24709919_3|s|In this study, we investigated the effects of Re, Rg1, and Rb1 ginsenosides, the bioactive components of ginseng, on OIH.
24709919_3	117	120	OIH	Disease	D006930
24709919_3	46	75	Re, Rg1, and Rb1 ginsenosides	Chemical	C049864|C035054|C442759

24709919_4|s|OIH was achieved in mice after subcutaneous administration of morphine for 7 consecutive days three times per day.
24709919_4	0	3	OIH	Disease	D006930
24709919_4	62	70	morphine	Chemical	D009020
24709919_4	CID	D009020	D006930

24709919_7|s|Re (300 mg/kg) inhibited OIH in both the thermal sensitivity test and the acetic acid-induced writhing test.
24709919_7	25	28	OIH	Disease	D006930
24709919_7	0	2	Re	Chemical	C049864
24709919_7	74	85	acetic acid	Chemical	D019342

24709919_8|s|However, the Rg1 and Rb1 ginsenosides failed to prevent OIH in either test.
24709919_8	56	59	OIH	Disease	D006930
24709919_8	13	37	Rg1 and Rb1 ginsenosides	Chemical	C035054|C442759

24709919_9|s|Furthermore, Rg1 showed a tendency to aggravate OIH in the acetic acid-induced writhing test.
24709919_9	48	51	OIH	Disease	D006930
24709919_9	13	16	Rg1	Chemical	C035054
24709919_9	59	70	acetic acid	Chemical	D019342

24709919_10|s|Our data suggested that the ginsenoside Re, but not Rg1 or Rb1, may contribute toward reversal of OIH.
24709919_10	98	101	OIH	Disease	D006930
24709919_10	28	42	ginsenoside Re	Chemical	C049864
24709919_10	52	55	Rg1	Chemical	C035054
24709919_10	59	62	Rb1	Chemical	C442759

24717468_12|s|CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.
24717468_12	20	31	hypotension	Disease	D007022
24717468_12	36	47	bradycardia	Disease	D001919
24717468_12	119	134	dexmedetomidine	Chemical	D020927
24717468_12	138	146	propofol	Chemical	D015742
24717468_12	CID	D015742	D001919
24717468_12	CID	D020927	D007022
24717468_12	CID	D020927	D001919
24717468_12	CID	D015742	D007022

24727461_0|s|Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.
24727461_0	48	73	mitochondrial dysfunction	Disease	D028361
24727461_0	97	111	cardiotoxicity	Disease	D066126
24727461_0	125	138	breast cancer	Disease	D001943
24727461_0	0	14	Hydroxytyrosol	Chemical	C005975
24727461_0	77	88	doxorubicin	Chemical	D004317

24727461_1|s|Oxidative stress is involved in several processes including cancer, aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin.
24727461_1	60	66	cancer	Disease	D009369
24727461_1	78	100	cardiovascular disease	Disease	D002318
24727461_1	175	186	doxorubicin	Chemical	D004317

24727461_2|s|Doxorubicin causes significant cardiotoxicity characterized by marked increases in oxidative stress and mitochondrial dysfunction.
24727461_2	31	45	cardiotoxicity	Disease	D066126
24727461_2	104	129	mitochondrial dysfunction	Disease	D028361
24727461_2	0	11	Doxorubicin	Chemical	D004317

24727461_3|s|Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer.
24727461_3	62	78	cardiac toxicity	Disease	D066126
24727461_3	147	160	breast cancer	Disease	D001943
24727461_3	31	42	doxorubicin	Chemical	D004317
24727461_3	119	133	hydroxytyrosol	Chemical	C005975

24727461_4|s|Thirty-six rats bearing breast tumors induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus hydroxytyrosol.
24727461_4	24	37	breast tumors	Disease	D001943
24727461_4	94	108	hydroxytyrosol	Chemical	C005975
24727461_4	133	144	doxorubicin	Chemical	D004317
24727461_4	164	175	doxorubicin	Chemical	D004317
24727461_4	181	195	hydroxytyrosol	Chemical	C005975

24727461_6|s|Hydroxytyrosol improved the cardiac disturbances enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage.
24727461_6	28	48	cardiac disturbances	Disease	D006331
24727461_6	0	14	Hydroxytyrosol	Chemical	C005975
24727461_6	61	72	doxorubicin	Chemical	D004317
24727461_6	CID	D004317	D006331

24727461_8|s|This study demonstrates that hydroxytyrosol protect rat heart damage provoked by doxorubicin decreasing oxidative damage and mitochondrial alterations.
24727461_8	56	68	heart damage	Disease	D006331
24727461_8	29	43	hydroxytyrosol	Chemical	C005975
24727461_8	81	92	doxorubicin	Chemical	D004317
24727461_8	CID	D004317	D006331

24729111_0|s|Amiodarone-induced myxoedema coma.
24729111_0	19	33	myxoedema coma	Disease	D007037|D003128
24729111_0	0	10	Amiodarone	Chemical	D000638
24729111_0	CID	D000638	D007037
24729111_0	CID	D000638	D003128

24729111_1|s|A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation.
24729111_1	36	47	bradycardia	Disease	D001919
24729111_1	49	60	hypothermia	Disease	D007035
24729111_1	65	84	respiratory failure	Disease	D012131
24729111_1	136	155	atrial fibrillation	Disease	D001281
24729111_1	113	123	amiodarone	Chemical	D000638
24729111_1	CID	D000638	D001919
24729111_1	CID	D000638	D007035
24729111_1	CID	D000638	D012131

24729111_10|s|The only two cases of amiodarone-induced myxoedema coma in the literature report patient death despite supportive therapy and thyroid hormone replacement.
24729111_10	41	55	myxoedema coma	Disease	D007037|D003128
24729111_10	22	32	amiodarone	Chemical	D000638
24729111_10	CID	D000638	D007037
24729111_10	CID	D000638	D003128

24729111_11|s|This case represents the most thoroughly investigated case of amiodarone-induced myxoedema coma with a history significant for subclinical thyroid disease.
24729111_11	81	95	myxoedema coma	Disease	D007037|D003128
24729111_11	139	154	thyroid disease	Disease	D013959
24729111_11	62	72	amiodarone	Chemical	D000638
24729111_11	CID	D000638	D007037
24729111_11	CID	D000638	D003128

24733133_0|s|Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis.
24733133_0	40	52	thrombolysis	Disease	D055499
24733133_0	112	128	thrombocytopenia	Disease	D013921
24733133_0	134	144	thrombosis	Disease	D013927
24733133_0	7	17	argatroban	Chemical	C031942
24733133_0	96	103	heparin	Chemical	D006493
24733133_0	CID	D006493	D013921

24733133_1|s|PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.
24733133_1	71	87	thrombocytopenia	Disease	D013921
24733133_1	93	103	thrombosis	Disease	D013927
24733133_1	105	109	HITT	Disease	D013921|D013927
24733133_1	166	178	thrombolysis	Disease	D055499
24733133_1	55	62	heparin	Chemical	D006493
24733133_1	132	142	argatroban	Chemical	C031942
24733133_1	CID	D006493	D013921

24733133_2|s|SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.
24733133_2	48	59	amyloidosis	Disease	D000686
24733133_2	178	216	upper-extremity deep venous thrombosis	Disease	D056824
24733133_2	218	221	DVT	Disease	D020246
24733133_2	227	245	pulmonary embolism	Disease	D011655
24733133_2	275	291	thrombocytopenia	Disease	D013921
24733133_2	259	266	heparin	Chemical	D006493
24733133_2	CID	D006493	D013921
24733133_2	CID	D006493	D011655
24733133_2	CID	D006493	D020246

24733133_6|s|The epistaxis resolved the next day, and the patient was restarted on argatroban.
24733133_6	4	13	epistaxis	Disease	D004844
24733133_6	70	80	argatroban	Chemical	C031942

24733133_11|s|CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase.
24733133_11	41	52	amyloidosis	Disease	D000686
24733133_11	57	69	SVC syndrome	Disease	D013479
24733133_11	83	87	HITT	Disease	D013921|D013927
24733133_11	118	128	argatroban	Chemical	C031942

24739405_0|s|Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice.
24739405_0	57	70	schizophrenia	Disease	D012559
24739405_0	11	33	dehydroepiandrosterone	Chemical	D003687
24739405_0	37	48	amphetamine	Chemical	D000661
24739405_0	CID	D000661	D012559

24739405_1|s|OBJECTIVE: To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia.
24739405_1	87	100	schizophrenia	Disease	D012559
24739405_1	37	59	dehydroepiandrosterone	Chemical	D003687
24739405_1	61	65	DHEA	Chemical	D003687

24739405_4|s|Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.
24739405_4	33	38	hyper	Disease	D006948
24739405_4	152	161	catalepsy	Disease	D002375
24739405_4	198	211	schizophrenia	Disease	D012559
24739405_4	0	11	Amphetamine	Chemical	D000661
24739405_4	51	62	apomorphine	Chemical	D001058
24739405_4	117	128	haloperidol	Chemical	D006220
24739405_4	CID	D001058	D012559
24739405_4	CID	D000661	D012559
24739405_4	CID	D006220	D002375
24739405_4	CID	D006220	D012559

24739405_9|s|There was a significant difference between groups in the haloperidol-induced catalepsy test (p<0.05).
24739405_9	77	86	catalepsy	Disease	D002375
24739405_9	57	68	haloperidol	Chemical	D006220
24739405_9	CID	D006220	D002375

24739405_11|s|CONCLUSION: We observed that DHEA reduced locomotor activity and increased catalepsy at both doses, while it had no effect on climbing behavior.
24739405_11	75	84	catalepsy	Disease	D002375
24739405_11	29	33	DHEA	Chemical	D003687

24739405_12|s|We suggest that DHEA displays typical neuroleptic-like effects, and may be used in the treatment of schizophrenia.
24739405_12	100	113	schizophrenia	Disease	D012559
24739405_12	16	20	DHEA	Chemical	D003687

24742750_6|s|Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause Torsade de Pointes (TdP) in clinical practice, produced early afterdepolarization (EAD). hiPS-CMs using MEA system and FPDc can predict the effects of drug candidates on QT interval.
24742750_6	83	101	Torsade de Pointes	Disease	D016171
24742750_6	103	106	TdP	Disease	D016171
24742750_6	27	38	Terfenadine	Chemical	D016593
24742750_6	43	53	Citalopram	Chemical	D015283
24742750_6	CID	D015283	D016171
24742750_6	CID	D016593	D016171

24753331_1|s|BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.
24753331_1	74	89	embryolethality	Disease	D020964
24753331_1	91	105	teratogenicity	Disease	D064793
24753331_1	114	140	ventricular septal defects	Disease	D006345
24753331_1	161	179	growth retardation	Disease	D005317
24753331_1	223	231	toxicity	Disease	D064420
24753331_1	12	19	S-53482	Chemical	C106487
24753331_1	24	31	S-23121	Chemical	C083440
24753331_1	CID	C106487	D005317
24753331_1	CID	C083440	D005317
24753331_1	CID	C083440	D064793
24753331_1	CID	C083440	D020964
24753331_1	CID	C106487	D020964
24753331_1	CID	C106487	D064793
24753331_1	CID	C083440	D006345
24753331_1	CID	C106487	D006345

24753331_5|s|RESULTS: Dermal exposure of rats to S-53482 at 300 mg/kg produced patterns of developmental toxicity similar to those resulting from oral exposure.
24753331_5	92	100	toxicity	Disease	D064420
24753331_5	36	43	S-53482	Chemical	C106487

24753331_7|s|Dermal administration of S-23121 at 800 mg/kg resulted in an increased incidence of embryonic death and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to S-23121.
24753331_7	84	99	embryonic death	Disease	D020964
24753331_7	104	129	ventricular septal defect	Disease	D006345
24753331_7	25	32	S-23121	Chemical	C083440
24753331_7	211	218	S-23121	Chemical	C083440
24753331_7	CID	C083440	D020964
24753331_7	CID	C083440	D006345

24753331_8|s|CONCLUSIONS: Based on the results, S-53482 and S-23121 were teratogenic when administered dermally to pregnant rats as were the compounds administered orally.
24753331_8	60	71	teratogenic	Disease	D064793
24753331_8	35	42	S-53482	Chemical	C106487
24753331_8	47	54	S-23121	Chemical	C083440
24753331_8	CID	C083440	D064793
24753331_8	CID	C106487	D064793

24778426_0|s|Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol.
24778426_0	9	23	Renal Toxicity	Disease	D007674
24778426_0	27	33	Cancer	Disease	D009369
24778426_0	53	62	Cisplatin	Chemical	D002945
24778426_0	80	88	Mannitol	Chemical	D008353

24778426_2|s|One of the major complications of cisplatin use is dose-limiting nephrotoxicity.
24778426_2	65	79	nephrotoxicity	Disease	D007674
24778426_2	34	43	cisplatin	Chemical	D002945

24778426_3|s|There are many strategies to prevent this toxicity, including the use of mannitol as a nephroprotectant in combination with hydration.
24778426_3	42	50	toxicity	Disease	D064420
24778426_3	73	81	mannitol	Chemical	D008353

24778426_4|s|OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent cisplatin with and without mannitol.
24778426_4	63	77	nephrotoxicity	Disease	D007674
24778426_4	81	87	cancer	Disease	D009369
24778426_4	45	54	cisplatin	Chemical	D002945
24778426_4	120	129	cisplatin	Chemical	D002945
24778426_4	147	155	mannitol	Chemical	D008353

24778426_6|s|Data were collected on adult cancer patients receiving single-agent cisplatin as an outpatient from January 2011 to September 2012.
24778426_6	29	35	cancer	Disease	D009369
24778426_6	68	77	cisplatin	Chemical	D002945

24778426_8|s|RESULTS: We evaluated 143 patients who received single-agent cisplatin; 97.2% of patients had head and neck cancer as their primary malignancy.
24778426_8	94	114	head and neck cancer	Disease	D006258
24778426_8	132	142	malignancy	Disease	D009369
24778426_8	61	70	cisplatin	Chemical	D002945

24778426_9|s|Patients who did not receive mannitol were more likely to develop nephrotoxicity: odds ratio [OR] = 2.646 (95% CI = 1.008, 6.944; P = 0.048).
24778426_9	66	80	nephrotoxicity	Disease	D007674
24778426_9	29	37	mannitol	Chemical	D008353

24778426_11|s|CONCLUSIONS: When limited quantities of mannitol are available, it should preferentially be given to patients at particularly high risk of nephrotoxicity.
24778426_11	139	153	nephrotoxicity	Disease	D007674
24778426_11	40	48	mannitol	Chemical	D008353

24778426_12|s|Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) cisplatin every 3 weeks and those with hypertension are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol.
24778426_12	126	138	hypertension	Disease	D006973
24778426_12	167	181	nephrotoxicity	Disease	D007674
24778426_12	87	96	cisplatin	Chemical	D002945
24778426_12	221	229	mannitol	Chemical	D008353

24802403_0|s|Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.
24802403_0	27	35	seizures	Disease	D012640
24802403_0	37	68	learning and memory impairments	Disease	D007859|D008569
24802403_0	0	9	Metformin	Chemical	D008687
24802403_0	101	119	pentylenetetrazole	Chemical	D010433
24802403_0	CID	D010433	D008569
24802403_0	CID	D010433	D007859
24802403_0	CID	D010433	D012640

24802403_6|s|This study was designed to evaluate the ameliorative effects of metformin on seizures, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.
24802403_6	77	85	seizures	Disease	D012640
24802403_6	87	107	cognitive impairment	Disease	D003072
24802403_6	64	73	metformin	Chemical	D008687
24802403_6	155	173	pentylenetetrazole	Chemical	D010433
24802403_6	CID	D010433	D003072
24802403_6	CID	D010433	D012640

24802403_9|s|We found that metformin suppressed the progression of kindling, ameliorated the cognitive impairment and decreased brain oxidative stress.
24802403_9	80	100	cognitive impairment	Disease	D003072
24802403_9	14	23	metformin	Chemical	D008687

24802403_10|s|Thus the present study concluded that metformin may be a potential agent for the treatment of epilepsy as well as a protective medicine against cognitive impairment induced by seizures.
24802403_10	94	102	epilepsy	Disease	D004827
24802403_10	144	164	cognitive impairment	Disease	D003072
24802403_10	176	184	seizures	Disease	D012640
24802403_10	38	47	metformin	Chemical	D008687

24812279_0|s|P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.
24812279_0	52	66	cardiotoxicity	Disease	D066126
24812279_0	38	51	anthracycline	Chemical	D018943

24812279_1|s|AIMS: Doxorubicin (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage cardiotoxicity.
24812279_1	45	51	cancer	Disease	D009369
24812279_1	114	128	cardiotoxicity	Disease	D066126
24812279_1	6	17	Doxorubicin	Chemical	D004317
24812279_1	19	22	DOX	Chemical	D004317

24812279_2|s|Children are particularly sensitive to DOX-induced heart failure.
24812279_2	51	64	heart failure	Disease	D006333
24812279_2	39	42	DOX	Chemical	D004317
24812279_2	CID	D004317	D006333

24812279_3|s|Here, the impact of p53 inhibition on acute vs. late-stage DOX cardiotoxicity was examined in a juvenile model.
24812279_3	63	77	cardiotoxicity	Disease	D066126
24812279_3	59	62	DOX	Chemical	D004317

24816962_0|s|Metronidazole-induced encephalopathy: an uncommon scenario.
24816962_0	22	36	encephalopathy	Disease	D001927
24816962_0	0	13	Metronidazole	Chemical	D008795
24816962_0	CID	D008795	D001927

24816962_2|s|We present a case where a patient developed features of encephalopathy following prolonged metronidazole intake.
24816962_2	56	70	encephalopathy	Disease	D001927
24816962_2	91	104	metronidazole	Chemical	D008795
24816962_2	CID	D008795	D001927

24816962_4|s|The diagnosis of metronidazole toxicity was made by the MRI findings and supported clinically.
24816962_4	31	39	toxicity	Disease	D064420
24816962_4	17	30	metronidazole	Chemical	D008795

24840785_0|s|Aconitine-induced Ca2+ overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats.
24840785_0	39	49	arrhythmia	Disease	D001145
24840785_0	0	9	Aconitine	Chemical	D000157
24840785_0	18	20	Ca	Chemical	D002118
24840785_0	CID	D000157	D001145

24840785_2|s|Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the cardiotoxicity of aconitine.
24840785_2	92	106	cardiotoxicity	Disease	D066126
24840785_2	51	53	Na	Chemical	D012964
24840785_2	110	119	aconitine	Chemical	D000157
24840785_2	CID	D000157	D066126

24840785_3|s|However, no reports are available on the role of Ca(2+) in aconitine poisoning.
24840785_3	69	78	poisoning	Disease	D011041
24840785_3	49	51	Ca	Chemical	D002118
24840785_3	59	68	aconitine	Chemical	D000157
24840785_3	CID	D000157	D011041

24840785_4|s|In this study, we explored the importance of pathological Ca(2+) signaling in aconitine poisoning in vitro and in vivo.
24840785_4	88	97	poisoning	Disease	D011041
24840785_4	58	60	Ca	Chemical	D002118
24840785_4	78	87	aconitine	Chemical	D000157
24840785_4	CID	D000157	D011041

24840785_5|s|We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats.
24840785_5	110	120	arrhythmia	Disease	D001145
24840785_5	14	16	Ca	Chemical	D002118

24840785_6|s|To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.
24840785_6	39	56	myocardial injury	Disease	D009202
24840785_6	71	83	cytotoxicity	Disease	D064420
24840785_6	26	35	aconitine	Chemical	D000157
24840785_6	156	163	lactate	Chemical	D019344

24840785_7|s|The results showed that aconitine resulted in myocardial injury and reduced NRVMs viability dose-dependently.
24840785_7	46	63	myocardial injury	Disease	D009202
24840785_7	24	33	aconitine	Chemical	D000157

24840785_13|s|Hence, our results suggest that aconitine significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.
24840785_13	94	104	arrhythmia	Disease	D001145
24840785_13	32	41	aconitine	Chemical	D000157
24840785_13	67	69	Ca	Chemical	D002118
24840785_13	CID	D000157	D001145

24842192_0|s|Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction.
24842192_0	90	118	left ventricular dysfunction	Disease	D018487
24842192_0	129	150	myocardial infarction	Disease	D009203
24842192_0	23	32	metformin	Chemical	D008687

24842192_1|s|Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).
24842192_1	58	79	myocardial infarction	Disease	D009203
24842192_1	21	30	metformin	Chemical	D008687
24842192_1	142	145	AMP	Chemical	D000667

24842192_2|s|In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.
24842192_2	76	95	cardiac dysfunction	Disease	D006331
24842192_2	149	170	myocardial infarction	Disease	D009203
24842192_2	63	72	metformin	Chemical	D008687

24842192_4|s|Isoproterenol (100mg/kg) was injected subcutaneously on the 13th and 14th days to induce acute myocardial infarction.
24842192_4	89	116	acute myocardial infarction	Disease	D009203
24842192_4	0	13	Isoproterenol	Chemical	D007545
24842192_4	CID	D007545	D009203

24842192_6|s|The left ventricular dysfunction was significantly lower in the groups treated with 25 and 50mg/kg of metformin.
24842192_6	4	32	left ventricular dysfunction	Disease	D018487
24842192_6	102	111	metformin	Chemical	D008687

24842192_7|s|Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.
24842192_7	131	136	tumor	Disease	D009369
24842192_7	137	145	necrosis	Disease	D009336
24842192_7	27	40	isoproterenol	Chemical	D007545

24842192_11|s|Chronic pre-treatment with metformin reduces post-myocardial infarction cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of TLR4 activities.
24842192_11	50	71	myocardial infarction	Disease	D009203
24842192_11	27	36	metformin	Chemical	D008687

24881749_0|s|Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.
24881749_0	0	30	Neuroleptic malignant syndrome	Disease	D009459
24881749_0	121	141	Huntington's disease	Disease	D006816
24881749_0	177	190	breast cancer	Disease	D001943
24881749_0	67	80	tetrabenazine	Chemical	D013747
24881749_0	85	93	tiapride	Chemical	D063325
24881749_0	CID	D013747	D009459
24881749_0	CID	D063325	D009459

24881749_1|s|We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease.
24881749_1	66	96	neuroleptic malignant syndrome	Disease	D009459
24881749_1	225	245	Huntington's disease	Disease	D006816
24881749_1	168	176	tiapride	Chemical	D063325
24881749_1	193	206	tetrabenazine	Chemical	D013747
24881749_1	CID	D013747	D009459
24881749_1	CID	D063325	D009459

24881749_4|s|To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported.
24881749_4	48	78	neuroleptic malignant syndrome	Disease	D009459
24881749_4	111	124	tetrabenazine	Chemical	D013747
24881749_4	129	137	tiapride	Chemical	D063325
24881749_4	CID	D013747	D009459
24881749_4	CID	D063325	D009459

24894748_0|s|A metoprolol-terbinafine combination induced bradycardia.
24894748_0	45	56	bradycardia	Disease	D001919
24894748_0	2	12	metoprolol	Chemical	D008790
24894748_0	13	24	terbinafine	Chemical	C041359
24894748_0	CID	D008790	D001919
24894748_0	CID	C041359	D001919

24894748_1|s|To report a sinus bradycardia induced by metoprolol and terbinafine drug-drug interaction and its management.
24894748_1	12	29	sinus bradycardia	Disease	D012804
24894748_1	41	51	metoprolol	Chemical	D008790
24894748_1	56	67	terbinafine	Chemical	C041359

24894748_2|s|A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis.
24894748_2	64	87	coronary artery disease	Disease	D003324
24894748_2	154	167	onychomycosis	Disease	D014009
24894748_2	31	41	metoprolol	Chemical	D008790
24894748_2	127	138	terbinafine	Chemical	C041359

24894748_3|s|On the 49th day of terbinafine therapy, he was brought to the emergency room for a decrease of his global health status, confusion and falls.
24894748_3	121	130	confusion	Disease	D003221
24894748_3	19	30	terbinafine	Chemical	C041359

24894748_5|s|A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine.
24894748_5	28	49	adverse drug reaction	Disease	D064420
24894748_5	124	141	sinus bradycardia	Disease	D012804
24894748_5	175	185	metoprolol	Chemical	D008790
24894748_5	190	201	terbinafine	Chemical	C041359

24894748_8|s|By inhibiting the cytochrome P450 2D6, terbinafine had decreased metoprolol's clearance, leading in metoprolol accumulation which has resulted in clinically significant sinus bradycardia.
24894748_8	169	186	sinus bradycardia	Disease	D012804
24894748_8	39	50	terbinafine	Chemical	C041359
24894748_8	65	75	metoprolol	Chemical	D008790
24894748_8	100	110	metoprolol	Chemical	D008790

24897009_0|s|Optochiasmatic and peripheral neuropathy due to ethambutol overtreatment.
24897009_0	19	40	peripheral neuropathy	Disease	D010523
24897009_0	48	58	ethambutol	Chemical	D004977

24897009_1|s|Ethambutol is known to cause optic neuropathy and, more rarely, axonal polyneuropathy.
24897009_1	29	45	optic neuropathy	Disease	D009901
24897009_1	71	85	polyneuropathy	Disease	D011115
24897009_1	0	10	Ethambutol	Chemical	D004977
24897009_1	CID	D004977	D011115
24897009_1	CID	D004977	D009901

24897009_2|s|We characterize the clinical, neurophysiological, and neuroimaging findings in a 72-year-old man who developed visual loss and paresthesias after 11 weeks of exposure to a supratherapeutic dose of ethambutol.
24897009_2	111	122	visual loss	Disease	D014786
24897009_2	127	139	paresthesias	Disease	D010292
24897009_2	197	207	ethambutol	Chemical	D004977
24897009_2	CID	D004977	D014786
24897009_2	CID	D004977	D010292

24897009_3|s|This case demonstrates the selective vulnerability of the anterior visual pathways and peripheral nerves to ethambutol toxicity.
24897009_3	119	127	toxicity	Disease	D064420
24897009_3	108	118	ethambutol	Chemical	D004977

24902786_0|s|Testosterone ameliorates streptozotocin-induced memory impairment in male rats.
24902786_0	48	65	memory impairment	Disease	D008569
24902786_0	0	12	Testosterone	Chemical	D013739
24902786_0	25	39	streptozotocin	Chemical	D013311
24902786_0	CID	D013311	D008569

24902786_1|s|AIM: To study the effects of testosterone on streptozotocin (STZ)-induced memory impairment in male rats.
24902786_1	74	91	memory impairment	Disease	D008569
24902786_1	29	41	testosterone	Chemical	D013739
24902786_1	45	59	streptozotocin	Chemical	D013311
24902786_1	61	64	STZ	Chemical	D013311
24902786_1	CID	D013311	D008569

24902786_7|s|Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.
24902786_7	66	85	impaired the memory	Disease	D008569
24902786_7	201	218	memory impairment	Disease	D008569
24902786_7	18	27	flutamide	Chemical	D005485
24902786_7	29	38	letrozole	Chemical	C067431
24902786_7	42	51	tamoxifen	Chemical	D013629
24902786_7	135	147	testosterone	Chemical	D013739
24902786_7	173	176	STZ	Chemical	D013311
24902786_7	CID	D013311	D008569
24902786_7	CID	D005485	D008569
24902786_7	CID	C067431	D008569
24902786_7	CID	D013629	D008569

24902786_8|s|CONCLUSION: Testosterone administration ameliorates STZ- and castration-induced memory impairment in male Wistar rats.
24902786_8	80	97	memory impairment	Disease	D008569
24902786_8	12	24	Testosterone	Chemical	D013739
24902786_8	52	55	STZ	Chemical	D013311
24902786_8	CID	D013311	D008569

24911645_0|s|Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.
24911645_0	104	112	seizures	Disease	D012640
24911645_0	61	80	garcinielliptone FC	Chemical	C573355
24911645_0	84	95	pilocarpine	Chemical	D010862
24911645_0	CID	D010862	D012640

24911645_4|s|The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
24911645_4	86	93	seizure	Disease	D012640
24911645_4	329	337	seizures	Disease	D012640
24911645_4	40	43	GFC	Chemical	C573355
24911645_4	167	177	amino acid	Chemical	D000596
24911645_4	179	198	r-aminobutyric acid	Chemical	D005680
24911645_4	200	204	GABA	Chemical	D005680
24911645_4	207	216	glutamine	Chemical	D018698
24911645_4	218	227	aspartate	Chemical	D001224
24911645_4	232	243	glutathione	Chemical	D005978

24911645_5|s|GFC produced an increased latency to first seizure, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice.
24911645_5	43	50	seizure	Disease	D012640
24911645_5	0	3	GFC	Chemical	C573355

24911645_9|s|The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.
24911645_9	128	146	status epilepticus	Disease	D013226
24911645_9	196	203	seizure	Disease	D012640
24911645_9	26	29	GFC	Chemical	C573355
24911645_9	108	119	pilocarpine	Chemical	D010862
24911645_9	CID	D010862	D012640
24911645_9	CID	D010862	D013226

24927617_0|s|Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.
24927617_0	0	14	Rhabdomyolysis	Disease	D012206
24927617_0	20	46	hepatitis C virus infected	Disease	D006526
24927617_0	68	78	telaprevir	Chemical	C486464
24927617_0	83	94	simvastatin	Chemical	D019821
24927617_0	CID	C486464	D012206
24927617_0	CID	D019821	D012206

24927617_1|s|A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.
24927617_1	33	60	hepatitis C virus infection	Disease	D006526
24927617_1	90	99	ribavirin	Chemical	D012254
24927617_1	101	121	pegylated interferon	Chemical	C417083
24927617_1	126	136	telaprevir	Chemical	C486464

24927617_4|s|At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.
24927617_4	75	83	toxicity	Disease	D064420
24927617_4	13	24	simvastatin	Chemical	D019821

24927617_10|s|Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.
24927617_10	87	102	muscle toxicity	Disease	D009135
24927617_10	0	11	Simvastatin	Chemical	D019821
24927617_10	72	78	statin	Chemical	D019821
24927617_10	142	148	statin	Chemical	D019821
24927617_10	CID	D019821	D009135

24928523_0|s|Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
24928523_0	150	166	multiple myeloma	Disease	D009101
24928523_0	15	25	bortezomib	Chemical	C400082
24928523_0	27	38	thalidomide	Chemical	D013792
24928523_0	44	57	dexamethasone	Chemical	D003907

24928523_2|s|In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed MM.
24928523_2	212	214	MM	Disease	D009101
24928523_2	93	103	bortezomib	Chemical	C400082
24928523_2	105	116	thalidomide	Chemical	D013792
24928523_2	122	135	dexamethasone	Chemical	D003907

24971338_0|s|Conversion to sirolimus ameliorates cyclosporine-induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.
24971338_0	57	68	nephropathy	Disease	D007674
24971338_0	14	23	sirolimus	Chemical	D020123
24971338_0	36	48	cyclosporine	Chemical	D016572
24971338_0	CID	D016572	D007674

24971338_1|s|Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.
24971338_1	152	163	nephropathy	Disease	D007674
24971338_1	29	42	cyclosporin A	Chemical	D016572
24971338_1	44	47	CsA	Chemical	D016572
24971338_1	52	61	sirolimus	Chemical	D020123
24971338_1	63	66	SRL	Chemical	D020123
24971338_1	140	143	CsA	Chemical	D016572
24971338_1	CID	D016572	D007674

24971338_5|s|Renal lesions were analyzed in hematoxylin and eosin, periodic acid-Schiff, and Masson's trichrome stains.
24971338_5	0	13	Renal lesions	Disease	D007674
24971338_5	31	42	hematoxylin	Chemical	D006416
24971338_5	47	52	eosin	Chemical	D004801

24971338_6|s|SRL-treated rats presented proteinuria and NGAL (serum and urinary) as the best markers of renal impairment.
24971338_6	27	38	proteinuria	Disease	D011507
24971338_6	91	107	renal impairment	Disease	D007674
24971338_6	0	3	SRL	Chemical	D020123
24971338_6	CID	D020123	D011507

24971338_7|s|Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.
24971338_7	52	66	kidney lesions	Disease	D007674
24971338_7	6	9	CsA	Chemical	D016572
24971338_7	CID	D016572	D007674

24971338_8|s|Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.
24971338_8	34	46	renal damage	Disease	D007674
24971338_8	10	13	CsA	Chemical	D016572
24971338_8	CID	D016572	D007674

24971338_9|s|Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.
24971338_9	40	52	renal damage	Disease	D007674
24971338_9	14	17	SRL	Chemical	D020123
24971338_9	28	31	CsA	Chemical	D016572
24971338_9	160	163	CsA	Chemical	D016572
24971338_9	179	182	SRL	Chemical	D020123
24971338_9	CID	D016572	D007674

24975837_0|s|Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.
24975837_0	70	88	acute renal injury	Disease	D058186
24975837_0	52	61	cisplatin	Chemical	D002945
24975837_0	CID	D002945	D058186

24975837_1|s|Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).
24975837_1	91	110	acute kidney injury	Disease	D058186
24975837_1	222	244	acute tubular necrosis	Disease	D007683
24975837_1	0	9	Cisplatin	Chemical	D002945
24975837_1	188	198	creatinine	Chemical	D003404
24975837_1	203	207	urea	Chemical	D014508
24975837_1	CID	D002945	D007683
24975837_1	CID	D002945	D058186

24975837_3|s|To examine the role of the kinin B2 receptor in cisplatin-induced acute kidney injury, kinin B2 receptor knockout mice were challenged with cisplatin.
24975837_3	66	85	acute kidney injury	Disease	D058186
24975837_3	48	57	cisplatin	Chemical	D002945
24975837_3	140	149	cisplatin	Chemical	D002945
24975837_3	CID	D002945	D058186

24975837_7|s|Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the necrotic process and the expression of inflammatory cytokines, thus resulting in declined renal function.
24975837_7	83	102	acute kidney injury	Disease	D058186
24975837_7	120	128	necrotic	Disease	D009336
24975837_7	65	74	cisplatin	Chemical	D002945
24975837_7	CID	D002945	D058186

24975837_8|s|These results highlight the kinin B2 receptor antagonist treatment in amelioration of nephrotoxicity induced by cisplatin therapy.
24975837_8	86	100	nephrotoxicity	Disease	D007674
24975837_8	112	121	cisplatin	Chemical	D002945

24999722_0|s|Safety and efficacy of fluocinolone acetonide intravitreal implant (0.59 mg) in birdshot retinochoroidopathy.
24999722_0	80	108	birdshot retinochoroidopathy	Disease	C537630
24999722_0	23	45	fluocinolone acetonide	Chemical	D005446

24999722_1|s|PURPOSE: To report the treatment outcomes of the fluocinolone acetonide intravitreal implant (0.59 mg) in patients with birdshot retinochoroidopathy whose disease is refractory or intolerant to conventional immunomodulatory therapy.
24999722_1	120	148	birdshot retinochoroidopathy	Disease	C537630
24999722_1	49	71	fluocinolone acetonide	Chemical	D005446

24999722_13|s|CONCLUSION: The data suggest that fluocinolone acetonide implant (0.59 mg) helps to control inflammation in otherwise treatment-refractory cases of birdshot retinochoroidopathy.
24999722_13	92	104	inflammation	Disease	D007249
24999722_13	148	176	birdshot retinochoroidopathy	Disease	C537630
24999722_13	34	56	fluocinolone acetonide	Chemical	D005446

25006369_0|s|Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration.
25006369_0	53	66	fasciculation	Disease	D005207
25006369_0	71	78	myalgia	Disease	D063806
25006369_0	30	40	rocuronium	Chemical	C061870
25006369_0	89	104	succinylcholine	Chemical	D013390
25006369_0	CID	D013390	D005207
25006369_0	CID	D013390	D063806

25006369_1|s|BACKGROUND: Succinylcholine commonly produces frequent adverse effects, including muscle fasciculation and myalgia.
25006369_1	82	102	muscle fasciculation	Disease	D005207
25006369_1	107	114	myalgia	Disease	D063806
25006369_1	12	27	Succinylcholine	Chemical	D013390
25006369_1	CID	D013390	D005207
25006369_1	CID	D013390	D063806

25006369_2|s|The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.
25006369_2	95	108	fasciculation	Disease	D005207
25006369_2	113	120	myalgia	Disease	D063806
25006369_2	49	59	rocuronium	Chemical	C061870
25006369_2	71	86	succinylcholine	Chemical	D013390
25006369_2	152	162	rocuronium	Chemical	C061870
25006369_2	197	212	succinylcholine	Chemical	D013390
25006369_2	CID	D013390	D005207
25006369_2	CID	D013390	D063806

25006369_6|s|All patients received succinylcholine 1.5 mg/kg at 2 minutes after the precurarization, and were assessed the incidence and severity of fasciculations, while myalgia was assessed at 24 hours after surgery.
25006369_6	136	150	fasciculations	Disease	D005207
25006369_6	158	165	myalgia	Disease	D063806
25006369_6	22	37	succinylcholine	Chemical	D013390
25006369_6	CID	D013390	D005207
25006369_6	CID	D013390	D063806

25006369_7|s|RESULTS: The incidence and severity of visible muscle fasciculation was significantly less with increasing the amount of precurarizing dose of rocuronium (P < 0.001).
25006369_7	47	67	muscle fasciculation	Disease	D005207
25006369_7	143	153	rocuronium	Chemical	C061870

25006369_8|s|Those of myalgia tend to decrease according to increasing the amount of precurarizing dose of rocuronium, but there was no significance (P = 0.072).
25006369_8	9	16	myalgia	Disease	D063806
25006369_8	94	104	rocuronium	Chemical	C061870

25006369_10|s|CONCLUSIONS: Precurarization with 0.04 mg/kg rocuronium was the optimal dose considering the reduction in the incidence and severity of fasciculation and myalgia with acceptable onset time, and the safe and effective precurarization.
25006369_10	136	149	fasciculation	Disease	D005207
25006369_10	154	161	myalgia	Disease	D063806
25006369_10	45	55	rocuronium	Chemical	C061870

25006961_0|s|Absence of PKC-alpha attenuates lithium-induced nephrogenic diabetes insipidus.
25006961_0	48	78	nephrogenic diabetes insipidus	Disease	D018500
25006961_0	32	39	lithium	Chemical	D008094
25006961_0	CID	D008094	D018500

25006961_1|s|Lithium, an effective antipsychotic, induces nephrogenic diabetes insipidus (NDI) in  40% of patients.
25006961_1	45	75	nephrogenic diabetes insipidus	Disease	D018500
25006961_1	77	80	NDI	Disease	D018500
25006961_1	0	7	Lithium	Chemical	D008094
25006961_1	CID	D008094	D018500

25006961_3|s|Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating lithium-induced polyuria.
25006961_3	131	139	polyuria	Disease	D011141
25006961_3	115	122	lithium	Chemical	D008094
25006961_3	CID	D008094	D011141

25006961_12|s|Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with lithium therapy.
25006961_12	116	119	NDI	Disease	D018500
25006961_12	164	172	polyuria	Disease	D011141
25006961_12	100	107	lithium	Chemical	D008094
25006961_12	189	196	lithium	Chemical	D008094
25006961_12	CID	D008094	D011141
25006961_12	CID	D008094	D018500

25031906_0|s|Is Dysguesia Going to be a Rare or a Common Side-effect of Amlodipine?
25031906_0	3	12	Dysguesia	Disease	D004408
25031906_0	59	69	Amlodipine	Chemical	D017311
25031906_0	CID	D017311	D004408

25031906_1|s|A very rare side-effect of amlodipine is dysguesia.
25031906_1	41	50	dysguesia	Disease	D004408
25031906_1	27	37	amlodipine	Chemical	D017311
25031906_1	CID	D017311	D004408

25031906_3|s|We report a case about a female with essential hypertension on drug treatment with amlodipine developed loss of taste sensation.
25031906_3	47	59	hypertension	Disease	D006973
25031906_3	104	127	loss of taste sensation	Disease	D012678
25031906_3	83	93	amlodipine	Chemical	D017311

25031906_5|s|We conclude that amlodipine can cause dysguesia.
25031906_5	38	47	dysguesia	Disease	D004408
25031906_5	17	27	amlodipine	Chemical	D017311
25031906_5	CID	D017311	D004408

25031906_6|s|Here, we describe the clinical presentation and review the relevant literature on amlodipine and dysguesia.
25031906_6	97	106	dysguesia	Disease	D004408
25031906_6	82	92	amlodipine	Chemical	D017311
25031906_6	CID	D017311	D004408

25041770_0|s|Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.
25041770_0	0	14	Rhabdomyolysis	Disease	D012206
25041770_0	35	46	simvastatin	Chemical	D019821
25041770_0	71	85	clarithromycin	Chemical	D017291
25041770_0	CID	D017291	D012206
25041770_0	CID	D019821	D012206

25041770_2|s|This particular case is of interest as rhabdomyolysis only occurred after an increase in the dose of clarithromycin.
25041770_2	39	53	rhabdomyolysis	Disease	D012206
25041770_2	101	115	clarithromycin	Chemical	D017291
25041770_2	CID	D017291	D012206

25041770_6|s|Our case suggests that troponin elevation could be associated with statin induced rhabdomyolysis, which may warrant further studies.
25041770_6	82	96	rhabdomyolysis	Disease	D012206
25041770_6	67	73	statin	Chemical	D019821
25041770_6	CID	D019821	D012206

25054547_0|s|Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.
25054547_0	117	122	apnea	Disease	D001049
25054547_0	128	141	suxamethonium	Chemical	D013390
25054547_0	CID	D013390	D001049

25054547_1|s|Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.
25054547_1	0	32	Butyrylcholinesterase deficiency	Disease	C537417
25054547_1	63	68	apnea	Disease	D001049
25054547_1	104	117	suxamethonium	Chemical	D013390
25054547_1	121	131	mivacurium	Chemical	C049430
25054547_1	CID	C049430	D001049
25054547_1	CID	D013390	D001049
25054547_1	CID	C049430	C537417
25054547_1	CID	D013390	C537417

25071004_0|s|Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo: a manageable issue.
25071004_0	8	14	anemia	Disease	D000740
25071004_0	47	57	artesunate	Chemical	C039726

25071004_1|s|Cases of delayed hemolytic anemia have been described after treatment with injectable artesunate, the current World Health Organization (WHO)-recommended first-line drug for the treatment of severe malaria.
25071004_1	17	33	hemolytic anemia	Disease	D000743
25071004_1	198	205	malaria	Disease	D008288
25071004_1	86	96	artesunate	Chemical	C039726
25071004_1	CID	C039726	D000743

25071004_2|s|A total of 350 patients (215 [61.4%] < 5 years of age and 135 [38.6%] > 5 years of age) were followed-up after treatment with injectable artesunate for severe malaria in hospitals and health centers of the Democratic Republic of the Congo.
25071004_2	159	166	malaria	Disease	D008288
25071004_2	137	147	artesunate	Chemical	C039726

25080425_0|s|Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats.
25080425_0	138	155	myocardial injury	Disease	D009202
25080425_0	91	98	betaine	Chemical	D001622
25080425_0	110	123	isoproterenol	Chemical	D007545

25080425_1|s|The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.
25080425_1	95	114	myocardial ischemia	Disease	D017202
25080425_1	78	85	betaine	Chemical	D001622

25080425_3|s|Acute myocardial ischemic injury was induced in rats by subcutaneous injection of isoproterenol (85 mg/kg), for two consecutive days.
25080425_3	6	32	myocardial ischemic injury	Disease	D017202
25080425_3	82	95	isoproterenol	Chemical	D007545
25080425_3	CID	D007545	D017202

25080425_5|s|Oral administration of betaine (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ventricular remodeling.
25080425_5	140	162	ventricular remodeling	Disease	D020257
25080425_5	23	30	betaine	Chemical	D001622

25080425_8|s|The protective role of betaine on myocardial damage was further confirmed by histopathological examination.
25080425_8	34	51	myocardial damage	Disease	D009202
25080425_8	23	30	betaine	Chemical	D001622

25080425_9|s|In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.
25080425_9	96	115	myocardial ischemia	Disease	D017202
25080425_9	36	43	betaine	Chemical	D001622
25080425_9	68	81	isoproterenol	Chemical	D007545
25080425_9	CID	D007545	D017202

25084821_0|s|Quetiapine-induced neutropenia in a bipolar patient with hepatocellular carcinoma.
25084821_0	19	30	neutropenia	Disease	D009503
25084821_0	36	43	bipolar	Disease	D001714
25084821_0	57	81	hepatocellular carcinoma	Disease	D006528
25084821_0	0	10	Quetiapine	Chemical	C069541
25084821_0	CID	C069541	D009503

25084821_1|s|OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia.
25084821_1	117	133	blood dyscrasias	Disease	D006402
25084821_1	146	157	neutropenia	Disease	D009503
25084821_1	11	21	Quetiapine	Chemical	C069541
25084821_1	68	77	clozapine	Chemical	D003024
25084821_1	CID	C069541	D009503

25084821_3|s|A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here.
25084821_3	25	49	hepatocellular carcinoma	Disease	D006528
25084821_3	65	76	neutropenia	Disease	D009503
25084821_3	98	108	quetiapine	Chemical	C069541
25084821_3	CID	C069541	D009503

25084821_5|s|She developed leucopenia after being treated with quetiapine.
25084821_5	14	24	leucopenia	Disease	D007970
25084821_5	50	60	quetiapine	Chemical	C069541
25084821_5	CID	C069541	D007970

25084821_7|s|CONCLUSIONS: Although neutropenia is not a common side effect of quetiapine, physicians should be cautious about its presentation and associated risk factors.
25084821_7	22	33	neutropenia	Disease	D009503
25084821_7	65	75	quetiapine	Chemical	C069541
25084821_7	CID	C069541	D009503

25084821_8|s|Hepatic dysfunction may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine.
25084821_8	0	19	Hepatic dysfunction	Disease	D008107
25084821_8	77	82	fever	Disease	D005334
25084821_8	134	144	quetiapine	Chemical	C069541
25084821_8	CID	C069541	D005334

25096313_0|s|Lateral antebrachial cutaneous neuropathy after steroid injection at lateral epicondyle.
25096313_0	31	41	neuropathy	Disease	D009422
25096313_0	48	55	steroid	Chemical	D013256

25096313_1|s|BACKGROUND AND OBJECTIVES: This report aimed to present a case of lateral antebrachial cutaneous neuropathy (LACNP) that occurred after a steroid injection in the lateral epicondyle to treat lateral epicondylitis in a 40-year-old woman.
25096313_1	97	107	neuropathy	Disease	D009422
25096313_1	191	212	lateral epicondylitis	Disease	D013716
25096313_1	138	145	steroid	Chemical	D013256

25096313_2|s|MATERIAL AND METHOD: A 40-year-old woman presented with decreased sensation and paresthesia over her right lateral forearm; the paresthesia had occurred after a steroid injection in the right lateral epicondyle 3 months before.
25096313_2	80	91	paresthesia	Disease	D010292
25096313_2	128	139	paresthesia	Disease	D010292
25096313_2	161	168	steroid	Chemical	D013256
25096313_2	CID	D013256	D010292

25096313_8|s|CONCLUSION: This report describes the case of a woman with LACNP that developed after a steroid injection for the treatment of lateral epicondylitis.
25096313_8	127	148	lateral epicondylitis	Disease	D013716
25096313_8	88	95	steroid	Chemical	D013256

25119790_0|s|Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.
25119790_0	34	48	nephrotoxicity	Disease	D007674
25119790_0	0	8	Curcumin	Chemical	D003474
25119790_0	18	25	maleate	Chemical	C030272
25119790_0	119	125	oxygen	Chemical	D010100
25119790_0	CID	C030272	D007674

25119790_1|s|The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.
25119790_1	107	119	renal injury	Disease	D007674
25119790_1	59	67	curcumin	Chemical	D003474
25119790_1	131	138	maleate	Chemical	C030272
25119790_1	CID	C030272	D007674

25119790_2|s|Tubular proteinuria and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats.
25119790_2	8	19	proteinuria	Disease	D011507
25119790_2	79	86	maleate	Chemical	C030272
25119790_2	CID	C030272	D011507

25119790_3|s|Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h.
25119790_3	16	28	renal injury	Disease	D007674
25119790_3	246	259	kidney injury	Disease	D007674
25119790_3	343	351	necrosis	Disease	D009336
25119790_3	0	7	Maleate	Chemical	C030272
25119790_3	123	130	glucose	Chemical	D005947
25119790_3	132	138	sodium	Chemical	D012964
25119790_3	CID	C030272	D009336
25119790_3	CID	C030272	D007674

25119790_10|s|It is concluded that curcumin is able to attenuate in vivo maleate-induced nephropathy and in vitro cell damage.
25119790_10	75	86	nephropathy	Disease	D007674
25119790_10	21	29	curcumin	Chemical	D003474
25119790_10	59	66	maleate	Chemical	C030272
25119790_10	CID	C030272	D007674

25907210_0|s|Incidence of solid tumours among pesticide applicators exposed to the organophosphate insecticide diazinon in the Agricultural Health Study: an updated analysis.
25907210_0	19	26	tumours	Disease	D009369
25907210_0	70	85	organophosphate	Chemical	D010755
25907210_0	98	106	diazinon	Chemical	D003976

25907210_1|s|OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.
25907210_1	116	127	lung cancer	Disease	D008175
25907210_1	247	253	cancer	Disease	D009369
25907210_1	11	19	Diazinon	Chemical	D003976
25907210_1	30	45	organophosphate	Chemical	D010755
25907210_1	227	235	diazinon	Chemical	D003976
25907210_1	CID	D003976	D008175

25907210_2|s|We used updated diazinon exposure and cancer incidence information to evaluate solid tumour risk in the AHS.
25907210_2	38	44	cancer	Disease	D009369
25907210_2	85	91	tumour	Disease	D009369
25907210_2	16	24	diazinon	Chemical	D003976

25907210_3|s|METHODS: Male pesticide applicators in Iowa and North Carolina reported lifetime diazinon use at enrolment (1993-1997) and follow-up (1998-2005); cancer incidence was assessed through 2010(North Carolina)/2011(Iowa).
25907210_3	146	152	cancer	Disease	D009369
25907210_3	81	89	diazinon	Chemical	D003976

25907210_5|s|RESULTS: We observed elevated lung cancer risks (N=283) among applicators with the greatest number of LT (RR=1.60; 95% CI 1.11 to 2.31; Ptrend=0.02) and IW days of diazinon use (RR=1.41; 95% CI 0.98 to 2.04; Ptrend=0.08).
25907210_5	30	41	lung cancer	Disease	D008175
25907210_5	164	172	diazinon	Chemical	D003976
25907210_5	CID	D003976	D008175

25907210_7|s|CONCLUSIONS: Our updated evaluation of diazinon provides additional evidence of an association with lung cancer risk.
25907210_7	100	111	lung cancer	Disease	D008175
25907210_7	39	47	diazinon	Chemical	D003976
25907210_7	CID	D003976	D008175

25951420_0|s|Associations of Ozone and PM2.5 Concentrations With Parkinson's Disease Among Participants in the Agricultural Health Study.
25951420_0	52	71	Parkinson's Disease	Disease	D010300
25951420_0	16	21	Ozone	Chemical	D010126
25951420_0	CID	D010126	D010300

25951420_1|s|OBJECTIVE: This study describes associations of ozone and fine particulate matter with Parkinson's disease observed among farmers in North Carolina and Iowa.
25951420_1	87	106	Parkinson's disease	Disease	D010300
25951420_1	48	53	ozone	Chemical	D010126
25951420_1	63	81	particulate matter	Chemical	D052638
25951420_1	CID	D052638	D010300
25951420_1	CID	D010126	D010300

25951420_4|s|RESULTS: We observed positive associations of Parkinson's disease with ozone (odds ratio = 1.39; 95% CI: 0.98 to 1.98) and fine particulate matter (odds ratio = 1.34; 95% CI: 0.93 to 1.93) in North Carolina but not in Iowa.
25951420_4	46	65	Parkinson's disease	Disease	D010300
25951420_4	71	76	ozone	Chemical	D010126
25951420_4	128	146	particulate matter	Chemical	D052638
25951420_4	CID	D052638	D010300
25951420_4	CID	D010126	D010300

25986755_0|s|Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure.
25986755_0	78	96	glomerulosclerosis	Disease	D005921
25986755_0	136	144	caffeine	Chemical	D002110

25986755_1|s|UNASSIGNED: Our previous study has indicated that prenatal caffeine exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring.
25986755_1	96	127	intrauterine growth retardation	Disease	D005317
25986755_1	129	133	IUGR	Disease	D005317
25986755_1	59	67	caffeine	Chemical	D002110
25986755_1	CID	D002110	D005317

25986755_6|s|The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein.
25986755_6	81	99	glomerulosclerosis	Disease	D005921
25986755_6	111	132	interstitial fibrosis	Disease	D005355
25986755_6	174	184	creatinine	Chemical	D003404

26002693_0|s|1,3-Butadiene, CML and the t(9:22) translocation: A reality check.
26002693_0	15	18	CML	Disease	D015464
26002693_0	0	13	1,3-Butadiene	Chemical	C031763

26002693_1|s|UNASSIGNED: Epidemiological studies of 1,3-butadiene have suggest that exposures to humans are associated with chronic myeloid leukemia (CML).
26002693_1	111	135	chronic myeloid leukemia	Disease	D015464
26002693_1	137	140	CML	Disease	D015464
26002693_1	39	52	1,3-butadiene	Chemical	C031763

26033014_0|s|Cancer incidence and metolachlor use in the Agricultural Health Study: An update.
26033014_0	0	6	Cancer	Disease	D009369
26033014_0	21	32	metolachlor	Chemical	C051786

26033014_5|s|We evaluated cancer incidence through 2010/2011 (NC/IA) for 49,616 applicators, 53% of whom reported ever using metolachlor.
26033014_5	13	19	cancer	Disease	D009369
26033014_5	112	123	metolachlor	Chemical	C051786

26033014_6|s|We used Poisson regression to evaluate relations between two metrics of metolachlor use (lifetime days, intensity-weighted lifetime days) and cancer incidence.
26033014_6	142	148	cancer	Disease	D009369
26033014_6	72	83	metolachlor	Chemical	C051786

26033014_7|s|We saw no association between metolachlor use and incidence of all cancers combined (n = 5,701 with a 5-year lag) or most site-specific cancers.
26033014_7	67	74	cancers	Disease	D009369
26033014_7	136	143	cancers	Disease	D009369
26033014_7	30	41	metolachlor	Chemical	C051786

26033014_11|s|An earlier suggestion of increased lung cancer risk at high levels of metolachlor use in this cohort was not confirmed in this update.
26033014_11	35	46	lung cancer	Disease	D008175
26033014_11	70	81	metolachlor	Chemical	C051786

26033014_12|s|This suggestion of an association between metolachlor and liver cancer among pesticide applicators is a novel finding and echoes observation of increased liver neoplasms in some animal studies.
26033014_12	58	70	liver cancer	Disease	D008113
26033014_12	154	169	liver neoplasms	Disease	D008113
26033014_12	42	53	metolachlor	Chemical	C051786
26033014_12	CID	C051786	D008113

26033014_13|s|However, our findings for both liver cancer and follicular cell lymphoma warrant follow-up to better differentiate effects of metolachlor use from other factors.
26033014_13	31	43	liver cancer	Disease	D008113
26033014_13	64	72	lymphoma	Disease	D008223
26033014_13	126	137	metolachlor	Chemical	C051786
26033014_13	CID	C051786	D008113

26115410_3|s|There is considerable interest in identifying the molecular mechanisms that relate early-life iAs exposure to the development of these latent diseases, particularly in relationship to cancer.
26115410_3	184	190	cancer	Disease	D009369
26115410_3	94	97	iAs	Chemical	D001152
26115410_3	CID	D001152	D009369

26115410_4|s|OBJECTIVES: This work summarizes research on the molecular mechanisms that underlie the increased risk of cancer development in adulthood that is associated with early-life iAs exposure.
26115410_4	106	112	cancer	Disease	D009369
26115410_4	173	176	iAs	Chemical	D001152
26115410_4	CID	D001152	D009369

26115410_5|s|DISCUSSION: Epigenetic reprogramming that imparts functional changes in gene expression, the development of cancer stem cells, and immunomodulation are plausible underlying mechanisms by which early-life iAs exposure elicits latent carcinogenic effects.
26115410_5	108	114	cancer	Disease	D009369
26115410_5	204	207	iAs	Chemical	D001152
26115410_5	CID	D001152	D009369

26115410_6|s|CONCLUSIONS: Evidence is mounting that relates early-life iAs exposure and cancer development later in life.
26115410_6	75	81	cancer	Disease	D009369
26115410_6	58	61	iAs	Chemical	D001152
26115410_6	CID	D001152	D009369

44072_2|s|Four types of experimental arrhythmia are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine.
44072_2	27	37	arrhythmia	Disease	D001145
44072_2	53	58	BaCl2	Chemical	C024986
44072_2	65	75	chloroform	Chemical	D002725
44072_2	76	86	adrenaline	Chemical	D004837
44072_2	93	107	strophantine G	Chemical	D010042
44072_2	117	126	aconitine	Chemical	D000157
44072_2	CID	D002725	D001145
44072_2	CID	C024986	D001145
44072_2	CID	D000157	D001145
44072_2	CID	D004837	D001145
44072_2	CID	D010042	D001145

44072_4|s|The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the arrhythmia induced by chloroform-adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent).
44072_4	77	87	arrhythmia	Disease	D001145
44072_4	129	139	arrhythmia	Disease	D001145
44072_4	151	161	chloroform	Chemical	D002725
44072_4	162	172	adrenaline	Chemical	D004837
44072_4	199	204	BaCl2	Chemical	C024986
44072_4	CID	D002725	D001145
44072_4	CID	C024986	D001145
44072_4	CID	D004837	D001145

753803_3|s|Myopathy due to lack of vitamin E and myopathy induced by certain viruses have much in common anatomically and pathologically with the human form.
753803_3	0	8	Myopathy	Disease	D009135
753803_3	38	46	myopathy	Disease	D009135
753803_3	24	33	vitamin E	Chemical	D014810

753803_4|s|The authors induced myodystrophy in the rat by giving it a diet lacking in vitamin E.
753803_4	20	32	myodystrophy	Disease	D009136
753803_4	75	84	vitamin E	Chemical	D014810
753803_4	CID	D014810	D009136

753803_7|s|The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.
753803_7	73	82	myopathic	Disease	D009135
753803_7	261	270	myopathic	Disease	D009135
753803_7	113	121	steroids	Chemical	D013256
753803_7	214	222	Dianabol	Chemical	D008696
753803_7	224	228	CIBA	Chemical	-1
753803_7	294	303	vitamin E	Chemical	D014810

753803_9|s|The authors conclude by affirming the undoubted efficacy of the anabolizing steroids in experimental myopathic disease, but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the tissue injury too often occurs at an irreversible stage vis-a-vis the "regeneration" of the muscle tissue; and finally because the dystrophic injurious agent is certainly not the lack of vitamin E but something as yet unknown.
753803_9	101	118	myopathic disease	Disease	D009135
753803_9	76	84	steroids	Chemical	D013256
753803_9	503	512	vitamin E	Chemical	D014810

920167_5|s|The baby showed warfarin-induced embryopathy with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata).
920167_5	33	44	embryopathy	Disease	D005315
920167_5	50	66	nasal hypoplasia	Disease	-1
920167_5	71	89	stippled epiphyses	Disease	D002806
920167_5	91	116	chondrodysplasia punctata	Disease	D002806
920167_5	16	24	warfarin	Chemical	D014859
920167_5	CID	D014859	D002806

920167_6|s|Nasal hypoplasia with or without stippled epiphyses has now been reported in 11 infants born to mothers treated with warfarin during the first trimester, and a causal association is probable.
920167_6	0	16	Nasal hypoplasia	Disease	-1
920167_6	33	51	stippled epiphyses	Disease	D002806
920167_6	117	125	warfarin	Chemical	D014859
920167_6	CID	D014859	D002806

1451544_0|s|Isradipine treatment for hypertension in general practice in Hong Kong.
1451544_0	25	37	hypertension	Disease	D006973
1451544_0	0	10	Isradipine	Chemical	D017275

1451544_1|s|A 6-week open study of the introduction of isradipine treatment was conducted in general practice in Hong Kong. 303 Chinese patients with mild to moderate hypertension entered the study.
1451544_1	155	167	hypertension	Disease	D006973
1451544_1	43	53	isradipine	Chemical	D017275

1451544_3|s|The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with isradipine or with placebo.
1451544_3	27	35	headache	Disease	D006261
1451544_3	37	46	dizziness	Disease	D004244
1451544_3	48	59	palpitation	Disease	-1
1451544_3	64	72	flushing	Disease	D005483
1451544_3	142	152	isradipine	Chemical	D017275
1451544_3	CID	D017275	D006261
1451544_3	CID	D017275	D004244
1451544_3	CID	D017275	D005483

2782734_0|s|Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics.
2782734_0	116	126	asthmatics	Disease	D001249
2782734_0	102	112	salbutamol	Chemical	D000420

2782734_1|s|High doses of inhaled salbutamol produce substantial improvements in airway response in patients with asthma, and are associated with dose-dependent systemic beta-adrenoceptor responses.
2782734_1	102	108	asthma	Disease	D001249
2782734_1	22	32	salbutamol	Chemical	D000420

2782734_3|s|Twelve asthmatic patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled salbutamol (HDS), 4,000 micrograms daily, low dose inhaled salbutamol (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design.
2782734_3	7	16	asthmatic	Disease	D001249
2782734_3	179	189	salbutamol	Chemical	D000420
2782734_3	238	248	salbutamol	Chemical	D000420

2782734_5|s|At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms).
2782734_5	127	133	tremor	Disease	D014202
2782734_5	150	151	K	Chemical	D011188
2782734_5	153	156	Glu	Chemical	D005947

2983630_0|s|Increased anxiogenic effects of caffeine in panic disorders.
2983630_0	44	59	panic disorders	Disease	D016584
2983630_0	32	40	caffeine	Chemical	D002110

2983630_1|s|The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.
2983630_1	277	288	agoraphobia	Disease	D000379
2983630_1	294	307	panic attacks	Disease	D016584
2983630_1	311	325	panic disorder	Disease	D016584
2983630_1	38	46	caffeine	Chemical	D002110
2983630_1	135	172	3-methoxy-4-hydroxyphenethyleneglycol	Chemical	D008734
2983630_1	174	178	MHPG	Chemical	D008734
2983630_1	184	192	cortisol	Chemical	D006854

2983630_2|s|Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects.
2983630_2	67	74	anxiety	Disease	D001008
2983630_2	95	101	nausea	Disease	D009325
2983630_2	103	115	palpitations	Disease	-1
2983630_2	117	129	restlessness	Disease	D011595
2983630_2	135	142	tremors	Disease	D014202
2983630_2	0	8	Caffeine	Chemical	D002110
2983630_2	CID	D002110	D014202
2983630_2	CID	D002110	D009325
2983630_2	CID	D002110	D001008

2983630_4|s|Seventy-one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks.
2983630_4	126	139	panic attacks	Disease	D016584
2983630_4	76	84	caffeine	Chemical	D002110

2983630_7|s|Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine.
2983630_7	86	100	panic disorder	Disease	D016584
2983630_7	119	152	abnormalities in neuronal systems	Disease	D009421
2983630_7	8	16	caffeine	Chemical	D002110
2983630_7	23	32	adenosine	Chemical	D000241
2983630_7	163	172	adenosine	Chemical	D000241

2983630_8|s|Patients with anxiety disorders may benefit by avoiding caffeine-containing foods and beverages.
2983630_8	14	31	anxiety disorders	Disease	D001008
2983630_8	56	64	caffeine	Chemical	D002110
2983630_8	CID	D002110	D001008

3711722_3|s|In the first, cobalt cardiomyopathy was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0.05).
3711722_3	21	35	cardiomyopathy	Disease	D009202
3711722_3	14	20	cobalt	Chemical	D003035
3711722_3	CID	D003035	D009202

3711722_4|s|In six dogs with doxorubicin-induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05).
3711722_4	37	50	heart failure	Disease	D006333
3711722_4	17	28	doxorubicin	Chemical	D004317
3711722_4	CID	D004317	D006333

6728873_3|s|Five phenotypic characteristics--locomotor activity, righting ability, clonic seizure induction, stress-induced lethality, death without external stress--were scored at various caffeine doses in drug-naive animals under empirically optimized, rigidly constant experimental conditions.
6728873_3	71	85	clonic seizure	Disease	D012640
6728873_3	177	185	caffeine	Chemical	D002110
6728873_3	CID	D002110	D012640

6728873_11|s|These results indicate that behavioral toxicity testing of alkylxanthines in a single mouse strain may be misleading and suggest that toxic responses of the central nervous system to this class of compounds are genetically influenced in mammals.
6728873_11	39	47	toxicity	Disease	D064420
6728873_11	59	73	alkylxanthines	Chemical	-1

7248895_0|s|Invasive carcinoma of the renal pelvis following cyclophosphamide therapy for nonmalignant disease.
7248895_0	9	38	carcinoma of the renal pelvis	Disease	D010386
7248895_0	49	65	cyclophosphamide	Chemical	D003520

7248895_1|s|A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis.
7248895_1	31	52	hydroureteronephrosis	Disease	D006869
7248895_1	106	115	hematuria	Disease	D006417
7248895_1	177	196	cerebral vasculitis	Disease	D020293
7248895_1	156	172	cyclophosphamide	Chemical	D003520
7248895_1	CID	D003520	D006417

7248895_4|s|Although the ability of cyclophosphamide to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract.
7248895_4	50	70	hemorrhagic cystitis	Disease	D006470|D003556
7248895_4	139	148	carcinoma	Disease	D002277
7248895_4	226	256	carcinoma of the urinary tract	Disease	D014571
7248895_4	24	40	cyclophosphamide	Chemical	D003520
7248895_4	CID	D003520	D002277

7248895_6|s|The present case is the first carcinoma of the renal pelvis reported in association with cyclophosphamide treatment.
7248895_6	30	59	carcinoma of the renal pelvis	Disease	D010386
7248895_6	89	105	cyclophosphamide	Chemical	D003520

7248895_7|s|It is the third urinary tract cancer reported in association with cyclophosphamide treatment for nonmalignant disease.
7248895_7	16	36	urinary tract cancer	Disease	D014571
7248895_7	66	82	cyclophosphamide	Chemical	D003520

7248895_8|s|The association of the tumor with preexisting hydroureteronephrosis suggests that stasis prolonged and intensified exposure of upper urinary tract epithelium to cyclophosphamide.
7248895_8	23	28	tumor	Disease	D009369
7248895_8	46	67	hydroureteronephrosis	Disease	D006869
7248895_8	161	177	cyclophosphamide	Chemical	D003520

7248895_9|s|Patients who are candidates for long-term cyclophosphamide treatment should be routinely evaluated for obstructive uropathy.
7248895_9	103	123	obstructive uropathy	Disease	-1
7248895_9	42	58	cyclophosphamide	Chemical	D003520

11423811_0|s|A pilot study to assess the safety of dobutamine stress echocardiography in the emergency department evaluation of cocaine-associated chest pain.
11423811_0	134	144	chest pain	Disease	D002637
11423811_0	38	48	dobutamine	Chemical	D004280
11423811_0	115	122	cocaine	Chemical	D003042
11423811_0	CID	D003042	D002637

11423811_1|s|STUDY OBJECTIVE: Chest pain in the setting of cocaine use poses a diagnostic dilemma.
11423811_1	17	27	Chest pain	Disease	D002637
11423811_1	46	53	cocaine	Chemical	D003042
11423811_1	CID	D003042	D002637

11423811_2|s|Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia.
11423811_2	105	113	ischemia	Disease	D007511
11423811_2	0	10	Dobutamine	Chemical	D004280

11423811_3|s|Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain.
11423811_3	217	227	chest pain	Disease	D002637
11423811_3	63	73	dobutamine	Chemical	D004280
11423811_3	92	99	cocaine	Chemical	D003042
11423811_3	198	205	cocaine	Chemical	D003042
11423811_3	CID	D003042	D002637

11423811_5|s|Patients were eligible for DSE if they had used cocaine within 24 hours preceding the onset of chest pain and had a normal ECG and tropinin I level.
11423811_5	95	105	chest pain	Disease	D002637
11423811_5	48	55	cocaine	Chemical	D003042
11423811_5	CID	D003042	D002637

11423811_6|s|Patients exhibiting signs of continuing cocaine toxicity were excluded from the study.
11423811_6	48	56	toxicity	Disease	D064420
11423811_6	40	47	cocaine	Chemical	D003042

11423811_13|s|CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with cocaine-related chest pain.
11423811_13	126	136	chest pain	Disease	D002637
11423811_13	65	75	dobutamine	Chemical	D004280
11423811_13	110	117	cocaine	Chemical	D003042
11423811_13	CID	D003042	D002637

12678199_0|s|Amiodarone-induced torsade de pointes during bladder irrigation: an unusual presentation--a case report.
12678199_0	19	37	torsade de pointes	Disease	D016171
12678199_0	0	10	Amiodarone	Chemical	D000638
12678199_0	CID	D000638	D016171

12678199_1|s|The authors present a case of early (within 4 days) development of torsade de pointes (TdP) associated with oral amiodarone therapy.
12678199_1	67	85	torsade de pointes	Disease	D016171
12678199_1	87	90	TdP	Disease	D016171
12678199_1	113	123	amiodarone	Chemical	D000638
12678199_1	CID	D000638	D016171

12678199_2|s|Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and digoxin excess.
12678199_2	43	46	TdP	Disease	D016171
12678199_2	114	125	hypokalemia	Disease	D007008
12678199_2	130	137	digoxin	Chemical	D004077

12678199_5|s|The authors speculate that the increased vagal tone during bladder irrigation, a vagal maneuver, in the context of amiodarone therapy resulted in amiodarone-induced proarrhythmia.
12678199_5	165	178	proarrhythmia	Disease	-1
12678199_5	115	125	amiodarone	Chemical	D000638
12678199_5	146	156	amiodarone	Chemical	D000638

12678199_6|s|In the absence of amiodarone therapy, a second bladder irrigation did not induce TdP despite hypokalemia and hypomagnesemia.
12678199_6	81	84	TdP	Disease	D016171
12678199_6	93	104	hypokalemia	Disease	D007008
12678199_6	109	123	hypomagnesemia	Disease	C537153
12678199_6	18	28	amiodarone	Chemical	D000638
12678199_6	CID	D000638	D016171

15696449_0|s|Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.
15696449_0	0	25	Acute renal insufficiency	Disease	D058186
15696449_0	69	97	primary systemic amyloidosis	Disease	C531616
15696449_0	42	51	melphalan	Chemical	D008558
15696449_0	CID	D008558	D058186

15696449_4|s|The authors have noted the development of acute renal insufficiency immediately after melphalan conditioning.
15696449_4	42	67	acute renal insufficiency	Disease	D058186
15696449_4	86	95	melphalan	Chemical	D008558
15696449_4	CID	D008558	D058186

15696449_7|s|Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning.
15696449_7	0	25	Acute renal insufficiency	Disease	D058186
15696449_7	27	30	ARI	Disease	D058186
15696449_7	48	57	melphalan	Chemical	D008558
15696449_7	134	144	creatinine	Chemical	D003404
15696449_7	CID	D008558	D058186

15696449_9|s|RESULTS: Of the 80 patients studied, ARI developed in 18.8% of the patients after high-dose melphalan.
15696449_9	37	40	ARI	Disease	D058186
15696449_9	92	101	melphalan	Chemical	D008558
15696449_9	CID	D008558	D058186

15696449_12|s|Patients who had ARI after high-dose melphalan underwent dialysis more often (P = 0.007), and had a worse 1-year survival (P = 0.03).
15696449_12	17	20	ARI	Disease	D058186
15696449_12	37	46	melphalan	Chemical	D008558
15696449_12	CID	D008558	D058186

15696449_13|s|CONCLUSION: The timing of renal injury strongly suggests melphalan as the causative agent.
15696449_13	26	38	renal injury	Disease	D058186
15696449_13	57	66	melphalan	Chemical	D008558
15696449_13	CID	D008558	D058186

15696449_14|s|Ongoing tubular injury may be a prerequisite for renal injury by melphalan as evidenced by the active urinary sediment.
15696449_14	8	22	tubular injury	Disease	-1
15696449_14	49	61	renal injury	Disease	D058186
15696449_14	65	74	melphalan	Chemical	D008558
15696449_14	CID	D008558	D058186

17554526_0|s|Impaired fear recognition in regular recreational cocaine users.
17554526_0	0	25	Impaired fear recognition	Disease	D001925
17554526_0	50	57	cocaine	Chemical	D003042
17554526_0	CID	D003042	D001925

17554526_10|s|The selective deficit in fear recognition accuracy manifested by the RC group cannot be explained by the subacute effects of cocaine, or ecstasy, because recent and less recent users of these drugs within this group were similarly impaired.
17554526_10	14	41	deficit in fear recognition	Disease	D001925
17554526_10	125	132	cocaine	Chemical	D003042
17554526_10	137	144	ecstasy	Chemical	D018817
17554526_10	CID	D003042	D001925

17721298_0|s|Corneal ulcers associated with aerosolized crack cocaine use.
17721298_0	0	14	Corneal ulcers	Disease	D003320
17721298_0	43	56	crack cocaine	Chemical	D016578
17721298_0	CID	D016578	D003320

17721298_4|s|RESULTS: Four patients with corneal ulcers associated with crack cocaine use were reviewed.
17721298_4	28	42	corneal ulcers	Disease	D003320
17721298_4	59	72	crack cocaine	Chemical	D016578
17721298_4	CID	D016578	D003320

17721298_10|s|CONCLUSIONS: Aerosolized crack cocaine use can be associated with the development of corneal ulcers.
17721298_10	85	99	corneal ulcers	Disease	D003320
17721298_10	25	38	crack cocaine	Chemical	D016578
17721298_10	CID	D016578	D003320

18341442_0|s|Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy.
18341442_0	78	97	idiopathic epilepsy	Disease	C562694
18341442_0	0	13	Levetiracetam	Chemical	C026098
18341442_0	31	44	phenobarbital	Chemical	D010634

18341442_1|s|OBJECTIVE: To assess pharmacokinetics, efficacy, and tolerability of oral levetiracetam administered as an adjunct to phenobarbital treatment in cats with poorly controlled suspected idiopathic epilepsy.
18341442_1	183	202	idiopathic epilepsy	Disease	C562694
18341442_1	74	87	levetiracetam	Chemical	C026098
18341442_1	118	131	phenobarbital	Chemical	D010634

18341442_3|s|ANIMALS: 12 cats suspected to have idiopathic epilepsy that was poorly controlled with phenobarbital or that had unacceptable adverse effects when treated with phenobarbital.
18341442_3	35	54	idiopathic epilepsy	Disease	C562694
18341442_3	87	100	phenobarbital	Chemical	D010634
18341442_3	160	173	phenobarbital	Chemical	D010634

18341442_6|s|Seizure frequencies before and after initiation of levetiracetam treatment were compared, and adverse effects were recorded.
18341442_6	0	7	Seizure	Disease	D012640
18341442_6	51	64	levetiracetam	Chemical	C026098

18341442_8|s|Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).
18341442_8	7	14	seizure	Disease	D012640
18341442_8	68	76	seizures	Disease	D012640
18341442_8	118	125	seizure	Disease	D012640
18341442_8	186	194	seizures	Disease	D012640
18341442_8	298	305	seizure	Disease	D012640
18341442_8	49	62	levetiracetam	Chemical	C026098
18341442_8	156	169	levetiracetam	Chemical	C026098
18341442_8	256	269	levetiracetam	Chemical	C026098

18341442_10|s|CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to phenobarbital treatment in cats with idiopathic epilepsy.
18341442_10	171	190	idiopathic epilepsy	Disease	C562694
18341442_10	59	72	levetiracetam	Chemical	C026098
18341442_10	134	147	phenobarbital	Chemical	D010634

19681452_0|s|Bilateral haemorrhagic infarction of the globus pallidus after cocaine and alcohol intoxication.
19681452_0	10	56	haemorrhagic infarction of the globus pallidus	Disease	D002543|D020520
19681452_0	63	70	cocaine	Chemical	D003042
19681452_0	75	82	alcohol	Chemical	D000431

19681452_1|s|Cocaine is a risk factor for both ischemic and haemorrhagic stroke.
19681452_1	34	66	ischemic and haemorrhagic stroke	Disease	D002544|D020521
19681452_1	0	7	Cocaine	Chemical	D003042

19681452_2|s|We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use.
19681452_2	56	87	ischemia of the globus pallidus	Disease	D002545
19681452_2	104	111	alcohol	Chemical	D000431
19681452_2	127	134	cocaine	Chemical	D003042
19681452_2	CID	D003042	D002545

19681452_3|s|Drug-related globus pallidus infarctions are most often associated with heroin.
19681452_3	13	40	globus pallidus infarctions	Disease	D020520
19681452_3	72	78	heroin	Chemical	D003932
19681452_3	CID	D003932	D020520

19681452_4|s|Bilateral basal ganglia infarcts after the use of cocaine, without concurrent heroin use, have never been reported.
19681452_4	10	32	basal ganglia infarcts	Disease	D020520
19681452_4	50	57	cocaine	Chemical	D003042
19681452_4	78	84	heroin	Chemical	D003932
19681452_4	CID	D003932	D020520

19681452_5|s|In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.
19681452_5	26	44	cardiac arrhythmia	Disease	D001145
19681452_5	48	71	respiratory dysfunction	Disease	D012131
19681452_5	141	163	cerebral hypoperfusion	Disease	-1
19681452_5	83	90	cocaine	Chemical	D003042
19681452_5	98	105	ethanol	Chemical	D000431

20009434_0|s|Acute renal failure after high-dose methotrexate therapy in a patient with ileostomy.
20009434_0	0	19	Acute renal failure	Disease	D058186
20009434_0	36	48	methotrexate	Chemical	D008727
20009434_0	CID	D008727	D058186

20009434_1|s|High-dose methotrexate (HD-MTX) is an important treatment for Burkitt lymphoma, but can cause hepatic and renal toxicity when its clearance is delayed.
20009434_1	62	78	Burkitt lymphoma	Disease	D002051
20009434_1	94	120	hepatic and renal toxicity	Disease	D056486|D007674
20009434_1	10	22	methotrexate	Chemical	D008727
20009434_1	27	30	MTX	Chemical	D008727

20009434_2|s|We report a case of acute renal failure after HD-MTX therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital biliary atresia.
20009434_2	20	39	acute renal failure	Disease	D058186
20009434_2	194	209	biliary atresia	Disease	D001656
20009434_2	49	52	MTX	Chemical	D008727
20009434_2	CID	D008727	D058186

20009434_5|s|Subsequent HD-MTX therapy caused acute renal failure that required continuous hemodialysis.
20009434_5	33	52	acute renal failure	Disease	D058186
20009434_5	14	17	MTX	Chemical	D008727
20009434_5	CID	D008727	D058186

20431083_5|s|RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).
20431083_5	38	41	ICH	Disease	D002543
20431083_5	51	53	IS	Disease	D002544
20431083_5	54	57	TIA	Disease	D002546
20431083_5	59	61	MB	Disease	-1
20431083_5	84	87	ICH	Disease	D002543
20431083_5	91	93	IS	Disease	D002544
20431083_5	94	97	TIA	Disease	D002546
20431083_5	288	296	warfarin	Chemical	D014859
20431083_5	CID	D014859	D002543

20431083_6|s|There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).
20431083_6	28	30	MB	Disease	-1
20431083_6	66	69	ICH	Disease	D002543
20431083_6	138	140	IS	Disease	D002544
20431083_6	141	144	TIA	Disease	D002546
20431083_6	34	42	warfarin	Chemical	D014859
20431083_6	118	126	warfarin	Chemical	D014859
20431083_6	CID	D014859	D002543

20431083_9|s|CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.
20431083_9	27	29	MB	Disease	-1
20431083_9	53	56	ICH	Disease	D002543
20431083_9	96	98	MB	Disease	-1
20431083_9	140	143	ICH	Disease	D002543
20431083_9	33	41	warfarin	Chemical	D014859
20431083_9	120	128	warfarin	Chemical	D014859
20431083_9	CID	D014859	D002543

20595935_0|s|Verapamil stimulation test in hyperprolactinemia: loss of prolactin response in anatomic or functional stalk effect.
20595935_0	30	48	hyperprolactinemia	Disease	D006966
20595935_0	0	9	Verapamil	Chemical	D014700

20595935_1|s|AIM: Verapamil stimulation test was previously investigated as a tool for differential diagnosis of hyperprolactinemia, but with conflicting results.
20595935_1	100	118	hyperprolactinemia	Disease	D006966
20595935_1	5	14	Verapamil	Chemical	D014700

20595935_3|s|Here, we aimed to re-investigate the diagnostic value of verapamil in a population who were all screened for macroprolactinemia.
20595935_3	109	127	macroprolactinemia	Disease	D015175
20595935_3	57	66	verapamil	Chemical	D014700

20595935_4|s|Prolactin responses to verapamil in 65 female patients (age: 29.9 +/- 8.1 years) with hyperprolactinemia were tested in a descriptive, matched case-control study.
20595935_4	86	104	hyperprolactinemia	Disease	D006966
20595935_4	23	32	verapamil	Chemical	D014700

20595935_7|s|RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).
20595935_7	93	110	macroprolactinoma	Disease	D015175
20595935_7	128	145	microprolactinoma	Disease	D015175
20595935_7	165	183	macroprolactinemia	Disease	D015175
20595935_7	215	233	pseudoprolactinoma	Disease	-1
20595935_7	277	295	hyperprolactinemia	Disease	D006966
20595935_7	9	18	Verapamil	Chemical	D014700
20595935_7	257	268	risperidone	Chemical	D018967
20595935_7	CID	D018967	D006966

20595935_8|s|ROC curve analysis revealed that unresponsiveness to verapamil defined as PRL <7%, discriminated anatomical or functional stalk effect (sensitivity: 74%, specificity: 73%, AUC: 0.855+/-0.04, P <0.001, CI: 0.768-0.942) associated with pseudoprolactinoma or risperidone-induced hyperprolactinemia, respectively.
20595935_8	234	252	pseudoprolactinoma	Disease	-1
20595935_8	276	294	hyperprolactinemia	Disease	D006966
20595935_8	53	62	verapamil	Chemical	D014700
20595935_8	256	267	risperidone	Chemical	D018967
20595935_8	CID	D018967	D006966

20595935_9|s|CONCLUSION: Verapamil responsiveness is not a reliable finding for the differential diagnosis of hyperprolactinemia.
20595935_9	97	115	hyperprolactinemia	Disease	D006966
20595935_9	12	21	Verapamil	Chemical	D014700

20595935_10|s|However, verapamil unresponsiveness discriminates stalk effect (i.e., anatomically or functionally inhibited dopaminergic tonus) from other causes of hyperprolactinemia with varying degrees of responsiveness.
20595935_10	150	168	hyperprolactinemia	Disease	D006966
20595935_10	9	18	verapamil	Chemical	D014700

35781_3|s|The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.
35781_3	132	142	cataleptic	Disease	D002375
35781_3	14	23	clonidine	Chemical	D003000
35781_3	25	36	naphazoline	Chemical	D009278
35781_3	41	55	xylometazoline	Chemical	C009695
35781_3	80	88	morphine	Chemical	D009020
35781_3	90	97	codeine	Chemical	D003061
35781_3	99	107	fentanyl	Chemical	D005283
35781_3	112	123	pentazocine	Chemical	D010423
35781_3	153	161	morphine	Chemical	D009020
35781_3	163	169	codine	Chemical	D003061
35781_3	174	182	fentanyl	Chemical	D005283
35781_3	CID	D003000	D002375
35781_3	CID	D005283	D002375
35781_3	CID	D009278	D002375
35781_3	CID	D003061	D002375
35781_3	CID	C009695	D002375
35781_3	CID	D009020	D002375

35781_5|s|It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and fentanyl.
35781_5	147	156	catalepsy	Disease	D002375
35781_5	50	52	NA	Chemical	D009638
35781_5	168	176	morphine	Chemical	D009020
35781_5	181	189	fentanyl	Chemical	D005283
35781_5	CID	D005283	D002375
35781_5	CID	D009020	D002375

35781_6|s|Codeine catalepsy was increased by clonidine and decreased by naphazoline and xylometazoline.
35781_6	8	17	catalepsy	Disease	D002375
35781_6	0	7	Codeine	Chemical	D003061
35781_6	35	44	clonidine	Chemical	D003000
35781_6	62	73	naphazoline	Chemical	D009278
35781_6	78	92	xylometazoline	Chemical	C009695
35781_6	CID	D003000	D002375
35781_6	CID	D009278	D002375
35781_6	CID	D003061	D002375
35781_6	CID	C009695	D002375

48835_0|s|Modification by propranolol of cardiovascular effects of induced hypoglycaemia.
48835_0	65	78	hypoglycaemia	Disease	D007003
48835_0	16	27	propranolol	Chemical	D011433

89511_0|s|Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy.
89511_0	28	47	endometrial disease	Disease	D014591
89511_0	79	88	oestrogen	Chemical	D004967

89511_1|s|The treatment regimens are described in 74 patients with endometrial disease among 850 climacteric women receiving oestrogen therapy.
89511_1	57	76	endometrial disease	Disease	D014591
89511_1	115	124	oestrogen	Chemical	D004967

89511_2|s|Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen.
89511_2	7	18	hyperplasia	Disease	D006965
89511_2	49	58	oestrogen	Chemical	D004967
89511_2	75	86	progestagen	Chemical	D011372
89511_2	CID	D004967	D006965

89511_3|s|Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy.
89511_3	105	116	hyperplasia	Disease	D006965
89511_3	150	161	hyperplasia	Disease	D006965
89511_3	174	195	endometrial carcinoma	Disease	D016889
89511_3	352	363	hyperplasia	Disease	D006965
89511_3	369	379	malignancy	Disease	D009369
89511_3	31	45	norethisterone	Chemical	D009640
89511_3	290	299	oestrogen	Chemical	D004967
89511_3	CID	D004967	D006965

89511_4|s|Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma.
89511_4	105	128	endometrial hyperplasia	Disease	D004714
89511_4	132	141	carcinoma	Disease	D002277
89511_4	18	27	oestrogen	Chemical	D004967
89511_4	55	66	progestagen	Chemical	D011372

146391_0|s|Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin.
146391_0	0	21	Pure red cell aplasia	Disease	D012010
146391_0	23	39	toxic dermatitis	Disease	D003875
146391_0	44	59	lymphadenopathy	Disease	D008206
146391_0	80	97	diphenylhydantoin	Chemical	D010672
146391_0	CID	D010672	D003875
146391_0	CID	D010672	D008206
146391_0	CID	D010672	D012010

146391_1|s|A patient taking diphenylhydantoin for 3 weeks developed a generalized skin rash, lymphadenopathy and pure red cell aplasia.
146391_1	71	80	skin rash	Disease	D005076
146391_1	82	97	lymphadenopathy	Disease	D008206
146391_1	102	123	pure red cell aplasia	Disease	D012010
146391_1	17	34	diphenylhydantoin	Chemical	D010672
146391_1	CID	D010672	D008206
146391_1	CID	D010672	D012010

146391_3|s|Skin rash is a well-known complication of diphenylhydantoin treatment as is benign and malignant lymphadenopathy.
146391_3	0	9	Skin rash	Disease	D005076
146391_3	97	112	lymphadenopathy	Disease	D008206
146391_3	42	59	diphenylhydantoin	Chemical	D010672
146391_3	CID	D010672	D008206

146391_4|s|Pure red cell aplasia associated with diphenylhydantoin medication has been reported in 3 patients.
146391_4	0	21	Pure red cell aplasia	Disease	D012010
146391_4	38	55	diphenylhydantoin	Chemical	D010672
146391_4	CID	D010672	D012010

146391_6|s|In this patient the time relation between the ingestion of diphenylhydantoin and the occurrence of the skin rash, lymphadenopathy and pure red cell aplasia is very suggestive of a direct connection.
146391_6	103	112	skin rash	Disease	D005076
146391_6	114	129	lymphadenopathy	Disease	D008206
146391_6	134	155	pure red cell aplasia	Disease	D012010
146391_6	59	76	diphenylhydantoin	Chemical	D010672
146391_6	CID	D010672	D008206
146391_6	CID	D010672	D012010

256433_0|s|Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients.
256433_0	63	73	infections	Disease	D007239
256433_0	77	83	cancer	Disease	D009369
256433_0	20	30	tobramycin	Chemical	D014031
256433_0	45	58	carbenicillin	Chemical	D002228

256433_3|s|To overcome the adverse effects of neutropenia, tobramycin was given by continuous infusion and combined with intermittent carbenicillin.
256433_3	35	46	neutropenia	Disease	D009503
256433_3	48	58	tobramycin	Chemical	D014031
256433_3	123	136	carbenicillin	Chemical	D002228

256433_13|s|Major azotemia (serum creatinine greater than 2.5 mg/dl or BUN greater than 50 mg/dl) occurred in only 2%.
256433_13	6	14	azotemia	Disease	D053099
256433_13	22	32	creatinine	Chemical	D003404

256433_14|s|Azotemia was not related to duration of therapy or serum tobramycin concentration.
256433_14	0	8	Azotemia	Disease	D053099
256433_14	57	67	tobramycin	Chemical	D014031
256433_14	CID	D014031	D053099

448423_0|s|Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis.
448423_0	10	33	subarachnoid hemorrhage	Disease	D013345
448423_0	80	109	acute renal artery thrombosis	Disease	D007674
448423_0	50	67	aminocaproic acid	Chemical	D000614

448423_2|s|Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH).
448423_2	86	109	subarachnoid hemorrhage	Disease	D013345
448423_2	111	114	SAH	Disease	D013345
448423_2	0	25	Epsilon aminocaproic acid	Chemical	D015119
448423_2	27	31	EACA	Chemical	D015119
448423_2	CID	D015119	D013345

448423_3|s|Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy.
448423_3	94	104	thrombotic	Disease	D013927
448423_3	122	126	EACA	Chemical	D015119
448423_3	CID	D015119	D013927

448423_4|s|These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.
448423_4	61	93	intracranial vascular thrombosis	Disease	D020767
448423_4	111	114	SAH	Disease	D013345
448423_4	148	155	thrombi	Disease	D013927
448423_4	224	248	thromboembolic phenomena	Disease	D013923
448423_4	209	213	EACA	Chemical	D015119
448423_4	CID	D015119	D013345
448423_4	CID	D015119	D013927
448423_4	CID	D015119	D020767

448423_5|s|Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other "consumption coagulopathies."
448423_5	27	34	thrombi	Disease	D013927
448423_5	155	162	thrombi	Disease	D013927
448423_5	180	218	disseminated intravascular coagulation	Disease	D004211
448423_5	229	255	consumption coagulopathies	Disease	D004211
448423_5	95	99	EACA	Chemical	D015119
448423_5	CID	D015119	D013927

448423_7|s|This occlusion occurred after EACA therapy in a patient with SAH and histopathological documentation of recurrent SAH.
448423_7	61	64	SAH	Disease	D013345
448423_7	114	117	SAH	Disease	D013345
448423_7	30	34	EACA	Chemical	D015119
448423_7	CID	D015119	D013345

573555_7|s|We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.
573555_7	37	49	hypoglycemia	Disease	D007003
573555_7	51	69	hyperbilirubinemia	Disease	D006932
573555_7	71	83	polycythemia	Disease	D011086
573555_7	85	99	neonatal apnea	Disease	D001049
573555_7	105	116	bradycardia	Disease	D001919
573555_7	188	199	propranolol	Chemical	D011433

611664_0|s|Use of propranolol in the treatment of idiopathic orthostatic hypotension.
611664_0	39	73	idiopathic orthostatic hypotension	Disease	C544351
611664_0	7	18	propranolol	Chemical	D011433

611664_2|s|They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused norepinephrine.
611664_2	139	155	hypersensitivity	Disease	D004342
611664_2	43	57	catecholamines	Chemical	D002395
611664_2	190	204	norepinephrine	Chemical	D009638

611664_5|s|In 1 patient, marked hypertension was induced by propranolol and the drug had to be withdrawn.
611664_5	21	33	hypertension	Disease	D006973
611664_5	49	60	propranolol	Chemical	D011433
611664_5	CID	D011433	D006973

611664_9|s|The studies suggest that propranolol is a useful drug in selected patients with severe idiopathic orthostatic hypotension.
611664_9	87	121	idiopathic orthostatic hypotension	Disease	C544351
611664_9	25	36	propranolol	Chemical	D011433

612112_7|s|It is considered unlikely that etomidate will prove to be the hypnotic of choice for a totally intravenous anesthetic technique in adults because of the high incidence of myoclonia after prolonged administration.
612112_7	171	180	myoclonia	Disease	D009207
612112_7	31	40	etomidate	Chemical	D005045
612112_7	CID	D005045	D009207

689020_8|s|After the end of fenoterol-hydrobromide infusion, tremor amplitudes decreased significantly faster than those following ritodrin-HCl infusion.
689020_8	50	56	tremor	Disease	D014202
689020_8	17	39	fenoterol-hydrobromide	Chemical	D005280
689020_8	120	132	ritodrin-HCl	Chemical	D012312
689020_8	CID	D005280	D014202
689020_8	CID	D012312	D014202

733189_0|s|Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting corticosteroid suspensions in combination with other drugs: I.
733189_0	10	55	retinal artery and choriocapillaris occlusion	Disease	D015356
733189_0	95	109	corticosteroid	Chemical	D000305

733189_2|s|Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.
733189_2	39	85	retinal artery and choriocapillaris occlusions	Disease	D015356
733189_2	91	100	blindness	Disease	D001766
733189_2	152	178	methylprednisolone acetate	Chemical	C000873
733189_2	199	208	lidocaine	Chemical	D008012
733189_2	210	221	epinephrine	Chemical	D004837
733189_2	226	236	penicillin	Chemical	D010406
733189_2	CID	C000873	D015356

816141_0|s|Cephalothin-induced immune hemolytic anemia.
816141_0	27	43	hemolytic anemia	Disease	D000743
816141_0	0	11	Cephalothin	Chemical	D002512
816141_0	CID	D002512	D000743

816141_1|s|A patient with renal disease developed Coombs-positive hemolytic anemia while receiving cephalothin therapy.
816141_1	15	28	renal disease	Disease	D007674
816141_1	55	71	hemolytic anemia	Disease	D000743
816141_1	88	99	cephalothin	Chemical	D002512
816141_1	CID	D002512	D000743

851038_0|s|Kaliuretic effect of L-dopa treatment in parkinsonian patients.
851038_0	41	53	parkinsonian	Disease	D010300
851038_0	21	27	L-dopa	Chemical	D007980

851038_1|s|Hypokalemia, sometimes severe, was observed in some L-dopa-treated parkinsonian patients.
851038_1	0	11	Hypokalemia	Disease	D007008
851038_1	67	79	parkinsonian	Disease	D010300
851038_1	52	58	L-dopa	Chemical	D007980
851038_1	CID	D007980	D007008

851038_2|s|The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.
851038_2	91	102	hypokalemia	Disease	D007008
851038_2	17	23	L-dopa	Chemical	D007980
851038_2	50	59	potassium	Chemical	D011188
851038_2	225	234	potassium	Chemical	D011188
851038_2	239	245	sodium	Chemical	D012964
851038_2	278	287	potassium	Chemical	D011188
851038_2	289	295	sodium	Chemical	D012964
851038_2	300	311	aldosterone	Chemical	D000450
851038_2	CID	D007980	D007008

891494_0|s|Phenytoin encephalopathy as probable idiosyncratic reaction: case report.
891494_0	10	24	encephalopathy	Disease	D001927
891494_0	0	9	Phenytoin	Chemical	D010672
891494_0	CID	D010672	D001927

891494_1|s|A case of phenytoin (DPH) encephalopathy with increasing seizures and EEG and mental changes is described.
891494_1	26	40	encephalopathy	Disease	D001927
891494_1	57	65	seizures	Disease	D012640
891494_1	10	19	phenytoin	Chemical	D010672
891494_1	21	24	DPH	Chemical	D010672
891494_1	CID	D010672	D001927

891494_4|s|In fact the concentration of free DPH was normal, the patient presented a retarded morbilliform rash during DPH treatment, the protidogram was normal, and an intradermic DPH injection had no local effect.
891494_4	96	100	rash	Disease	D005076
891494_4	34	37	DPH	Chemical	D010672
891494_4	108	111	DPH	Chemical	D010672
891494_4	170	173	DPH	Chemical	D010672

891494_5|s|The authors conclude that in a patient starting DPH treatment an unexpected increase in seizures, with EEG and mental changes occurring simultaneously, should alert the physician to the possible need for eliminating DPH from the therapeutic regimen, even if plasma concentrations are low.
891494_5	88	96	seizures	Disease	D012640
891494_5	48	51	DPH	Chemical	D010672
891494_5	216	219	DPH	Chemical	D010672

895432_0|s|Effects of exercise on the severity of isoproterenol-induced myocardial infarction.
895432_0	61	82	myocardial infarction	Disease	D009203
895432_0	39	52	isoproterenol	Chemical	D007545
895432_0	CID	D007545	D009203

895432_1|s|The effect of exercise on the severity of isoproterenol-induced myocardial infarction was studied in male rats.
895432_1	64	85	myocardial infarction	Disease	D009203
895432_1	42	55	isoproterenol	Chemical	D007545
895432_1	CID	D007545	D009203

895432_9|s|The results indicated that exercise reduced the mortality associated with the effects of large dosages of isoproterenol but had little on the severity of the infarction.
895432_9	158	168	infarction	Disease	D007238
895432_9	106	119	isoproterenol	Chemical	D007545

931801_0|s|Effect of D-Glucarates on basic antibiotic-induced renal damage in rats.
931801_0	51	63	renal damage	Disease	D007674
931801_0	10	22	D-Glucarates	Chemical	D005937

931801_1|s|Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only.
931801_1	0	10	Dehydrated	Disease	D003681
931801_1	34	53	acute renal failure	Disease	D058186
931801_1	84	98	aminoglycoside	Chemical	D000617
931801_1	CID	D000617	D058186

931801_2|s|Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran.
931801_2	90	103	renal failure	Disease	D051437
931801_2	23	66	2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone	Chemical	C038936
931801_2	115	124	kanamycin	Chemical	D007612

931801_4|s|D-Glucarates were effective against renal damage induced by peptide antibiotics as well as various aminoglycoside antibitocis.
931801_4	36	48	renal damage	Disease	D007674
931801_4	0	12	D-Glucarates	Chemical	D005937
931801_4	99	113	aminoglycoside	Chemical	D000617

931801_6|s|With a D-glucarate of a fixed size of dose, approximately the same degree of protection was obtained against renal damages induced by different basic antibiotics despite large disparities in administration doses of different antibiotics.
931801_6	109	122	renal damages	Disease	D007674
931801_6	7	18	D-glucarate	Chemical	D005937

931801_7|s|D-Glucarates had the ability to prevent renal damage but not to cure it.
931801_7	40	52	renal damage	Disease	D007674
931801_7	0	12	D-Glucarates	Chemical	D005937

931801_8|s|Rats excreted acidic urine when they were spared from renal lesions by monosaccharides.
931801_8	54	67	renal lesions	Disease	D007674
931801_8	71	86	monosaccharides	Chemical	D009005

931801_9|s|The reduction effect of D-glucarates against nephrotoxicity of basic antibiotics was discussed.
931801_9	45	59	nephrotoxicity	Disease	D007674
931801_9	24	36	D-glucarates	Chemical	D005937

946593_0|s|Paraplegia following intrathecal methotrexate: report of a case and review of the literature.
946593_0	0	10	Paraplegia	Disease	D010264
946593_0	33	45	methotrexate	Chemical	D008727
946593_0	CID	D008727	D010264

946593_1|s|A patient who developed paraplegia following the intrathecal instillation of methotrexate is discribed.
946593_1	24	34	paraplegia	Disease	D010264
946593_1	77	89	methotrexate	Chemical	D008727
946593_1	CID	D008727	D010264

946593_3|s|The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.
946593_3	143	174	central nervous system leukemia	Disease	D002493
946593_3	450	460	neurotoxic	Disease	D020258
946593_3	241	253	methothexate	Chemical	D008727
946593_3	345	357	methotrexate	Chemical	D008727
946593_3	501	513	methotrexate	Chemical	D008727
946593_3	556	568	methotrexate	Chemical	D008727

946593_4|s|The role of methotrexate contaminants, local folate deficiency, and cranial irradiation in the pathogenesis of intrathecal methotrexate toxicity is unclear.
946593_4	45	62	folate deficiency	Disease	C536409
946593_4	136	144	toxicity	Disease	D064420
946593_4	12	24	methotrexate	Chemical	D008727
946593_4	123	135	methotrexate	Chemical	D008727

946593_5|s|The incidence of neurotoxicity may be reduced by employing lower doses of methotrexate in the presence of central nervous system leukemia, in older children and adults, and in the presence of epidural leakage.
946593_5	17	30	neurotoxicity	Disease	D020258
946593_5	106	137	central nervous system leukemia	Disease	D002493
946593_5	74	86	methotrexate	Chemical	D008727

946593_7|s|Periodic monitoring of cerebruspinal fluid methotrexate levels may be predictive of the development of serious neurotoxicity.
946593_7	111	124	neurotoxicity	Disease	D020258
946593_7	43	55	methotrexate	Chemical	D008727

978847_2|s|This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
978847_2	270	299	enlargement of pulse pressure	Disease	D006973
978847_2	308	319	tachycardia	Disease	D013610
978847_2	79	91	guanethidine	Chemical	D006145
978847_2	100	113	hexamethonium	Chemical	D018738
978847_2	125	137	phentolamine	Chemical	D010646
978847_2	182	201	desmethylimipramine	Chemical	D003891
978847_2	218	229	propranolol	Chemical	D011433
978847_2	335	344	carbachol	Chemical	D002217
978847_2	CID	D002217	D013610
978847_2	CID	D002217	D006973
978847_2	CID	D003891	D006973

1117341_0|s|Hyperglycemic effect of amino compounds structurally related to caproate in rats.
1117341_0	0	13	Hyperglycemic	Disease	D006943
1117341_0	24	29	amino	Chemical	D015119
1117341_0	64	72	caproate	Chemical	C037652
1117341_0	CID	D015119	D006943

1117341_1|s|The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, glucosuria.
1117341_1	114	127	hyperglycemia	Disease	D006943
1117341_1	184	194	glucosuria	Disease	D006030
1117341_1	72	77	amino	Chemical	D015119
1117341_1	93	101	caproate	Chemical	C037652
1117341_1	141	148	glucose	Chemical	D005947
1117341_1	CID	D015119	D006943

1158089_0|s|Fatty liver induced by tetracycline in the rat.
1158089_0	0	11	Fatty liver	Disease	D005234
1158089_0	23	35	tetracycline	Chemical	D013752
1158089_0	CID	D013752	D005234

1158089_2|s|Dose-response relationships, biochemical mechanisms, and sex differences in the experimental fatty liver induced by tetracycline were studied in the intact rat and with the isolated perfused rat liver in vitro.
1158089_2	93	104	fatty liver	Disease	D005234
1158089_2	116	128	tetracycline	Chemical	D013752
1158089_2	CID	D013752	D005234

1158089_4|s|With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and depression of output of triglyceride by livers from male and female rats.
1158089_4	205	215	depression	Disease	D003866
1158089_4	27	37	oleic acid	Chemical	D019301
1158089_4	137	149	tetracycline	Chemical	D013752
1158089_4	175	187	triglyceride	Chemical	D014280
1158089_4	229	241	triglyceride	Chemical	D014280

1158089_7|s|However, livers from female, and especially pregnant female rats, were strikingly resistant to the effects of tetracycline on depression of output of triglyceride under these experimental conditions.
1158089_7	126	136	depression	Disease	D003866
1158089_7	110	122	tetracycline	Chemical	D013752
1158089_7	150	162	triglyceride	Chemical	D014280

1158089_9|s|Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich fatty liver in response to tetracycline.
1158089_9	208	219	fatty liver	Disease	D005234
1158089_9	31	43	triglyceride	Chemical	D014280
1158089_9	96	108	triglyceride	Chemical	D014280
1158089_9	190	202	triglyceride	Chemical	D014280
1158089_9	235	247	tetracycline	Chemical	D013752
1158089_9	CID	D013752	D005234

1280054_0|s|Fatal myeloencephalopathy due to intrathecal vincristine administration.
1280054_0	6	25	myeloencephalopathy	Disease	D001927
1280054_0	45	56	vincristine	Chemical	D014750
1280054_0	CID	D014750	D001927

1280054_1|s|Vincristine was accidentally given intrathecally to a child with leukaemia, producing sensory and motor dysfunction followed by encephalopathy and death.
1280054_1	65	74	leukaemia	Disease	D007938
1280054_1	86	115	sensory and motor dysfunction	Disease	D007049
1280054_1	128	142	encephalopathy	Disease	D001927
1280054_1	0	11	Vincristine	Chemical	D014750
1280054_1	CID	D014750	D007049
1280054_1	CID	D014750	D001927

1280707_2|s|After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become arrhythmic), we determined the effect of 1-hour progesterone HCl exposure on myocyte contractile rhythm.
1280707_2	141	151	arrhythmic	Disease	D001145
1280707_2	22	33	bupivacaine	Chemical	D002045
1280707_2	61	72	bupivacaine	Chemical	D002045
1280707_2	189	201	progesterone	Chemical	D011374
1280707_2	202	205	HCl	Chemical	D006851
1280707_2	CID	D002045	D001145
1280707_2	CID	D011374	D001145

1280707_9|s|Potentiation of bupivacaine arrhythmia in myocyte cultures suggests that this effect is at least partly mediated at the myocyte level.
1280707_9	28	38	arrhythmia	Disease	D001145
1280707_9	16	27	bupivacaine	Chemical	D002045
1280707_9	CID	D002045	D001145

1289188_0|s|Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis.
1289188_0	0	19	Acute renal failure	Disease	D058186
1289188_0	49	64	desferrioxamine	Chemical	D003676

1289188_1|s|A patient with transfusion-dependent thalassemia was undergoing home intravenous desferrioxamine (DFX) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy.
1289188_1	37	48	thalassemia	Disease	D013789
1289188_1	81	96	desferrioxamine	Chemical	D003676
1289188_1	98	101	DFX	Chemical	D003676

1289188_4|s|From the results obtained, haemodialysis can therefore be suggested as a useful therapy in rare cases of progressive acute renal failure caused by desferrioxamine.
1289188_4	117	136	acute renal failure	Disease	D058186
1289188_4	147	162	desferrioxamine	Chemical	D003676

1359137_0|s|Neuroleptic-associated hyperprolactinemia.
1359137_0	23	41	hyperprolactinemia	Disease	D006966
1359137_0	0	11	Neuroleptic	Chemical	D014150
1359137_0	CID	D014150	D006966

1359137_2|s|Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.
1359137_2	40	58	hyperprolactinemia	Disease	D006966
1359137_2	63	73	amenorrhea	Disease	D000568
1359137_2	74	88	oligomenorrhea	Disease	D009839
1359137_2	111	134	neuroleptic medications	Chemical	D014150
1359137_2	153	166	bromocriptine	Chemical	D001971
1359137_2	CID	D014150	D000568
1359137_2	CID	D014150	D009839
1359137_2	CID	D014150	D006966

1359137_4|s|One woman, however, developed worsened psychiatric symptoms while taking bromocriptine, and it was discontinued.
1359137_4	39	59	psychiatric symptoms	Disease	D011618
1359137_4	73	86	bromocriptine	Chemical	D001971
1359137_4	CID	D001971	D011618

1359137_6|s|This suggests that bromocriptine should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and amenorrhea/galactorrhea.
1359137_6	109	127	hyperprolactinemia	Disease	D006966
1359137_6	132	142	amenorrhea	Disease	D000568
1359137_6	143	155	galactorrhea	Disease	D005687
1359137_6	19	32	bromocriptine	Chemical	D001971
1359137_6	86	97	neuroleptic	Chemical	D014150
1359137_6	CID	D014150	D000568
1359137_6	CID	D014150	D006966

1360900_0|s|Ethacrynic acid-induced convulsions and brain neurotransmitters in mice.
1360900_0	24	35	convulsions	Disease	D012640
1360900_0	0	15	Ethacrynic acid	Chemical	D004976
1360900_0	CID	D004976	D012640

1360900_1|s|Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.
1360900_1	58	68	convulsive	Disease	D012640
1360900_1	37	52	ethacrynic acid	Chemical	D004976
1360900_1	134	153	5-hydroxytryptamine	Chemical	D012701
1360900_1	155	159	5-HT	Chemical	D012701
1360900_1	193	216	gamma-aminobutyric acid	Chemical	D005680
1360900_1	221	234	acetylcholine	Chemical	D000109
1360900_1	CID	D004976	D012640

1360900_3|s|In ethacrynic acid-induced convulsions, these neurotransmitter systems may be differentially modulated, probably through activation of glutaminergic neurons in the brain.
1360900_3	27	38	convulsions	Disease	D012640
1360900_3	3	18	ethacrynic acid	Chemical	D004976
1360900_3	CID	D004976	D012640

1361574_8|s|Moreover, 0.05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the convulsions induced by isoniazid (200 mg/kg s.c.).
1361574_8	103	114	convulsions	Disease	D012640
1361574_8	29	43	beta-carboline	Chemical	D002243
1361574_8	77	86	[35S]TBPS	Chemical	C037476
1361574_8	126	135	isoniazid	Chemical	D007538
1361574_8	CID	D007538	D012640

1395192_0|s|Recurrent myocardial infarction in a postpartum patient receiving bromocriptine.
1395192_0	10	31	myocardial infarction	Disease	D009203
1395192_0	66	79	bromocriptine	Chemical	D001971
1395192_0	CID	D001971	D009203

1395192_3|s|Bromocriptine has been implicated in several previous case reports of myocardial infarction in the puerperium.
1395192_3	70	91	myocardial infarction	Disease	D009203
1395192_3	0	13	Bromocriptine	Chemical	D001971
1395192_3	CID	D001971	D009203

1420650_0|s|Asterixis induced by carbamazepine therapy.
1420650_0	0	9	Asterixis	Disease	D020820
1420650_0	21	34	carbamazepine	Chemical	D002220

1420650_2|s|In this report we present four patients treated with a combination of different psychotropic drugs, in whom asterixis was triggered either by adding carbamazepine (CBZ) to a treatment regimen, or by increasing its dosage.
1420650_2	108	117	asterixis	Disease	D020820
1420650_2	149	162	carbamazepine	Chemical	D002220
1420650_2	164	167	CBZ	Chemical	D002220

1420650_4|s|We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.
1420650_4	12	21	asterixis	Disease	D020820
1420650_4	57	70	neurotoxicity	Disease	D020258
1420650_4	147	154	lithium	Chemical	D008094
1420650_4	158	167	clozapine	Chemical	D003024
1420650_4	197	200	CBZ	Chemical	D002220
1420650_4	CID	D008094	D020820
1420650_4	CID	D003024	D020820

1423336_0|s|Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients.
1423336_0	24	35	hypotensive	Disease	D007022
1423336_0	58	70	parkinsonian	Disease	D010300
1423336_0	46	54	levodopa	Chemical	D007980
1423336_0	CID	D007980	D007022

1423336_1|s|Blood pressure effects of i.v. levodopa were examined in parkinsonian patients with stable and fluctuating responses to levodopa.
1423336_1	57	69	parkinsonian	Disease	D010300
1423336_1	31	39	levodopa	Chemical	D007980
1423336_1	120	128	levodopa	Chemical	D007980

1423336_2|s|The magnitude of the hypotensive effect of levodopa was concentration dependent and was fit to an Emax model in fluctuating responders.
1423336_2	21	32	hypotensive	Disease	D007022
1423336_2	43	51	levodopa	Chemical	D007980
1423336_2	CID	D007980	D007022

1423336_6|s|Phenylalanine, a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa.
1423336_6	131	142	hypotensive	Disease	D007022
1423336_6	0	13	Phenylalanine	Chemical	D010649
1423336_6	31	41	amino acid	Chemical	D000596
1423336_6	64	72	levodopa	Chemical	D007980
1423336_6	175	183	levodopa	Chemical	D007980
1423336_6	CID	D007980	D007022

1423336_7|s|We conclude that levodopa has a central hypotensive action that parallels the motor effects in fluctuating patients.
1423336_7	40	51	hypotensive	Disease	D007022
1423336_7	17	25	levodopa	Chemical	D007980
1423336_7	CID	D007980	D007022

1424076_0|s|Syndrome of inappropriate secretion of antidiuretic hormone after infusional vincristine.
1424076_0	0	59	Syndrome of inappropriate secretion of antidiuretic hormone	Disease	D007177
1424076_0	77	88	vincristine	Chemical	D014750
1424076_0	CID	D014750	D007177

1424076_1|s|A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone.
1424076_1	36	52	multiple myeloma	Disease	D009101
1424076_1	113	124	vincristine	Chemical	D014750
1424076_1	129	140	doxorubicin	Chemical	D004317
1424076_1	160	173	dexamethasone	Chemical	D003907

1424076_3|s|Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone, which was attributed to the vincristine infusion.
1424076_3	24	83	syndrome of inappropriate secretion of antidiuretic hormone	Disease	D007177
1424076_3	113	124	vincristine	Chemical	D014750
1424076_3	CID	D014750	D007177

1449452_3|s|In patients with atrial fibrillation digoxin is beneficial for ventricular rate control.
1449452_3	17	36	atrial fibrillation	Disease	D001281
1449452_3	37	44	digoxin	Chemical	D004077

1449452_6|s|Also, digoxin has undesirable effects such as increasing peripheral resistance and myocardial demands, and causing arrhythmias.
1449452_6	115	126	arrhythmias	Disease	D001145
1449452_6	6	13	digoxin	Chemical	D004077
1449452_6	CID	D004077	D001145

1449452_11|s|Pooled analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that digoxin may increase mortality after myocardial infarction (MI).
1449452_11	151	172	myocardial infarction	Disease	D009203
1449452_11	174	176	MI	Disease	D009203
1449452_11	114	121	digoxin	Chemical	D004077

1522360_0|s|Intravascular hemolysis and acute renal failure following intermittent rifampin therapy.
1522360_0	14	23	hemolysis	Disease	D006461
1522360_0	28	47	acute renal failure	Disease	D058186
1522360_0	71	79	rifampin	Chemical	D012293
1522360_0	CID	D012293	D058186
1522360_0	CID	D012293	D006461

1522360_1|s|Renal failure is a rare complication associated with the use of rifampin.
1522360_1	0	13	Renal failure	Disease	D051437
1522360_1	64	72	rifampin	Chemical	D012293

1522360_2|s|Intravascular hemolysis leading to acute renal failure following rifampin therapy is extremely rare.
1522360_2	14	23	hemolysis	Disease	D006461
1522360_2	35	54	acute renal failure	Disease	D058186
1522360_2	65	73	rifampin	Chemical	D012293
1522360_2	CID	D012293	D058186
1522360_2	CID	D012293	D006461

1522360_3|s|Two patients with leprosy who developed hemolysis and acute renal failure following rifampin are reported.
1522360_3	18	25	leprosy	Disease	D007918
1522360_3	40	49	hemolysis	Disease	D006461
1522360_3	54	73	acute renal failure	Disease	D058186
1522360_3	84	92	rifampin	Chemical	D012293
1522360_3	CID	D012293	D058186
1522360_3	CID	D012293	D006461

1556529_0|s|Zidovudine-induced hepatitis.
1556529_0	19	28	hepatitis	Disease	D056486
1556529_0	0	10	Zidovudine	Chemical	D015215
1556529_0	CID	D015215	D056486

1556529_1|s|A case of acute hepatitis induced by zidovudine in a 38-year-old patient with AIDS is presented.
1556529_1	16	25	hepatitis	Disease	D056486
1556529_1	78	82	AIDS	Disease	D000163
1556529_1	37	47	zidovudine	Chemical	D015215
1556529_1	CID	D015215	D056486

1563460_0|s|Thoracic hematomyelia secondary to coumadin anticoagulant therapy: a case report.
1563460_0	0	21	Thoracic hematomyelia	Disease	D020758
1563460_0	35	43	coumadin	Chemical	D014859
1563460_0	CID	D014859	D020758

1564030_0|s|Mania associated with fluoxetine treatment in adolescents.
1564030_0	0	5	Mania	Disease	D001714
1564030_0	22	32	fluoxetine	Chemical	D005473
1564030_0	CID	D005473	D001714

1564030_1|s|Fluoxetine, a selective serotonin reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression.
1564030_1	117	127	depression	Disease	D003866
1564030_1	0	10	Fluoxetine	Chemical	D005473
1564030_1	24	33	serotonin	Chemical	D012701

1564030_2|s|Generally safe and well tolerated by adults, fluoxetine has been reported to induce mania.
1564030_2	84	89	mania	Disease	D001714
1564030_2	45	55	fluoxetine	Chemical	D005473
1564030_2	CID	D005473	D001714

1564030_3|s|The cases of five depressed adolescents, 14-16 years of age, who developed mania during pharmacotherapy with fluoxetine, are reported here.
1564030_3	18	27	depressed	Disease	D003866
1564030_3	75	80	mania	Disease	D001714
1564030_3	109	119	fluoxetine	Chemical	D005473
1564030_3	CID	D005473	D001714

1564030_4|s|Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.
1564030_4	45	50	mania	Disease	D001714
1564030_4	54	63	hypomania	Disease	D001714
1564030_4	141	181	attention-deficit hyperactivity disorder	Disease	D001289
1564030_4	215	225	depression	Disease	D003866
1564030_4	231	240	psychotic	Disease	D011618
1564030_4	271	289	affective disorder	Disease	D019964
1564030_4	302	318	bipolar disorder	Disease	D001714
1564030_4	339	355	bipolar disorder	Disease	D001714
1564030_4	71	81	fluoxetine	Chemical	D005473
1564030_4	CID	D005473	D001714

1564030_5|s|Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to fluoxetine induced mania in adolescents.
1564030_5	146	151	mania	Disease	D001714
1564030_5	127	137	fluoxetine	Chemical	D005473
1564030_5	CID	D005473	D001714

1615846_0|s|Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.
1615846_0	43	64	hyperlipoproteinemias	Disease	D006951
1615846_0	0	11	Gemfibrozil	Chemical	D015248
1615846_0	12	22	lovastatin	Chemical	D008148

1615846_1|s|The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease).
1615846_1	207	221	hyperlipidemia	Disease	D006949
1615846_1	239	271	atherosclerotic vascular disease	Disease	D002340
1615846_1	140	151	gemfibrozil	Chemical	D015248
1615846_1	152	162	lovastatin	Chemical	D008148

1615846_7|s|Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria.
1615846_7	0	8	Myositis	Disease	D009220
1615846_7	202	216	rhabdomyolysis	Disease	D012206
1615846_7	220	233	myoglobinuria	Disease	D009212
1615846_7	85	87	it	Disease	D009220
1615846_7	148	156	creatine	Chemical	D003401

1655018_0|s|Hepatocellular carcinoma in Fanconi's anemia treated with androgen and corticosteroid.
1655018_0	0	24	Hepatocellular carcinoma	Disease	D006528
1655018_0	28	44	Fanconi's anemia	Disease	D005199
1655018_0	58	66	androgen	Chemical	D000728
1655018_0	71	85	corticosteroid	Chemical	D000305
1655018_0	CID	D000305	D006528
1655018_0	CID	D000728	D006528

1655018_1|s|The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with androgens, corticosteroids and transfusions.
1655018_1	65	81	Fanconi's anemia	Disease	D005199
1655018_1	115	124	androgens	Chemical	D000728
1655018_1	126	141	corticosteroids	Chemical	D000305

1655018_4|s|This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and corticosteroid-treated Fanconi's anemia.
1655018_4	74	91	hepatic neoplasms	Disease	D008113
1655018_4	96	104	peliosis	Disease	D010382
1655018_4	171	187	Fanconi's anemia	Disease	D005199
1655018_4	134	142	androgen	Chemical	D000728
1655018_4	148	162	corticosteroid	Chemical	D000305
1655018_4	CID	D000305	D010382
1655018_4	CID	D000728	D010382

1735570_8|s|The trimethaphan-induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion.
1735570_8	25	36	hypotension	Disease	D007022
1735570_8	70	81	bradycardia	Disease	D001919
1735570_8	135	146	tachycardia	Disease	D013610
1735570_8	4	16	trimethaphan	Chemical	D014294
1735570_8	CID	D014294	D007022
1735570_8	CID	D014294	D013610

1756784_0|s|Damage of substantia nigra pars reticulata during pilocarpine-induced status epilepticus in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation.
1756784_0	0	42	Damage of substantia nigra pars reticulata	Disease	D001930
1756784_0	70	88	status epilepticus	Disease	D013226
1756784_0	50	61	pilocarpine	Chemical	D010862
1756784_0	CID	D010862	D001930
1756784_0	CID	D010862	D013226

1756784_3|s|In this study, status epilepticus was induced by systemic injection of pilocarpine in rats.
1756784_3	15	33	status epilepticus	Disease	D013226
1756784_3	71	82	pilocarpine	Chemical	D010862
1756784_3	CID	D010862	D013226

1756784_6|s|Nissl-staining and antibodies against the neuron-specific calcium-binding protein, parvalbumin, served to detect neuronal damage in SNR.
1756784_6	113	128	neuronal damage	Disease	D009422
1756784_6	58	65	calcium	Chemical	D002118

1760851_0|s|Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.
1760851_0	8	22	cardiotoxicity	Disease	D066126
1760851_0	26	37	doxorubicin	Chemical	D004317
1760851_0	59	92	N-(2-hydroxypropyl)methacrylamide	Chemical	C032976
1760851_0	CID	D004317	D066126

1760851_1|s|A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.
1760851_1	51	59	toxicity	Disease	D064420
1760851_1	73	87	cardiotoxicity	Disease	D066126
1760851_1	99	110	doxorubicin	Chemical	D004317
1760851_1	112	115	DOX	Chemical	D004317
1760851_1	167	200	N-(2-hydroxypropyl)methacrylamide	Chemical	C032976
1760851_1	202	206	HPMA	Chemical	C032976
1760851_1	CID	D004317	D066126

1760851_6|s|Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.
1760851_6	51	65	cardiotoxicity	Disease	D066126
1760851_6	292	306	cardiotoxicity	Disease	D066126
1760851_6	122	125	DOX	Chemical	D004317
1760851_6	144	148	HPMA	Chemical	C032976
1760851_6	168	171	DOX	Chemical	D004317
1760851_6	280	283	DOX	Chemical	D004317
1760851_6	CID	D004317	D066126

1779253_0|s|Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course.
1779253_0	36	59	post-herpetic neuralgia	Disease	D051474
1779253_0	15	24	capsaicin	Chemical	D002211

1779253_1|s|In order to evaluate the efficacy, time-course of action and predictors of response to topical capsaicin, 39 patients with chronic post-herpetic neuralgia (PHN), median duration 24 months, were treated with 0.025% capsaicin cream for 8 weeks.
1779253_1	131	154	post-herpetic neuralgia	Disease	D051474
1779253_1	156	159	PHN	Disease	D051474
1779253_1	95	104	capsaicin	Chemical	D002211
1779253_1	214	223	capsaicin	Chemical	D002211

1779253_4|s|Nineteen patients (48.7%) substantially improved after the 8-week trial; 5 (12.8%) discontinued therapy due to side-effects such as intolerable capsaicin-induced burning sensations (4) or mastitis (1); 15 (38.5%) reported no benefit.
1779253_4	188	196	mastitis	Disease	D008413
1779253_4	144	153	capsaicin	Chemical	D002211
1779253_4	CID	D002211	D008413

1779253_9|s|If confirmed in controlled trials, the long-term results of this open, non-randomized study might indicate that the analgesic effect of capsaicin in PHN is mediated by both interference with neuropeptide metabolism and morphological changes (perhaps degeneration) of nociceptive afferents.
1779253_9	149	152	PHN	Disease	D051474
1779253_9	136	145	capsaicin	Chemical	D002211

1837756_0|s|Serotonin reuptake inhibitors, paranoia, and the ventral basal ganglia.
1837756_0	31	39	paranoia	Disease	D010259
1837756_0	0	9	Serotonin	Chemical	D012701

1837756_2|s|Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here.
1837756_2	14	22	paranoid	Disease	D010259
1837756_2	45	54	serotonin	Chemical	D012701
1837756_2	75	85	fluoxetine	Chemical	D005473
1837756_2	90	103	amitriptyline	Chemical	D000639
1837756_2	CID	D005473	D010259
1837756_2	CID	D000639	D010259

1837756_4|s|Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.
1837756_4	12	32	depressive disorders	Disease	D003866
1837756_4	98	107	psychosis	Disease	D011605
1837756_4	168	177	psychosis	Disease	D011605
1837756_4	219	227	paranoid	Disease	D010259
1837756_4	258	267	serotonin	Chemical	D012701

1837756_5|s|Although the pharmacology and neurobiology of paranoia remain cryptic, several mechanisms, including 5HT3 receptor-mediated dopamine release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon.
1837756_5	46	54	paranoia	Disease	D010259
1837756_5	124	132	dopamine	Chemical	D004298

1837756_6|s|These cases call attention to possible paranoid exacerbations with serotonin reuptake blockers in select patients and raise neurobiological considerations regarding paranoia.
1837756_6	39	47	paranoid	Disease	D010259
1837756_6	165	173	paranoia	Disease	D010259
1837756_6	67	76	serotonin	Chemical	D012701

1858969_0|s|Five cases of encephalitis during treatment of loiasis with diethylcarbamazine.
1858969_0	14	26	encephalitis	Disease	D004660
1858969_0	47	54	loiasis	Disease	D008118
1858969_0	60	78	diethylcarbamazine	Chemical	D004049
1858969_0	CID	D004049	D004660

1858969_1|s|Five cases of encephalitis following treatment with diethylcarbamazine (DEC) were observed in Congolese patients with Loa loa filariasis.
1858969_1	14	26	encephalitis	Disease	D004660
1858969_1	126	136	filariasis	Disease	D005368
1858969_1	52	70	diethylcarbamazine	Chemical	D004049
1858969_1	72	75	DEC	Chemical	D004049
1858969_1	CID	D004049	D004660

1905439_0|s|Delirium in an elderly woman possibly associated with administration of misoprostol.
1905439_0	0	8	Delirium	Disease	D003693
1905439_0	72	83	misoprostol	Chemical	D016595
1905439_0	CID	D016595	D003693

1905439_1|s|Misoprostol has been associated with adverse reactions, including gastrointestinal symptoms, gynecologic problems, and headache.
1905439_1	119	127	headache	Disease	D006261
1905439_1	0	11	Misoprostol	Chemical	D016595

1905439_5|s|Her delirium significantly improved after misoprostol was discontinued and her mental status returned to normal within a week.
1905439_5	4	12	delirium	Disease	D003693
1905439_5	42	53	misoprostol	Chemical	D016595
1905439_5	CID	D016595	D003693

1905439_6|s|Because no other factors related to this patient changed significantly, the delirium experienced by this patient possibly resulted from misoprostol therapy.
1905439_6	76	84	delirium	Disease	D003693
1905439_6	136	147	misoprostol	Chemical	D016595
1905439_6	CID	D016595	D003693

1943082_6|s|There was no change in hepatic tissue total glutathione following intestinal ischemia-reperfusion injury.
1943082_6	77	85	ischemia	Disease	D007511
1943082_6	86	104	reperfusion injury	Disease	D015427
1943082_6	44	55	glutathione	Chemical	D005978

2021990_9|s|We conclude that an H1 antagonist may be useful in preventing hypotension caused by iv cimetidine, since the vasodilating activity of cimetidine is mediated, in part, through the H1 receptor.
2021990_9	62	73	hypotension	Disease	D007022
2021990_9	87	97	cimetidine	Chemical	D002927
2021990_9	134	144	cimetidine	Chemical	D002927
2021990_9	CID	D002927	D007022

2083961_0|s|Acute renal failure due to rifampicin.
2083961_0	0	19	Acute renal failure	Disease	D058186
2083961_0	27	37	rifampicin	Chemical	D012293
2083961_0	CID	D012293	D058186

2083961_2|s|Rifampicin was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, vomiting and fever with chills and rigors.
2083961_2	120	126	nausea	Disease	D009325
2083961_2	128	136	vomiting	Disease	D014839
2083961_2	141	146	fever	Disease	D005334
2083961_2	0	10	Rifampicin	Chemical	D012293

2131034_0|s|Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases.
2131034_0	7	21	polyneuropathy	Disease	D011115
2131034_0	55	63	thiotepa	Chemical	D013852
2131034_0	CID	D013852	D011115

2131034_1|s|Two cases of severe delayed neurologic toxicity related to the administration of intrathecal (IT) combination chemotherapy including thiotepa (TSPA) are presented.
2131034_1	28	47	neurologic toxicity	Disease	D020258
2131034_1	133	141	thiotepa	Chemical	D013852
2131034_1	143	147	TSPA	Chemical	D013852
2131034_1	CID	D013852	D020258

2131034_3|s|Neurologic toxicities have been described with IT-methotrexate, IT-cytosine arabinoside and IT-TSPA.
2131034_3	0	21	Neurologic toxicities	Disease	D020258
2131034_3	50	62	methotrexate	Chemical	D008727
2131034_3	67	87	cytosine arabinoside	Chemical	D003561
2131034_3	95	99	TSPA	Chemical	D013852
2131034_3	CID	D003561	D020258
2131034_3	CID	D008727	D020258
2131034_3	CID	D013852	D020258

2131034_5|s|In spite of the fact that TSPA is a useful IT agent, its combination with MTX, ara-C and radiotherapy could cause severe neurotoxicity.
2131034_5	121	134	neurotoxicity	Disease	D020258
2131034_5	26	30	TSPA	Chemical	D013852
2131034_5	74	77	MTX	Chemical	D008727
2131034_5	79	84	ara-C	Chemical	D003561
2131034_5	CID	D003561	D020258
2131034_5	CID	D008727	D020258
2131034_5	CID	D013852	D020258

2173761_5|s|Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.
2173761_5	53	64	hypotension	Disease	D007022
2173761_5	204	215	tachycardia	Disease	D013610
2173761_5	76	86	cromakalim	Chemical	D019806
2173761_5	91	100	pinacidil	Chemical	D020110
2173761_5	137	186	beta adrenergic and muscarinic receptors blockade	Chemical	D000319|D018727
2173761_5	CID	D019806	D007022
2173761_5	CID	D020110	D013610
2173761_5	CID	D019806	D013610
2173761_5	CID	D020110	D007022

2217015_0|s|Mefenamic acid-induced neutropenia and renal failure in elderly females with hypothyroidism.
2217015_0	23	34	neutropenia	Disease	D009503
2217015_0	39	52	renal failure	Disease	D051437
2217015_0	77	91	hypothyroidism	Disease	D007037
2217015_0	0	14	Mefenamic acid	Chemical	D008528
2217015_0	CID	D008528	D009503
2217015_0	CID	D008528	D051437

2217015_1|s|We report mefenamic acid-induced non-oliguric renal failure and severe neutropenia occurring simultaneously in two elderly females.
2217015_1	46	59	renal failure	Disease	D051437
2217015_1	71	82	neutropenia	Disease	D009503
2217015_1	10	24	mefenamic acid	Chemical	D008528
2217015_1	CID	D008528	D009503
2217015_1	CID	D008528	D051437

2217015_4|s|However, it would seem prudent not to use mefenamic acid in hypothyroid patients until the hypothyroidism has been corrected.
2217015_4	60	71	hypothyroid	Disease	D007037
2217015_4	91	105	hypothyroidism	Disease	D007037
2217015_4	42	56	mefenamic acid	Chemical	D008528

2239937_0|s|Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy.
2239937_0	12	25	hypercalcemia	Disease	D006934
2239937_0	54	71	calcium carbonate	Chemical	D002119
2239937_0	CID	D002119	D006934

2239937_1|s|Fourteen of 39 dialysis patients (36%) became hypercalcemic after switching to calcium carbonate as their principal phosphate binder.
2239937_1	46	59	hypercalcemic	Disease	D006934
2239937_1	79	96	calcium carbonate	Chemical	D002119
2239937_1	116	125	phosphate	Chemical	D010710
2239937_1	CID	D002119	D006934

2239937_2|s|In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of renal disease.
2239937_2	69	82	hypercalcemia	Disease	D006934
2239937_2	302	315	renal disease	Disease	D007674
2239937_2	118	125	calcium	Chemical	D002118

2239937_3|s|In addition to experiencing hypercalcemic episodes with peak calcium values of 2.7 to 3.8 mmol/L (10.7 to 15.0 mg/dL), patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/- 0.03 to 2.5 +/- 0.03 mmol/L [9.7 +/- 0.2 to 10.2 +/- 0.1 mg/dL], P = 0.006).
2239937_3	28	41	hypercalcemic	Disease	D006934
2239937_3	135	148	hypercalcemic	Disease	D006934
2239937_3	61	68	calcium	Chemical	D002118
2239937_3	200	207	calcium	Chemical	D002118

2320485_0|s|Methyldopa-induced hemolytic anemia in a 15 year old presenting as near-syncope.
2320485_0	19	35	hemolytic anemia	Disease	D000743
2320485_0	72	79	syncope	Disease	D013575
2320485_0	0	10	Methyldopa	Chemical	D008750
2320485_0	CID	D008750	D000743

2320485_2|s|Methyldopa causes an autoimmune hemolytic anemia in a small percentage of patients who take the drug.
2320485_2	21	48	autoimmune hemolytic anemia	Disease	D000744
2320485_2	0	10	Methyldopa	Chemical	D008750

2320485_3|s|We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near-syncope.
2320485_3	39	55	hemolytic anemia	Disease	D000743
2320485_3	98	118	emergency department	Disease	D004630
2320485_3	129	136	syncope	Disease	D013575
2320485_3	20	30	methyldopa	Chemical	D008750
2320485_3	CID	D008750	D000743

2320485_4|s|The boy had been treated with intravenous methyldopa during a trauma admission seven weeks prior to presentation.
2320485_4	62	68	trauma	Disease	D014947
2320485_4	42	52	methyldopa	Chemical	D008750

2358093_0|s|The long-term safety of danazol in women with hereditary angioedema.
2358093_0	46	67	hereditary angioedema	Disease	D054179
2358093_0	24	31	danazol	Chemical	D003613

2358093_2|s|We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with danazol for a continuous period of 6 months or longer.
2358093_2	128	149	hereditary angioedema	Disease	D054179
2358093_2	50	57	danazol	Chemical	D003613
2358093_2	163	170	danazol	Chemical	D003613

2383364_0|s|Patient tolerance study of topical chlorhexidine diphosphanilate: a new topical agent for burns.
2383364_0	90	95	burns	Disease	D002056
2383364_0	35	64	chlorhexidine diphosphanilate	Chemical	C048279

2383364_2|s|Chlorhexidine phosphanilate (CHP), a new broad-spectrum antimicrobial agent, has been evaluated as a topical burn wound dressing in cream form, but preliminary clinical trials reported that it was painful upon application.
2383364_2	109	113	burn	Disease	D002056
2383364_2	0	27	Chlorhexidine phosphanilate	Chemical	C048279
2383364_2	29	32	CHP	Chemical	C048279

2383364_5|s|One burn site was treated with each of four different CHP concentrations, from 0.25 per cent to 2 per cent, their vehicle, and 1 per cent silver sulphadiazine (AgSD) cream, an antimicrobial agent frequently used for topical treatment of burn wounds.
2383364_5	4	8	burn	Disease	D002056
2383364_5	237	241	burn	Disease	D002056
2383364_5	54	57	CHP	Chemical	C048279
2383364_5	138	158	silver sulphadiazine	Chemical	D012837
2383364_5	160	164	AgSD	Chemical	D012837

2383364_7|s|There was a direct relationship between CHP concentration and patients' ratings of pain on an analogue scale.
2383364_7	83	87	pain	Disease	D010146
2383364_7	40	43	CHP	Chemical	C048279
2383364_7	CID	C048279	D010146

2383364_8|s|The 0.25 per cent CHP cream was closest to AgSD in pain tolerance; however, none of the treatments differed statistically from AgSD or from each other.
2383364_8	51	55	pain	Disease	D010146
2383364_8	18	21	CHP	Chemical	C048279
2383364_8	43	47	AgSD	Chemical	D012837
2383364_8	127	131	AgSD	Chemical	D012837
2383364_8	CID	C048279	D010146

2400986_0|s|Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.
2400986_0	15	28	neurotoxicity	Disease	D020258
2400986_0	42	50	busulfan	Chemical	D002066

2400986_1|s|Busulfan is known to be neurotoxic in animals and humans, but its acute neurotoxicity remains poorly characterized in children.
2400986_1	24	34	neurotoxic	Disease	D020258
2400986_1	72	85	neurotoxicity	Disease	D020258
2400986_1	0	8	Busulfan	Chemical	D002066
2400986_1	62	65	its	Chemical	D002066

2400986_2|s|We report here a retrospective study of 123 children (median age, 6.5 years) receiving high-dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid tumors, brain tumors excluded.
2400986_2	186	192	tumors	Disease	D009369
2400986_2	194	206	brain tumors	Disease	D001932
2400986_2	97	105	busulfan	Chemical	D002066

2400986_6|s|Ninety-six patients were not given anticonvulsive prophylaxis; 7 (7.5%) developed seizures during the 4 days of the busulfan course or within 24 h after the last dosing.
2400986_6	82	90	seizures	Disease	D012640
2400986_6	116	124	busulfan	Chemical	D002066
2400986_6	CID	D002066	D012640

2400986_7|s|When the total busulfan dose was taken into account, there was a significant difference in terms of neurotoxicity incidence among patients under 16 mg/kg (1 of 57, 1.7%) and patients under 600 mg/m2 (6 of 39, 15.4%) (P less than 0.02).
2400986_7	100	113	neurotoxicity	Disease	D020258
2400986_7	15	23	busulfan	Chemical	D002066

2400986_8|s|Twenty-seven patients were given a 600-mg/m2 busulfan total dose with continuous i.v. infusion of clonazepam; none had any neurological symptoms.
2400986_8	123	144	neurological symptoms	Disease	D009461
2400986_8	45	53	busulfan	Chemical	D002066
2400986_8	98	108	clonazepam	Chemical	D002998

2400986_9|s|Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1.39.
2400986_9	139	169	central nervous system disease	Disease	D002493
2400986_9	0	8	Busulfan	Chemical	D002066
2400986_9	186	194	busulfan	Chemical	D002066
2400986_9	200	210	clonazepam	Chemical	D002998
2400986_9	211	219	busulfan	Chemical	D002066

2400986_11|s|This study shows that busulfan neurotoxicity is dose-dependent in children and efficiently prevented by clonazepam.
2400986_11	31	44	neurotoxicity	Disease	D020258
2400986_11	22	30	busulfan	Chemical	D002066
2400986_11	104	114	clonazepam	Chemical	D002998

2400986_12|s|A busulfan dose calculated on the basis of body surface area, resulting in higher doses in young children, was followed by increased neurotoxicity, close to neurotoxicity incidence observed in adults.
2400986_12	133	146	neurotoxicity	Disease	D020258
2400986_12	157	170	neurotoxicity	Disease	D020258
2400986_12	2	10	busulfan	Chemical	D002066

2429800_0|s|Histamine antagonists and d-tubocurarine-induced hypotension in cardiac surgical patients.
2429800_0	49	60	hypotension	Disease	D007022
2429800_0	0	9	Histamine	Chemical	D006632
2429800_0	26	40	d-tubocurarine	Chemical	D014403
2429800_0	CID	D014403	D007022

2453942_1|s|Lindane (gamma-hexachlorocyclohexane) is an organochlorine insecticide with known neurotoxic effects.
2453942_1	82	92	neurotoxic	Disease	D020258
2453942_1	0	7	Lindane	Chemical	D001556
2453942_1	9	36	gamma-hexachlorocyclohexane	Chemical	D001556

2453942_3|s|We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, dopamine and its metabolites in 7 brain areas at the onset of seizures.
2453942_3	189	197	seizures	Disease	D012640
2453942_3	25	32	lindane	Chemical	D001556
2453942_3	121	125	GABA	Chemical	D005680
2453942_3	127	135	dopamine	Chemical	D004298
2453942_3	CID	D001556	D012640

2453942_4|s|All animals suffered tonic convulsions at 18.3 +/- 1.4 min after lindane administration.
2453942_4	27	38	convulsions	Disease	D012640
2453942_4	65	72	lindane	Chemical	D001556
2453942_4	CID	D001556	D012640

2484903_1|s|Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.
2484903_1	47	56	hepatitis	Disease	D056486
2484903_1	99	122	hepatocellular necrosis	Disease	D047508
2484903_1	167	186	lupus-like syndrome	Disease	D008180
2484903_1	13	29	propylthiouracil	Chemical	D011441
2484903_1	76	87	methimazole	Chemical	D008713
2484903_1	139	155	propylthiouracil	Chemical	D011441
2484903_1	CID	D011441	D008180
2484903_1	CID	D008713	D047508
2484903_1	CID	D011441	D056486

2553470_0|s|Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of status epilepticus in rats.
2553470_0	69	87	status epilepticus	Disease	D013226
2553470_0	26	32	MK-801	Chemical	D016291
2553470_0	40	47	lithium	Chemical	D008094
2553470_0	48	59	pilocarpine	Chemical	D010862
2553470_0	CID	D010862	D013226
2553470_0	CID	D008094	D013226

2553470_1|s|MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two seizure models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone.
2553470_1	130	137	seizure	Disease	D012640
2553470_1	0	6	MK-801	Chemical	D016291
2553470_1	25	45	N-methyl-D-aspartate	Chemical	D016202
2553470_1	47	51	NMDA	Chemical	D016202
2553470_1	166	173	lithium	Chemical	D008094
2553470_1	178	189	pilocarpine	Chemical	D010862
2553470_1	227	238	pilocarpine	Chemical	D010862

2553470_3|s|First, pretreatment with MK-801 produced an effective and dose-dependent anticonvulsant action with the lithium-pilocarpine model but not with rats treated with pilocarpine alone, suggesting that different biochemical mechanisms control seizures in these two models.
2553470_3	237	245	seizures	Disease	D012640
2553470_3	25	31	MK-801	Chemical	D016291
2553470_3	104	111	lithium	Chemical	D008094
2553470_3	112	123	pilocarpine	Chemical	D010862
2553470_3	161	172	pilocarpine	Chemical	D010862

2553470_4|s|Second, the anticonvulsant effect of MK-801 in the lithium-pilocarpine model only occurred after initial periods of seizure activity.
2553470_4	116	123	seizure	Disease	D012640
2553470_4	37	43	MK-801	Chemical	D016291
2553470_4	51	58	lithium	Chemical	D008094
2553470_4	59	70	pilocarpine	Chemical	D010862

2553470_6|s|Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.
2553470_6	47	55	seizures	Disease	D012640
2553470_6	192	210	status epilepticus	Disease	D013226
2553470_6	242	250	seizures	Disease	D012640
2553470_6	67	74	lithium	Chemical	D008094
2553470_6	79	90	pilocarpine	Chemical	D010862
2553470_6	137	148	pilocarpine	Chemical	D010862
2553470_6	CID	D010862	D013226
2553470_6	CID	D008094	D013226

2553470_7|s|Administration of MK-801 30 or 60 min after pilocarpine, i.e., during status epilepticus, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate.
2553470_7	70	88	status epilepticus	Disease	D013226
2553470_7	134	141	seizure	Disease	D012640
2553470_7	18	24	MK-801	Chemical	D016291
2553470_7	44	55	pilocarpine	Chemical	D010862
2553470_7	CID	D010862	D013226

2553470_8|s|These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-pilocarpine model.
2553470_8	83	101	status epilepticus	Disease	D013226
2553470_8	106	118	brain damage	Disease	D001930
2553470_8	41	45	NMDA	Chemical	D016202
2553470_8	126	133	lithium	Chemical	D008094
2553470_8	134	145	pilocarpine	Chemical	D010862
2553470_8	CID	D010862	D013226
2553470_8	CID	D008094	D013226

2553470_9|s|This was further supported by results showing that nonconvulsive doses of NMDA and pilocarpine were synergistic, resulting in status epilepticus and subsequent mortality.
2553470_9	126	144	status epilepticus	Disease	D013226
2553470_9	74	78	NMDA	Chemical	D016202
2553470_9	83	94	pilocarpine	Chemical	D010862
2553470_9	CID	D010862	D013226

2614930_0|s|Nifedipine induced bradycardia in a patient with autonomic neuropathy.
2614930_0	19	30	bradycardia	Disease	D001919
2614930_0	49	69	autonomic neuropathy	Disease	D009422
2614930_0	0	10	Nifedipine	Chemical	D009543
2614930_0	CID	D009543	D001919

2614930_2|s|He was found to have atrial flutter at a ventricular rate of 70/min which slowed down to 30-40/min when nifedipine (60 mg) in 3 divided doses, during which he was paced at a rate of 70/min.
2614930_2	21	35	atrial flutter	Disease	D001282
2614930_2	104	114	nifedipine	Chemical	D009543

2614930_3|s|This is inconsistent with the well-established finding that nifedipine induces tachycardia in normally innervated hearts.
2614930_3	79	90	tachycardia	Disease	D013610
2614930_3	60	70	nifedipine	Chemical	D009543
2614930_3	CID	D009543	D013610

2625524_3|s|Haloperidol failed to prevent amphetamine-induced seizures, but did lower the mortality rate at most doses tested.
2625524_3	50	58	seizures	Disease	D012640
2625524_3	0	11	Haloperidol	Chemical	D006220
2625524_3	30	41	amphetamine	Chemical	D000661
2625524_3	CID	D000661	D012640

2625524_4|s|Haloperidol decreased the incidence of cocaine-induced seizures at the two highest doses, but the lowering of the mortality rate did not reach statistical significance at any dose.
2625524_4	55	63	seizures	Disease	D012640
2625524_4	0	11	Haloperidol	Chemical	D006220
2625524_4	39	46	cocaine	Chemical	D003042
2625524_4	CID	D003042	D012640

2625524_5|s|These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of seizures.
2625524_5	166	174	seizures	Disease	D012640
2625524_5	53	61	dopamine	Chemical	D004298
2625524_5	70	81	haloperidol	Chemical	D006220
2625524_5	111	122	amphetamine	Chemical	D000661
2625524_5	CID	D000661	D012640

2625524_6|s|In contrast, haloperidol demonstrated an ability to reduce cocaine-induced seizures without significantly reducing mortality.
2625524_6	75	83	seizures	Disease	D012640
2625524_6	13	24	haloperidol	Chemical	D006220
2625524_6	59	66	cocaine	Chemical	D003042
2625524_6	CID	D003042	D012640

2650911_0|s|Autoradiographic evidence of estrogen binding sites in nuclei of diethylstilbesterol induced hamster renal carcinomas.
2650911_0	101	117	renal carcinomas	Disease	D002292
2650911_0	29	37	estrogen	Chemical	D004967
2650911_0	65	84	diethylstilbesterol	Chemical	D004054
2650911_0	CID	D004054	D002292

2650911_1|s|Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters.
2650911_1	127	143	renal carcinomas	Disease	D002292
2650911_1	0	8	Estrogen	Chemical	D004967
2650911_1	99	118	diethylstilbesterol	Chemical	D004054
2650911_1	CID	D004054	D002292

2650911_2|s|Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of tumor cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced silver grains over nuclei than cytoplasm of these cells.
2650911_2	111	116	tumor	Disease	D009369
2650911_2	62	71	estradiol	Chemical	D004958
2650911_2	206	212	silver	Chemical	D012834

2650911_4|s|This is the first published report documenting the preferential in vivo binding of estrogen to nuclei of cells in estrogen induced hamster renal carcinomas.
2650911_4	139	155	renal carcinomas	Disease	D002292
2650911_4	83	91	estrogen	Chemical	D004967
2650911_4	114	122	estrogen	Chemical	D004967

2710809_0|s|Bradycardia due to biperiden.
2710809_0	0	11	Bradycardia	Disease	D001919
2710809_0	19	28	biperiden	Chemical	D001712
2710809_0	CID	D001712	D001919

2710809_1|s|In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia.
2710809_1	54	66	postzosteric	Disease	D006562
2710809_1	67	87	trigeminal neuralgia	Disease	D014277
2710809_1	213	224	bradycardia	Disease	D001919
2710809_1	226	236	dysarthria	Disease	D004401
2710809_1	242	251	dysphagia	Disease	D003680
2710809_1	122	139	biperiden lactate	Chemical	C036432

2710809_3|s|Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors.
2710809_3	0	11	Bradycardia	Disease	D001919
2710809_3	23	32	biperiden	Chemical	D001712
2710809_3	110	118	atropine	Chemical	D001285
2710809_3	133	142	muscarine	Chemical	D009116
2710809_3	CID	D001712	D001919

2718706_0|s|Deliberate hypotension induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.
2718706_0	11	22	hypotension	Disease	D007022
2718706_0	34	43	labetalol	Chemical	D007741
2718706_0	49	58	halothane	Chemical	D006221
2718706_0	60	69	enflurane	Chemical	D004737
2718706_0	73	83	isoflurane	Chemical	D007530
2718706_0	CID	D004737	D007022
2718706_0	CID	D007530	D007022
2718706_0	CID	D006221	D007022
2718706_0	CID	D007741	D007022

2718706_1|s|The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a hypotensive agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery.
2718706_1	87	98	hypotensive	Disease	D007022
2718706_1	25	34	labetalol	Chemical	D007741
2718706_1	150	159	halothane	Chemical	D006221
2718706_1	161	170	enflurane	Chemical	D004737
2718706_1	174	184	isoflurane	Chemical	D007530
2718706_1	CID	D004737	D007022
2718706_1	CID	D007530	D007022
2718706_1	CID	D006221	D007022
2718706_1	CID	D007741	D007022

2718706_3|s|The mean H concentration during hypotension in the inspiratory gas was 0.7 +/- 0.1 vol%, the mean E concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%.
2718706_3	32	43	hypotension	Disease	D007022
2718706_3	9	10	H	Chemical	D006221
2718706_3	98	99	E	Chemical	D004737
2718706_3	145	146	I	Chemical	D007530
2718706_3	CID	D004737	D007022
2718706_3	CID	D007530	D007022
2718706_3	CID	D006221	D007022

2718706_8|s|During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group.
2718706_8	7	18	hypotension	Disease	D007022
2718706_8	111	122	hypotension	Disease	D007022
2718706_8	30	40	creatinine	Chemical	D003404
2718706_8	205	215	isoflurane	Chemical	D007530
2718706_8	CID	D007530	D007022

2718706_10|s|These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound hypertension.
2718706_10	64	75	hypotension	Disease	D007022
2718706_10	97	108	tachycardia	Disease	D013610
2718706_10	121	133	hypertension	Disease	D006973
2718706_10	28	37	labetalol	Chemical	D007741
2718706_10	CID	D007741	D007022

2765447_0|s|Convulsion following intravenous fluorescein angiography.
2765447_0	0	10	Convulsion	Disease	D012640
2765447_0	33	44	fluorescein	Chemical	D019793

2765447_1|s|Tonic-clonic seizures followed intravenous fluorescein injection for fundus angiography in a 47-year-old male.
2765447_1	0	21	Tonic-clonic seizures	Disease	D004830
2765447_1	43	54	fluorescein	Chemical	D019793
2765447_1	CID	D019793	D004830

2767010_3|s|ACC-9653 and phenytoin sodium have equivalent anticonvulsant activity against seizures induced by maximal electroshock (MES) in mice following i.p., oral, or i.v. administration.
2767010_3	78	86	seizures	Disease	D012640
2767010_3	0	8	ACC-9653	Chemical	C043114
2767010_3	13	29	phenytoin sodium	Chemical	C043114

2767010_6|s|ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain-induced ventricular tachycardia in anesthetized dogs.
2767010_6	91	114	ventricular tachycardia	Disease	D017180
2767010_6	0	8	ACC-9653	Chemical	C043114
2767010_6	13	29	phenytoin sodium	Chemical	C043114
2767010_6	75	82	ouabain	Chemical	D010042
2767010_6	CID	D010042	D017180

2767010_7|s|The total doses of ACC-9653 or phenytoin sodium necessary to convert the arrhythmia to a normal sinus rhythm were 24 +/- 6 and 14 +/- 3 mg/kg, respectively.
2767010_7	73	83	arrhythmia	Disease	D001145
2767010_7	19	27	ACC-9653	Chemical	C043114
2767010_7	31	47	phenytoin sodium	Chemical	C043114

2767010_8|s|Only phenytoin sodium displayed in vitro antiarrhythmic activity against strophanthidin-induced arrhythmias in guinea pig right atria.
2767010_8	96	107	arrhythmias	Disease	D001145
2767010_8	5	21	phenytoin sodium	Chemical	C043114
2767010_8	73	87	strophanthidin	Chemical	D013327
2767010_8	CID	D013327	D001145

2767010_12|s|Acute toxicity studies of ACC-9653 and phenytoin sodium were carried out in mice, rats, rabbits, and dogs by i.v., i.m., and i.p. routes of administration.
2767010_12	6	14	toxicity	Disease	D064420
2767010_12	26	34	ACC-9653	Chemical	C043114
2767010_12	39	55	phenytoin sodium	Chemical	C043114

2818777_0|s|Phenytoin induced fatal hepatic injury.
2818777_0	24	38	hepatic injury	Disease	D056486
2818777_0	0	9	Phenytoin	Chemical	D010672

2818777_1|s|A 61 year old female developed fatal hepatic failure after phenytoin administration.
2818777_1	37	52	hepatic failure	Disease	D017093
2818777_1	59	68	phenytoin	Chemical	D010672
2818777_1	CID	D010672	D017093

2884595_4|s|Blockade of histamine H1 receptors may reduce mortality in pertussis immunization-induced encephalopathy in mice.
2884595_4	59	68	pertussis	Disease	D014917
2884595_4	90	104	encephalopathy	Disease	D001927
2884595_4	12	21	histamine	Chemical	D006632

2904523_0|s|Support for adrenaline-hypertension hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion.
2904523_0	23	35	hypertension	Disease	D006973
2904523_0	12	22	adrenaline	Chemical	D004837
2904523_0	85	95	adrenaline	Chemical	D004837
2904523_0	CID	D004837	D006973

2904523_6|s|These findings are strong support for the adrenaline-hypertension hypothesis in man.
2904523_6	53	65	hypertension	Disease	D006973
2904523_6	42	52	adrenaline	Chemical	D004837
2904523_6	CID	D004837	D006973

2907577_0|s|Effect of alkylxanthines on gentamicin-induced acute renal failure in the rat.
2907577_0	47	66	acute renal failure	Disease	D058186
2907577_0	10	24	alkylxanthines	Chemical	-1
2907577_0	28	38	gentamicin	Chemical	D005839
2907577_0	CID	D005839	D058186

2907577_1|s|Adenosine antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of acute renal failure (ARF).
2907577_1	74	83	ischaemic	Disease	D007511
2907577_1	88	99	nephrotoxic	Disease	D007674
2907577_1	110	129	acute renal failure	Disease	D058186
2907577_1	131	134	ARF	Disease	D058186
2907577_1	0	9	Adenosine	Chemical	D000241

2907577_2|s|In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1).
2907577_2	194	213	acute renal failure	Disease	D058186
2907577_2	43	57	alkylxanthines	Chemical	-1
2907577_2	86	95	adenosine	Chemical	D000241
2907577_2	108	128	8-phenyltheophylline	Chemical	C028322
2907577_2	130	142	theophylline	Chemical	D013806
2907577_2	147	159	enprofylline	Chemical	C034347
2907577_2	242	252	gentamicin	Chemical	D005839
2907577_2	CID	D005839	D058186

2907577_3|s|Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices.
2907577_3	186	194	necrosis	Disease	D009336
2907577_3	51	55	urea	Chemical	D014508
2907577_3	60	70	creatinine	Chemical	D003404
2907577_3	124	144	p-aminohippuric acid	Chemical	D010130

2907577_6|s|The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little, if any, pathophysiological role in gentamicin-induced ARF.
2907577_6	196	199	ARF	Disease	D058186
2907577_6	60	74	alkylxanthines	Chemical	-1
2907577_6	118	127	adenosine	Chemical	D000241
2907577_6	177	187	gentamicin	Chemical	D005839
2907577_6	CID	D005839	D058186

2931989_1|s|A total of 261 adverse ocular reactions occurred in 237 patients who received isotretinoin, a commonly used drug in the treatment of severe cystic acne.
2931989_1	147	151	acne	Disease	D000152
2931989_1	78	90	isotretinoin	Chemical	D015474

2931989_5|s|Isotretinoin is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia).
2931989_5	74	98	congenital abnormalities	Disease	D000013
2931989_5	129	143	microphthalmos	Disease	D008850
2931989_5	153	166	hypertelorism	Disease	D006972
2931989_5	172	194	optic nerve hypoplasia	Disease	C563492
2931989_5	0	12	Isotretinoin	Chemical	D015474

2933998_0|s|Procaterol and terbutaline in bronchial asthma.
2933998_0	30	46	bronchial asthma	Disease	D001249
2933998_0	0	10	Procaterol	Chemical	D017265
2933998_0	15	26	terbutaline	Chemical	D013726

2933998_2|s|Procaterol, a new beta-2 adrenoceptor stimulant, was studied in a double-blind, placebo-controlled, cross-over trial in patients with bronchial asthma.
2933998_2	134	150	bronchial asthma	Disease	D001249
2933998_2	0	10	Procaterol	Chemical	D017265

2933998_5|s|Both anti-asthmatic and tremorgenic effects of procaterol were dose-related.
2933998_5	10	19	asthmatic	Disease	D001249
2933998_5	24	35	tremorgenic	Disease	D014202
2933998_5	47	57	procaterol	Chemical	D017265
2933998_5	CID	D017265	D014202

2974281_0|s|Subacute effects of propranolol and B 24/76 on isoproterenol-induced rat heart hypertrophy in correlation with blood pressure.
2974281_0	73	90	heart hypertrophy	Disease	D006332
2974281_0	20	31	propranolol	Chemical	D011433
2974281_0	47	60	isoproterenol	Chemical	D007545
2974281_0	CID	D007545	D006332

2974281_2|s|The studies were performed using an experimental model of isoproterenol-induced heart hypertrophy in rats.
2974281_2	80	97	heart hypertrophy	Disease	D006332
2974281_2	58	71	isoproterenol	Chemical	D007545
2974281_2	CID	D007545	D006332

2974281_5|s|It was possible to suppress the increased ornithine decarboxylase activity with both beta-blockers in hypertrophied hearts, but there was no effect on the heart mass.
2974281_5	102	122	hypertrophied hearts	Disease	D006332
2974281_5	42	51	ornithine	Chemical	D009952

2974281_6|s|Neither propranolol nor B 24/76 could stop the changes in the characteristic myosin isoenzyme pattern of the hypertrophied rat heart.
2974281_6	109	122	hypertrophied	Disease	D006984
2974281_6	8	19	propranolol	Chemical	D011433

2974281_7|s|Thus, the investigations did not provide any evidence that the beta-receptor blockers propranolol and B 24/76 have the potency to prevent isoproterenol from producing heart hypertrophy.
2974281_7	167	184	heart hypertrophy	Disease	D006332
2974281_7	86	97	propranolol	Chemical	D011433
2974281_7	138	151	isoproterenol	Chemical	D007545
2974281_7	CID	D007545	D006332

3074291_0|s|Comparison of the effect of oxitropium bromide and of slow-release theophylline on nocturnal asthma.
3074291_0	93	99	asthma	Disease	D001249
3074291_0	28	46	oxitropium bromide	Chemical	C017590
3074291_0	67	79	theophylline	Chemical	D013806

3074291_1|s|The effects of a new inhaled antimuscarinic drug, oxitropium bromide, and of a slow-release theophylline preparation upon nocturnal asthma were compared in a placebo-controlled double-blind study.
3074291_1	132	138	asthma	Disease	D001249
3074291_1	50	68	oxitropium bromide	Chemical	C017590
3074291_1	92	104	theophylline	Chemical	D013806

3074291_5|s|No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.
3074291_5	88	94	nausea	Disease	D009325
3074291_5	96	104	vomiting	Disease	D014839
3074291_5	109	116	tremors	Disease	D014202
3074291_5	36	46	oxitropium	Chemical	C017590
3074291_5	123	135	theophylline	Chemical	D013806
3074291_5	CID	D013806	D014202
3074291_5	CID	D013806	D009325
3074291_5	CID	D013806	D014839

3074291_6|s|Oxitropium proves to be a valuable alternative to theophylline in nocturnal asthma, since it is equally potent, safer and does not require the titration of dosage.
3074291_6	76	82	asthma	Disease	D001249
3074291_6	0	10	Oxitropium	Chemical	C017590
3074291_6	50	62	theophylline	Chemical	D013806

3083835_0|s|Penicillin anaphylaxis.
3083835_0	11	22	anaphylaxis	Disease	D000707
3083835_0	0	10	Penicillin	Chemical	D010406
3083835_0	CID	D010406	D000707

3083835_1|s|A case of oral penicillin anaphylaxis is described, and the terminology, occurrence, clinical manifestations, pathogenesis, prevention, and treatment of anaphylaxis are reviewed.
3083835_1	26	37	anaphylaxis	Disease	D000707
3083835_1	153	164	anaphylaxis	Disease	D000707
3083835_1	15	25	penicillin	Chemical	D010406
3083835_1	CID	D010406	D000707

3083835_2|s|Emergency physicians should be aware of oral penicillin anaphylaxis in order to prevent its occurrence by prescribing the antibiotic judiciously and knowledgeably and to offer optimal medical therapy once this life-threatening reaction has begun.
3083835_2	56	67	anaphylaxis	Disease	D000707
3083835_2	45	55	penicillin	Chemical	D010406
3083835_2	CID	D010406	D000707

3084231_0|s|Reversible valproic acid-induced dementia: a case report.
3084231_0	33	41	dementia	Disease	D003704
3084231_0	11	24	valproic acid	Chemical	D014635
3084231_0	CID	D014635	D003704

3084231_1|s|Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.
3084231_1	33	41	dementia	Disease	D003704
3084231_1	83	91	epilepsy	Disease	D004827
3084231_1	11	24	valproic acid	Chemical	D014635
3084231_1	CID	D014635	D003704

3084231_3|s|Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.
3084231_3	290	304	hyperammonemia	Disease	D022124
3084231_3	145	158	valproic acid	Chemical	D014635
3084231_3	268	281	valproic acid	Chemical	D014635
3084231_3	CID	D014635	D022124

3088653_0|s|Reversal of scopolamine-induced amnesia of passive avoidance by pre- and post-training naloxone.
3088653_0	32	39	amnesia	Disease	D000647
3088653_0	12	23	scopolamine	Chemical	D012601
3088653_0	87	95	naloxone	Chemical	D009270
3088653_0	CID	D012601	D000647

3088653_1|s|In a series of five experiments, the modulating role of naloxone on a scopolamine-induced retention deficit in a passive avoidance paradigm was investigated in mice.
3088653_1	90	107	retention deficit	Disease	D008569
3088653_1	56	64	naloxone	Chemical	D009270
3088653_1	70	81	scopolamine	Chemical	D012601

3088653_2|s|Scopolamine, but not methyl scopolamine (1 and 3 mg/kg), induced an amnesia as measured by latency and duration parameters.
3088653_2	68	75	amnesia	Disease	D000647
3088653_2	0	11	Scopolamine	Chemical	D012601
3088653_2	21	39	methyl scopolamine	Chemical	D019832
3088653_2	CID	D012601	D000647

3088653_3|s|Naloxone (0.3, 1, 3, and 10 mg/kg) injected prior to training attenuated the retention deficit with a peak of activity at 3 mg/kg.
3088653_3	77	94	retention deficit	Disease	D008569
3088653_3	0	8	Naloxone	Chemical	D009270

3088653_5|s|Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced amnesia.
3088653_5	122	129	amnesia	Disease	D000647
3088653_5	32	40	naloxone	Chemical	D009270
3088653_5	102	113	scopolamine	Chemical	D012601
3088653_5	CID	D012601	D000647

3088653_6|s|Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.
3088653_6	58	62	pain	Disease	D010146
3088653_6	236	253	retention deficit	Disease	D008569
3088653_6	89	97	naloxone	Chemical	D009270
3088653_6	144	152	naloxone	Chemical	D009270
3088653_6	200	208	naloxone	Chemical	D009270
3088653_6	216	227	scopolamine	Chemical	D012601

3109094_0|s|Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesna.
3109094_0	68	98	lesions of the urinary bladder	Disease	D001745
3109094_0	43	59	cyclophosphamide	Chemical	D003520
3109094_0	134	139	mesna	Chemical	D015080
3109094_0	CID	D003520	D001745

3109094_1|s|Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses.
3109094_1	41	49	cystitis	Disease	D003556
3109094_1	134	139	edema	Disease	D004487
3109094_1	198	206	necroses	Disease	D009336
3109094_1	16	32	cyclophosphamide	Chemical	D003520

3125850_0|s|Increase in intragastric pressure during suxamethonium-induced muscle fasciculations in children: inhibition by alfentanil.
3125850_0	63	84	muscle fasciculations	Disease	D005207
3125850_0	41	54	suxamethonium	Chemical	D013390
3125850_0	112	122	alfentanil	Chemical	D015760
3125850_0	CID	D013390	D005207

3125850_3|s|The incidence and intensity of muscle fasciculations caused by suxamethonium were significantly greater in the control than in the alfentanil group.
3125850_3	31	52	muscle fasciculations	Disease	D005207
3125850_3	63	76	suxamethonium	Chemical	D013390
3125850_3	131	141	alfentanil	Chemical	D015760
3125850_3	CID	D013390	D005207

3125850_4|s|The intragastric pressure during muscle fasciculations was significantly higher in the control group (16 +/- 0.7 (SEM) cm H2O) than in the alfentanil group (7.7 +/- 1.5 (SEM) cm H2O).
3125850_4	33	54	muscle fasciculations	Disease	D005207
3125850_4	122	125	H2O	Chemical	D014867
3125850_4	139	149	alfentanil	Chemical	D015760
3125850_4	178	181	H2O	Chemical	D014867

3125850_6|s|It is concluded that intragastric pressure increases significantly during muscle fasciculations caused by suxamethonium in healthy children.
3125850_6	74	95	muscle fasciculations	Disease	D005207
3125850_6	106	119	suxamethonium	Chemical	D013390
3125850_6	CID	D013390	D005207

3125850_7|s|Alfentanil 50 micrograms kg-1 effectively inhibits the incidence and intensity of suxamethonium-induced muscle fasciculations; moreover, intragastric pressure remains at its control value.
3125850_7	104	125	muscle fasciculations	Disease	D005207
3125850_7	0	10	Alfentanil	Chemical	D015760
3125850_7	82	95	suxamethonium	Chemical	D013390
3125850_7	CID	D013390	D005207

3155884_0|s|Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats.
3155884_0	57	68	cardiotoxic	Disease	D066126
3155884_0	111	119	diabetic	Disease	D003920
3155884_0	79	92	isoproterenol	Chemical	D007545
3155884_0	96	110	streptozotocin	Chemical	D013311
3155884_0	CID	D013311	D003920

3155884_1|s|A morphometric study of isoproterenol induced myocardial fibrosis.
3155884_1	57	65	fibrosis	Disease	D005355
3155884_1	24	37	isoproterenol	Chemical	D007545
3155884_1	CID	D007545	D005355

3155884_2|s|The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.
3155884_2	98	106	diabetes	Disease	D003920
3155884_2	119	130	cardiotoxic	Disease	D066126
3155884_2	83	97	streptozotocin	Chemical	D013311
3155884_2	155	168	isoproterenol	Chemical	D007545
3155884_2	170	173	ISO	Chemical	D007545
3155884_2	CID	D013311	D003920

3155884_3|s|Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared.
3155884_3	112	120	fibrosis	Disease	D005355
3155884_3	62	65	ISO	Chemical	D007545
3155884_3	100	103	ISO	Chemical	D007545
3155884_3	274	281	glucose	Chemical	D005947
3155884_3	CID	D007545	D005355

3155884_4|s|The myocardial content of catecholamines was estimated in these 8 day diabetic rats.
3155884_4	70	78	diabetic	Disease	D003920
3155884_4	26	40	catecholamines	Chemical	D002395

3155884_7|s|The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the ISO resistance and points towards a direct insulin effect on myocardial catecholamine sensitivity in diabetic rats.
3155884_7	211	219	diabetic	Disease	D003920
3155884_7	74	88	streptozotocin	Chemical	D013311
3155884_7	110	113	ISO	Chemical	D007545
3155884_7	182	195	catecholamine	Chemical	D002395
3155884_7	CID	D013311	D003920

3191389_0|s|Differential effects of non-steroidal anti-inflammatory drugs on seizures produced by pilocarpine in rats.
3191389_0	65	73	seizures	Disease	D012640
3191389_0	86	97	pilocarpine	Chemical	D010862
3191389_0	CID	D010862	D012640

3191389_1|s|The muscarinic cholinergic agonist pilocarpine induces in rats seizures and status epilepticus followed by widespread damage to the forebrain.
3191389_1	63	71	seizures	Disease	D012640
3191389_1	76	94	status epilepticus	Disease	D013226
3191389_1	35	46	pilocarpine	Chemical	D010862
3191389_1	CID	D010862	D012640
3191389_1	CID	D010862	D013226

3191389_2|s|The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.
3191389_2	183	191	seizures	Disease	D012640
3191389_2	101	118	sodium salicylate	Chemical	D012980
3191389_2	120	134	phenylbutazone	Chemical	D010653
3191389_2	136	148	indomethacin	Chemical	D007213
3191389_2	150	159	ibuprofen	Chemical	D007052
3191389_2	164	178	mefenamic acid	Chemical	D008528
3191389_2	204	215	pilocarpine	Chemical	D010862
3191389_2	CID	D010653	D012640
3191389_2	CID	D012980	D012640
3191389_2	CID	D010862	D012640

3191389_4|s|Indomethacin, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by pilocarpine.
3191389_4	74	82	seizures	Disease	D012640
3191389_4	0	12	Indomethacin	Chemical	D007213
3191389_4	30	39	ibuprofen	Chemical	D007052
3191389_4	95	106	pilocarpine	Chemical	D010862
3191389_4	CID	D010862	D012640

3191389_5|s|Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.
3191389_5	44	52	seizures	Disease	D012640
3191389_5	77	84	seizure	Disease	D012640
3191389_5	93	105	brain damage	Disease	D001930
3191389_5	0	14	Mefenamic acid	Chemical	D008528
3191389_5	117	128	pilocarpine	Chemical	D010862
3191389_5	CID	D010862	D012640

3191389_6|s|These results indicate that non-steroidal anti-inflammatory drugs differentially modulate the threshold for pilocarpine-induced seizures.
3191389_6	128	136	seizures	Disease	D012640
3191389_6	108	119	pilocarpine	Chemical	D010862
3191389_6	CID	D010862	D012640

3289726_0|s|Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma.
3289726_0	0	28	Acute neurologic dysfunction	Disease	D009422
3289726_0	67	83	malignant glioma	Disease	D005910
3289726_0	45	54	etoposide	Chemical	D005047

3289726_1|s|Etoposide (VP-16-213) has been used in the treatment of many solid tumors and hematologic malignancies.
3289726_1	67	73	tumors	Disease	D009369
3289726_1	78	102	hematologic malignancies	Disease	D019337
3289726_1	0	9	Etoposide	Chemical	D005047
3289726_1	11	20	VP-16-213	Chemical	D005047

3289726_8|s|This complication appears to represent a significant new toxicity of high-dose etoposide therapy for malignant glioma.
3289726_8	57	65	toxicity	Disease	D064420
3289726_8	101	117	malignant glioma	Disease	D005910
3289726_8	79	88	etoposide	Chemical	D005047

3297909_0|s|Progressive bile duct injury after thiabendazole administration.
3297909_0	12	28	bile duct injury	Disease	D001649
3297909_0	35	48	thiabendazole	Chemical	D013827

3297909_1|s|A 27-yr-old man developed jaundice 2 wk after exposure to thiabendazole.
3297909_1	26	34	jaundice	Disease	D007565
3297909_1	58	71	thiabendazole	Chemical	D013827

3323259_1|s|Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases.
3323259_1	75	97	cardiovascular disease	Disease	D002318
3323259_1	200	223	cardiovascular diseases	Disease	D002318
3323259_1	44	51	calcium	Chemical	D002118
3323259_1	138	169	calcium channel blocking agents	Chemical	D002121

3323259_5|s|As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function.
3323259_5	89	95	angina	Disease	D000787
3323259_5	100	112	hypertension	Disease	D006973
3323259_5	13	28	dihydropyridine	Chemical	C038806
3323259_5	69	79	nifedipine	Chemical	D009543

3323259_7|s|Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension.
3323259_7	175	187	hypertension	Disease	D006973
3323259_7	41	53	nitrendipine	Chemical	D009568
3323259_7	58	69	nisoldipine	Chemical	D015737

3323259_8|s|The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina.
3323259_8	107	113	angina	Disease	D000787
3323259_8	40	51	nisoldipine	Chemical	D015737

3323259_9|s|Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke.
3323259_9	96	119	subarachnoid hemorrhage	Disease	D013345
3323259_9	121	138	migraine headache	Disease	D008881
3323259_9	140	148	dementia	Disease	D003704
3323259_9	154	160	stroke	Disease	D020521
3323259_9	46	56	nimodipine	Chemical	D009553

3323259_10|s|In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.
3323259_10	90	98	headache	Disease	D006261
3323259_10	107	115	flushing	Disease	D005483
3323259_10	117	129	palpitations	Disease	-1
3323259_10	131	136	edema	Disease	D004487
3323259_10	138	144	nausea	Disease	D009325
3323259_10	146	154	anorexia	Disease	D000855
3323259_10	160	169	dizziness	Disease	D004244
3323259_10	16	31	dihydropyridine	Chemical	C038806
3323259_10	32	56	calcium channel blockers	Chemical	D002121
3323259_10	CID	D002121	D000855
3323259_10	CID	D002121	D004244
3323259_10	CID	D002121	D004487
3323259_10	CID	D002121	D006261
3323259_10	CID	D002121	D009325
3323259_10	CID	D002121	D005483

3323599_0|s|The enhancement of aminonucleoside nephrosis by the co-administration of protamine.
3323599_0	35	44	nephrosis	Disease	D009401
3323599_0	19	34	aminonucleoside	Chemical	D011692

3323599_1|s|An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS).
3323599_1	25	61	focal segmental glomerular sclerosis	Disease	D005923
3323599_1	63	67	FSGS	Disease	D005923
3323599_1	125	150	puromycin-aminonucleoside	Chemical	D011692
3323599_1	152	156	AMNS	Chemical	D011692
3323599_1	162	179	protamine sulfate	Chemical	D011479
3323599_1	181	183	PS	Chemical	D011479
3323599_1	CID	D011692	D005923

3323599_9|s|Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease.
3323599_9	70	78	toxicity	Disease	D064420
3323599_9	138	142	FSGS	Disease	D005923
3323599_9	168	191	end-stage renal disease	Disease	D007676
3323599_9	54	56	PS	Chemical	D011479
3323599_9	82	86	AMNS	Chemical	D011692
3323599_9	CID	D011692	D005923
3323599_9	CID	D011692	D007676

3339945_0|s|Theophylline neurotoxicity in pregnant rats.
3339945_0	13	26	neurotoxicity	Disease	D020258
3339945_0	0	12	Theophylline	Chemical	D013806

3339945_1|s|The purpose of this investigation was to determine whether the neurotoxicity of theophylline is altered in advanced pregnancy.
3339945_1	63	76	neurotoxicity	Disease	D020258
3339945_1	80	92	theophylline	Chemical	D013806

3339945_2|s|Sprague-Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of aminophylline until onset of maximal seizures which occurred after 28 and 30 minutes respectively.
3339945_2	154	162	seizures	Disease	D012640
3339945_2	117	130	aminophylline	Chemical	D000628
3339945_2	CID	D000628	D012640

3339945_6|s|It is concluded that advanced pregnancy has a negligible effect on the neurotoxic response to theophylline in rats.
3339945_6	71	81	neurotoxic	Disease	D020258
3339945_6	94	106	theophylline	Chemical	D013806

3375885_0|s|Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.
3375885_0	0	12	Hyperkalemia	Disease	D006947
3375885_0	24	36	indomethacin	Chemical	D007213
3375885_0	41	49	naproxen	Chemical	D009288
3375885_0	66	81	fludrocortisone	Chemical	D005438
3375885_0	CID	D007213	D006947
3375885_0	CID	D009288	D006947

3375885_1|s|We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
3375885_1	40	60	rheumatoid arthritis	Disease	D001172
3375885_1	93	104	nephropathy	Disease	D007674
3375885_1	113	125	hyperkalemia	Disease	D006947
3375885_1	144	161	hypoaldosteronism	Disease	D006994
3375885_1	78	92	mefenamic acid	Chemical	D008528
3375885_1	182	194	indomethacin	Chemical	D007213
3375885_1	199	207	naproxen	Chemical	D009288
3375885_1	CID	D008528	D007674
3375885_1	CID	D007213	D006947
3375885_1	CID	D009288	D006994
3375885_1	CID	D009288	D006947
3375885_1	CID	D007213	D006994

3375885_2|s|It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with prostaglandin synthetase inhibitors.
3375885_2	30	43	renal disease	Disease	D007674
3375885_2	72	102	type IV renal tubular acidosis	Disease	D006994
3375885_2	108	121	prostaglandin	Chemical	D011453

3375885_3|s|Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, fludrocortisone was added, correcting the hyperkalemia and allowing indomethacin therapy to be continued safely.
3375885_3	124	136	hyperkalemia	Disease	D006947
3375885_3	82	97	fludrocortisone	Chemical	D005438
3375885_3	150	162	indomethacin	Chemical	D007213
3375885_3	CID	D007213	D006947

3383127_0|s|Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.
3383127_0	0	11	Hypotension	Disease	D007022
3383127_0	34	48	cardiotoxicity	Disease	D066126
3383127_0	77	86	cisplatin	Chemical	D002945
3383127_0	91	105	5-fluorouracil	Chemical	D005472
3383127_0	CID	D005472	D007022
3383127_0	CID	D002945	D007022

3383127_1|s|Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).
3383127_1	28	39	hypotension	Disease	D007022
3383127_1	83	103	colorectal carcinoma	Disease	D015179
3383127_1	129	138	cisplatin	Chemical	D002945
3383127_1	140	144	CDDP	Chemical	D002945
3383127_1	150	164	5-fluorouracil	Chemical	D005472
3383127_1	166	170	5-FU	Chemical	D005472
3383127_1	CID	D005472	D007022
3383127_1	CID	D002945	D007022

3383127_5|s|The presentation and cardiac evaluation (hemodynamic, echocardiographic, and scintigraphic) of these patients suggest new manifestations of 5-FU cardiotoxicity that may be influenced by CDDP.
3383127_5	145	159	cardiotoxicity	Disease	D066126
3383127_5	140	144	5-FU	Chemical	D005472
3383127_5	186	190	CDDP	Chemical	D002945

3409843_0|s|Fatal aplastic anemia in a patient treated with carbamazepine.
3409843_0	6	21	aplastic anemia	Disease	D000741
3409843_0	48	61	carbamazepine	Chemical	D002220
3409843_0	CID	D002220	D000741

3409843_1|s|A case of fatal aplastic anemia due to carbamazepine treatment in an epileptic woman is reported.
3409843_1	16	31	aplastic anemia	Disease	D000741
3409843_1	69	78	epileptic	Disease	D004827
3409843_1	39	52	carbamazepine	Chemical	D002220
3409843_1	CID	D002220	D000741

3409843_2|s|Despite concerns of fatal bone marrow toxicity due to carbamazepine, this is only the fourth documented and published report.
3409843_2	26	46	bone marrow toxicity	Disease	D001855
3409843_2	54	67	carbamazepine	Chemical	D002220

3423103_0|s|Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine-induced hypotension and bradycardia.
3423103_0	90	101	hypotension	Disease	D007022
3423103_0	106	117	bradycardia	Disease	D001919
3423103_0	72	81	clonidine	Chemical	D003000
3423103_0	CID	D003000	D007022
3423103_0	CID	D003000	D001919

3423103_3|s|The clonidine-induced hypotension was antagonized by prior spinal transection, but not bilateral vagotomy.
3423103_3	22	33	hypotension	Disease	D007022
3423103_3	4	13	clonidine	Chemical	D003000
3423103_3	CID	D003000	D007022

3423103_4|s|On the other hand, the clonidine-induced bradycardia was antagonized by prior bilateral vagotomy, but not spinal transection.
3423103_4	41	52	bradycardia	Disease	D001919
3423103_4	23	32	clonidine	Chemical	D003000
3423103_4	CID	D003000	D001919

3423103_5|s|Furthermore, selective destruction of the spinal 5-HT nerves, produced by bilateral spinal injection of 5,7-dihydroxytryptamine, reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats.
3423103_5	179	191	bradycardiac	Disease	D001919
3423103_5	49	53	5-HT	Chemical	D012701
3423103_5	104	127	5,7-dihydroxytryptamine	Chemical	D015116
3423103_5	205	214	clonidine	Chemical	D003000
3423103_5	CID	D003000	D001919

3423103_6|s|The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine-induced hypotension and bradycardia.
3423103_6	106	117	hypotension	Disease	D007022
3423103_6	122	133	bradycardia	Disease	D001919
3423103_6	88	97	clonidine	Chemical	D003000
3423103_6	CID	D003000	D007022
3423103_6	CID	D003000	D001919

3439580_0|s|Hypertension in neuroblastoma induced by imipramine.
3439580_0	0	12	Hypertension	Disease	D006973
3439580_0	16	29	neuroblastoma	Disease	D009447
3439580_0	41	51	imipramine	Chemical	D007099
3439580_0	CID	D007099	D006973

3439580_3|s|We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given Imipramine to control a behavior disorder.
3439580_3	35	47	hypertension	Disease	D006973
3439580_3	99	112	neuroblastoma	Disease	D009447
3439580_3	151	168	behavior disorder	Disease	D002653
3439580_3	127	137	Imipramine	Chemical	D007099
3439580_3	CID	D007099	D006973

3439580_5|s|Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the Imipramine (when she was in florid relapse), we believe that this drug rather than her underlying disease alone caused her hypertension.
3439580_5	228	240	hypertension	Disease	D006973
3439580_5	105	115	Imipramine	Chemical	D007099
3439580_5	CID	D007099	D006973

3475563_0|s|Rechallenge of patients who developed oral candidiasis or hoarseness with beclomethasone dipropionate.
3475563_0	38	54	oral candidiasis	Disease	D002180
3475563_0	58	68	hoarseness	Disease	D006685
3475563_0	74	101	beclomethasone dipropionate	Chemical	D001507
3475563_0	CID	D001507	D002180
3475563_0	CID	D001507	D006685

3475563_1|s|Of 158 asthmatic patients who were placed on inhaled beclomethasone, 15 (9.5%) developed either hoarseness (8), oral thrush (6), or both (1).
3475563_1	7	16	asthmatic	Disease	D001249
3475563_1	96	106	hoarseness	Disease	D006685
3475563_1	117	123	thrush	Disease	D002180
3475563_1	53	67	beclomethasone	Chemical	D001507
3475563_1	CID	D001507	D002180
3475563_1	CID	D001507	D006685

3475563_6|s|We conclude that patients may be restarted on inhaled beclomethasone when clinically indicated; however, because of the high recurrence rate, patients who develop hoarseness should not be re-challenged.
3475563_6	163	173	hoarseness	Disease	D006685
3475563_6	54	68	beclomethasone	Chemical	D001507
3475563_6	CID	D001507	D006685

3475563_7|s|Concomitant use of oral prednisone and topical beclomethasone may increase the risk of developing hoarseness or candidiasis.
3475563_7	98	108	hoarseness	Disease	D006685
3475563_7	112	123	candidiasis	Disease	D002177
3475563_7	24	34	prednisone	Chemical	D011241
3475563_7	47	61	beclomethasone	Chemical	D001507
3475563_7	CID	D001507	D006685

3533179_0|s|Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor.
3533179_0	17	31	cardiotoxicity	Disease	D066126
3533179_0	0	16	Cyclophosphamide	Chemical	D003520

3533179_2|s|At these high doses of CYA, serious cardiotoxicity may occur, but definitive risk factors for the development of such cardiotoxicity have not been described.
3533179_2	36	50	cardiotoxicity	Disease	D066126
3533179_2	118	132	cardiotoxicity	Disease	D066126
3533179_2	23	26	CYA	Chemical	D003520

3533179_3|s|Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of CYA cardiotoxicity correlated with the dose per body surface area.
3533179_3	29	37	toxicity	Disease	D064420
3533179_3	224	238	cardiotoxicity	Disease	D066126
3533179_3	134	137	CYA	Chemical	D003520
3533179_3	220	223	CYA	Chemical	D003520

3533179_4|s|Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or severe combined immunodeficiency syndrome.
3533179_4	140	155	aplastic anemia	Disease	D000741
3533179_4	157	181	Wiskott-Aldrich syndrome	Disease	D014923
3533179_4	186	227	severe combined immunodeficiency syndrome	Disease	D016511
3533179_4	36	39	CYA	Chemical	D003520

3533179_5|s|Fourteen of 84 (17%) patients had symptoms and signs consistent with CYA cardiotoxicity within ten days of receiving 1 to 4 doses of CYA.
3533179_5	73	87	cardiotoxicity	Disease	D066126
3533179_5	69	72	CYA	Chemical	D003520
3533179_5	133	136	CYA	Chemical	D003520

3533179_8|s|Cardiotoxicity that was thought to be related to CYA occurred in 1/32 (3%) of patients in Group 1 and in 13/52 (25%) patients in Group 2 (P less than 0.025).
3533179_8	0	14	Cardiotoxicity	Disease	D066126
3533179_8	49	52	CYA	Chemical	D003520

3533179_11|s|We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.
3533179_11	25	39	cardiotoxicity	Disease	D066126
3533179_11	126	141	aplastic anemia	Disease	D000741
3533179_11	146	164	immunodeficiencies	Disease	D007153
3533179_11	287	301	cardiotoxicity	Disease	D066126
3533179_11	21	24	CYA	Chemical	D003520
3533179_11	56	59	CYA	Chemical	D003520
3533179_11	223	226	CYA	Chemical	D003520
3533179_11	322	325	CYA	Chemical	D003520

3538855_0|s|Studies of risk factors for aminoglycoside nephrotoxicity.
3538855_0	43	57	nephrotoxicity	Disease	D007674
3538855_0	28	42	aminoglycoside	Chemical	D000617
3538855_0	CID	D000617	D007674

3538855_1|s|The epidemiology of aminoglycoside-induced nephrotoxicity is not fully understood.
3538855_1	43	57	nephrotoxicity	Disease	D007674
3538855_1	20	34	aminoglycoside	Chemical	D000617
3538855_1	CID	D000617	D007674

3538855_2|s|Experimental studies in healthy human volunteers indicate aminoglycosides cause proximal tubular damage in most patients, but rarely, if ever, cause glomerular or tubular dysfunction.
3538855_2	149	182	glomerular or tubular dysfunction	Disease	D007674
3538855_2	58	73	aminoglycosides	Chemical	D000617
3538855_2	CID	D000617	D007674

3538855_3|s|Clinical trials of aminoglycosides in seriously ill patients indicate that the relative risk for developing acute renal failure during therapy ranges from 8 to 10 and that the attributable risk is 70% to 80%.
3538855_3	108	127	acute renal failure	Disease	D058186
3538855_3	19	34	aminoglycosides	Chemical	D000617

3538855_4|s|Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity.
3538855_4	100	113	liver disease	Disease	D008107
3538855_4	228	242	nephrotoxicity	Disease	D007674
3538855_4	77	91	aminoglycoside	Chemical	D000617
3538855_4	152	162	creatinine	Chemical	D003404
3538855_4	CID	D000617	D007674

3538855_7|s|These models may also be useful in developing insights into the pathophysiology of aminoglycoside-induced nephrotoxicity.
3538855_7	106	120	nephrotoxicity	Disease	D007674
3538855_7	83	97	aminoglycoside	Chemical	D000617
3538855_7	CID	D000617	D007674

3685052_0|s|Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl seizure testing.
3685052_0	10	17	seizure	Disease	D012640
3685052_0	162	169	seizure	Disease	D012640
3685052_0	0	9	Flurothyl	Chemical	D005481
3685052_0	83	103	monosodium glutamate	Chemical	D012970
3685052_0	105	108	MSG	Chemical	D012970
3685052_0	152	161	flurothyl	Chemical	D005481

3685052_1|s|Monosodium glutamate (MSG) administration to neonatal rodents produces convulsions and results in numerous biochemical and behavioral deficits.
3685052_1	71	82	convulsions	Disease	D012640
3685052_1	0	20	Monosodium glutamate	Chemical	D012970
3685052_1	22	25	MSG	Chemical	D012970

3685052_2|s|These studies were undertaken to determine if neonatal administration of MSG produced permanent alterations in seizure susceptibility, since previous investigations were inconclusive.
3685052_2	111	118	seizure	Disease	D012640
3685052_2	73	76	MSG	Chemical	D012970

3685052_3|s|A flurothyl ether seizure screening technique was used to evaluate seizure susceptibility in adult mice that received neonatal injections of MSG (4 mg/g and 1 mg/g).
3685052_3	18	25	seizure	Disease	D012640
3685052_3	67	74	seizure	Disease	D012640
3685052_3	2	11	flurothyl	Chemical	D005481
3685052_3	12	17	ether	Chemical	D004986
3685052_3	141	144	MSG	Chemical	D012970

3685052_4|s|MSG treatment resulted in significant reductions in whole brain weight but did not alter seizure threshold.
3685052_4	89	96	seizure	Disease	D012640
3685052_4	0	3	MSG	Chemical	D012970

3685052_5|s|A naloxone (5 mg/kg) challenge was also ineffective in altering the seizure thresholds of either control of MSG-treated mice.
3685052_5	68	75	seizure	Disease	D012640
3685052_5	2	10	naloxone	Chemical	D009270
3685052_5	108	111	MSG	Chemical	D012970

3685052_6|s|Flurothyl ether produced hypothermia which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear.
3685052_6	25	36	hypothermia	Disease	D007035
3685052_6	128	139	hypothermia	Disease	D007035
3685052_6	143	150	seizure	Disease	D012640
3685052_6	0	9	Flurothyl	Chemical	D005481
3685052_6	10	15	ether	Chemical	D004986
3685052_6	79	88	flurothyl	Chemical	D005481
3685052_6	CID	D005481	D007035

3685052_7|s|Flurothyl seizure testing proved to be a rapid and reliable technique with which to evaluate seizure susceptibility.
3685052_7	10	17	seizure	Disease	D012640
3685052_7	93	100	seizure	Disease	D012640
3685052_7	0	9	Flurothyl	Chemical	D005481

3708328_0|s|Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.
3708328_0	18	26	seizures	Disease	D012640
3708328_0	39	50	pilocarpine	Chemical	D010862
3708328_0	83	92	isoniazid	Chemical	D007538
3708328_0	96	112	gamma-vinyl-GABA	Chemical	D020888
3708328_0	CID	D010862	D012640

3708328_1|s|Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of temporal lobe epilepsy and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain.
3708328_1	91	113	temporal lobe epilepsy	Disease	D004833
3708328_1	189	199	convulsive	Disease	D012640
3708328_1	273	281	seizures	Disease	D012640
3708328_1	0	11	Pilocarpine	Chemical	D010862
3708328_1	CID	D010862	D012640

3708328_2|s|In the present study, the effects of manipulating the activity of the gamma-aminobutyric acid (GABA)-mediated synaptic inhibition within the substantia nigra on seizures produced by pilocarpine in rats, were investigated.
3708328_2	161	169	seizures	Disease	D012640
3708328_2	70	93	gamma-aminobutyric acid	Chemical	D005680
3708328_2	95	99	GABA	Chemical	D005680
3708328_2	182	193	pilocarpine	Chemical	D010862
3708328_2	CID	D010862	D012640

3708328_3|s|In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.
3708328_3	312	320	seizures	Disease	D012640
3708328_3	325	343	status epilepticus	Disease	D013226
3708328_3	46	55	isoniazid	Chemical	D007538
3708328_3	105	109	GABA	Chemical	D005680
3708328_3	131	146	L-glutamic acid	Chemical	D018698
3708328_3	248	259	pilocarpine	Chemical	D010862
3708328_3	CID	D010862	D012640

3708328_4|s|Electroencephalographic and behavioral monitoring revealed a profound reduction of the threshold for pilocarpine-induced convulsions.
3708328_4	121	132	convulsions	Disease	D012640
3708328_4	101	112	pilocarpine	Chemical	D010862
3708328_4	CID	D010862	D012640

3708328_5|s|Morphological analysis of frontal forebrain sections with light microscopy revealed seizure-related damage to the hippocampal formation, thalamus, amygdala, olfactory cortex, substantia nigra and neocortex, which is typically observed with pilocarpine in doses exceeding 350 mg/kg.
3708328_5	84	91	seizure	Disease	D012640
3708328_5	240	251	pilocarpine	Chemical	D010862
3708328_5	CID	D010862	D012640

3708328_6|s|Bilateral intrastriatal injections of isoniazid did not augment seizures produced by pilocarpine, 200 mg/kg.
3708328_6	64	72	seizures	Disease	D012640
3708328_6	38	47	isoniazid	Chemical	D007538
3708328_6	85	96	pilocarpine	Chemical	D010862
3708328_6	CID	D010862	D012640

3708328_7|s|Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg.
3708328_7	212	220	seizures	Disease	D012640
3708328_7	44	48	GABA	Chemical	D005680
3708328_7	63	79	gamma-vinyl-GABA	Chemical	D020888
3708328_7	81	109	D,L-4-amino-hex-5-enoic acid	Chemical	D020888
3708328_7	233	244	pilocarpine	Chemical	D010862
3708328_7	CID	D010862	D012640

3708328_9|s|Microinjections of gamma-vinyl-GABA, 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of convulsions produced by pilocarpine, 380 mg/kg.
3708328_9	127	138	convulsions	Disease	D012640
3708328_9	19	35	gamma-vinyl-GABA	Chemical	D020888
3708328_9	151	162	pilocarpine	Chemical	D010862
3708328_9	CID	D010862	D012640

3708328_10|s|The results demonstrate that the threshold for pilocarpine-induced seizures in rats is subjected to the regulation of the GABA-mediated synaptic inhibition within the substantia nigra.
3708328_10	67	75	seizures	Disease	D012640
3708328_10	47	58	pilocarpine	Chemical	D010862
3708328_10	122	126	GABA	Chemical	D005680
3708328_10	CID	D010862	D012640

3746148_0|s|Non-invasive detection of coronary artery disease by body surface electrocardiographic mapping after dipyridamole infusion.
3746148_0	26	49	coronary artery disease	Disease	D003324
3746148_0	101	113	dipyridamole	Chemical	D004176

3746148_1|s|Electrocardiographic changes after dipyridamole infusion (0.568 mg/kg/4 min) were studied in 41 patients with coronary artery disease and compared with those after submaximal treadmill exercise by use of the body surface mapping technique.
3746148_1	110	133	coronary artery disease	Disease	D003324
3746148_1	35	47	dipyridamole	Chemical	D004176

3746148_4|s|After dipyridamole, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population.
3746148_4	20	28	ischemic	Disease	D007511
3746148_4	40	50	depression	Disease	D003866
3746148_4	100	102	MI	Disease	D009203
3746148_4	121	127	ANT-MI	Disease	D056988
3746148_4	146	152	INF-MI	Disease	D056989
3746148_4	6	18	dipyridamole	Chemical	D004176

3746148_8|s|The data suggest that the dipyridamole-induced myocardial ischemia is caused by the inhomogenous distribution of myocardial blood flow.
3746148_8	47	66	myocardial ischemia	Disease	D017202
3746148_8	26	38	dipyridamole	Chemical	D004176
3746148_8	CID	D004176	D017202

3746148_9|s|We conclude that the dipyridamole ECG test is as useful as the exercise ECG test for the assessment of coronary artery disease.
3746148_9	103	126	coronary artery disease	Disease	D003324
3746148_9	21	33	dipyridamole	Chemical	D004176

3798047_0|s|Bradycardia after high-dose intravenous methylprednisolone therapy.
3798047_0	0	11	Bradycardia	Disease	D001919
3798047_0	40	58	methylprednisolone	Chemical	D008775
3798047_0	CID	D008775	D001919

3798047_1|s|In 5 consecutive patients with rheumatoid arthritis who received intravenous high-dose methylprednisolone (MP) therapy (1 g daily for 2 or 3 consecutive days), a decline in pulse rate was observed, most pronounced on day 4.
3798047_1	31	51	rheumatoid arthritis	Disease	D001172
3798047_1	87	105	methylprednisolone	Chemical	D008775
3798047_1	107	109	MP	Chemical	D008775

3798047_7|s|High-dose MP may be contraindicated in patients with known heart disease.
3798047_7	59	72	heart disease	Disease	D006331
3798047_7	10	12	MP	Chemical	D008775

3812624_0|s|Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine.
3812624_0	13	31	downbeat nystagmus	Disease	D009759
3812624_0	36	47	oscillopsia	Disease	D015835
3812624_0	64	77	carbamazepine	Chemical	D002220
3812624_0	CID	D002220	D015835

3812624_2|s|We recorded the eye movements of two patients with reversible downbeat nystagmus related to carbamazepine therapy.
3812624_2	62	80	downbeat nystagmus	Disease	D009759
3812624_2	92	105	carbamazepine	Chemical	D002220

3812624_3|s|The nystagmus of both patients resolved after reduction of the serum carbamazepine levels.
3812624_3	4	13	nystagmus	Disease	D009759
3812624_3	69	82	carbamazepine	Chemical	D002220

3831029_0|s|Improvement by denopamine (TA-064) of pentobarbital-induced cardiac failure in the dog heart-lung preparation.
3831029_0	60	75	cardiac failure	Disease	D006333
3831029_0	15	25	denopamine	Chemical	C037293
3831029_0	27	33	TA-064	Chemical	C037293
3831029_0	38	51	pentobarbital	Chemical	D010424
3831029_0	CID	D010424	D006333

3831029_1|s|The efficacy of denopamine, an orally active beta 1-adrenoceptor agonist, in improving cardiac failure was assessed in dog heart-lung preparations.
3831029_1	87	102	cardiac failure	Disease	D006333
3831029_1	16	26	denopamine	Chemical	C037293

3831029_4|s|No arrhythmias were induced by these doses of denopamine.
3831029_4	3	14	arrhythmias	Disease	D001145
3831029_4	46	56	denopamine	Chemical	C037293

3831029_5|s|The results warrant clinical trials of denopamine in the treatment of cardiac failure.
3831029_5	70	85	cardiac failure	Disease	D006333
3831029_5	39	49	denopamine	Chemical	C037293

3832950_0|s|Clonazepam monotherapy for epilepsy in childhood.
3832950_0	27	35	epilepsy	Disease	D004827
3832950_0	0	10	Clonazepam	Chemical	D002998

3832950_1|s|Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with clonazepam.
3832950_1	69	77	epilepsy	Disease	D004827
3832950_1	83	99	infantile spasms	Disease	D013036
3832950_1	118	128	clonazepam	Chemical	D002998

3833372_1|s|A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of timolol maleate and 25 mg of hydrochlorothiazide, administered twice daily for one month to hypertensive patients.
3833372_1	227	239	hypertensive	Disease	D006973
3833372_1	135	150	timolol maleate	Chemical	D013999
3833372_1	164	183	hydrochlorothiazide	Chemical	D006852

3864191_0|s|Salicylate nephropathy in the Gunn rat: potential role of prostaglandins.
3864191_0	11	22	nephropathy	Disease	D007674
3864191_0	0	10	Salicylate	Chemical	D012459
3864191_0	58	72	prostaglandins	Chemical	D011453

3864191_1|s|We examined the potential role of prostaglandins in the development of analgesic nephropathy in the Gunn strain of rat.
3864191_1	81	92	nephropathy	Disease	D007674
3864191_1	34	48	prostaglandins	Chemical	D011453

3864191_2|s|The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla.
3864191_2	43	61	hyperbilirubinemia	Disease	D006932
3864191_2	84	94	glucuronyl	Chemical	-1
3864191_2	126	135	bilirubin	Chemical	D001663

3864191_12|s|The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).
3864191_12	77	89	renal damage	Disease	D007674
3864191_12	181	190	hematuria	Disease	D006417
3864191_12	21	34	prostaglandin	Chemical	D011453
3864191_12	93	100	aspirin	Chemical	D001241
3864191_12	227	237	creatinine	Chemical	D003404
3864191_12	371	378	aspirin	Chemical	D001241
3864191_12	CID	D001241	D007674

3864191_13|s|These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity, and that inhibition of prostaglandin synthesis may lead to pathological renal medullary lesions and deterioration of renal function.
3864191_13	193	229	pathological renal medullary lesions	Disease	D058186
3864191_13	234	265	deterioration of renal function	Disease	D007674
3864191_13	36	49	prostaglandin	Chemical	D011453
3864191_13	157	170	prostaglandin	Chemical	D011453

3895875_0|s|Prophylactic lidocaine in the early phase of suspected myocardial infarction.
3895875_0	55	76	myocardial infarction	Disease	D009203
3895875_0	13	22	lidocaine	Chemical	D008012

3895875_1|s|Four hundred two patients with suspected myocardial infarction seen within 6 hours of the onset of symptoms entered a double-blind randomized trial of lidocaine vs placebo.
3895875_1	41	62	myocardial infarction	Disease	D009203
3895875_1	151	160	lidocaine	Chemical	D008012

3895875_3|s|Lidocaine, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0.05).
3895875_3	110	133	ventricular tachycardia	Disease	D017180
3895875_3	217	228	arrhythmias	Disease	D001145
3895875_3	0	9	Lidocaine	Chemical	D008012
3895875_3	283	292	lidocaine	Chemical	D008012

3895875_4|s|The average plasma lidocaine level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute infarction.
3895875_4	90	111	myocardial infarction	Disease	D009203
3895875_4	174	184	infarction	Disease	D007238
3895875_4	19	28	lidocaine	Chemical	D008012

3895875_6|s|During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine.
3895875_6	135	146	hypotension	Disease	D007022
3895875_6	237	245	asystole	Disease	D006323
3895875_6	118	127	lidocaine	Chemical	D008012
3895875_6	198	207	lidocaine	Chemical	D008012
3895875_6	269	278	lidocaine	Chemical	D008012
3895875_6	CID	D008012	D007022

3895875_7|s|We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.
3895875_7	100	121	myocardial infarction	Disease	D009203
3895875_7	41	50	lidocaine	Chemical	D008012

3925479_0|s|Evidence for a cholinergic role in haloperidol-induced catalepsy.
3925479_0	55	64	catalepsy	Disease	D002375
3925479_0	35	46	haloperidol	Chemical	D006220
3925479_0	CID	D006220	D002375

3925479_1|s|Experiments in mice tested previous evidence that activation of cholinergic systems promotes catalepsy and that cholinergic mechanisms need to be intact for full expression of neuroleptic-induced catalepsy.
3925479_1	93	102	catalepsy	Disease	D002375
3925479_1	196	205	catalepsy	Disease	D002375
3925479_1	176	187	neuroleptic	Chemical	D014150

3925479_2|s|Large doses of the cholinomimetic, pilocarpine, could induce catalepsy when peripheral cholinergic receptors were blocked.
3925479_2	61	70	catalepsy	Disease	D002375
3925479_2	35	46	pilocarpine	Chemical	D010862
3925479_2	CID	D010862	D002375

3925479_3|s|Low doses of pilocarpine caused a pronounced enhancement of the catalepsy that was induced by the dopaminergic blocker, haloperidol.
3925479_3	64	73	catalepsy	Disease	D002375
3925479_3	13	24	pilocarpine	Chemical	D010862
3925479_3	120	131	haloperidol	Chemical	D006220
3925479_3	CID	D010862	D002375
3925479_3	CID	D006220	D002375

3925479_4|s|A muscarinic receptor blocker, atropine, disrupted haloperidol-induced catalepsy.
3925479_4	71	80	catalepsy	Disease	D002375
3925479_4	31	39	atropine	Chemical	D001285
3925479_4	51	62	haloperidol	Chemical	D006220
3925479_4	CID	D006220	D002375

3925479_5|s|Intracranial injection of an acetylcholine-synthesis inhibitor, hemicholinium, prevented the catalepsy that is usually induced by haloperidol.
3925479_5	93	102	catalepsy	Disease	D002375
3925479_5	29	42	acetylcholine	Chemical	D000109
3925479_5	64	77	hemicholinium	Chemical	D006426
3925479_5	130	141	haloperidol	Chemical	D006220
3925479_5	CID	D006220	D002375

3925479_6|s|These findings suggest the hypothesis that the catalepsy that is produced by neuroleptics such as haloperidol is actually mediated by intrinsic central cholinergic systems.
3925479_6	47	56	catalepsy	Disease	D002375
3925479_6	77	89	neuroleptics	Chemical	D014150
3925479_6	98	109	haloperidol	Chemical	D006220
3925479_6	CID	D006220	D002375

3975902_0|s|Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion.
3975902_0	0	26	Cardiovascular dysfunction	Disease	D002318
3975902_0	31	47	hypersensitivity	Disease	D004342
3975902_0	51	71	sodium pentobarbital	Chemical	D010424
3975902_0	91	106	barium chloride	Chemical	C024986

3975902_1|s|Barium-supplemented Long-Evans hooded rats were characterized by a persistent hypertension that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment.
3975902_1	78	90	hypertension	Disease	D006973
3975902_1	0	6	Barium	Chemical	D001464
3975902_1	125	131	barium	Chemical	D001464

3975902_2|s|Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced disturbances within the cardiovascular system.
3975902_2	145	190	disturbances within the cardiovascular system	Disease	D002318
3975902_2	130	136	barium	Chemical	D001464

3975902_3|s|The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital.
3975902_3	68	84	hypersensitivity	Disease	D004342
3975902_3	35	41	barium	Chemical	D001464
3975902_3	117	137	sodium pentobarbital	Chemical	D010424

3975902_10|s|Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.
3975902_10	92	114	metabolic disturbances	Disease	D008659
3975902_10	124	140	hypersensitivity	Disease	D004342
3975902_10	244	268	cardiomyopathic disorder	Disease	D009202
3975902_10	173	193	sodium pentobarbital	Chemical	D010424
3975902_10	288	294	barium	Chemical	D001464

3987172_0|s|Propranolol antagonism of phenylpropanolamine-induced hypertension.
3987172_0	54	66	hypertension	Disease	D006973
3987172_0	0	11	Propranolol	Chemical	D011433
3987172_0	26	45	phenylpropanolamine	Chemical	D010665
3987172_0	CID	D010665	D006973

3987172_1|s|Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.
3987172_1	26	34	overdose	Disease	D062787
3987172_1	52	64	hypertension	Disease	D006973
3987172_1	66	90	intracerebral hemorrhage	Disease	D002543
3987172_1	0	19	Phenylpropanolamine	Chemical	D010665
3987172_1	21	24	PPA	Chemical	D010665
3987172_1	CID	D010665	D006973

3987172_2|s|We studied the efficacy and safety of propranolol in the treatment of PPA-induced hypertension.
3987172_2	82	94	hypertension	Disease	D006973
3987172_2	38	49	propranolol	Chemical	D011433
3987172_2	70	73	PPA	Chemical	D010665
3987172_2	CID	D010665	D006973

3987172_6|s|Left ventricular function (assessed by echocardiography) showed that PPA increased the stroke volume 30% (from 62.5 +/- 20.9 to 80.8 +/- 22.4 ml), the ejection fraction 9% (from 64% +/- 10% to 70% +/- 7%), and cardiac output 14% (from 3.6 +/- 0.6 to 4.1 +/- 1.0 L/min).
3987172_6	87	93	stroke	Disease	D020521
3987172_6	69	72	PPA	Chemical	D010665

3990093_0|s|Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis.
3990093_0	23	43	glomerular sclerosis	Disease	D007674
3990093_0	73	82	nephrosis	Disease	D009401
3990093_0	57	72	aminonucleoside	Chemical	D011692

3990093_1|s|The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the puromycin aminonucleoside (PAN) model.
3990093_1	34	55	mesangial dysfunction	Disease	D007674
3990093_1	75	95	glomerular sclerosis	Disease	D007674
3990093_1	115	140	puromycin aminonucleoside	Chemical	D011692
3990093_1	142	145	PAN	Chemical	D011692

3990093_3|s|After 4 weeks the PAN rats were severely proteinuric (190 +/- 80 mg/24 hr), and all rats were given colloidal carbon (CC) intravenously.
3990093_3	41	52	proteinuric	Disease	D011507
3990093_3	18	21	PAN	Chemical	D011692
3990093_3	110	116	carbon	Chemical	D002244
3990093_3	CID	D011692	D011507

3990093_4|s|At 5 months glomerular sclerosis was found in 7.6 +/- 3.4% of the glomeruli of PAN rats; glomeruli of the controls were normal.
3990093_4	12	32	glomerular sclerosis	Disease	D007674
3990093_4	79	82	PAN	Chemical	D011692

3990093_8|s|Since mesangial CC clearance from the mesangium did not change during chronic PAN treatment, we conclude that this preferential CC localization within the lesions is caused by an increased CC uptake shortly after injection in apparent vulnerable areas where sclerosis will develop subsequently.
3990093_8	258	267	sclerosis	Disease	D012598
3990093_8	78	81	PAN	Chemical	D011692

3990093_10|s|Similar to the remnant kidney model in PAN nephrosis the development of glomerular sclerosis may be related to "mesangial overloading."
3990093_10	43	52	nephrosis	Disease	D009401
3990093_10	72	92	glomerular sclerosis	Disease	D007674
3990093_10	39	42	PAN	Chemical	D011692

4010471_0|s|Relationship between nicotine-induced seizures and hippocampal nicotinic receptors.
4010471_0	38	46	seizures	Disease	D012640
4010471_0	21	29	nicotine	Chemical	D009538
4010471_0	CID	D009538	D012640

4010471_2|s|Using mice derived from a classical F2 and backcross genetic design, a relationship between nicotine-induced seizures and alpha-bungarotoxin nicotinic receptor concentration was found.
4010471_2	109	117	seizures	Disease	D012640
4010471_2	92	100	nicotine	Chemical	D009538
4010471_2	CID	D009538	D012640

4010471_3|s|Mice sensitive to the convulsant effects of nicotine had greater alpha-bungarotoxin binding in the hippocampus than seizure insensitive mice.
4010471_3	116	123	seizure	Disease	D012640
4010471_3	44	52	nicotine	Chemical	D009538
4010471_3	CID	D009538	D012640

4010471_4|s|The binding sites from seizure sensitive and resistant mice were equally affected by treatment with dithiothreitol, trypsin or heat.
4010471_4	23	30	seizure	Disease	D012640
4010471_4	100	114	dithiothreitol	Chemical	D004229

4082192_0|s|The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.
4082192_0	51	65	nephrotoxicity	Disease	D007674
4082192_0	141	155	nephrotoxicity	Disease	D007674
4082192_0	12	25	p-aminophenol	Chemical	C026729
4082192_0	29	42	acetaminophen	Chemical	D000082
4082192_0	77	105	bis(p-nitrophenyl) phosphate	Chemical	C002887
4082192_0	109	122	acetaminophen	Chemical	D000082
4082192_0	127	140	p-aminophenol	Chemical	C026729

4082192_1|s|Acetaminophen (APAP) produces proximal tubular necrosis in Fischer 344 (F344) rats.
4082192_1	39	55	tubular necrosis	Disease	D007683
4082192_1	0	13	Acetaminophen	Chemical	D000082
4082192_1	15	19	APAP	Chemical	D000082
4082192_1	CID	D000082	D007683

4082192_3|s|The purpose of this study was to determine if PAP formation is a requisite step in APAP-induced nephrotoxicity.
4082192_3	96	110	nephrotoxicity	Disease	D007674
4082192_3	46	49	PAP	Chemical	C026729
4082192_3	83	87	APAP	Chemical	D000082

4082192_4|s|Therefore, the effect of bis(p-nitrophenyl) phosphate (BNPP), an acylamidase inhibitor, on APAP and PAP nephrotoxicity and metabolism was determined.
4082192_4	104	118	nephrotoxicity	Disease	D007674
4082192_4	25	53	bis(p-nitrophenyl) phosphate	Chemical	C002887
4082192_4	55	59	BNPP	Chemical	C002887
4082192_4	91	95	APAP	Chemical	D000082
4082192_4	100	103	PAP	Chemical	C026729

4082192_6|s|Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.
4082192_6	119	133	nephrotoxicity	Disease	D007674
4082192_6	146	160	nephrotoxicity	Disease	D007674
4082192_6	29	33	BNPP	Chemical	C002887
4082192_6	43	47	APAP	Chemical	D000082
4082192_6	51	54	PAP	Chemical	C026729
4082192_6	102	106	APAP	Chemical	D000082
4082192_6	142	145	PAP	Chemical	C026729

4082192_10|s|Therefore, the BNPP-induced reduction in APAP-induced nephrotoxicity appears to be due to inhibition of APAP deacetylation.
4082192_10	54	68	nephrotoxicity	Disease	D007674
4082192_10	15	19	BNPP	Chemical	C002887
4082192_10	41	45	APAP	Chemical	D000082
4082192_10	104	108	APAP	Chemical	D000082

4082192_11|s|It is concluded that PAP formation, in vivo, accounts, at least in part, for APAP-induced renal tubular necrosis.
4082192_11	90	112	renal tubular necrosis	Disease	D007683
4082192_11	21	24	PAP	Chemical	C026729
4082192_11	77	81	APAP	Chemical	D000082
4082192_11	CID	C026729	D007683
4082192_11	CID	D000082	D007683

4082466_0|s|Morphine-induced seizures in newborn infants.
4082466_0	17	25	seizures	Disease	D012640
4082466_0	0	8	Morphine	Chemical	D009020
4082466_0	CID	D009020	D012640

4082466_1|s|Two neonates suffered from generalized seizures during the course of intravenous morphine sulfate for post-operative analgesia.
4082466_1	39	47	seizures	Disease	D012640
4082466_1	81	97	morphine sulfate	Chemical	D009020
4082466_1	CID	D009020	D012640

4082466_2|s|They received morphine in doses of 32 micrograms/kg/hr and 40 micrograms/kg/hr larger than a group of 10 neonates who received 6-24 micrograms/kg/hr and had no seizures.
4082466_2	160	168	seizures	Disease	D012640
4082466_2	14	22	morphine	Chemical	D009020
4082466_2	CID	D009020	D012640

4082466_4|s|Other known reasons for seizures were ruled out and the convulsions stopped a few hours after cessation of morphine and did not reoccur in the subsequent 8 months.
4082466_4	24	32	seizures	Disease	D012640
4082466_4	56	67	convulsions	Disease	D012640
4082466_4	107	115	morphine	Chemical	D009020
4082466_4	CID	D009020	D012640

4631913_0|s|Effect of vincristine sulfate on Pseudomonas infections in monkeys.
4631913_0	33	55	Pseudomonas infections	Disease	D011552
4631913_0	10	29	vincristine sulfate	Chemical	D014750
4631913_0	CID	D014750	D011552

4631913_3|s|Intravenous or intratracheal inoculation of 2.0 to 2.5 mg of vincristine sulfate was followed by leukopenia in 4 to 5 days.
4631913_3	97	107	leukopenia	Disease	D007970
4631913_3	61	80	vincristine sulfate	Chemical	D014750
4631913_3	CID	D014750	D007970

4631913_4|s|Intravenous inoculation of 4.2 x 10(10) to 7.8 x 10(10) pyocin type 6 Pseudomonas organisms in monkeys given vincristine sulfate 4 days previously resulted in fatal infection in 11 of 14 monkeys, whereas none of four receiving Pseudomonas alone died.
4631913_4	165	174	infection	Disease	D007239
4631913_4	109	128	vincristine sulfate	Chemical	D014750

6106951_5|s|Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions.
6106951_5	13	21	toxocity	Disease	D064420
6106951_5	49	59	salivation	Disease	D012798
6106951_5	102	116	muscle tremors	Disease	D014202
6106951_5	121	132	convulsions	Disease	D012640
6106951_5	9	12	FZP	Chemical	D005479
6106951_5	CID	D005479	D012640

6106951_7|s|As a function of dose, FZP first protected against convulsions and death.
6106951_7	51	62	convulsions	Disease	D012640
6106951_7	23	26	FZP	Chemical	D005479
6106951_7	CID	D005479	D012640

6106951_9|s|These doses of FZP were lower than those that would alone cause convulsions.
6106951_9	64	75	convulsions	Disease	D012640
6106951_9	15	18	FZP	Chemical	D005479
6106951_9	CID	D005479	D012640

6106951_10|s|These results may be relevant to the use of FZP in clinical situations in which there is increased neural excitability, such as epilepsy or sedative-hypnotic drug withdrawal.
6106951_10	128	136	epilepsy	Disease	D004827
6106951_10	44	47	FZP	Chemical	D005479

6299641_1|s|We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and isoproterenol-induced tachycardia in two experiments involving nine normal subjects.
6299641_1	167	178	tachycardia	Disease	D013610
6299641_1	49	57	atenolol	Chemical	D001262
6299641_1	83	94	propranolol	Chemical	D011433
6299641_1	145	158	isoproterenol	Chemical	D007545
6299641_1	CID	D007545	D013610

6299641_3|s|The effects on isoproterenol tachycardia were determined before and after atropine (0.04 mg/kg IV).
6299641_3	29	40	tachycardia	Disease	D013610
6299641_3	15	28	isoproterenol	Chemical	D007545
6299641_3	74	82	atropine	Chemical	D001285
6299641_3	CID	D007545	D013610

6299641_8|s|These data are consistent with the hypothesis that exercise-induced tachycardia results largely from beta 1-receptor activation that is blocked by both cardioselective and nonselective drugs, whereas isoproterenol activates both beta 1- and beta 2-receptors so that after cardioselective blockade there remains a beta 2-component that can be blocked with a nonselective drug.
6299641_8	68	79	tachycardia	Disease	D013610
6299641_8	200	213	isoproterenol	Chemical	D007545
6299641_8	CID	D007545	D013610

6310832_0|s|Early infections in kidney, heart, and liver transplant recipients on cyclosporine.
6310832_0	6	16	infections	Disease	D007239
6310832_0	70	82	cyclosporine	Chemical	D016572
6310832_0	CID	D016572	D007239

6310832_4|s|The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients.
6310832_4	45	55	infections	Disease	D007239
6310832_4	93	103	infections	Disease	D007239
6310832_4	15	18	Aza	Chemical	D001379
6310832_4	143	155	cyclosporine	Chemical	D016572
6310832_4	CID	D016572	D007239
6310832_4	CID	D001379	D007239

6310832_5|s|Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients.
6310832_5	34	44	infections	Disease	D007239
6310832_5	88	98	infections	Disease	D007239
6310832_5	50	62	cyclosporine	Chemical	D016572
6310832_5	108	111	Aza	Chemical	D001379
6310832_5	CID	D016572	D007239
6310832_5	CID	D001379	D007239

6310832_6|s|There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.
6310832_6	89	98	infection	Disease	D007239
6310832_6	64	76	cyclosporine	Chemical	D016572
6310832_6	80	83	Aza	Chemical	D001379
6310832_6	CID	D016572	D007239
6310832_6	CID	D001379	D007239

6310832_7|s|Renal patients on cyclosporine had the fewest bacteremias.
6310832_7	46	57	bacteremias	Disease	D016470
6310832_7	18	30	cyclosporine	Chemical	D016572

6310832_9|s|Pulmonary infections were less common in cyclosporine-treated renal patients than in Aza-treated patients (P less than 0.05).
6310832_9	10	20	infections	Disease	D007239
6310832_9	41	53	cyclosporine	Chemical	D016572
6310832_9	85	88	Aza	Chemical	D001379
6310832_9	CID	D016572	D007239
6310832_9	CID	D001379	D007239

6310832_10|s|Aza patients had significantly more staphylococcal infections than all other transplant groups (P less than 0.005), and systemic fungal infections occurred only in the liver transplant group.
6310832_10	36	61	staphylococcal infections	Disease	D013203
6310832_10	129	146	fungal infections	Disease	D009181
6310832_10	0	3	Aza	Chemical	D001379

6310832_12|s|Of the cyclosporine patients, 15% had symptoms related to CMV infection.
6310832_12	58	71	CMV infection	Disease	D003586
6310832_12	7	19	cyclosporine	Chemical	D016572

6310832_13|s|Serological evidence for Epstein Barr Virus infection was found in 20% of 65 cyclosporine patients studied.
6310832_13	25	53	Epstein Barr Virus infection	Disease	D020031
6310832_13	77	89	cyclosporine	Chemical	D016572

6316193_0|s|Structure-activity and dose-effect relationships of the antagonism of picrotoxin-induced seizures by cholecystokinin, fragments and analogues of cholecystokinin in mice.
6316193_0	89	97	seizures	Disease	D012640
6316193_0	70	80	picrotoxin	Chemical	D010852
6316193_0	101	116	cholecystokinin	Chemical	D002766
6316193_0	145	160	cholecystokinin	Chemical	D002766
6316193_0	CID	D010852	D012640

6316193_1|s|Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of seizures induced by picrotoxin in mice.
6316193_1	168	176	seizures	Disease	D012640
6316193_1	34	61	cholecystokinin octapeptide	Chemical	D012844
6316193_1	78	83	CCK-8	Chemical	D012844
6316193_1	105	132	cholecystokinin octapeptide	Chemical	D012844
6316193_1	134	139	CCK-8	Chemical	D012844
6316193_1	188	198	picrotoxin	Chemical	D010852
6316193_1	CID	D010852	D012640

6316193_4|s|The peptide CCK-5-8 had weak anticonvulsant activity in comparison to the octapeptides, 3.2 mumol/kg and larger doses of the reference drug, diazepam, totally prevented picrotoxin-induced seizures and mortality.
6316193_4	188	196	seizures	Disease	D012640
6316193_4	141	149	diazepam	Chemical	D003975
6316193_4	169	179	picrotoxin	Chemical	D010852
6316193_4	CID	D010852	D012640

6321816_0|s|Vasopressin as a possible contributor to hypertension.
6321816_0	41	53	hypertension	Disease	D006973
6321816_0	0	11	Vasopressin	Chemical	D014667

6321816_1|s|The role of vasopressin as a pressor agent to the hypertensive process was examined.
6321816_1	50	62	hypertensive	Disease	D006973
6321816_1	12	23	vasopressin	Chemical	D014667

6321816_2|s|Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.
6321816_2	64	76	hypertension	Disease	D006973
6321816_2	169	187	diabetes insipidus	Disease	D003919
6321816_2	0	11	Vasopressin	Chemical	D014667
6321816_2	54	58	DOCA	Chemical	D003900
6321816_2	153	160	lithium	Chemical	D008094
6321816_2	194	198	DOCA	Chemical	D003900
6321816_2	CID	D003900	D006973
6321816_2	CID	D008094	D003919

6321816_4|s|Furthermore, the pressor action of vasopressin appears to be important in the development of this model of hypertension, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension.
6321816_4	107	119	hypertension	Disease	D006973
6321816_4	215	227	hypertension	Disease	D006973
6321816_4	35	46	vasopressin	Chemical	D014667

6321816_5|s|Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension.
6321816_5	126	138	hypertension	Disease	D006973
6321816_5	23	34	vasopressin	Chemical	D014667

6321816_7|s|However, the role of vasopressin remains to be determined in human essential hypertension.
6321816_7	77	89	hypertension	Disease	D006973
6321816_7	21	32	vasopressin	Chemical	D014667

6453500_0|s|Toxic hepatitis induced by disulfiram in a non-alcoholic.
6453500_0	0	15	Toxic hepatitis	Disease	D056486
6453500_0	27	37	disulfiram	Chemical	D004221
6453500_0	CID	D004221	D056486

6453500_1|s|A reversible toxic liver damage was observed in a non-alcoholic woman treated with disulfiram.
6453500_1	13	31	toxic liver damage	Disease	D056486
6453500_1	83	93	disulfiram	Chemical	D004221
6453500_1	CID	D004221	D056486

6517710_0|s|Atrial thrombosis involving the heart of F-344 rats ingesting quinacrine hydrochloride.
6517710_0	0	17	Atrial thrombosis	Disease	D003328
6517710_0	62	86	quinacrine hydrochloride	Chemical	D011796
6517710_0	CID	D011796	D003328

6517710_2|s|Rats treated with 500 ppm quinacrine hydrochloride in the diet all developed a high incidence of left atrial thrombosis.
6517710_2	102	119	atrial thrombosis	Disease	D003328
6517710_2	26	50	quinacrine hydrochloride	Chemical	D011796
6517710_2	CID	D011796	D003328

6517710_5|s|Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis.
6517710_5	123	133	thrombosis	Disease	D013927
6517710_5	222	239	atrial thrombosis	Disease	D003328
6517710_5	38	62	quinacrine hydrochloride	Chemical	D011796
6517710_5	77	91	sodium nitrite	Chemical	D012977
6517710_5	CID	D011796	D003328

6529939_0|s|Alternating sinus rhythm and intermittent sinoatrial block induced by propranolol.
6529939_0	0	24	Alternating sinus rhythm	Disease	D001146
6529939_0	42	58	sinoatrial block	Disease	D012848
6529939_0	70	81	propranolol	Chemical	D011433
6529939_0	CID	D011433	D012848
6529939_0	CID	D011433	D001146

6529939_1|s|Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg propranolol daily.
6529939_1	0	24	Alternating sinus rhythm	Disease	D001146
6529939_1	42	64	sinoatrial (S-A) block	Disease	D012848
6529939_1	122	128	angina	Disease	D000787
6529939_1	140	151	propranolol	Chemical	D011433
6529939_1	CID	D011433	D012848
6529939_1	CID	D011433	D001146

6529939_11|s|Atropine 1 mg given intravenously resulted in shortening of all P-P intervals without changing the rhythm.
6529939_11	95	105	the rhythm	Disease	D001146
6529939_11	0	8	Atropine	Chemical	D001285

6529939_12|s|The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2/1 S-A block was seen.
6529939_12	105	114	S-A block	Disease	D012848
6529939_12	55	66	propranolol	Chemical	D011433
6529939_12	CID	D011433	D012848

6529939_13|s|This was accepted as evidence for propranolol being the cause of this conduction disorder.
6529939_13	70	89	conduction disorder	Disease	D019955
6529939_13	34	45	propranolol	Chemical	D011433

6585590_0|s|Antitumor effect, cardiotoxicity, and nephrotoxicity of doxorubicin in the IgM solid immunocytoma-bearing LOU/M/WSL rat.
6585590_0	18	32	cardiotoxicity	Disease	D066126
6585590_0	38	52	nephrotoxicity	Disease	D007674
6585590_0	85	97	immunocytoma	Disease	-1
6585590_0	56	67	doxorubicin	Chemical	D004317

6585590_1|s|Antitumor activity, cardiotoxicity, and nephrotoxicity induced by doxorubicin were studied in LOU/M/WSL inbred rats each bearing a transplantable solid IgM immunocytoma.
6585590_1	20	34	cardiotoxicity	Disease	D066126
6585590_1	40	54	nephrotoxicity	Disease	D007674
6585590_1	156	168	immunocytoma	Disease	-1
6585590_1	66	77	doxorubicin	Chemical	D004317

6585590_2|s|Animals with a tumor (diameter, 15.8 +/- 3.3 mm) were treated with iv injections of doxorubicin on 5 consecutive days, followed by 1 weekly injection for 7 weeks (dose range, 0.015-4.0 mg/kg body wt).
6585590_2	15	20	tumor	Disease	D009369
6585590_2	84	95	doxorubicin	Chemical	D004317

6585590_3|s|Tumor regression was observed with 0.5 mg doxorubicin/kg.
6585590_3	0	5	Tumor	Disease	D009369
6585590_3	42	53	doxorubicin	Chemical	D004317

6585590_4|s|Complete disappearance of the tumor was induced with 1.0 mg doxorubicin/kg.
6585590_4	30	35	tumor	Disease	D009369
6585590_4	60	71	doxorubicin	Chemical	D004317

6585590_5|s|Histologic evidence of cardiotoxicity scored as grade III was only observed at a dose of 1.0 mg doxorubicin/kg.
6585590_5	23	37	cardiotoxicity	Disease	D066126
6585590_5	96	107	doxorubicin	Chemical	D004317

6585590_6|s|Light microscopic evidence of renal damage was seen above a dose of 0.5 mg doxorubicin/kg, which resulted in albuminuria and very low serum albumin levels.
6585590_6	30	42	renal damage	Disease	D007674
6585590_6	109	120	albuminuria	Disease	D000419
6585590_6	75	86	doxorubicin	Chemical	D004317
6585590_6	CID	D004317	D000419

6615679_0|s|Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops.
6615679_0	15	26	bradycardia	Disease	D001919
6615679_0	31	42	hypotension	Disease	D007022
6615679_0	59	66	timolol	Chemical	D013999
6615679_0	71	82	pilocarpine	Chemical	D010862
6615679_0	CID	D013999	D007022
6615679_0	CID	D010862	D001919
6615679_0	CID	D010862	D007022
6615679_0	CID	D013999	D001919

6615679_1|s|A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became hypotensive during halothane anaesthesia.
6615679_1	120	131	bradycardia	Disease	D001919
6615679_1	143	154	hypotensive	Disease	D007022
6615679_1	57	76	pilocarpine nitrate	Chemical	D010862
6615679_1	81	96	timolol maleate	Chemical	D013999
6615679_1	162	171	halothane	Chemical	D006221
6615679_1	CID	D013999	D007022
6615679_1	CID	D010862	D001919
6615679_1	CID	D010862	D007022
6615679_1	CID	D013999	D001919

6615679_4|s|It is postulated that this action may have been enhanced during halothane anaesthesia with resultant bradycardia and hypotension.
6615679_4	101	112	bradycardia	Disease	D001919
6615679_4	117	128	hypotension	Disease	D007022
6615679_4	64	73	halothane	Chemical	D006221

6627074_0|s|Succinylcholine apnoea: attempted reversal with anticholinesterases.
6627074_0	16	22	apnoea	Disease	D001049
6627074_0	0	15	Succinylcholine	Chemical	D013390
6627074_0	CID	D013390	D001049

6627074_1|s|Anticholinesterases were administered in an attempt to antagonize prolonged neuromuscular blockade following the administration of succinylcholine in a patient later found to be homozygous for atypical plasma cholinesterase.
6627074_1	76	98	neuromuscular blockade	Disease	D020879
6627074_1	131	146	succinylcholine	Chemical	D013390

6627074_5|s|It is concluded that anticholinesterases are only partially effective in restoring neuromuscular function in succinylcholine apnoea despite muscle twitch activity typical of phase II block.
6627074_5	125	131	apnoea	Disease	D001049
6627074_5	109	124	succinylcholine	Chemical	D013390
6627074_5	CID	D013390	D001049

6631522_6|s|Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I-131 HA are not the initiating factor in doxorubicin cardiotoxicity.
6631522_6	152	166	cardiotoxicity	Disease	D066126
6631522_6	98	106	I-131 HA	Chemical	C013102
6631522_6	140	151	doxorubicin	Chemical	D004317
6631522_6	CID	D004317	D066126

6673474_2|s|Coronary blood flow, cardiac work and metabolism were studied in dogs under sodium nitroprusside (SNP) and trimetaphan (TMP) deliberate hypotension (20% and 40% mean pressure decrease from baseline).
6673474_2	136	147	hypotension	Disease	D007022
6673474_2	76	96	sodium nitroprusside	Chemical	D009599
6673474_2	98	101	SNP	Chemical	D009599
6673474_2	107	118	trimetaphan	Chemical	D014294
6673474_2	120	123	TMP	Chemical	D014294
6673474_2	CID	D014294	D007022
6673474_2	CID	D009599	D007022

6673474_3|s|Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.
6673474_3	38	49	hypotension	Disease	D007022
6673474_3	167	178	hypotension	Disease	D007022
6673474_3	262	273	hypotension	Disease	D007022
6673474_3	153	166	nitroprusside	Chemical	D009599
6673474_3	250	261	trimetaphan	Chemical	D014294
6673474_3	CID	D014294	D007022
6673474_3	CID	D009599	D007022

6673474_4|s|Cardiac work was significantly reduced during SNP hypotension.
6673474_4	50	61	hypotension	Disease	D007022
6673474_4	46	49	SNP	Chemical	D009599
6673474_4	CID	D009599	D007022

6687006_2|s|The hyperactivity induced by D-amphetamine (10 mumol/kg) was significantly reduced by DSP4 pretreatment.
6687006_2	4	17	hyperactivity	Disease	D006948
6687006_2	29	42	D-amphetamine	Chemical	D003913
6687006_2	86	90	DSP4	Chemical	C012102
6687006_2	CID	D003913	D006948

6687006_3|s|However, the increased rearings and the amphetamine-induced stereotypies were not blocked by pretreatment with DSP4.
6687006_3	60	72	stereotypies	Disease	D019956
6687006_3	40	51	amphetamine	Chemical	D000661
6687006_3	111	115	DSP4	Chemical	C012102

6687006_4|s|The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.
6687006_4	29	42	hyperactivity	Disease	D006948
6687006_4	165	175	neurotoxic	Disease	D020258
6687006_4	17	28	amphetamine	Chemical	D000661
6687006_4	54	58	DSP4	Chemical	C012102
6687006_4	96	109	noradrenaline	Chemical	D009638
6687006_4	133	144	desipramine	Chemical	D003891
6687006_4	186	190	DSP4	Chemical	C012102

6695685_0|s|Accelerated junctional rhythms during oral verapamil therapy.
6695685_0	0	30	Accelerated junctional rhythms	Disease	D001145
6695685_0	43	52	verapamil	Chemical	D014700
6695685_0	CID	D014700	D001145

6695685_1|s|This study examined the frequency of atrioventricular (AV) dissociation and accelerated junctional rhythms in 59 patients receiving oral verapamil.
6695685_1	76	106	accelerated junctional rhythms	Disease	D001145
6695685_1	137	146	verapamil	Chemical	D014700
6695685_1	CID	D014700	D001145

6695685_4|s|In patients with various chest pain syndromes, verapamil neither increased the frequency of junctional rhythms nor suppressed their role as escape rhythms under physiologically appropriate circumstances.
6695685_4	25	35	chest pain	Disease	D002637
6695685_4	47	56	verapamil	Chemical	D014700

6806735_0|s|Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
6806735_0	13	27	ovarian cancer	Disease	D010051
6806735_0	50	62	cis-platinum	Chemical	D002945
6806735_0	64	74	adriamycin	Chemical	D004317
6806735_0	76	92	cyclophosphamide	Chemical	D003520
6806735_0	97	115	hexamethylmelamine	Chemical	D006585

6806735_1|s|During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.
6806735_1	46	60	ovarian cancer	Disease	D010051
6806735_1	96	107	cisplatinum	Chemical	D002945
6806735_1	109	113	CPDD	Chemical	C034868
6806735_1	126	136	adriamycin	Chemical	D004317
6806735_1	148	164	cyclophosphamide	Chemical	D003520
6806735_1	191	209	hexamethylmelamine	Chemical	D006585
6806735_1	211	214	HMM	Chemical	D006585

6806735_6|s|HMM gastrointestinal toxicity necessitated discontinuation of the drug in 5 patients.
6806735_6	4	29	gastrointestinal toxicity	Disease	D005767
6806735_6	0	3	HMM	Chemical	D006585

6884395_1|s|A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension, smoke, and oral contraceptives is reported in a young female patient with a locked-in syndrome.
6884395_1	23	42	dissecting aneurysm	Disease	D000784
6884395_1	85	97	hypertension	Disease	D006973
6884395_1	175	193	locked-in syndrome	Disease	D011782
6884395_1	110	129	oral contraceptives	Chemical	D003276
6884395_1	CID	D003276	D000784

6893265_0|s|Propylthiouracil-induced hepatic damage.
6893265_0	25	39	hepatic damage	Disease	D056486
6893265_0	0	16	Propylthiouracil	Chemical	D011441
6893265_0	CID	D011441	D056486

6893265_1|s|Two cases of propylthiouracil-induced liver damage have been observed.
6893265_1	38	50	liver damage	Disease	D056486
6893265_1	13	29	propylthiouracil	Chemical	D011441
6893265_1	CID	D011441	D056486

6985297_0|s|Studies on the bradycardia induced by bepridil.
6985297_0	15	26	bradycardia	Disease	D001919
6985297_0	38	46	bepridil	Chemical	D015764
6985297_0	CID	D015764	D001919

6985297_1|s|Bepridil, a novel active compound for prophylactic treatment of anginal attacks, induced persistent bradycardia and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo.
6985297_1	64	79	anginal attacks	Disease	D000787
6985297_1	100	111	bradycardia	Disease	D001919
6985297_1	136	148	tachycardial	Disease	D013610
6985297_1	0	8	Bepridil	Chemical	D015764
6985297_1	CID	D015764	D001919

6985498_0|s|Hepatitis and renal tubular acidosis after anesthesia with methoxyflurane.
6985498_0	0	9	Hepatitis	Disease	D056486
6985498_0	14	36	renal tubular acidosis	Disease	D000141
6985498_0	59	73	methoxyflurane	Chemical	D008733
6985498_0	CID	D008733	D000141
6985498_0	CID	D008733	D056486

6985498_1|s|A 69-year-old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis.
6985498_1	31	50	acute cholecystitis	Disease	D041881
6985498_1	111	141	hepatic insufficiency syndrome	Disease	D048550
6985498_1	146	168	renal tubular acidosis	Disease	D000141
6985498_1	57	71	methoxyflurane	Chemical	D008733
6985498_1	CID	D008733	D000141

7018927_0|s|Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia.
7018927_0	87	105	hyperprolactinemia	Disease	D006966
7018927_0	67	78	haloperidol	Chemical	D006220
7018927_0	CID	D006220	D006966

7018927_4|s|During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.
7018927_4	56	74	hyperprolactinemia	Disease	D006966
7018927_4	21	32	haloperidol	Chemical	D006220
7018927_4	CID	D006220	D006966

7121659_0|s|Antirifampicin antibodies in acute rifampicin-associated renal failure.5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.
7121659_0	57	70	renal failure	Disease	D051437
7121659_0	88	107	acute renal failure	Disease	D058186
7121659_0	116	128	thrombopenia	Disease	D013921
7121659_0	133	142	hemolysis	Disease	D006461
7121659_0	35	45	rifampicin	Chemical	D012293
7121659_0	177	187	rifampicin	Chemical	D012293
7121659_0	CID	D012293	D006461
7121659_0	CID	D012293	D013921

7147232_0|s|Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts.
7147232_0	26	37	hypotension	Disease	D007022
7147232_0	49	71	adenosine triphosphate	Chemical	D000255
7147232_0	76	96	sodium nitroprusside	Chemical	D009599
7147232_0	CID	D009599	D007022
7147232_0	CID	D000255	D007022

7147232_1|s|Adenosine triphosphate (ATP) and sodium nitroprusside (SNP) are administered to patients to induce and control hypotension during anesthesia.
7147232_1	111	122	hypotension	Disease	D007022
7147232_1	0	22	Adenosine triphosphate	Chemical	D000255
7147232_1	24	27	ATP	Chemical	D000255
7147232_1	33	53	sodium nitroprusside	Chemical	D009599
7147232_1	55	58	SNP	Chemical	D009599
7147232_1	CID	D009599	D007022
7147232_1	CID	D000255	D007022

7147232_6|s|Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body oxygen consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped.
7147232_6	0	11	Hypotension	Disease	D007022
7147232_6	23	26	ATP	Chemical	D000255
7147232_6	334	340	oxygen	Chemical	D010100
7147232_6	465	468	ATP	Chemical	D000255
7147232_6	CID	D000255	D007022

7147232_8|s|During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and oxygen content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased.
7147232_8	7	18	hypotension	Disease	D007022
7147232_8	31	34	SNP	Chemical	D009599
7147232_8	324	330	oxygen	Chemical	D010100
7147232_8	CID	D009599	D007022

7173007_2|s|The Dimer-X group had a higher incidence of nausea and dizziness.
7173007_2	44	50	nausea	Disease	D009325
7173007_2	55	64	dizziness	Disease	D004244
7173007_2	4	11	Dimer-X	Chemical	C025504
7173007_2	CID	C025504	D004244
7173007_2	CID	C025504	D009325

7173007_3|s|The Endografine group had a higher incidence of abdominal pain.
7173007_3	48	62	abdominal pain	Disease	D015746
7173007_3	4	15	Endografine	Chemical	C006753
7173007_3	CID	C006753	D015746

7173007_5|s|Hexabrix and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred.
7173007_5	128	136	toxicity	Disease	D064420
7173007_5	0	8	Hexabrix	Chemical	D007485
7173007_5	13	31	Vasurix polyvidone	Chemical	D000100
7173007_5	56	70	contrast media	Chemical	D003287
7173007_5	137	145	Hexabrix	Chemical	D007485

7176945_0|s|Post-suxamethonium pains in Nigerian surgical patients.
7176945_0	19	24	pains	Disease	D010146
7176945_0	5	18	suxamethonium	Chemical	D013390
7176945_0	CID	D013390	D010146

7176945_1|s|Contrary to an earlier report by Coxon, scoline pain occurs in African negroes.
7176945_1	48	52	pain	Disease	D010146
7176945_1	40	47	scoline	Chemical	D013390
7176945_1	CID	D013390	D010146

7176945_3|s|About 62% of the out-patients developed scoline pain as compared with about 26% among the in-patients.
7176945_3	48	52	pain	Disease	D010146
7176945_3	40	47	scoline	Chemical	D013390
7176945_3	CID	D013390	D010146

7176945_4|s|The abolition of muscle fasciculations (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain.
7176945_4	24	38	fasciculations	Disease	D005207
7176945_4	118	122	pain	Disease	D010146
7176945_4	62	72	Fazadinium	Chemical	C084773
7176945_4	110	117	scoline	Chemical	D013390
7176945_4	CID	D013390	D005207
7176945_4	CID	D013390	D010146

7176945_5|s|Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain.
7176945_5	166	170	pain	Disease	D010146
7176945_5	37	45	Althesin	Chemical	D000530
7176945_5	49	60	Thiopentone	Chemical	D013874
7176945_5	90	103	suxamethonium	Chemical	D013390
7176945_5	110	118	chloride	Chemical	D002712
7176945_5	122	129	bromide	Chemical	D001965
7176945_5	158	165	scoline	Chemical	D013390
7176945_5	CID	D013390	D010146

7315949_0|s|Medial changes in arterial spasm induced by L-norepinephrine.
7315949_0	27	32	spasm	Disease	D013035
7315949_0	44	60	L-norepinephrine	Chemical	D009638
7315949_0	CID	D009638	D013035

7315949_3|s|In the media of the saphenous artery and its distal branch, vasoconstriction induced by L-norepinephrine produced many cell-to-cell hernias within 15 minutes.
7315949_3	132	139	hernias	Disease	D006547
7315949_3	88	104	L-norepinephrine	Chemical	D009638

7369302_0|s|Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.
7369302_0	66	75	amblyopia	Disease	D000550
7369302_0	58	65	quinine	Chemical	D011803
7369302_0	CID	D011803	D000550

7369302_1|s|Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.
7369302_1	6	15	blindness	Disease	D001766
7369302_1	33	48	tonic pupillary	Disease	D015845
7369302_1	195	205	leg cramps	Disease	D009120
7369302_1	175	190	quinine sulfate	Chemical	D011803
7369302_1	CID	D011803	D015845
7369302_1	CID	D011803	D001766

7369302_3|s|A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.
7369302_3	12	27	tonic pupillary	Disease	D015845
7369302_3	117	125	toxicity	Disease	D064420
7369302_3	109	116	quinine	Chemical	D011803
7369302_3	CID	D011803	D015845

7378868_0|s|Suxamethonium-induced jaw stiffness and myalgia associated with atypical cholinesterase: case report.
7378868_0	22	35	jaw stiffness	Disease	D014313
7378868_0	40	47	myalgia	Disease	D063806
7378868_0	0	13	Suxamethonium	Chemical	D013390
7378868_0	CID	D013390	D014313
7378868_0	CID	D013390	D063806

7378868_6|s|The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.
7378868_6	20	42	prolonged jaw rigidity	Disease	D014313
7378868_6	47	54	myalgia	Disease	D063806
7378868_6	71	84	suxamethonium	Chemical	D013390
7378868_6	152	163	pancuronium	Chemical	D010197
7378868_6	CID	D013390	D014313
7378868_6	CID	D013390	D063806

7411769_0|s|Indomethacin-induced hyperkalemia in three patients with gouty arthritis.
7411769_0	21	33	hyperkalemia	Disease	D006947
7411769_0	57	72	gouty arthritis	Disease	D015210
7411769_0	0	12	Indomethacin	Chemical	D007213
7411769_0	CID	D007213	D006947

7411769_1|s|We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin.
7411769_1	60	72	hyperkalemia	Disease	D006947
7411769_1	77	96	renal insufficiency	Disease	D051437
7411769_1	132	147	gouty arthritis	Disease	D015210
7411769_1	153	165	indomethacin	Chemical	D007213
7411769_1	CID	D007213	D006947
7411769_1	CID	D007213	D051437

7411769_2|s|This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism.
7411769_2	90	121	hyporeninemic hypoaidosteronism	Disease	D006994
7411769_2	51	64	prostaglandin	Chemical	D011453

7411769_3|s|Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication.
7411769_3	177	194	diabetes mellitus	Disease	D003920
7411769_3	210	223	renal disease	Disease	D007674
7411769_3	40	49	potassium	Chemical	D011188
7411769_3	80	92	indomethacin	Chemical	D007213

7477981_0|s|Levodopa-induced dyskinesias are improved by fluoxetine.
7477981_0	17	28	dyskinesias	Disease	D004409
7477981_0	0	8	Levodopa	Chemical	D007980
7477981_0	45	55	fluoxetine	Chemical	D005473
7477981_0	CID	D005473	D004409

7477981_1|s|We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days.
7477981_1	29	45	motor disability	Disease	D009069
7477981_1	50	61	dyskinesias	Disease	D004409
7477981_1	105	124	Parkinson's disease	Disease	D010300
7477981_1	71	79	levodopa	Chemical	D007980
7477981_1	165	173	dopamine	Chemical	D004298
7477981_1	183	194	apomorphine	Chemical	D001058
7477981_1	235	245	fluoxetine	Chemical	D005473
7477981_1	CID	D001058	D004409
7477981_1	CID	D005473	D004409

7477981_2|s|After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability.
7477981_2	102	113	dyskinesias	Disease	D004409
7477981_2	138	150	parkinsonian	Disease	D010300
7477981_2	151	167	motor disability	Disease	D009069
7477981_2	6	16	fluoxetine	Chemical	D005473
7477981_2	82	93	apomorphine	Chemical	D001058
7477981_2	CID	D001058	D004409
7477981_2	CID	D005473	D004409

7477981_4|s|The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.
7477981_4	134	145	dyskinesias	Disease	D004409
7477981_4	166	178	parkinsonian	Disease	D010300
7477981_4	179	195	motor disability	Disease	D009069
7477981_4	74	84	fluoxetine	Chemical	D005473
7477981_4	96	104	levodopa	Chemical	D007980
7477981_4	109	117	dopamine	Chemical	D004298
7477981_4	CID	D005473	D004409

7479194_0|s|A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity.
7479194_0	125	138	drug toxicity	Disease	D064420
7479194_0	44	73	trimethoprim-sulfamethoxazole	Chemical	D015662
7479194_0	75	87	trimethoprim	Chemical	D014295
7479194_0	93	103	cephalexin	Chemical	D002506

7479194_1|s|We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.
7479194_1	240	279	liver, blood, skin, and renal disorders	Disease	D008107|D006402|D012871|D007674
7479194_1	93	122	trimethoprim-sulfamethoxazole	Chemical	D015662
7479194_1	124	131	TMP-SMZ	Chemical	D015662
7479194_1	153	165	trimethoprim	Chemical	D014295
7479194_1	196	206	cephalexin	Chemical	D002506
7479194_1	CID	D014295	D008107
7479194_1	CID	D015662	D008107
7479194_1	CID	D002506	D008107

7479194_3|s|The risk of clinically important idiopathic liver disease was similar for persons prescribed TMP-SMZ (5.2/100,000) and those prescribed trimethoprim alone (3.8/100,000).
7479194_3	44	57	liver disease	Disease	D008107
7479194_3	93	100	TMP-SMZ	Chemical	D015662
7479194_3	136	148	trimethoprim	Chemical	D014295
7479194_3	CID	D014295	D008107
7479194_3	CID	D015662	D008107

7479194_5|s|Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.
7479194_5	98	117	erythema multiforme	Disease	D004892
7479194_5	122	146	Stevens-Johnson syndrome	Disease	D013262
7479194_5	75	82	TMP-SMZ	Chemical	D015662
7479194_5	169	176	TMP-SMZ	Chemical	D015662
7479194_5	CID	D015662	D013262

7479194_6|s|The one case of toxic epidermal necrolysis occurred in a patient who took cephalexin.
7479194_6	16	42	toxic epidermal necrolysis	Disease	D013262
7479194_6	74	84	cephalexin	Chemical	D002506
7479194_6	CID	D002506	D013262

7492040_0|s|Clinical safety of lidocaine in patients with cocaine-associated myocardial infarction.
7492040_0	65	86	myocardial infarction	Disease	D009203
7492040_0	19	28	lidocaine	Chemical	D008012
7492040_0	46	53	cocaine	Chemical	D003042
7492040_0	CID	D003042	D009203

7492040_1|s|STUDY OBJECTIVE: To evaluate the safety of lidocaine in the setting of cocaine-induced myocardial infarction (MI).
7492040_1	87	108	myocardial infarction	Disease	D009203
7492040_1	110	112	MI	Disease	D009203
7492040_1	43	52	lidocaine	Chemical	D008012
7492040_1	71	78	cocaine	Chemical	D003042
7492040_1	CID	D003042	D009203

7492040_4|s|PARTICIPANTS: Patients with cocaine-associated MI who received lidocaine in the emergency department.
7492040_4	47	49	MI	Disease	D009203
7492040_4	28	35	cocaine	Chemical	D003042
7492040_4	63	72	lidocaine	Chemical	D008012
7492040_4	CID	D003042	D009203

7492040_5|s|RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).
7492040_5	84	86	MI	Disease	D009203
7492040_5	115	132	bradydysrhythmias	Disease	D001919
7492040_5	134	157	ventricular tachycardia	Disease	D017180
7492040_5	162	186	ventricular fibrillation	Disease	D014693
7492040_5	203	211	seizures	Disease	D012640
7492040_5	37	46	lidocaine	Chemical	D008012
7492040_5	65	72	cocaine	Chemical	D003042
7492040_5	236	245	lidocaine	Chemical	D008012
7492040_5	CID	D003042	D009203

7492040_6|s|CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.
7492040_6	76	84	toxicity	Disease	D064420
7492040_6	143	145	MI	Disease	D009203
7492040_6	182	231	cardiovascular or central nervous system toxicity	Disease	D002318|D002493
7492040_6	46	55	lidocaine	Chemical	D008012
7492040_6	68	75	cocaine	Chemical	D003042
7492040_6	97	106	lidocaine	Chemical	D008012
7492040_6	124	131	cocaine	Chemical	D003042
7492040_6	CID	D003042	D009203

7644931_1|s|Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with non-small cell lung cancer.
7644931_1	161	187	non-small cell lung cancer	Disease	D002289
7644931_1	0	10	Paclitaxel	Chemical	D017239
7644931_1	12	17	Taxol	Chemical	D017239
7644931_1	101	112	carboplatin	Chemical	D016190

7644931_5|s|Toxicities were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels.
7644931_5	0	10	Toxicities	Disease	D064420
7644931_5	73	83	paclitaxel	Chemical	D017239

7644931_6|s|Carboplatin did not appear to add to the hematologic toxicities observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks.
7644931_6	41	63	hematologic toxicities	Disease	D006402
7644931_6	0	11	Carboplatin	Chemical	D016190
7644931_6	82	92	paclitaxel	Chemical	D017239
7644931_6	93	104	carboplatin	Chemical	D016190
7644931_6	CID	D017239	D006402

7661171_0|s|The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis.
7661171_0	65	82	renal dysfunction	Disease	D007674
7661171_0	103	112	cirrhosis	Disease	D005355
7661171_0	29	40	misoprostol	Chemical	D016595
7661171_0	44	56	indomethacin	Chemical	D007213
7661171_0	CID	D007213	D007674

7661171_1|s|Misoprostol (200 micrograms) has been shown to acutely counteract the indomethacin-induced renal dysfunction in well compensated cirrhotic patients.
7661171_1	91	108	renal dysfunction	Disease	D007674
7661171_1	129	138	cirrhotic	Disease	D005355
7661171_1	0	11	Misoprostol	Chemical	D016595
7661171_1	70	82	indomethacin	Chemical	D007213
7661171_1	CID	D007213	D007674

7661171_3|s|Parameters of renal hemodynamics and tubular sodium and water handling were assessed by clearance techniques in 26 well compensated cirrhotic patients before and after an oral combination of 50 mg of indomethacin and various doses of misoprostol.
7661171_3	132	141	cirrhotic	Disease	D005355
7661171_3	45	51	sodium	Chemical	D012964
7661171_3	200	212	indomethacin	Chemical	D007213
7661171_3	234	245	misoprostol	Chemical	D016595

7661171_7|s|However, until this apparent ability of 200 micrograms of misoprostol to prevent the adverse effects of indomethacin on renal function is confirmed with chronic frequent dosing, it would be prudent to avoid nonsteroidal anti-inflammatory therapy in patients with cirrhosis.
7661171_7	263	272	cirrhosis	Disease	D005355
7661171_7	58	69	misoprostol	Chemical	D016595
7661171_7	104	116	indomethacin	Chemical	D007213

7671401_0|s|Increased frequency and severity of angio-oedema related to long-term therapy with angiotensin-converting enzyme inhibitor in two patients.
7671401_0	36	48	angio-oedema	Disease	D000799
7671401_0	83	122	angiotensin-converting enzyme inhibitor	Chemical	D000806
7671401_0	CID	D000806	D000799

7671401_2|s|Angiotensin-converting enzyme (ACE) inhibitors, used to treat hypertension and congestive heart failure, were introduced in Europe in the middle of the eighties, and the use of these drugs has increased progressively.
7671401_2	62	74	hypertension	Disease	D006973
7671401_2	79	103	congestive heart failure	Disease	D006333
7671401_2	0	46	Angiotensin-converting enzyme (ACE) inhibitors	Chemical	D000806

7671401_3|s|Soon after the introduction of ACE inhibitors, acute bouts of angio-oedema were reported in association with the use of these drugs.
7671401_3	62	74	angio-oedema	Disease	D000799
7671401_3	31	45	ACE inhibitors	Chemical	D000806
7671401_3	CID	D000806	D000799

7671401_4|s|We wish to draw attention to the possibility of adverse reactions to ACE inhibitors after long-term use and in patients with pre-existing angio-oedema.
7671401_4	138	150	angio-oedema	Disease	D000799
7671401_4	69	83	ACE inhibitors	Chemical	D000806
7671401_4	CID	D000806	D000799

7727612_0|s|Myoclonus associated with lorazepam therapy in very-low-birth-weight infants.
7727612_0	0	9	Myoclonus	Disease	D009207
7727612_0	26	35	lorazepam	Chemical	D008140
7727612_0	CID	D008140	D009207

7727612_3|s|Three young infants, all of birth weight < 1,500 g, experienced myoclonus following the intravenous administration of lorazepam.
7727612_3	64	73	myoclonus	Disease	D009207
7727612_3	118	127	lorazepam	Chemical	D008140
7727612_3	CID	D008140	D009207

7739955_2|s|Three patients had acute viral myocarditis, one had a carbamazepine-induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock.
7739955_2	31	42	myocarditis	Disease	D009205
7739955_2	82	106	eosinophilic myocarditis	Disease	D004802|D009205
7739955_2	161	178	cardiogenic shock	Disease	D012770
7739955_2	54	67	carbamazepine	Chemical	D002220
7739955_2	CID	D002220	D004802
7739955_2	CID	D002220	D009205

7931490_0|s|Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
7931490_0	112	118	nausea	Disease	D009325
7931490_0	123	131	vomiting	Disease	D014839
7931490_0	23	34	granisetron	Chemical	D017829
7931490_0	48	67	5-hydroxytryptamine	Chemical	D012701
7931490_0	153	162	cisplatin	Chemical	D002945
7931490_0	CID	D002945	D014839
7931490_0	CID	D002945	D009325

7931490_1|s|PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and vomiting.
7931490_1	252	258	nausea	Disease	D009325
7931490_1	263	271	vomiting	Disease	D014839
7931490_1	88	99	granisetron	Chemical	D017829
7931490_1	101	107	Kytril	Chemical	D017829
7931490_1	234	243	cisplatin	Chemical	D002945
7931490_1	CID	D002945	D014839
7931490_1	CID	D002945	D009325

7931490_5|s|RESULTS: After granisetron doses of 5, 10, 20, and 40 micrograms/kg, a major response (< or = two vomiting or retching episodes, and no antiemetic rescue) was recorded in 23%, 57%, 58%, and 60% of patients, respectively, and a complete response (no vomiting or retching, and no antiemetic rescue) in 18%, 41%, 40%, and 47% of patients, respectively.
7931490_5	98	106	vomiting	Disease	D014839
7931490_5	249	257	vomiting	Disease	D014839
7931490_5	15	26	granisetron	Chemical	D017829

7931490_9|s|CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of granisetron was effective in controlling vomiting in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients.
7931490_9	100	108	vomiting	Disease	D014839
7931490_9	211	219	vomiting	Disease	D014839
7931490_9	59	70	granisetron	Chemical	D017829
7931490_9	148	157	cisplatin	Chemical	D002945
7931490_9	CID	D002945	D014839

7949506_1|s|OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular (AV) block in both patients and severe hypotension in one patient.
7949506_1	110	137	atrioventricular (AV) block	Disease	D054537
7949506_1	166	177	hypotension	Disease	D007022
7949506_1	73	82	clonidine	Chemical	D003000
7949506_1	87	96	verapamil	Chemical	D014700
7949506_1	CID	D014700	D007022
7949506_1	CID	D014700	D054537
7949506_1	CID	D003000	D054537
7949506_1	CID	D003000	D007022

7949506_2|s|CASE SUMMARIES: A 54-year-old woman with hyperaldosteronism was treated with verapamil 480 mg/d and spironolactone 100 mg/d.
7949506_2	41	59	hyperaldosteronism	Disease	D006929
7949506_2	77	86	verapamil	Chemical	D014700
7949506_2	100	114	spironolactone	Chemical	D013148

7949506_3|s|After the addition of a minimal dose of clonidine (0.15 mg bid), she developed complete AV block and severe hypotension, which resolved upon cessation of all medications.
7949506_3	88	96	AV block	Disease	D054537
7949506_3	108	119	hypotension	Disease	D007022
7949506_3	40	49	clonidine	Chemical	D003000
7949506_3	CID	D003000	D054537
7949506_3	CID	D003000	D007022

7949506_5|s|After the addition of clonidine 0.15 mg bid she developed complete AV block, which resolved after all therapy was stopped.
7949506_5	67	75	AV block	Disease	D054537
7949506_5	22	31	clonidine	Chemical	D003000
7949506_5	CID	D003000	D054537

7967231_1|s|S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o.
7967231_1	106	134	audiogenic tonic convulsions	Disease	D020195
7967231_1	0	5	S-312	Chemical	C059447
7967231_1	7	14	S-312-d	Chemical	C059447
7967231_1	24	31	S-312-l	Chemical	-1
7967231_1	40	47	calcium	Chemical	D002118
7967231_1	268	279	flunarizine	Chemical	D005444

7967231_2|s|Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
7967231_2	101	112	convulsions	Disease	D012640
7967231_2	219	230	convulsions	Disease	D012640
7967231_2	44	51	S-312-d	Chemical	C059447
7967231_2	124	142	pentylenetetrazole	Chemical	D010433
7967231_2	163	172	bemegride	Chemical	D001534
7967231_2	242	262	N-methyl-D-aspartate	Chemical	D016202
7967231_2	264	274	picrotoxin	Chemical	D010852
7967231_2	CID	D010852	D012640
7967231_2	CID	D010433	D012640
7967231_2	CID	D001534	D012640

7967231_3|s|S-312-d may be useful in the therapy of certain types of human epilepsy.
7967231_3	63	71	epilepsy	Disease	D004827
7967231_3	0	7	S-312-d	Chemical	C059447

8096565_0|s|Transmural myocardial infarction with sumatriptan.
8096565_0	11	32	myocardial infarction	Disease	D009203
8096565_0	38	49	sumatriptan	Chemical	D018170
8096565_0	CID	D018170	D009203

8096565_2|s|We describe a 47-year-old woman with an acute myocardial infarction after administration of sumatriptan 6 mg subcutaneously for cluster headache.
8096565_2	46	67	myocardial infarction	Disease	D009203
8096565_2	128	144	cluster headache	Disease	D003027
8096565_2	92	103	sumatriptan	Chemical	D018170
8096565_2	CID	D018170	D009203

8135424_0|s|Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications.
8135424_0	19	27	seizures	Disease	D012640
8135424_0	0	10	Flumazenil	Chemical	D005442
8135424_0	47	54	cocaine	Chemical	D003042
8135424_0	55	63	diazepam	Chemical	D003975
8135424_0	CID	D003975	D012640
8135424_0	CID	D005442	D012640
8135424_0	CID	D003042	D012640

8135424_1|s|STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask seizures in mixed cocaine-benzodiazepine intoxication.
8135424_1	88	96	seizures	Disease	D012640
8135424_1	40	54	benzodiazepine	Chemical	D001569
8135424_1	66	76	flumazenil	Chemical	D005442
8135424_1	106	113	cocaine	Chemical	D003042
8135424_1	114	128	benzodiazepine	Chemical	D001569
8135424_1	CID	D005442	D012640
8135424_1	CID	D003042	D012640

8135424_18|s|CONCLUSION: Flumazenil can unmask seizures and increase the incidence of death in a model of combined cocaine-diazepam intoxications.
8135424_18	34	42	seizures	Disease	D012640
8135424_18	12	22	Flumazenil	Chemical	D005442
8135424_18	102	109	cocaine	Chemical	D003042
8135424_18	110	118	diazepam	Chemical	D003975
8135424_18	CID	D003975	D012640
8135424_18	CID	D005442	D012640
8135424_18	CID	D003042	D012640

8160791_0|s|Mechanisms for protective effects of free radical scavengers on gentamicin-mediated nephropathy in rats.
8160791_0	84	95	nephropathy	Disease	D007674
8160791_0	64	74	gentamicin	Chemical	D005839
8160791_0	CID	D005839	D007674

8160791_1|s|Studies were performed to examine the mechanisms for the protective effects of free radical scavengers on gentamicin (GM)-mediated nephropathy.
8160791_1	131	142	nephropathy	Disease	D007674
8160791_1	106	116	gentamicin	Chemical	D005839
8160791_1	118	120	GM	Chemical	D005839
8160791_1	CID	D005839	D007674

8160791_2|s|Administration of GM at 40 mg/kg sc for 13 days to rats induced a significant reduction in renal blood flow (RBF) and inulin clearance (CIn) as well as marked tubular damage.
8160791_2	159	173	tubular damage	Disease	D007674
8160791_2	18	20	GM	Chemical	D005839
8160791_2	CID	D005839	D007674

8160791_3|s|A significant reduction in urinary guanosine 3',5'-cyclic monophosphate (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in GM-mediated nephropathy.
8160791_3	200	211	nephropathy	Disease	D007674
8160791_3	35	71	guanosine 3',5'-cyclic monophosphate	Chemical	D006152
8160791_3	73	77	cGMP	Chemical	D006152
8160791_3	188	190	GM	Chemical	D005839
8160791_3	CID	D005839	D007674

8160791_7|s|In contrast, DMTU significantly reduced the tubular damage and lipid peroxidation, but it did not affect renal hemodynamics and vasoactive substances.
8160791_7	44	58	tubular damage	Disease	D007674
8160791_7	13	17	DMTU	Chemical	C038983

8160791_9|s|These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated nephropathy, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.
8160791_9	87	98	nephropathy	Disease	D007674
8160791_9	43	47	DMTU	Chemical	C038983
8160791_9	75	77	GM	Chemical	D005839
8160791_9	164	168	DMTU	Chemical	C038983
8160791_9	177	187	superoxide	Chemical	D013481
8160791_9	219	221	GM	Chemical	D005839
8160791_9	CID	D005839	D007674

8184922_6|s|These data indicate that adult mouse atrial and ventricular cardiomyocytes do not synthesize DNA in response to isoproterenol-induced cardiac hypertrophy.
8184922_6	134	153	cardiac hypertrophy	Disease	D006332
8184922_6	112	125	isoproterenol	Chemical	D007545
8184922_6	CID	D007545	D006332

8188982_0|s|Central cardiovascular effects of AVP and ANP in normotensive and spontaneously hypertensive rats.
8188982_0	80	92	hypertensive	Disease	D006973
8188982_0	34	37	AVP	Chemical	D001127
8188982_0	CID	D001127	D006973

8188982_1|s|The purpose of the present study was to compare influence of central arginine vasopressin (AVP) and of atrial natriuretic peptide (ANP) on control of arterial blood pressure (MAP) and heart rate (HR) in normotensive (WKY) and spontaneously hypertensive (SHR) rats.
8188982_1	240	252	hypertensive	Disease	D006973
8188982_1	69	89	arginine vasopressin	Chemical	D001127
8188982_1	91	94	AVP	Chemical	D001127
8188982_1	CID	D001127	D006973

8188982_4|s|Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.
8188982_4	228	240	hypertension	Disease	D006973
8188982_4	279	290	hypotension	Disease	D007022
8188982_4	200	213	phenylephrine	Chemical	D010656
8188982_4	215	218	Phe	Chemical	D010656
8188982_4	245	265	sodium nitroprusside	Chemical	D009599
8188982_4	267	269	SN	Chemical	D009599
8188982_4	CID	D010656	D006973
8188982_4	CID	D009599	D007022

8188982_8|s|CCB was reduced in WKY and SHR after LV administration of AVP during SN-induced hypotension.
8188982_8	80	91	hypotension	Disease	D007022
8188982_8	58	61	AVP	Chemical	D001127
8188982_8	69	71	SN	Chemical	D009599
8188982_8	CID	D009599	D007022

8308951_0|s|Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.
8308951_0	61	85	intracerebral hemorrhage	Disease	D002543
8308951_0	22	30	warfarin	Chemical	D014859
8308951_0	CID	D014859	D002543

8308951_1|s|A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.
8308951_1	24	32	hematoma	Disease	D006406
8308951_1	57	69	coagulopathy	Disease	D001778
8308951_1	40	48	warfarin	Chemical	D014859

8308951_3|s|Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.
8308951_3	44	56	coagulopathy	Disease	D001778
8308951_3	27	35	warfarin	Chemical	D014859

8308951_4|s|An adverse drug interaction with piroxicam, which she took occasionally, may have exacerbated the coagulopathy.
8308951_4	98	110	coagulopathy	Disease	D001778
8308951_4	33	42	piroxicam	Chemical	D010894

8312343_2|s|Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).
8312343_2	37	62	idiopathic cardiomyopathy	Disease	D002311
8312343_2	70	94	congenital heart disease	Disease	D006331
8312343_2	160	187	hypertrophic cardiomyopathy	Disease	D002312
8312343_2	194	216	valvular heart disease	Disease	D006349
8312343_2	239	253	cardiomyopathy	Disease	D009202
8312343_2	227	238	doxorubicin	Chemical	D004317
8312343_2	CID	D004317	D009202

8312343_14|s|Cytomegalovirus infections were treated successfully with ganciclovir in 11 patients.
8312343_14	0	26	Cytomegalovirus infections	Disease	D003586
8312343_14	58	69	ganciclovir	Chemical	D015774

8312983_0|s|Delirium during fluoxetine treatment.
8312983_0	0	8	Delirium	Disease	D003693
8312983_0	16	26	fluoxetine	Chemical	D005473
8312983_0	CID	D005473	D003693

8312983_4|s|In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties.
8312983_4	126	136	somnolence	Disease	D006970
8312983_4	141	162	movement difficulties	Disease	D020820
8312983_4	45	55	citalopram	Chemical	D015283

8312983_6|s|In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration.
8312983_6	49	61	hyperkinetic	Disease	D006948
8312983_6	62	70	delirium	Disease	D003693
8312983_6	105	115	fluoxetine	Chemical	D005473
8312983_6	117	127	fluoxetine	Chemical	D005473
8312983_6	133	152	desmethylfluoxetine	Chemical	C036139
8312983_6	CID	D005473	D006948
8312983_6	CID	D005473	D003693

8318674_0|s|Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF.
8318674_0	0	15	Pulmonary edema	Disease	D011654
8318674_0	20	25	shock	Disease	D012769
8318674_0	58	66	lymphoma	Disease	D008223
8318674_0	42	53	aracytine-C	Chemical	D003561
8318674_0	CID	D003561	D011654
8318674_0	CID	D003561	D012769

8318674_1|s|Four out of 23 consecutive patients treated with high-dose Ara-C for lymphomas in our institution developed a strikingly similar syndrome during the perfusion.
8318674_1	69	78	lymphomas	Disease	D008223
8318674_1	59	64	Ara-C	Chemical	D003561

8318674_6|s|As TNF and PAF are thought to be involved in the development of septic shock and adult respiratory distress syndrome, we hypothesize that high-dose Ara-C may be associated with cytokine release.
8318674_6	71	76	shock	Disease	D012769
8318674_6	81	116	adult respiratory distress syndrome	Disease	D012128
8318674_6	148	153	Ara-C	Chemical	D003561
8318674_6	CID	D003561	D012769

8392553_0|s|Protective effect of clentiazem against epinephrine-induced cardiac injury in rats.
8392553_0	60	74	cardiac injury	Disease	D006331
8392553_0	21	31	clentiazem	Chemical	C056595
8392553_0	40	51	epinephrine	Chemical	D004837

8392553_1|s|We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced cardiomyopathy in rats.
8392553_1	108	122	cardiomyopathy	Disease	D009202
8392553_1	31	41	clentiazem	Chemical	C056595
8392553_1	45	64	1,5-benzothiazepine	Chemical	C106746
8392553_1	65	72	calcium	Chemical	D002118
8392553_1	88	99	epinephrine	Chemical	D004837
8392553_1	CID	D004837	D009202

8392553_2|s|With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and fibrosis of the left ventricles were observed.
8392553_2	87	103	ischemic lesions	Disease	D007511
8392553_2	108	116	fibrosis	Disease	D005355
8392553_2	20	31	epinephrine	Chemical	D004837

8392553_5|s|Treatment with clentiazem prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.
8392553_5	104	120	ischemic lesions	Disease	D007511
8392553_5	125	133	fibrosis	Disease	D005355
8392553_5	15	25	clentiazem	Chemical	C056595
8392553_5	36	47	epinephrine	Chemical	D004837

8392553_10|s|In conclusion, clentiazem attenuated epinephrine-induced cardiac injury, possibly through its effect on the adrenergic pathway.
8392553_10	57	71	cardiac injury	Disease	D006331
8392553_10	15	25	clentiazem	Chemical	C056595
8392553_10	37	48	epinephrine	Chemical	D004837

8511251_0|s|Cocaine induced myocardial ischemia.
8511251_0	16	35	myocardial ischemia	Disease	D017202
8511251_0	0	7	Cocaine	Chemical	D003042
8511251_0	CID	D003042	D017202

8511251_1|s|We report a case of myocardial ischemia induced by cocaine.
8511251_1	20	39	myocardial ischemia	Disease	D017202
8511251_1	51	58	cocaine	Chemical	D003042
8511251_1	CID	D003042	D017202

8511251_2|s|The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents.
8511251_2	4	12	ischemia	Disease	D007511
8511251_2	33	54	coronary artery spasm	Disease	D003329
8511251_2	71	84	nitroglycerin	Chemical	D005996
8511251_2	89	96	calcium	Chemical	D002118

8603459_0|s|Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice.
8603459_0	20	34	cardiotoxicity	Disease	D066126
8603459_0	0	11	Doxorubicin	Chemical	D004317
8603459_0	CID	D004317	D066126

8603459_2|s|In laboratory animals, histology is most commonly used to study doxorubicin-induced cardiotoxicity.
8603459_2	84	98	cardiotoxicity	Disease	D066126
8603459_2	64	75	doxorubicin	Chemical	D004317
8603459_2	CID	D004317	D066126

8603459_8|s|After sacrifice the hearts of doxorubicin-treated animals were enlarged and the atria were hypertrophic.
8603459_8	91	103	hypertrophic	Disease	D006984
8603459_8	30	41	doxorubicin	Chemical	D004317

8603459_9|s|As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general toxicity (6 weekly doses of 4 mg/kg doxorubicin given i.v. plus 2 weeks of observation).
8603459_9	30	38	toxicity	Disease	D064420
8603459_9	168	176	toxicity	Disease	D064420
8603459_9	103	111	ICRF-187	Chemical	D064730
8603459_9	204	215	doxorubicin	Chemical	D004317

8603459_13|s|These findings result in a model that allows the testing of protectors against doxorubicin-induced cardiotoxicity as demonstrated by the protection provided by ICRF-187.
8603459_13	99	113	cardiotoxicity	Disease	D066126
8603459_13	79	90	doxorubicin	Chemical	D004317
8603459_13	160	168	ICRF-187	Chemical	D064730
8603459_13	CID	D004317	D066126

8659767_1|s|Since bupivacaine and epinephrine may both precipitate dysrhythmias, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine.
8659767_1	55	67	dysrhythmias	Disease	D001145
8659767_1	6	17	bupivacaine	Chemical	D002045
8659767_1	22	33	epinephrine	Chemical	D004837
8659767_1	81	92	bupivacaine	Chemical	D002045
8659767_1	164	175	epinephrine	Chemical	D004837

8659767_2|s|We therefore examined whether bupivacaine alters the dysrhythmogenicity of subsequent administration of epinephrine in conscious, healthy dogs and in anesthetized dogs with myocardial infarction.
8659767_2	173	194	myocardial infarction	Disease	D009203
8659767_2	30	41	bupivacaine	Chemical	D002045
8659767_2	104	115	epinephrine	Chemical	D004837

8659767_9|s|One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared.
8659767_9	27	48	myocardial infarction	Disease	D009203
8659767_9	144	146	VT	Disease	D017180
8659767_9	65	74	halothane	Chemical	D006221
8659767_9	126	137	epinephrine	Chemical	D004837
8659767_9	CID	D004837	D017180

8659767_12|s|Bupivacaine antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct dysrhythmias.
8659767_12	88	90	VT	Disease	D017180
8659767_12	145	157	dysrhythmias	Disease	D001145
8659767_12	0	11	Bupivacaine	Chemical	D002045
8659767_12	24	35	epinephrine	Chemical	D004837
8659767_12	CID	D004837	D017180

8667442_0|s|Milk-alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism.
8667442_0	0	20	Milk-alkali syndrome	Disease	D006934
8667442_0	61	79	hypoparathyroidism	Disease	D007011
8667442_0	32	42	1,25(OH)2D	Chemical	D002117
8667442_0	CID	D002117	D006934

8667442_1|s|Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali.
8667442_1	0	20	Milk-alkali syndrome	Disease	D006934
8667442_1	89	109	peptic ulcer disease	Disease	D010437
8667442_1	132	139	calcium	Chemical	D002118
8667442_1	144	150	alkali	Chemical	D000468
8667442_1	CID	D000468	D006934
8667442_1	CID	D002118	D006934

8667442_2|s|Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.
8667442_2	22	27	ulcer	Disease	D014456
8667442_2	97	117	milk-alkali syndrome	Disease	D006934
8667442_2	168	181	hypercalcemia	Disease	D006934
8667442_2	183	192	alkalosis	Disease	D000471
8667442_2	198	214	renal impairment	Disease	D051437
8667442_2	51	61	omeprazole	Chemical	D009853
8667442_2	67	77	sucralfate	Chemical	D013392

8667442_4|s|This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.
8667442_4	37	55	hypoparathyroidism	Disease	D007011
8667442_4	158	178	milk-alkali syndrome	Disease	D006934
8667442_4	77	94	calcium carbonate	Chemical	D002119
8667442_4	99	109	calcitriol	Chemical	D002117
8667442_4	CID	D002117	D006934
8667442_4	CID	D002119	D006934

8667442_6|s|This illustrates intravenous pamidronate as a valuable therapeutic tool when milk-alkali syndrome presents as hypercalcemic emergency.
8667442_6	77	97	milk-alkali syndrome	Disease	D006934
8667442_6	110	133	hypercalcemic emergency	Disease	D006934
8667442_6	29	40	pamidronate	Chemical	C019248

8748050_0|s|Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?
8748050_0	0	14	Encephalopathy	Disease	D001927
8748050_0	49	79	neuroleptic malignant syndrome	Disease	D009459
8748050_0	84	102	serotonin syndrome	Disease	D020230
8748050_0	22	35	amitriptyline	Chemical	D000639
8748050_0	CID	D000639	D001927

8748050_1|s|This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression.
8748050_1	32	46	encephalopathy	Disease	D001927
8748050_1	119	138	unipolar depression	Disease	D003866
8748050_1	74	87	amitriptyline	Chemical	D000639
8748050_1	CID	D000639	D001927

8755612_0|s|Genetic separation of tumor growth and hemorrhagic phenotypes in an estrogen-induced tumor.
8755612_0	22	27	tumor	Disease	D009369
8755612_0	39	50	hemorrhagic	Disease	D006470
8755612_0	85	90	tumor	Disease	D009369
8755612_0	68	76	estrogen	Chemical	D004967

8755612_1|s|Chronic administration of estrogen to the Fischer 344 (F344) rat induces growth of large, hemorrhagic pituitary tumors.
8755612_1	90	101	hemorrhagic	Disease	D006470
8755612_1	102	118	pituitary tumors	Disease	D010911
8755612_1	26	34	estrogen	Chemical	D004967

8755612_2|s|Ten weeks of diethylstilbestrol (DES) treatment caused female F344 rat pituitaries to grow to an average of 109.2 +/- 6.3 mg (mean +/- SE) versus 11.3 +/- 1.4 mg for untreated rats, and to become highly hemorrhagic.
8755612_2	203	214	hemorrhagic	Disease	D006470
8755612_2	13	31	diethylstilbestrol	Chemical	D004054
8755612_2	33	36	DES	Chemical	D004054

8755612_7|s|However, while DES-induced pituitary growth exhibited quantitative, additive inheritance, the hemorrhagic phenotype exhibited recessive, epistatic inheritance.
8755612_7	94	105	hemorrhagic	Disease	D006470
8755612_7	15	18	DES	Chemical	D004054

8808730_0|s|Increased expression of neuronal nitric oxide synthase in bladder afferent pathways following chronic bladder irritation.
8808730_0	102	120	bladder irritation	Disease	D001745
8808730_0	33	45	nitric oxide	Chemical	D009569

8808730_1|s|Immunocytochemical techniques were used to examine alterations in the expression of neuronal nitric oxide synthase (NOS) in bladder pathways following acute and chronic irritation of the urinary tract of the rat.
8808730_1	169	200	irritation of the urinary tract	Disease	D014570
8808730_1	93	105	nitric oxide	Chemical	D009569

8808730_2|s|Chemical cystitis was induced by cyclophosphamide (CYP) which is metabolized to acrolein, an irritant eliminated in the urine.
8808730_2	9	17	cystitis	Disease	D003556
8808730_2	33	49	cyclophosphamide	Chemical	D003520
8808730_2	51	54	CYP	Chemical	D003520
8808730_2	80	88	acrolein	Chemical	D000171
8808730_2	CID	D003520	D003556

8819482_0|s|Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.
8819482_0	70	89	myocardial ischemia	Disease	D017202
8819482_0	111	128	coronary stenosis	Disease	D023921
8819482_0	17	24	calcium	Chemical	D002118
8819482_0	37	43	CD-832	Chemical	C082828
8819482_0	48	61	isoproterenol	Chemical	D007545
8819482_0	CID	D007545	D017202

8819482_1|s|Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.
8819482_1	49	68	myocardial ischemia	Disease	D017202
8819482_1	103	120	coronary stenosis	Disease	D023921
8819482_1	11	17	CD-832	Chemical	C082828
8819482_1	21	34	isoproterenol	Chemical	D007545
8819482_1	36	39	ISO	Chemical	D007545
8819482_1	202	212	nifedipine	Chemical	D009543
8819482_1	216	225	diltiazem	Chemical	D004110
8819482_1	CID	D007545	D017202

8819482_2|s|In the presence of coronary artery stenosis, 3-min periods of intracoronary ISO infusion (10 ng/kg/min) increased heart rate and maximal rate of left ventricular pressure rise, which resulted in a decrease in percentage segmental shortening and ST-segment elevation of the epicardial electrocardiogram.
8819482_2	19	43	coronary artery stenosis	Disease	D023921
8819482_2	76	79	ISO	Chemical	D007545

8819482_3|s|After the control ISO infusion with stenosis was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion.
8819482_3	36	44	stenosis	Disease	D003251
8819482_3	18	21	ISO	Chemical	D007545
8819482_3	85	91	CD-832	Chemical	C082828
8819482_3	129	139	nifedipine	Chemical	D009543
8819482_3	178	187	diltiazem	Chemical	D004110
8819482_3	283	286	ISO	Chemical	D007545

8819482_5|s|In contrast to nifedipine, CD-832 (10 micrograms/kg/min) prevented the decrease in percentage segmental shortening from 32 +/- 12% to 115 +/- 26% of the control value (P < .01) and ST-segment elevation from 5.6 +/- 1.0 mV to 1.6 +/- 1.3 mV (P < .01) at 3 min after ISO infusion with stenosis.
8819482_5	283	291	stenosis	Disease	D003251
8819482_5	15	25	nifedipine	Chemical	D009543
8819482_5	27	33	CD-832	Chemical	C082828
8819482_5	265	268	ISO	Chemical	D007545

8819482_6|s|Diltiazem (30 micrograms/kg/min) also prevented the decrease in percentage segmental shortening from 34 +/- 14% to 63 +/- 18% of the control value (P < .05) and ST-segment elevation from 4.7 +/- 0.7 mV to 2.1 +/- 0.7 mV (P < .01) at 3 min after ISO infusion with stenosis.
8819482_6	263	271	stenosis	Disease	D003251
8819482_6	0	9	Diltiazem	Chemical	D004110
8819482_6	245	248	ISO	Chemical	D007545

8819482_7|s|These data show that CD-832 improves myocardial ischemia during ISO infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832.
8819482_7	37	56	myocardial ischemia	Disease	D017202
8819482_7	82	90	stenosis	Disease	D003251
8819482_7	21	27	CD-832	Chemical	C082828
8819482_7	64	67	ISO	Chemical	D007545
8819482_7	146	152	CD-832	Chemical	C082828
8819482_7	201	207	CD-832	Chemical	C082828
8819482_7	CID	D007545	D017202

8825380_0|s|The effect of recombinant human insulin-like growth factor-I on chronic puromycin aminonucleoside nephropathy in rats.
8825380_0	98	109	nephropathy	Disease	D007674
8825380_0	72	97	puromycin aminonucleoside	Chemical	D011692
8825380_0	CID	D011692	D007674

8825380_1|s|We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease.
8825380_1	140	151	nephropathy	Disease	D007674
8825380_1	178	196	glomerular disease	Disease	D007674
8825380_1	108	133	puromycin aminonucleoside	Chemical	D011692
8825380_1	135	138	PAN	Chemical	D011692
8825380_1	CID	D011692	D007674

8825380_2|s|Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic PAN nephropathy.
8825380_2	104	118	growth failure	Disease	D006130
8825380_2	144	155	nephropathy	Disease	D007674
8825380_2	140	143	PAN	Chemical	D011692
8825380_2	CID	D011692	D007674

8825380_3|s|The glomerulopathy was induced by seven serial injections of PAN over 12 wk.
8825380_3	4	18	glomerulopathy	Disease	D007674
8825380_3	61	64	PAN	Chemical	D011692
8825380_3	CID	D011692	D007674

8825380_5|s|Urinary protein excretion was unaltered by rhIGF-I treatment in rats with chronic PAN nephropathy.
8825380_5	86	97	nephropathy	Disease	D007674
8825380_5	82	85	PAN	Chemical	D011692
8825380_5	CID	D011692	D007674

8825380_6|s|After 12 wk, the inulin clearance was higher in rhIGF-I-treated rats, 0.48 +/- 0.08 versus 0.24 +/- 0.06 mL/min/100 g of body weight in untreated PAN nephropathy animals, p < 0.05.
8825380_6	150	161	nephropathy	Disease	D007674
8825380_6	146	149	PAN	Chemical	D011692
8825380_6	CID	D011692	D007674

8825380_7|s|The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical malondialdehyde content.
8825380_7	56	78	glomerular hypertrophy	Disease	D007674
8825380_7	102	120	glomerulosclerosis	Disease	D005921
8825380_7	122	147	tubulointerstitial injury	Disease	-1
8825380_7	167	182	malondialdehyde	Chemical	D008315

8825380_8|s|In rats with PAN nephropathy, administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA.
8825380_8	17	28	nephropathy	Disease	D007674
8825380_8	13	16	PAN	Chemical	D011692
8825380_8	CID	D011692	D007674

8825380_9|s|In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, proteinuria, GFR, glomerular planar area, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4). rhIGF-I treatment reduced the steady state renal IGF-I mRNA level but did not modify gene expression of the IGF-I or GH receptors.
8825380_9	110	121	proteinuria	Disease	D011507
8825380_9	209	234	tubulointerstitial damage	Disease	D007674
8825380_9	167	182	malondialdehyde	Chemical	D008315

8825380_10|s|We conclude that: 1) administration of rhIGF-I improves growth and GFR in rats with chronic PAN nephropathy and 2) unlike rhGH, long-term use of rhIGF-I does not worsen renal functional and structural injury in this disease model.
8825380_10	96	107	nephropathy	Disease	D007674
8825380_10	92	95	PAN	Chemical	D011692
8825380_10	CID	D011692	D007674

8829135_0|s|Nefiracetam (DM-9384) reverses apomorphine-induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects.
8829135_0	51	58	amnesia	Disease	D000647
8829135_0	0	11	Nefiracetam	Chemical	C058876
8829135_0	13	20	DM-9384	Chemical	C058876
8829135_0	31	42	apomorphine	Chemical	D001058
8829135_0	CID	D001058	D000647

8829135_1|s|Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced learning and post-training consolidation deficits.
8829135_1	83	132	learning and post-training consolidation deficits	Disease	D007859
8829135_1	0	11	Nefiracetam	Chemical	C058876
8829135_1	23	34	pyrrolidone	Chemical	D011760
8829135_1	63	74	scopolamine	Chemical	D012601
8829135_1	CID	D012601	D007859

8829135_2|s|Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism.
8829135_2	185	192	amnesia	Disease	D000647
8829135_2	11	22	apomorphine	Chemical	D001058
8829135_2	160	171	nefiracetam	Chemical	C058876
8829135_2	CID	D001058	D000647

8829135_5|s|However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true.
8829135_5	79	86	amnesia	Disease	D000647
8829135_5	27	38	nefiracetam	Chemical	C058876
8829135_5	98	109	apomorphine	Chemical	D001058
8829135_5	CID	D001058	D000647

8957205_0|s|Human corticotropin-releasing hormone and thyrotropin-releasing hormone modulate the hypercapnic ventilatory response in humans.
8957205_0	85	96	hypercapnic	Disease	D006935
8957205_0	6	19	corticotropin	Chemical	D000324
8957205_0	42	53	thyrotropin	Chemical	D013972

8985298_0|s|Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.
8985298_0	39	50	hepatitis B	Disease	D006509
8985298_0	0	10	Lamivudine	Chemical	D019259
8985298_0	72	99	hepatitis B surface antigen	Chemical	D006514
8985298_0	CID	D006514	D006509

8985298_1|s|Lamivudine is a novel 2',3'-dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo.
8985298_1	92	103	hepatitis B	Disease	D006509
8985298_1	0	10	Lamivudine	Chemical	D019259
8985298_1	22	44	2',3'-dideoxy cytosine	Chemical	D019259

8985298_6|s|All 36 patients receiving lamivudine had a decrease in hepatitis B virus (HBV) DNA values of >90% (P < .001 compared with placebo).
8985298_6	55	66	hepatitis B	Disease	D006509
8985298_6	26	36	lamivudine	Chemical	D019259

8996419_0|s|Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
8996419_0	34	56	venous thromboembolism	Disease	D054556
8996419_0	81	100	oral contraceptives	Chemical	D003276
8996419_0	CID	D003276	D054556

8996419_1|s|BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.
8996419_1	88	110	venous thromboembolism	Disease	D054556
8996419_1	112	115	VTE	Disease	D054556
8996419_1	146	165	oral contraceptives	Chemical	D003276
8996419_1	167	170	OCs	Chemical	D003276
8996419_1	204	216	progestagens	Chemical	D011374
8996419_1	217	226	gestodene	Chemical	C033273
8996419_1	230	241	desogestrel	Chemical	D017135
8996419_1	259	262	OCs	Chemical	D003276
8996419_1	292	304	progestagens	Chemical	D011374
8996419_1	CID	D003276	D054556

8996419_3|s|The aim of our study was to re-examine the association between risk of VTE and OC use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies.
8996419_3	71	74	VTE	Disease	D054556
8996419_3	79	81	OC	Chemical	D003276
8996419_3	CID	D003276	D054556

8996419_7|s|We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of OC, after adjustment for potential confounding factors.
8996419_7	62	65	VTE	Disease	D054556
8996419_7	168	171	VTE	Disease	D054556
8996419_7	87	89	OC	Chemical	D003276
8996419_7	214	216	OC	Chemical	D003276
8996419_7	CID	D003276	D054556

8996419_10|s|FINDINGS: 85 women met the inclusion criteria for VTE, two of whom were users of progestagen-only OCs.
8996419_10	50	53	VTE	Disease	D054556
8996419_10	81	92	progestagen	Chemical	D011372
8996419_10	98	101	OCs	Chemical	D003276
8996419_10	CID	D003276	D054556

8996419_11|s|Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified.
8996419_11	19	22	VTE	Disease	D054556
8996419_11	80	100	deep-vein thrombosis	Disease	D020246
8996419_11	118	128	thrombosis	Disease	D013927
8996419_11	142	159	venous thrombosis	Disease	D020246
8996419_11	55	58	OCs	Chemical	D003276
8996419_11	CID	D003276	D054556

8996419_12|s|The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations.
8996419_12	18	21	VTE	Disease	D054556
8996419_12	78	80	OC	Chemical	D003276
8996419_12	117	120	OCs	Chemical	D003276
8996419_12	CID	D003276	D054556

8996419_13|s|After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75).
8996419_13	44	47	VTE	Disease	D054556
8996419_13	107	110	OCs	Chemical	D003276
8996419_13	CID	D003276	D054556

8996419_14|s|Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs.
8996419_14	68	71	VTE	Disease	D054556
8996419_14	128	131	OCs	Chemical	D003276
8996419_14	CID	D003276	D054556

8996419_15|s|Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.
8996419_15	58	61	VTE	Disease	D054556
8996419_15	32	44	progestagens	Chemical	D011374
8996419_15	85	96	desogestrel	Chemical	D017135
8996419_15	107	124	ethinyloestradiol	Chemical	D004997
8996419_15	142	151	gestodene	Chemical	C033273
8996419_15	155	166	desogestrel	Chemical	D017135
8996419_15	177	194	ethinyloestradiol	Chemical	D004997

8996419_16|s|With all second-generation OCs as the reference, the odds ratios for VTE were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens.
8996419_16	69	72	VTE	Disease	D054556
8996419_16	27	30	OCs	Chemical	D003276
8996419_16	100	111	desogestrel	Chemical	D017135
8996419_16	122	139	ethinyloestradiol	Chemical	D004997
8996419_16	192	204	progestagens	Chemical	D011374
8996419_16	CID	D003276	D054556

9061777_0|s|MK-801 augments pilocarpine-induced electrographic seizure but protects against brain damage in rats.1.
9061777_0	51	58	seizure	Disease	D012640
9061777_0	80	92	brain damage	Disease	D001930
9061777_0	0	6	MK-801	Chemical	D016291
9061777_0	16	27	pilocarpine	Chemical	D010862
9061777_0	CID	D010862	D012640
9061777_0	CID	D016291	D012640

9061777_1|s|The authors examined the anticonvulsant effects of MK-801 on the pilocarpine-induced seizure model.
9061777_1	85	92	seizure	Disease	D012640
9061777_1	51	57	MK-801	Chemical	D016291
9061777_1	65	76	pilocarpine	Chemical	D010862
9061777_1	CID	D010862	D012640
9061777_1	CID	D016291	D012640

9061777_2|s|Intraperitoneal injection of pilocarpine (400 mg/kg) induced tonic and clonic seizure.
9061777_2	61	85	tonic and clonic seizure	Disease	D012640
9061777_2	29	40	pilocarpine	Chemical	D010862
9061777_2	CID	D010862	D012640

9061777_3|s|Scopolamine (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral seizure but MK-801 (0.5 mg/kg) did not. 2.
9061777_3	107	114	seizure	Disease	D012640
9061777_3	0	11	Scopolamine	Chemical	D012601
9061777_3	27	40	pentobarbital	Chemical	D010424
9061777_3	76	87	pilocarpine	Chemical	D010862
9061777_3	119	125	MK-801	Chemical	D016291
9061777_3	CID	D010862	D012640
9061777_3	CID	D016291	D012640

9061777_4|s|An electrical seizure measured with hippocampal EEG appeared in the pilocarpine-treated group.
9061777_4	14	21	seizure	Disease	D012640
9061777_4	68	79	pilocarpine	Chemical	D010862
9061777_4	CID	D010862	D012640

9061777_5|s|Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine. 3.
9061777_5	77	84	seizure	Disease	D012640
9061777_5	132	139	seizure	Disease	D012640
9061777_5	0	11	Scopolamine	Chemical	D012601
9061777_5	16	29	pentobarbital	Chemical	D010424
9061777_5	42	53	pilocarpine	Chemical	D010862
9061777_5	86	92	MK-801	Chemical	D016291
9061777_5	151	162	pilocarpine	Chemical	D010862
9061777_5	CID	D010862	D012640
9061777_5	CID	D016291	D012640

9061777_7|s|Pilocarpine produced neuronal death in the hippocampus, which showed pyknotic changes.
9061777_7	21	35	neuronal death	Disease	D009410
9061777_7	0	11	Pilocarpine	Chemical	D010862
9061777_7	CID	D010862	D009410

9061777_8|s|Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.
9061777_8	52	64	brain damage	Disease	D001930
9061777_8	0	13	Pentobarbital	Chemical	D010424
9061777_8	15	26	scopolamine	Chemical	D012601
9061777_8	31	37	MK-801	Chemical	D016291
9061777_8	68	79	pilocarpine	Chemical	D010862
9061777_8	95	101	MK-801	Chemical	D016291

9061777_10|s|These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism.
9061777_10	28	46	status epilepticus	Disease	D013226
9061777_10	193	205	brain damage	Disease	D001930
9061777_10	58	69	pilocarpine	Chemical	D010862
9061777_10	228	232	NMDA	Chemical	D016202
9061777_10	CID	D010862	D013226

9071336_0|s|Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients.
9071336_0	59	72	breast cancer	Disease	D001943
9071336_0	248	261	breast cancer	Disease	D001943
9071336_0	0	10	Paclitaxel	Chemical	D017239
9071336_0	12	26	5-fluorouracil	Chemical	D005472
9071336_0	32	44	folinic acid	Chemical	D002955
9071336_0	100	114	5-Fluorouracil	Chemical	D005472
9071336_0	120	132	folinic acid	Chemical	D002955
9071336_0	137	147	paclitaxel	Chemical	D017239
9071336_0	149	154	Taxol	Chemical	D017239

9071336_1|s|Paclitaxel and 5-fluorouracil have additive cytotoxicity in MCF-7 cell lines.
9071336_1	44	56	cytotoxicity	Disease	D064420
9071336_1	0	10	Paclitaxel	Chemical	D017239
9071336_1	15	29	5-fluorouracil	Chemical	D005472

9071336_2|s|We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer.
9071336_2	212	225	breast cancer	Disease	D001943
9071336_2	33	43	paclitaxel	Chemical	D017239
9071336_2	88	100	folinic acid	Chemical	D002955
9071336_2	127	141	5-fluorouracil	Chemical	D005472

9071336_3|s|Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to neutropenia; no patient required platelet transfusions.
9071336_3	164	175	neutropenia	Disease	D009503
9071336_3	291	302	neutropenia	Disease	D009503
9071336_3	246	283	granulocyte colony-stimulating factor	Chemical	D016179

9125676_0|s|Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
9125676_0	13	26	proarrhythmia	Disease	-1
9125676_0	69	97	ventricular tachyarrhythmias	Disease	D017180
9125676_0	43	54	d,l-sotalol	Chemical	D013015

9125676_1|s|This study prospectively evaluated the clinical efficacy, the incidence of torsades de pointes, and the presumable risk factors for torsades de pointes in patients treated with d,l-sotalol for sustained ventricular tachyarrhythmias.
9125676_1	75	94	torsades de pointes	Disease	D016171
9125676_1	132	151	torsades de pointes	Disease	D016171
9125676_1	203	231	ventricular tachyarrhythmias	Disease	D017180
9125676_1	132	140	torsades	Disease	D016171
9125676_1	177	188	d,l-sotalol	Chemical	D013015
9125676_1	CID	D013015	D016171

9125676_2|s|Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.
9125676_2	41	64	coronary artery disease	Disease	D003324
9125676_2	78	100	dilated cardiomyopathy	Disease	D002311
9125676_2	127	150	ventricular tachycardia	Disease	D017180
9125676_2	154	178	ventricular fibrillation	Disease	D014693
9125676_2	233	260	ventricular tachyarrhythmia	Disease	D017180
9125676_2	193	204	d,l-sotalol	Chemical	D013015

9125676_4|s|Those patients in whom d,l-sotalol prevented induction of ventricular tachycardia or ventricular fibrillation were discharged with the drug and followed up on an outpatient basis for 21 +/- 18 months.
9125676_4	58	81	ventricular tachycardia	Disease	D017180
9125676_4	85	109	ventricular fibrillation	Disease	D014693
9125676_4	23	34	d,l-sotalol	Chemical	D013015

9125676_5|s|Induction of the ventricular tachyarrhythmia was prevented by oral d,l-sotalol in 35 (43%) patients; the ventricular tachyarrhythmia remained inducible in 40 (49%) patients; and two (2.5%) patients did not tolerate even 40 mg of d,l-sotalol once daily.
9125676_5	17	44	ventricular tachyarrhythmia	Disease	D017180
9125676_5	105	132	ventricular tachyarrhythmia	Disease	D017180
9125676_5	67	78	d,l-sotalol	Chemical	D013015
9125676_5	229	240	d,l-sotalol	Chemical	D013015

9125676_6|s|Four (5%) patients had from torsades de pointes during the initial oral treatment with d,l-sotalol.
9125676_6	28	47	torsades de pointes	Disease	D016171
9125676_6	87	98	d,l-sotalol	Chemical	D013015
9125676_6	CID	D013015	D016171

9125676_8|s|However, the oral dose of d,l-sotalol was significantly lower in patients with torsades de pointes (200 +/- 46 vs. 328 +/- 53 mg/day; p = 0.0017).
9125676_8	79	98	torsades de pointes	Disease	D016171
9125676_8	26	37	d,l-sotalol	Chemical	D013015
9125676_8	CID	D013015	D016171

9125676_11|s|One female patient with stable cardiac disease had recurrent torsades de pointes after 2 years of successful treatment with d,l-sotalol.
9125676_11	31	46	cardiac disease	Disease	D006331
9125676_11	61	80	torsades de pointes	Disease	D016171
9125676_11	124	135	d,l-sotalol	Chemical	D013015
9125676_11	CID	D013015	D016171

9125676_12|s|Torsades de pointes occurred early during treatment even with low doses of oral d,l-sotalol.
9125676_12	0	19	Torsades de pointes	Disease	D016171
9125676_12	80	91	d,l-sotalol	Chemical	D013015
9125676_12	CID	D013015	D016171

9125676_13|s|Pronounced changes in the surface ECG (cycle length, QT, and QTc) in relation to the dose of oral d,l-sotalol might identify a subgroup of patients with an increased risk for torsades de pointes.
9125676_13	175	194	torsades de pointes	Disease	D016171
9125676_13	98	109	d,l-sotalol	Chemical	D013015
9125676_13	CID	D013015	D016171

9125676_14|s|Other ECG parameters before the application of d,l-sotalol did not identify patients at increased risk for torsades de pointes.
9125676_14	107	126	torsades de pointes	Disease	D016171
9125676_14	47	58	d,l-sotalol	Chemical	D013015
9125676_14	CID	D013015	D016171

9128918_0|s|Chronic hyperprolactinemia and changes in dopamine neurons.
9128918_0	8	26	hyperprolactinemia	Disease	D006966
9128918_0	42	50	dopamine	Chemical	D004298

9128918_5|s|Hyperprolactinemia was induced by treatment with haloperidol, a dopamine receptor antagonist, and Palkovits' microdissection technique in combination with high-performance liquid chromatography was used to measure neurotransmitter concentrations in several areas of the brain.
9128918_5	0	18	Hyperprolactinemia	Disease	D006966
9128918_5	49	60	haloperidol	Chemical	D006220
9128918_5	64	72	dopamine	Chemical	D004298
9128918_5	CID	D006220	D006966

9128918_6|s|After 6 months of hyperprolactinemia, dopamine (DA) concentrations in the median eminence (ME) increased by 84% over the control group.
9128918_6	18	36	hyperprolactinemia	Disease	D006966
9128918_6	38	46	dopamine	Chemical	D004298
9128918_6	48	50	DA	Chemical	D004298

9128918_7|s|Nine months of hyperprolactinemia produced a 50% increase in DA concentrations in the ME over the control group.
9128918_7	15	33	hyperprolactinemia	Disease	D006966
9128918_7	61	63	DA	Chemical	D004298

9128918_8|s|However, DA response was lost if a 9-month long haloperidol-induced hyperprolactinemia was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule.
9128918_8	68	86	hyperprolactinemia	Disease	D006966
9128918_8	9	11	DA	Chemical	D004298
9128918_8	48	59	haloperidol	Chemical	D006220
9128918_8	CID	D006220	D006966

9128918_9|s|There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.
9128918_9	315	333	hyperprolactinemia	Disease	D006966
9128918_9	399	417	hyperprolactinemia	Disease	D006966
9128918_9	37	39	DA	Chemical	D004298
9128918_9	41	55	norepinephrine	Chemical	D009638
9128918_9	57	59	NE	Chemical	D009638
9128918_9	62	71	serotonin	Chemical	D012701
9128918_9	73	77	5-HT	Chemical	D012701
9128918_9	251	277	5-hydroxyindoleacetic acid	Chemical	D006897
9128918_9	279	285	5-HIAA	Chemical	D006897
9128918_9	353	355	DA	Chemical	D004298

9132810_1|s|This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from acute lymphoblastic leukemia treated with high-dose methotrexate.
9132810_1	157	176	leukoencephalopathy	Disease	D056784
9132810_1	199	227	acute lymphoblastic leukemia	Disease	D054198
9132810_1	251	263	methotrexate	Chemical	D008727
9132810_1	CID	D008727	D056784

9158667_0|s|Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy.
9158667_0	0	10	Thrombotic	Disease	D013927
9158667_0	28	56	acute promyelocytic leukemia	Disease	D015473
9158667_0	64	87	all-trans-retinoic acid	Chemical	D014212
9158667_0	CID	D014212	D013927

9158667_1|s|A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.
9158667_1	10	29	acute renal failure	Disease	D058186
9158667_1	38	64	occlusion of renal vessels	Disease	-1
9158667_1	83	111	acute promyelocytic leukemia	Disease	D015473
9158667_1	113	116	APL	Disease	D015473
9158667_1	131	154	all-trans-retinoic acid	Chemical	D014212
9158667_1	156	160	ATRA	Chemical	D014212
9158667_1	166	181	tranexamic acid	Chemical	D014148
9158667_1	CID	D014212	D058186

9158667_2|s|We report a case of acute renal failure in an APL patient treated with ATRA alone.
9158667_2	20	39	acute renal failure	Disease	D058186
9158667_2	46	49	APL	Disease	D015473
9158667_2	71	75	ATRA	Chemical	D014212
9158667_2	CID	D014212	D058186

9158667_3|s|This case further supports the concern about thromboembolic complications associated with ATRA therapy in APL patients.
9158667_3	45	59	thromboembolic	Disease	D013923
9158667_3	106	109	APL	Disease	D015473
9158667_3	90	94	ATRA	Chemical	D014212

9158667_4|s|The patients, a 43-year-old man, presented all the signs and symptoms of APL and was included in a treatment protocol with ATRA.
9158667_4	73	76	APL	Disease	D015473
9158667_4	123	127	ATRA	Chemical	D014212

9158667_6|s|We conclude that ATRA is a valid therapeutic choice for patients with APL, although the procoagulant tendency is not completely corrected.
9158667_6	70	73	APL	Disease	D015473
9158667_6	17	21	ATRA	Chemical	D014212

9158667_7|s|Thrombotic events, however, could be avoided by using low-dose heparin.
9158667_7	0	10	Thrombotic	Disease	D013927
9158667_7	63	70	heparin	Chemical	D006493

9197951_1|s|A 30-year-old cocaine-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became manic during his second week on the study drug.
9197951_1	157	162	manic	Disease	D001714
9197951_1	14	21	cocaine	Chemical	D003042
9197951_1	129	143	diethylpropion	Chemical	D004053
9197951_1	145	148	DEP	Chemical	D004053
9197951_1	CID	D004053	D001714

9197951_2|s|Pupillometric changes while on DEP, especially changes in the total power of pupillary oscillation, were dramatically different than those observed in the eight other study subjects who did not become manic.
9197951_2	77	98	pupillary oscillation	Disease	D011681
9197951_2	201	206	manic	Disease	D001714
9197951_2	31	34	DEP	Chemical	D004053
9197951_2	CID	D004053	D001714

9272404_4|s|Phasic pain was applied by means of short pulses of CO2 to the nasal mucosa (stimulus duration 500 ms, interval approximately 60 s), and tonic pain was induced in the nasal cavity by means of dry air of controlled temperature, humidity and flow rate (22 degrees C, 0% relative humidity, 145 ml.s-1).
9272404_4	7	11	pain	Disease	D010146
9272404_4	143	147	pain	Disease	D010146
9272404_4	52	55	CO2	Chemical	D002245

9272404_5|s|Both CSSEPs as central and NMPs as peripheral correlates of pain were obtained in response to the CO2 stimuli.
9272404_5	60	64	pain	Disease	D010146
9272404_5	98	101	CO2	Chemical	D002245

9272404_7|s|RESULTS: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.
9272404_7	95	99	pain	Disease	D010146
9272404_7	160	164	pain	Disease	D010146
9272404_7	239	243	pain	Disease	D010146
9272404_7	49	58	ibuprofen	Chemical	D007052
9272404_7	198	207	ibuprofen	Chemical	D007052
9272404_7	CID	D007052	D010146

9323412_0|s|Acute severe depression following peri-operative ondansetron.
9323412_0	13	23	depression	Disease	D003866
9323412_0	49	60	ondansetron	Chemical	D017294

9323412_1|s|A 41-year-old woman with a strong history of postoperative nausea and vomiting presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used.
9323412_1	45	78	postoperative nausea and vomiting	Disease	D020250
9323412_1	160	171	ondansetron	Chemical	D017294

9323412_2|s|She had developed a severe acute major depression disorder almost immediately thereafter, possibly related to the use of a serotonin antagonist.
9323412_2	33	58	major depression disorder	Disease	D003865
9323412_2	123	132	serotonin	Chemical	D012701

9323412_4|s|Anaesthesia with a propofol infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder.
9323412_4	87	93	nausea	Disease	D009325
9323412_4	148	167	depression disorder	Disease	D003866
9323412_4	19	27	propofol	Chemical	D015742
9323412_4	54	63	serotonin	Chemical	D012701

9382023_0|s|Hypertensive response during dobutamine stress echocardiography.
9382023_0	0	12	Hypertensive	Disease	D006973
9382023_0	29	39	dobutamine	Chemical	D004280
9382023_0	CID	D004280	D006973

9382023_1|s|Among 3,129 dobutamine stress echocardiographic studies, a hypertensive response, defined as systolic blood pressure (BP) > or = 220 mm Hg and/or diastolic BP > or = 110 mm Hg, occurred in 30 patients (1%).
9382023_1	59	71	hypertensive	Disease	D006973
9382023_1	12	22	dobutamine	Chemical	D004280
9382023_1	CID	D004280	D006973

9382023_2|s|Patients with this response more often had a history of hypertension and had higher resting systolic and diastolic BP before dobutamine infusion.
9382023_2	56	68	hypertension	Disease	D006973
9382023_2	125	135	dobutamine	Chemical	D004280
9382023_2	CID	D004280	D006973

9428298_0|s|Continuously nebulized albuterol in severe exacerbations of asthma in adults: a case-controlled study.
9428298_0	60	66	asthma	Disease	D001249
9428298_0	23	32	albuterol	Chemical	D000420

9428298_1|s|A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent albuterol (INA) treatments is reported.
9428298_1	132	138	asthma	Disease	D001249
9428298_1	175	184	albuterol	Chemical	D000420
9428298_1	211	220	albuterol	Chemical	D000420

9538487_0|s|Hyperosmolar nonketotic coma precipitated by lithium-induced nephrogenic diabetes insipidus.
9538487_0	0	28	Hyperosmolar nonketotic coma	Disease	D006944
9538487_0	61	91	nephrogenic diabetes insipidus	Disease	D018500
9538487_0	45	52	lithium	Chemical	D008094
9538487_0	CID	D008094	D018500
9538487_0	CID	D008094	D006944

9538487_1|s|A 45-year-old man, with a 10-year history of manic depression treated with lithium, was admitted with hyperosmolar, nonketotic coma.
9538487_1	45	61	manic depression	Disease	D001714
9538487_1	102	131	hyperosmolar, nonketotic coma	Disease	D006944
9538487_1	75	82	lithium	Chemical	D008094
9538487_1	CID	D008094	D006944

9538487_2|s|He gave a five-year history of polyuria and polydipsia, during which time urinalysis had been negative for glucose.
9538487_2	31	39	polyuria	Disease	D011141
9538487_2	44	54	polydipsia	Disease	D059606
9538487_2	107	114	glucose	Chemical	D005947

9538487_3|s|After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium-induced.
9538487_3	20	34	hyperglycaemia	Disease	-1
9538487_3	48	56	polyuric	Disease	D011141
9538487_3	138	168	nephrogenic diabetes insipidus	Disease	D018500
9538487_3	78	85	glucose	Chemical	D005947
9538487_3	183	190	lithium	Chemical	D008094
9538487_3	CID	D008094	D011141
9538487_3	CID	D008094	D018500

9570197_1|s|BACKGROUND: In dogs, a large amount of intravenous cocaine causes a profound deterioration of left ventricular (LV) systolic function and an increase in LV end-diastolic pressure.
9570197_1	77	133	deterioration of left ventricular (LV) systolic function	Disease	D018487
9570197_1	51	58	cocaine	Chemical	D003042
9570197_1	CID	D003042	D018487

9570197_3|s|METHODS AND RESULTS: In 20 patients (14 men and 6 women aged 39 to 72 years) referred for cardiac catheterization for the evaluation of chest pain, we measured heart rate, systemic arterial pressure, LV pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or cocaine hydrochloride 1 mg/min (n=10).
9570197_3	136	146	chest pain	Disease	D002637
9570197_3	402	423	cocaine hydrochloride	Chemical	D003042

9570197_7|s|CONCLUSIONS: In humans, the intracoronary infusion of cocaine sufficient in amount to achieve a high drug concentration in coronary sinus blood causes a deterioration of LV systolic and diastolic performance.
9570197_7	153	207	deterioration of LV systolic and diastolic performance	Disease	D018487
9570197_7	54	61	cocaine	Chemical	D003042
9570197_7	CID	D003042	D018487

9646784_0|s|Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy.
9646784_0	16	32	thrombocytopenia	Disease	D013921
9646784_0	46	61	thromboembolism	Disease	D013923
9646784_0	0	7	Heparin	Chemical	D006493
9646784_0	89	96	heparin	Chemical	D006493
9646784_0	CID	D006493	D013923
9646784_0	CID	D006493	D013921

9646784_3|s|Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.
9646784_3	72	88	thrombocytopenia	Disease	D013921
9646784_3	109	121	osteoporosis	Disease	D010024
9646784_3	123	135	eosinophilia	Disease	D004802
9646784_3	137	151	skin reactions	Disease	D012871
9646784_3	153	171	allergic reactions	Disease	D004342
9646784_3	183	199	thrombocytopenia	Disease	D013921
9646784_3	204	212	alopecia	Disease	D000505
9646784_3	30	37	heparin	Chemical	D006493
9646784_3	56	63	heparin	Chemical	D006493
9646784_3	90	97	heparin	Chemical	D006493
9646784_3	CID	D006493	D000505
9646784_3	CID	D006493	D010024
9646784_3	CID	D006493	D013921
9646784_3	CID	D006493	D004342
9646784_3	CID	D006493	D004802
9646784_3	CID	D006493	D012871

9725303_0|s|Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy.
9725303_0	37	57	ureteric obstruction	Disease	D014517
9725303_0	90	99	indinavir	Chemical	D019469

9725303_1|s|OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving indinavir, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of urolithiasis.
9725303_1	49	65	ureteric calculi	Disease	D014514
9725303_1	73	85	HIV-infected	Disease	D015658
9725303_1	214	226	urolithiasis	Disease	D052878
9725303_1	105	114	indinavir	Chemical	D019469
9725303_1	CID	D019469	D014514

9725303_2|s|CONCLUSION: Ureteric obstruction caused by precipitated indinavir crystals may be difficult to diagnose with unenhanced CT.
9725303_2	12	32	Ureteric obstruction	Disease	D014517
9725303_2	56	65	indinavir	Chemical	D019469

9725303_4|s|Images may need to be obtained using i.v. contrast material to enable diagnosis of ureteric stones or obstruction in patients with HIV infection who receive indinavir therapy.
9725303_4	83	113	ureteric stones or obstruction	Disease	D014514|D014517
9725303_4	131	144	HIV infection	Disease	D015658
9725303_4	157	166	indinavir	Chemical	D019469
9725303_4	CID	D019469	D014514

9759693_0|s|Ischemic colitis and sumatriptan use.
9759693_0	0	16	Ischemic colitis	Disease	D017091
9759693_0	21	32	sumatriptan	Chemical	D018170
9759693_0	CID	D018170	D017091

9759693_3|s|Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after sumatriptan use.
9759693_3	29	47	coronary vasospasm	Disease	D003329
9759693_3	49	68	myocardial ischemia	Disease	D017202
9759693_3	74	95	myocardial infarction	Disease	D009203
9759693_3	112	123	sumatriptan	Chemical	D018170

9759693_4|s|We report on the development of 8 serious cases of ischemic colitis in patients with migraine treated with sumatriptan.
9759693_4	51	67	ischemic colitis	Disease	D017091
9759693_4	85	93	migraine	Disease	D008881
9759693_4	107	118	sumatriptan	Chemical	D018170
9759693_4	CID	D018170	D017091

9782254_0|s|Pallidotomy with the gamma knife: a positive experience.51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and L-DOPA-induced dyskinesias.
9782254_0	95	114	Parkinson's disease	Disease	D010300
9782254_0	219	231	bradykinesia	Disease	D018476
9782254_0	233	241	rigidity	Disease	D009127
9782254_0	262	273	dyskinesias	Disease	D004409
9782254_0	247	253	L-DOPA	Chemical	D007980
9782254_0	CID	D007980	D004409

9831002_0|s|Neuroleptic malignant syndrome and methylphenidate.
9831002_0	0	30	Neuroleptic malignant syndrome	Disease	D009459
9831002_0	35	50	methylphenidate	Chemical	D008774
9831002_0	CID	D008774	D009459

9831002_1|s|A 1-year-old female presented with neuroleptic malignant syndrome probably caused by methylphenidate.
9831002_1	35	65	neuroleptic malignant syndrome	Disease	D009459
9831002_1	85	100	methylphenidate	Chemical	D008774
9831002_1	CID	D008774	D009459

9831002_6|s|This is the first reported patient with neuroleptic malignant syndrome probably caused by methylphenidate.
9831002_6	40	70	neuroleptic malignant syndrome	Disease	D009459
9831002_6	90	105	methylphenidate	Chemical	D008774
9831002_6	CID	D008774	D009459

9869655_10|s|This study shows that 17alpha-ethinylestradiol (EE)-induced intrahepatic cholestasis in rats is associated with selective inhibition of the neutral pathway of bile salt (BS) synthesis.
9869655_10	60	84	intrahepatic cholestasis	Disease	D002780
9869655_10	22	46	17alpha-ethinylestradiol	Chemical	D004997
9869655_10	48	50	EE	Chemical	D004997
9869655_10	159	168	bile salt	Chemical	D001647
9869655_10	170	172	BS	Chemical	D001647
9869655_10	CID	D004997	D002780

9881641_0|s|Glibenclamide-sensitive hypotension produced by helodermin assessed in the rat.
9881641_0	24	35	hypotension	Disease	D007022
9881641_0	0	13	Glibenclamide	Chemical	D005905
9881641_0	48	58	helodermin	Chemical	C040442
9881641_0	CID	C040442	D007022

9881641_3|s|Helodermin produced hypotension in a dose-dependent manner with approximately similar potency and duration to VIP.
9881641_3	20	31	hypotension	Disease	D007022
9881641_3	0	10	Helodermin	Chemical	C040442
9881641_3	CID	C040442	D007022

9881641_4|s|Hypotension induced by both peptides was significantly attenuated by glibenclamide, which abolished a levcromakalim-produced decrease in arterial blood pressure.
9881641_4	0	11	Hypotension	Disease	D007022
9881641_4	69	82	glibenclamide	Chemical	D005905
9881641_4	102	115	levcromakalim	Chemical	D019806
9881641_4	CID	D019806	D007022

9881641_5|s|Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of acetylcholine (ACh)-produced hypotension.
9881641_5	48	59	hypotension	Disease	D007022
9881641_5	127	138	hypotension	Disease	D007022
9881641_5	29	39	helodermin	Chemical	C040442
9881641_5	98	111	acetylcholine	Chemical	D000109
9881641_5	113	116	ACh	Chemical	D000109
9881641_5	CID	D000109	D007022
9881641_5	CID	C040442	D007022

9881641_6|s|These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells.
9881641_6	48	59	hypotension	Disease	D007022
9881641_6	28	38	helodermin	Chemical	C040442
9881641_6	104	117	glibenclamide	Chemical	D005905
9881641_6	128	129	K	Chemical	D011188
9881641_6	141	142	K	Chemical	D011188
9881641_6	143	146	ATP	Chemical	D000255
9881641_6	CID	C040442	D007022

9881641_7|s|EDRF (endothelium-derived relaxing factor)/nitric oxide does not seem to play an important role in the peptide-produced hypotension.
9881641_7	120	131	hypotension	Disease	D007022
9881641_7	43	55	nitric oxide	Chemical	D009569

9889429_0|s|Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.
9889429_0	103	115	hypertension	Disease	D006973
9889429_0	133	142	psoriasis	Disease	D011565
9889429_0	40	50	nifedipine	Chemical	D009543
9889429_0	81	94	cyclosporin A	Chemical	D016572
9889429_0	CID	D016572	D006973

9889429_1|s|Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs.
9889429_1	9	18	psoriatic	Disease	D011565
9889429_1	33	45	hypertension	Disease	D006973
9889429_1	67	80	cyclosporin A	Chemical	D016572
9889429_1	123	130	calcium	Chemical	D002118
9889429_1	166	176	nifedipine	Chemical	D009543
9889429_1	CID	D016572	D006973

9889429_2|s|Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy.
9889429_2	53	65	hypertensive	Disease	D006973
9889429_2	79	92	cyclosporin A	Chemical	D016572
9889429_2	CID	D016572	D006973

9889429_4|s|The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients.
9889429_4	171	191	gingival hyperplasia	Disease	D005885
9889429_4	48	61	cyclosporin A	Chemical	D016572
9889429_4	66	76	nifedipine	Chemical	D009543
9889429_4	101	120	blood urea nitrogen	Chemical	D001806
9889429_4	CID	D016572	D005885
9889429_4	CID	D009543	D005885

9889429_5|s|Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.
9889429_5	70	82	hypertensive	Disease	D006973
9889429_5	83	92	psoriatic	Disease	D011565
9889429_5	196	216	gingival hyperplasia	Disease	D005885
9889429_5	45	55	nifedipine	Chemical	D009543
9889429_5	133	146	cyclosporin A	Chemical	D016572
9889429_5	CID	D016572	D005885
9889429_5	CID	D016572	D006973
9889429_5	CID	D009543	D005885

10087562_0|s|Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.
10087562_0	0	18	Torsade de pointes	Disease	D016171
10087562_0	19	42	ventricular tachycardia	Disease	D017180
10087562_0	111	133	dilated cardiomyopathy	Disease	D002311
10087562_0	138	162	congestive heart failure	Disease	D006333
10087562_0	72	82	dobutamine	Chemical	D004280
10087562_0	CID	D004280	D016171

10087562_1|s|The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.
10087562_1	74	87	heart failure	Disease	D006333
10087562_1	101	123	dilated cardiomyopathy	Disease	D002311
10087562_1	151	174	ventricular arrhythmias	Disease	D001145
10087562_1	189	204	QT prolongation	Disease	D008133
10087562_1	209	227	torsade de pointes	Disease	D016171
10087562_1	228	251	ventricular tachycardia	Disease	D017180
10087562_1	315	325	dobutamine	Chemical	D004280
10087562_1	CID	D004280	D016171

10087562_2|s|This report of torsade de pointes ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances.
10087562_2	15	33	torsade de pointes	Disease	D016171
10087562_2	34	57	ventricular tachycardia	Disease	D017180
10087562_2	138	149	arrhythmias	Disease	D001145
10087562_2	78	88	dobutamine	Chemical	D004280
10087562_2	CID	D004280	D016171

10327032_0|s|Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.
10327032_0	18	47	hyperammonemic encephalopathy	Disease	D022124|D001927
10327032_0	51	57	cancer	Disease	D009369
10327032_0	143	154	dehydration	Disease	D003681
10327032_0	159	168	infection	Disease	D007239
10327032_0	103	117	5-fluorouracil	Chemical	D005472
10327032_0	CID	D005472	D022124
10327032_0	CID	D005472	D001927

10327032_1|s|From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (5-FU) were identified.
10327032_1	22	28	cancer	Disease	D009369
10327032_1	71	100	hyperammonemic encephalopathy	Disease	D022124|D001927
10327032_1	135	149	5-fluorouracil	Chemical	D005472
10327032_1	151	155	5-FU	Chemical	D005472
10327032_1	CID	D005472	D022124
10327032_1	CID	D005472	D001927

10327032_6|s|Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).
10327032_6	54	68	hyperammonemia	Disease	D022124
10327032_6	99	119	bacterial infections	Disease	D001424
10327032_6	14	22	ammonium	Chemical	D000644
10327032_6	227	231	5-FU	Chemical	D005472
10327032_6	CID	D005472	D022124

10327032_8|s|In conclusion, hyperammonemic encephalopathy can occur in patients receiving continuous infusion of 5-FU.
10327032_8	15	44	hyperammonemic encephalopathy	Disease	D022124|D001927
10327032_8	100	104	5-FU	Chemical	D005472
10327032_8	CID	D005472	D022124
10327032_8	CID	D005472	D001927

10390729_4|s|In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity. 3.
10390729_4	129	141	hypoactivity	Disease	D009069
10390729_4	211	224	hyperactivity	Disease	D006948
10390729_4	81	82	K	Chemical	D011188
10390729_4	112	120	morphine	Chemical	D009020
10390729_4	152	153	K	Chemical	D011188
10390729_4	184	192	morphine	Chemical	D009020
10390729_4	CID	D009020	D006948

10390729_6|s|It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.
10390729_6	130	142	hypoactivity	Disease	D009069
10390729_6	168	181	hyperactivity	Disease	D006948
10390729_6	42	43	K	Chemical	D011188
10390729_6	113	121	morphine	Chemical	D009020
10390729_6	151	159	morphine	Chemical	D009020
10390729_6	212	219	quinine	Chemical	D011803
10390729_6	225	240	4-aminopyridine	Chemical	D015761
10390729_6	251	252	K	Chemical	D011188
10390729_6	CID	D009020	D006948

10401555_0|s|Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice.1.
10401555_0	41	71	learning and memory impairment	Disease	D007859|D008569
10401555_0	0	10	Nociceptin	Chemical	C096012
10401555_0	11	22	orphanin FQ	Chemical	C096012
10401555_0	27	37	nocistatin	Chemical	C111148
10401555_0	83	94	scopolamine	Chemical	D012601
10401555_0	CID	D012601	D008569
10401555_0	CID	D012601	D007859

10401555_2|s|On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced allodynia and hyperalgesia. 2.
10401555_2	119	128	allodynia	Disease	D006930
10401555_2	133	145	hyperalgesia	Disease	D006930
10401555_2	19	29	nocistatin	Chemical	C111148
10401555_2	78	88	nociceptin	Chemical	C096012
10401555_2	100	110	nociceptin	Chemical	C096012

10401555_4|s|The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice. 4.
10401555_4	107	140	impairment of learning and memory	Disease	D007859|D008569
10401555_4	54	64	nociceptin	Chemical	C096012
10401555_4	65	76	orphanin FQ	Chemical	C096012
10401555_4	81	91	nocistatin	Chemical	C111148
10401555_4	152	163	scopolamine	Chemical	D012601
10401555_4	CID	D012601	D008569
10401555_4	CID	D012601	D007859

10427794_0|s|Meloxicam-induced liver toxicity.
10427794_0	18	32	liver toxicity	Disease	D056486
10427794_0	0	9	Meloxicam	Chemical	C065757
10427794_0	CID	C065757	D056486

10427794_1|s|We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic hepatitis due to meloxicam.
10427794_1	44	64	rheumatoid arthritis	Disease	D001172
10427794_1	95	104	hepatitis	Disease	D056486
10427794_1	112	121	meloxicam	Chemical	C065757
10427794_1	CID	C065757	D056486

10427794_3|s|The acute cytolytic hepatitis occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a hypersensitivity mechanism.
10427794_3	20	29	hepatitis	Disease	D056486
10427794_3	157	173	hypersensitivity	Disease	D004342
10427794_3	53	62	meloxicam	Chemical	C065757
10427794_3	CID	C065757	D004342
10427794_3	CID	C065757	D056486

10427794_4|s|This first case of meloxicam related liver toxicity demonstrates the potential of this drug to induce hepatic damage.
10427794_4	37	51	liver toxicity	Disease	D056486
10427794_4	102	116	hepatic damage	Disease	D056486
10427794_4	19	28	meloxicam	Chemical	C065757
10427794_4	CID	C065757	D056486

10462057_0|s|Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19- human bone marrow progenitor cells: potential relevance to remoxipride-induced aplastic anemia.
10462057_0	153	168	aplastic anemia	Disease	D000741
10462057_0	26	37	remoxipride	Chemical	D017330
10462057_0	133	144	remoxipride	Chemical	D017330
10462057_0	CID	D017330	D000741

10462057_1|s|The antipsychotic agent, remoxipride [(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide] has been associated with acquired aplastic anemia.
10462057_1	148	163	aplastic anemia	Disease	D000741
10462057_1	25	36	remoxipride	Chemical	D017330
10462057_1	38	112	(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide	Chemical	D017330
10462057_1	CID	D017330	D000741

10462057_7|s|No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations.
10462057_7	3	11	necrosis	Disease	D009336
10462057_7	154	162	necrosis	Disease	D009336
10462057_7	47	53	NCQ436	Chemical	C084325
10462057_7	58	64	NCQ344	Chemical	C112341

10462057_11|s|We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.
10462057_11	51	66	aplastic anemia	Disease	D000741
10462057_11	242	257	aplastic anemia	Disease	D000741
10462057_11	16	27	remoxipride	Chemical	D017330
10462057_11	32	39	benzene	Chemical	D001554
10462057_11	138	144	NCQ436	Chemical	C084325
10462057_11	149	155	NCQ344	Chemical	C112341
10462057_11	288	299	remoxipride	Chemical	D017330
10462057_11	CID	D017330	D000741
10462057_11	CID	D001554	D000741

10510854_3|s|Compound 7e, 5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy dro-1H- indol-2-one, from this series showed significant affinities at the 5-HT1A and 5-HT2A receptors and moderate affinity at the D2 receptor. 7e exhibits a high reversal of catalepsy induced by haloperidol indicating its atypical antipsychotic nature.
10510854_3	256	265	catalepsy	Disease	D002375
10510854_3	13	99	5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy dro-1H- indol-2-one	Chemical	-1
10510854_3	277	288	haloperidol	Chemical	D006220
10510854_3	CID	D006220	D002375

10672628_0|s|Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice.
10672628_0	78	87	catalepsy	Disease	D002375
10672628_0	26	38	nitric-oxide	Chemical	D009569
10672628_0	58	69	haloperidol	Chemical	D006220
10672628_0	106	111	NADPH	Chemical	D009249
10672628_0	CID	D006220	D002375

10672628_1|s|RATIONALE: NG-nitro-L-arginine (L-NOARG), an inhibitor of nitric-oxide synthase (NOS), induces catalepsy in mice.
10672628_1	95	104	catalepsy	Disease	D002375
10672628_1	11	30	NG-nitro-L-arginine	Chemical	D019335
10672628_1	32	39	L-NOARG	Chemical	D019335
10672628_1	58	70	nitric-oxide	Chemical	D009569

10672628_4|s|Neuroleptic drugs such as haloperidol, which block dopamine receptors, also cause catalepsy in rodents.
10672628_4	82	91	catalepsy	Disease	D002375
10672628_4	26	37	haloperidol	Chemical	D006220
10672628_4	51	59	dopamine	Chemical	D004298
10672628_4	CID	D006220	D002375

10672628_5|s|OBJECTIVES: To investigate the effects of subchronic L-NOARG treatment in haloperidol-induced catalepsy and the number of NOS neurons in areas related to motor control.
10672628_5	94	103	catalepsy	Disease	D002375
10672628_5	53	60	L-NOARG	Chemical	D019335
10672628_5	74	85	haloperidol	Chemical	D006220
10672628_5	CID	D006220	D002375

10672628_9|s|RESULTS: L-NOARG sub-chronic administration produced tolerance of L-NOARG and of haloperidol-induced catalepsy.
10672628_9	101	110	catalepsy	Disease	D002375
10672628_9	9	16	L-NOARG	Chemical	D019335
10672628_9	66	73	L-NOARG	Chemical	D019335
10672628_9	81	92	haloperidol	Chemical	D006220
10672628_9	CID	D006220	D002375

10677406_0|s|Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia.
10677406_0	10	38	left ventricular dysfunction	Disease	D018487
10677406_0	63	86	coronary artery disease	Disease	D003324
10677406_0	130	150	myocardial ischaemia	Disease	D017202
10677406_0	98	108	dobutamine	Chemical	D004280
10677406_0	CID	D004280	D018487

10677406_2|s|DESIGN: A randomised crossover study of recovery time of systolic and diastolic left ventricular function after exercise and dobutamine induced ischaemia.
10677406_2	144	153	ischaemia	Disease	D007511
10677406_2	125	135	dobutamine	Chemical	D004280

10677406_11|s|CONCLUSIONS: In patients with coronary artery disease, dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise.
10677406_11	30	53	coronary artery disease	Disease	D003324
10677406_11	74	83	ischaemia	Disease	D007511
10677406_11	116	144	left ventricular dysfunction	Disease	D018487
10677406_11	161	180	myocardial stunning	Disease	D017682
10677406_11	55	65	dobutamine	Chemical	D004280
10677406_11	CID	D004280	D018487
10677406_11	CID	D004280	D017682

10677406_12|s|Dobutamine induced ischaemia could therefore be used to study the pathophysiology of this phenomenon further in patients with coronary artery disease.
10677406_12	19	28	ischaemia	Disease	D007511
10677406_12	126	149	coronary artery disease	Disease	D003324
10677406_12	0	10	Dobutamine	Chemical	D004280

10713017_9|s|However, of the medications surveyed, only the fenfluramines had a significant preferential association with PPH as compared with SPH (adjusted odds ratio for use > 6 months, 7.5; 95% confidence interval, 1.7 to 32.4).
10713017_9	109	112	PPH	Disease	D006976
10713017_9	47	60	fenfluramines	Chemical	D005277
10713017_9	CID	D005277	D006976

10713017_12|s|CONCLUSION: The magnitude of the association with PPH, the increase of association with increasing duration of use, and the specificity for fenfluramines are consistent with previous studies indicating that fenfluramines are causally related to PPH.
10713017_12	50	53	PPH	Disease	D006976
10713017_12	245	248	PPH	Disease	D006976
10713017_12	140	153	fenfluramines	Chemical	D005277
10713017_12	207	220	fenfluramines	Chemical	D005277
10713017_12	CID	D005277	D006976

10726030_0|s|Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy.
10726030_0	36	52	thrombocytopenia	Disease	D013921
10726030_0	57	67	thrombosis	Disease	D013927
10726030_0	20	27	heparin	Chemical	D006493
10726030_0	94	101	heparin	Chemical	D006493
10726030_0	CID	D006493	D013921

10726030_1|s|Heparin, first used to prevent the clotting of blood in vitro, has been clinically used to treat thrombosis for more than 50 years.
10726030_1	97	107	thrombosis	Disease	D013927
10726030_1	0	7	Heparin	Chemical	D006493

10726030_2|s|Although several new anticoagulant drugs are in development, heparin remains the anticoagulant of choice to treat acute thrombotic episodes.
10726030_2	120	130	thrombotic	Disease	D013927
10726030_2	61	68	heparin	Chemical	D006493

10726030_4|s|Bleeding is the primary untoward effect of heparin.
10726030_4	0	8	Bleeding	Disease	D006470
10726030_4	43	50	heparin	Chemical	D006493

10726030_5|s|Major bleeding is of primary concern in patients receiving heparin therapy.
10726030_5	6	14	bleeding	Disease	D006470
10726030_5	59	66	heparin	Chemical	D006493

10726030_6|s|However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.
10726030_6	90	106	thrombocytopenia	Disease	D013921
10726030_6	127	139	osteoporosis	Disease	D010024
10726030_6	141	153	eosinophilia	Disease	D004802
10726030_6	155	169	skin reactions	Disease	D012871
10726030_6	171	189	allergic reactions	Disease	D004342
10726030_6	201	217	thrombocytopenia	Disease	D013921
10726030_6	219	227	alopecia	Disease	D000505
10726030_6	246	258	hyperkalemia	Disease	D006947
10726030_6	260	277	hypoaldosteronism	Disease	D006994
10726030_6	283	291	priapism	Disease	D011317
10726030_6	50	57	heparin	Chemical	D006493
10726030_6	74	81	heparin	Chemical	D006493
10726030_6	108	115	heparin	Chemical	D006493
10726030_6	CID	D006493	D012871
10726030_6	CID	D006493	D004342
10726030_6	CID	D006493	D013921
10726030_6	CID	D006493	D006947
10726030_6	CID	D006493	D010024
10726030_6	CID	D006493	D011317
10726030_6	CID	D006493	D006994
10726030_6	CID	D006493	D004802
10726030_6	CID	D006493	D000505

10726030_7|s|These side effects are relatively rare in a given individual, but given the extremely widespread use of heparin, some are quite common, particularly HITT and osteoporosis.
10726030_7	149	153	HITT	Disease	D013921|D013927
10726030_7	158	170	osteoporosis	Disease	D010024
10726030_7	104	111	heparin	Chemical	D006493
10726030_7	CID	D006493	D013921
10726030_7	CID	D006493	D010024

10764869_0|s|A case of bilateral optic neuropathy in a patient on tacrolimus (FK506) therapy after liver transplantation.
10764869_0	20	36	optic neuropathy	Disease	D009901
10764869_0	53	63	tacrolimus	Chemical	D016559
10764869_0	65	70	FK506	Chemical	D016559
10764869_0	CID	D016559	D009901

10764869_1|s|PURPOSE: To report a case of bilateral optic neuropathy in a patient receiving tacrolimus (FK 506, Prograf; Fujisawa USA, Inc, Deerfield, Illinois) for immunosuppression after orthotropic liver transplantation.
10764869_1	39	55	optic neuropathy	Disease	D009901
10764869_1	79	89	tacrolimus	Chemical	D016559
10764869_1	91	97	FK 506	Chemical	D016559
10764869_1	CID	D016559	D009901

10764869_5|s|Deterioration of vision occurred despite discontinuation of the tacrolimus.
10764869_5	0	23	Deterioration of vision	Disease	D015354
10764869_5	64	74	tacrolimus	Chemical	D016559

10764869_6|s|CONCLUSION: Tacrolimus and other immunosuppressive agents may be associated with optic nerve toxicity.
10764869_6	81	101	optic nerve toxicity	Disease	D009901
10764869_6	12	22	Tacrolimus	Chemical	D016559
10764869_6	CID	D016559	D009901

10770468_1|s|Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.
10770468_1	21	28	bipolar	Disease	D001714
10770468_1	89	102	hypercalcemia	Disease	D006934
10770468_1	114	129	bradyarrhythmia	Disease	D001919
10770468_1	187	194	bipolar	Disease	D001714
10770468_1	228	241	hypercalcemia	Disease	D006934
10770468_1	59	66	lithium	Chemical	D008094
10770468_1	209	216	lithium	Chemical	D008094
10770468_1	CID	D008094	D006934

10770468_3|s|After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).
10770468_3	27	41	hypercalcemias	Disease	D006934
10770468_3	147	161	hypercalcemias	Disease	D006934
10770468_3	173	185	malignancies	Disease	D009369
10770468_3	265	278	hypercalcemia	Disease	D006934
10770468_3	117	124	lithium	Chemical	D008094
10770468_3	246	253	lithium	Chemical	D008094
10770468_3	CID	D008094	D006934

10770468_5|s|Thus, two control groups were generated: group C1, which included age- and sex-comparable lithium-treated bipolar normocalcemic patients, and group C2, which included bipolar normocalcemic patients treated with anticonvulsant mood stabilizers.
10770468_5	106	113	bipolar	Disease	D001714
10770468_5	167	174	bipolar	Disease	D001714
10770468_5	90	97	lithium	Chemical	D008094

10770468_8|s|Patients with hypercalcemia resulting from medical diseases and bipolar patients with lithium-associated hypercalcemia had significantly higher frequencies of conduction defects.
10770468_8	14	27	hypercalcemia	Disease	D006934
10770468_8	64	71	bipolar	Disease	D001714
10770468_8	105	118	hypercalcemia	Disease	D006934
10770468_8	86	93	lithium	Chemical	D008094
10770468_8	CID	D008094	D006934

10933650_0|s|Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.
10933650_0	15	29	nephrotoxicity	Disease	D007674
10933650_0	81	95	amphotericin B	Chemical	D000666

10933650_1|s|NS-718, a lipid nanosphere incorporating amphotericin B, is effective against pathogenic fungi and has low toxicity.
10933650_1	107	115	toxicity	Disease	D064420
10933650_1	41	55	amphotericin B	Chemical	D000666

10933650_2|s|We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.
10933650_2	16	24	toxicity	Disease	D064420
10933650_2	48	57	Fungizone	Chemical	D000666
10933650_2	59	93	amphotericin B-sodium deoxycholate	Chemical	C059765
10933650_2	95	100	D-AmB	Chemical	C059765
10933650_2	241	255	amphotericin B	Chemical	D000666

10933650_5|s|Histopathological examination of the kidney showed tubular necrosis in D-AmB-treated rats but no change in NS-718-treated rats.
10933650_5	51	67	tubular necrosis	Disease	D007683
10933650_5	71	76	D-AmB	Chemical	C059765
10933650_5	CID	C059765	D007683

10933650_7|s|Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the nephrotoxicity of amphotericin B.
10933650_7	126	140	nephrotoxicity	Disease	D007674
10933650_7	63	77	amphotericin B	Chemical	D000666
10933650_7	144	158	amphotericin B	Chemical	D000666

10939760_0|s|Patterns of sulfadiazine acute nephrotoxicity.
10939760_0	25	45	acute nephrotoxicity	Disease	D058186
10939760_0	12	24	sulfadiazine	Chemical	D013411
10939760_0	CID	D013411	D058186

10939760_1|s|Sulfadiazine acute nephrotoxicity is reviving specially because of its use in toxoplasmosis in HIV-positive patients.
10939760_1	13	33	acute nephrotoxicity	Disease	D058186
10939760_1	78	91	toxoplasmosis	Disease	D014123
10939760_1	0	12	Sulfadiazine	Chemical	D013411
10939760_1	CID	D013411	D058186

10939760_3|s|Under treatment with sulfadiazine they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography.
10939760_3	49	57	oliguria	Disease	D009846
10939760_3	59	73	abdominal pain	Disease	D015746
10939760_3	75	88	renal failure	Disease	D051437
10939760_3	121	134	renal calculi	Disease	D007669
10939760_3	21	33	sulfadiazine	Chemical	D013411
10939760_3	CID	D013411	D007669

10960401_0|s|Downbeat nystagmus associated with intravenous patient-controlled administration of morphine.
10960401_0	0	18	Downbeat nystagmus	Disease	D009759
10960401_0	84	92	morphine	Chemical	D009020
10960401_0	CID	D009020	D009759

10960401_1|s|IMPLICATIONS: This case documents a patient who developed dizziness with downbeating nystagmus while receiving a relatively large dose of IV patient-controlled analgesia morphine.
10960401_1	58	67	dizziness	Disease	D004244
10960401_1	73	94	downbeating nystagmus	Disease	D009759
10960401_1	170	178	morphine	Chemical	D009020
10960401_1	CID	D009020	D004244
10960401_1	CID	D009020	D009759

10975596_0|s|Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.
10975596_0	94	115	myocardial infarction	Disease	D009203
10975596_0	42	53	dronedarone	Chemical	C118667
10975596_0	58	68	amiodarone	Chemical	D000638

10975596_1|s|The hemodynamic and antiadrenergic effects of dronedarone, a noniodinated compound structurally related to amiodarone, were compared with those of amiodarone after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed myocardial infarction.
10975596_1	275	296	myocardial infarction	Disease	D009203
10975596_1	46	57	dronedarone	Chemical	C118667
10975596_1	107	117	amiodarone	Chemical	D000638
10975596_1	147	157	amiodarone	Chemical	D000638

10975596_5|s|Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced tachycardia.
10975596_5	75	86	tachycardia	Disease	D013610
10975596_5	149	160	tachycardia	Disease	D013610
10975596_5	5	16	dronedarone	Chemical	C118667
10975596_5	21	31	amiodarone	Chemical	D000638
10975596_5	127	140	isoproterenol	Chemical	D007545
10975596_5	CID	D007545	D013610

10975596_7|s|Consequently, dronedarone might be particularly suitable for the treatment and prevention of various clinical arrhythmias, without compromising the left ventricular function.
10975596_7	110	121	arrhythmias	Disease	D001145
10975596_7	14	25	dronedarone	Chemical	C118667

10985896_0|s|Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
10985896_0	86	120	ovarian and fallopian tube cancers	Disease	D010051|D005185
10985896_0	133	160	carcinoma of the peritoneum	Disease	D010534
10985896_0	27	38	doxorubicin	Chemical	D004317
10985896_0	55	63	platinum	Chemical	D010984
10985896_0	64	74	paclitaxel	Chemical	D017239

10985896_1|s|BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and stomatitis.
10985896_1	135	149	ovarian cancer	Disease	D010051
10985896_1	170	178	toxicity	Disease	D064420
10985896_1	246	264	erythrodysesthesia	Disease	D060831
10985896_1	267	285	hand-foot syndrome	Disease	D060831
10985896_1	292	302	stomatitis	Disease	D013280
10985896_1	56	67	doxorubicin	Chemical	D004317
10985896_1	69	74	Doxil	Chemical	D004317
10985896_1	116	124	platinum	Chemical	D010984
10985896_1	CID	D004317	D013280
10985896_1	CID	D004317	D060831

10985896_3|s|METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.
10985896_3	37	70	ovarian or fallopian tube cancers	Disease	D010051|D005185
10985896_3	82	102	peritoneal carcinoma	Disease	D010534
10985896_3	108	116	platinum	Chemical	D010984
10985896_3	117	127	paclitaxel	Chemical	D017239
10985896_3	298	309	doxorubicin	Chemical	D004317

10985896_11|s|CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule.
10985896_11	72	80	toxicity	Disease	D064420
10985896_11	82	92	stomatitis	Disease	D013280
10985896_11	94	112	hand-foot syndrome	Disease	D060831
10985896_11	36	47	doxorubicin	Chemical	D004317
10985896_11	CID	D004317	D013280
10985896_11	CID	D004317	D060831

10985896_12|s|Definite, although limited, antineoplastic activity is observed in patients with well-defined platinum- and paclitaxel-refractory ovarian cancer.
10985896_12	130	144	ovarian cancer	Disease	D010051
10985896_12	94	102	platinum	Chemical	D010984
10985896_12	108	118	paclitaxel	Chemical	D017239

10986547_0|s|Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study.
10986547_0	32	45	bipolar mania	Disease	D001714
10986547_0	12	22	olanzapine	Chemical	C076029

10986547_2|s|BACKGROUND: We compared the efficacy and safety of olanzapine vs placebo for the treatment of acute bipolar mania.
10986547_2	100	113	bipolar mania	Disease	D001714
10986547_2	51	61	olanzapine	Chemical	C076029

10986547_4|s|A total of 115 patients with a DSM-IV diagnosis of bipolar disorder, manic or mixed, were randomized to olanzapine, 5 to 20 mg/d (n = 55), or placebo (n = 60).
10986547_4	51	67	bipolar disorder	Disease	D001714
10986547_4	69	74	manic	Disease	D001714
10986547_4	104	114	olanzapine	Chemical	C076029

10986547_11|s|However, olanzapine-treated patients had a statistically significant greater mean (+/- SD) weight gain than placebo-treated patients (2.1 +/- 2.8 vs 0.45 +/- 2.3 kg, respectively) and also experienced more treatment-emergent somnolence (21 patients [38.2%] vs 5 [8.3% ], respectively).
10986547_11	91	102	weight gain	Disease	D015430
10986547_11	225	235	somnolence	Disease	D006970
10986547_11	9	19	olanzapine	Chemical	C076029
10986547_11	CID	C076029	D006970
10986547_11	CID	C076029	D015430

10986547_12|s|CONCLUSION: Olanzapine demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated.
10986547_12	92	105	bipolar mania	Disease	D001714
10986547_12	12	22	Olanzapine	Chemical	C076029

11026989_0|s|The effect of pupil dilation with tropicamide on vision and driving simulator performance.
11026989_0	14	28	pupil dilation	Disease	D015878
11026989_0	34	45	tropicamide	Chemical	D014331
11026989_0	CID	D014331	D015878

11026989_2|s|METHODS: A series of tests on various parameters of visual function and driving simulator performance were performed on 12 healthy drivers, before and after pupil dilation using guttae tropicamide 1%.
11026989_2	157	171	pupil dilation	Disease	D015878
11026989_2	185	196	tropicamide	Chemical	D014331
11026989_2	CID	D014331	D015878

11105626_1|s|We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester.
11105626_1	63	69	anotia	Disease	D065817
11105626_1	74	99	Taussig-Bing malformation	Disease	D004310
11105626_1	120	132	isotretinoin	Chemical	D015474
11105626_1	CID	D015474	D004310
11105626_1	CID	D015474	D065817

11135381_0|s|Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence: a placebo-controlled, double-blind crossover study.
11135381_0	73	92	stress incontinence	Disease	D014550
11135381_0	10	21	methoxamine	Chemical	D008729

11135381_3|s|Half log incremental doses of intravenous methoxamine or placebo (saline) were administered to a group of women with genuine stress incontinence while measuring maximum urethral pressure (MUP), blood pressure, heart rate, and symptomatic side effects.
11135381_3	125	144	stress incontinence	Disease	D014550
11135381_3	42	53	methoxamine	Chemical	D008729

11135381_4|s|Methoxamine evoked non-significant increases in MUP and diastolic blood pressure but caused a significant rise in systolic blood pressure and significant fall in heart rate at maximum dosage.
11135381_4	92	137	a significant rise in systolic blood pressure	Disease	D006973
11135381_4	0	11	Methoxamine	Chemical	D008729
11135381_4	CID	D008729	D006973

11176729_0|s|Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial.
11176729_0	94	107	heart failure	Disease	D006333
11176729_0	28	68	angiotensin-converting enzyme inhibitors	Chemical	D000806

11176729_2|s|BACKGROUND: Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients are not receiving these agents or are being treated with doses lower than those found to be efficacious in trials, primarily because of concerns about the safety and tolerability of these agents, especially at the recommended doses.
11176729_2	131	144	heart failure	Disease	D006333
11176729_2	146	149	CHF	Disease	D006333
11176729_2	27	73	angiotensin-converting enzyme (ACE) inhibitors	Chemical	D000806

11176729_3|s|The present study examines the safety and tolerability of high- compared with low-dose lisinopril in CHF.
11176729_3	101	104	CHF	Disease	D006333
11176729_3	87	97	lisinopril	Chemical	D017706

11176729_7|s|RESULTS: Of 405 patients not previously receiving an ACE inhibitor, doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of renal dysfunction or hyperkalemia (2.3%).
11176729_7	196	207	hypotension	Disease	D007022
11176729_7	229	246	renal dysfunction	Disease	D007674
11176729_7	250	262	hyperkalemia	Disease	D006947
11176729_7	53	66	ACE inhibitor	Chemical	D000806

11176729_10|s|Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; creatinine, > or =132.6 micromol/L [> or =1.5 mg/dL]; age, > or =70 years; and patients with diabetes) generally tolerated the high-dose strategy.
11176729_10	192	200	diabetes	Disease	D003920
11176729_10	44	57	ACE inhibitor	Chemical	D000806
11176729_10	99	109	creatinine	Chemical	D003404

11176729_11|s|CONCLUSIONS: These findings demonstrate that ACE inhibitor therapy in most patients with CHF can be successfully titrated to and maintained at high doses, and that more aggressive use of these agents is warranted.
11176729_11	89	92	CHF	Disease	D006333
11176729_11	45	58	ACE inhibitor	Chemical	D000806

11229942_0|s|Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse.
11229942_0	35	47	cardiotoxity	Disease	D066126
11229942_0	70	95	cocaine and ethanol abuse	Disease	D019970|D000437
11229942_0	0	7	Cocaine	Chemical	D003042
11229942_0	9	16	ethanol	Chemical	D000431
11229942_0	22	34	cocaethylene	Chemical	C066444

11229942_3|s|Their combined cardiac toxicity may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a cocaine metabolite formed only in the presence of ethanol.
11229942_3	15	31	cardiac toxicity	Disease	D066126
11229942_3	113	125	cocaethylene	Chemical	C066444
11229942_3	127	129	CE	Chemical	C066444
11229942_3	134	141	cocaine	Chemical	D003042
11229942_3	184	191	ethanol	Chemical	D000431

11229942_4|s|The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of cocaine and ethanol in a model simulating their abuse.
11229942_4	74	88	cardiotoxicity	Disease	D066126
11229942_4	134	145	their abuse	Disease	D019970|D000437
11229942_4	55	57	CE	Chemical	C066444
11229942_4	92	99	cocaine	Chemical	D003042
11229942_4	104	111	ethanol	Chemical	D000431

11229942_9|s|Peak CE levels were associated with a 45% (SD +/- 22%, 95% CI = 22% to 69%) decrease in cardiac output (p < 0.05), a 56% (SD +/- 23%, 95% CI = 32% to 80%) decrease in dP/dt(max) (p <.006), and a 23% (SD +/- 15%, 95% CI = 7% to 49%) decrease in SVO(2) (p < 0.025).
11229942_9	76	102	decrease in cardiac output	Disease	D002303
11229942_9	5	7	CE	Chemical	C066444
11229942_9	CID	C066444	D002303

11229942_13|s|Peak serum cocaethylene concentrations were associated with prolonged myocardial depression.
11229942_13	70	91	myocardial depression	Disease	D009202
11229942_13	11	23	cocaethylene	Chemical	C066444

11299446_0|s|Worsening of Parkinsonism after the use of veralipride for treatment of menopause: case report.
11299446_0	13	25	Parkinsonism	Disease	D010302
11299446_0	43	54	veralipride	Chemical	C027429
11299446_0	CID	C027429	D010302

11299446_1|s|We describe a female patient with stable Parkinson's disease who has shown a marked worsening of her motor functions following therapy of menopause related symptoms with veralipride, as well as the improvement of her symptoms back to baseline after discontinuation of the drug.
11299446_1	41	60	Parkinson's disease	Disease	D010302
11299446_1	170	181	veralipride	Chemical	C027429
11299446_1	CID	C027429	D010302

11366874_0|s|Viracept and irregular heartbeat warning.
11366874_0	13	32	irregular heartbeat	Disease	D001145
11366874_0	0	8	Viracept	Chemical	D019888

11366874_1|s|A group of doctors in Boston warn that the protease inhibitor Viracept may cause an irregular heart beat, known as bradycardia, in people with HIV.
11366874_1	84	104	irregular heart beat	Disease	D001145
11366874_1	115	126	bradycardia	Disease	D001919
11366874_1	62	70	Viracept	Chemical	D019888
11366874_1	CID	D019888	D001919

11366874_2|s|Bradycardia occurred in a 45-year-old male patient who was Viracept in combination with other anti-HIV drugs.
11366874_2	0	11	Bradycardia	Disease	D001919
11366874_2	59	67	Viracept	Chemical	D019888
11366874_2	CID	D019888	D001919

11380496_0|s|Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations.
11380496_0	93	108	Graves' disease	Disease	D006111
11380496_0	131	147	propylthiouracil	Chemical	D011441

11380496_1|s|OBJECTIVE: Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-positive vasculitis has been reported in patients with Graves' disease who were treated with propylthiouracil (PTU).
11380496_1	83	93	vasculitis	Disease	D014657
11380496_1	129	144	Graves' disease	Disease	D006111
11380496_1	167	183	propylthiouracil	Chemical	D011441
11380496_1	185	188	PTU	Chemical	D011441

11380496_3|s|Nevertheless, there have been no studies on the temporal relationship between the appearance of MPO-ANCA and vasculitis during PTU therapy, or on the incidence of MPO-ANCA in untreated Graves' disease patients.
11380496_3	109	119	vasculitis	Disease	D014657
11380496_3	185	200	Graves' disease	Disease	D006111
11380496_3	127	130	PTU	Chemical	D011441

11380496_5|s|PATIENTS: We investigated 102 untreated patients with hyperthyroidism due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting PTU therapy.
11380496_5	54	69	hyperthyroidism	Disease	D006980
11380496_5	77	92	Graves' disease	Disease	D006111
11380496_5	147	157	vasculitis	Disease	D014657
11380496_5	173	176	PTU	Chemical	D011441

11380496_12|s|In two of them, the MPO-ANCA titres transiently increased to 12.8 and 15.0 U/ml, respectively, despite continued PTU therapy, but no vasculitic disorders developed.
11380496_12	133	153	vasculitic disorders	Disease	D014652
11380496_12	113	116	PTU	Chemical	D011441

11380496_13|s|In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.
11380496_13	90	95	fever	Disease	D005334
11380496_13	97	108	oral ulcers	Disease	D019226
11380496_13	113	127	polyarthralgia	Disease	D018771
11380496_13	178	181	PTU	Chemical	D011441
11380496_13	269	272	PTU	Chemical	D011441
11380496_13	CID	D011441	D005334
11380496_13	CID	D011441	D018771
11380496_13	CID	D011441	D019226

11380496_14|s|CONCLUSIONS: PTU therapy may be related to the appearance of MPO-ANCA, but MPO-ANCA does not appear to be closely related to vasculitis.
11380496_14	125	135	vasculitis	Disease	D014657
11380496_14	13	16	PTU	Chemical	D011441

11385188_0|s|Prevalence of heart disease in asymptomatic chronic cocaine users.
11385188_0	14	27	heart disease	Disease	D006331
11385188_0	52	59	cocaine	Chemical	D003042

11385188_1|s|To determine the prevalence of heart disease in outpatient young asymptomatic chronic cocaine users, 35 cocaine users and 32 age-matched controls underwent resting and exercise electrocardiography (ECG) and Doppler echocardiography.
11385188_1	31	44	heart disease	Disease	D006331
11385188_1	86	93	cocaine	Chemical	D003042
11385188_1	104	111	cocaine	Chemical	D003042

11385188_5|s|We conclude that coronary artery or myocardial disease is common (38%) in young asymptomatic chronic cocaine users.
11385188_5	17	54	coronary artery or myocardial disease	Disease	D003324|D009202
11385188_5	101	108	cocaine	Chemical	D003042
11385188_5	CID	D003042	D003324
11385188_5	CID	D003042	D009202

11395263_1|s|The cardioprotective effect of the ethanol extract of Picrorrhiza kurroa rhizomes and roots (PK) on isoproterenol-induced myocardial infarction in rats with respect to lipid metabolism in serum and heart tissue has been investigated.
11395263_1	122	143	myocardial infarction	Disease	D009203
11395263_1	35	42	ethanol	Chemical	D000431
11395263_1	100	113	isoproterenol	Chemical	D007545
11395263_1	CID	D007545	D009203

11395263_2|s|Oral pre-treatment with PK (80 mg kg(-1) day(-1) for 15 days) significantly prevented the isoproterenol-induced myocardial infarction and maintained the rats at near normal status.
11395263_2	112	133	myocardial infarction	Disease	D009203
11395263_2	90	103	isoproterenol	Chemical	D007545
11395263_2	CID	D007545	D009203

11401944_1|s|BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide.
11401944_1	119	137	torsade de pointes	Disease	D016171
11401944_1	139	142	TdP	Disease	D016171
11401944_1	149	164	QT prolongation	Disease	D008133
11401944_1	179	186	sotalol	Chemical	D013015
11401944_1	191	200	azimilide	Chemical	C086123
11401944_1	CID	D013015	D008133
11401944_1	CID	D013015	D016171

11401944_3|s|METHODS AND RESULTS: Transmembrane action potentials from epicardium, midmyocardium, and endocardium were recorded simultaneously, together with a transmural ECG, in arterially perfused canine and rabbit left ventricular preparations. dl-Sotalol preferentially prolonged action potential duration (APD) in M cells dose-dependently (1 to 100 micromol/L), leading to QT prolongation and an increase in TDR.
11401944_3	365	380	QT prolongation	Disease	D008133
11401944_3	238	245	Sotalol	Chemical	D013015
11401944_3	CID	D013015	D008133

11401944_6|s|Although both dl-sotalol and azimilide rarely induced EADs in canine left ventricles, they produced frequent EADs in rabbits, in which more pronounced QT prolongation was seen.
11401944_6	151	166	QT prolongation	Disease	D008133
11401944_6	17	24	sotalol	Chemical	D013015
11401944_6	29	38	azimilide	Chemical	C086123
11401944_6	CID	D013015	D008133

11401944_7|s|An increase in TDR by dl-sotalol facilitated transmural propagation of EADs that initiated multiple episodes of spontaneous TdP in 3 of 6 rabbit left ventricles.
11401944_7	124	127	TdP	Disease	D016171
11401944_7	25	32	sotalol	Chemical	D013015
11401944_7	CID	D013015	D016171

11425091_0|s|Prenatal cocaine exposure and cranial sonographic findings in preterm infants.
11425091_0	62	77	preterm infants	Disease	D007235
11425091_0	9	16	cocaine	Chemical	D003042
11425091_0	CID	D003042	D007235

11425091_1|s|PURPOSE: Prenatal cocaine exposure has been linked with subependymal hemorrhage and the formation of cysts that are detectable on cranial sonography in neonates born at term.
11425091_1	69	79	hemorrhage	Disease	D006470
11425091_1	101	106	cysts	Disease	D003560
11425091_1	18	25	cocaine	Chemical	D003042
11425091_1	CID	D003042	D003560

11425091_2|s|We sought to determine if prenatal cocaine exposure increases the incidence of subependymal cysts in preterm infants.
11425091_2	79	97	subependymal cysts	Disease	D001927|D003560
11425091_2	101	116	preterm infants	Disease	D007235
11425091_2	35	42	cocaine	Chemical	D003042
11425091_2	CID	D003042	D003560
11425091_2	CID	D003042	D001927
11425091_2	CID	D003042	D007235

11425091_5|s|Infants were assigned to the cocaine-exposed group if there was a maternal history of cocaine abuse during pregnancy or if maternal or neonatal urine toxicology results were positive at the time of delivery.
11425091_5	86	99	cocaine abuse	Disease	D019970
11425091_5	29	36	cocaine	Chemical	D003042

11425091_8|s|The incidence of subependymal cysts in infants exposed to cocaine prenatally was 44% (8 of 18) compared with 8% (8 of 99) in the unexposed group (p < 0.01).
11425091_8	17	35	subependymal cysts	Disease	D001927|D003560
11425091_8	58	65	cocaine	Chemical	D003042
11425091_8	CID	D003042	D003560
11425091_8	CID	D003042	D001927

11425091_9|s|CONCLUSIONS: We found an increased incidence of subependymal cyst formation in preterm infants who were exposed to cocaine prenatally.
11425091_9	48	65	subependymal cyst	Disease	D001927|D003560
11425091_9	79	94	preterm infants	Disease	D007235
11425091_9	115	122	cocaine	Chemical	D003042
11425091_9	CID	D003042	D003560
11425091_9	CID	D003042	D001927
11425091_9	CID	D003042	D007235

11439380_0|s|Thalidomide neuropathy in patients treated for metastatic prostate cancer.
11439380_0	12	22	neuropathy	Disease	D009422
11439380_0	58	73	prostate cancer	Disease	D011471
11439380_0	0	11	Thalidomide	Chemical	D013792

11439380_1|s|We prospectively evaluated thalidomide-induced neuropathy using electrodiagnostic studies.
11439380_1	47	57	neuropathy	Disease	D009422
11439380_1	27	38	thalidomide	Chemical	D013792

11439380_2|s|Sixty-seven men with metastatic androgen-independent prostate cancer in an open-label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment.
11439380_2	53	68	prostate cancer	Disease	D011471
11439380_2	32	40	androgen	Chemical	D000728
11439380_2	100	111	thalidomide	Chemical	D013792

11439380_11|s|Neuropathy may thus be a common complication of thalidomide in older patients.
11439380_11	0	10	Neuropathy	Disease	D009422
11439380_11	48	59	thalidomide	Chemical	D013792

11474137_0|s|Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced hearing loss.
11474137_0	83	95	hearing loss	Disease	D034381
11474137_0	18	24	copper	Chemical	D003300
11474137_0	25	29	zinc	Chemical	D015032
11474137_0	30	40	superoxide	Chemical	D013481
11474137_0	65	74	kanamycin	Chemical	D007612
11474137_0	CID	D007612	D034381

11474137_1|s|The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.
11474137_1	71	82	ototoxicity	Disease	D006311
11474137_1	240	251	ototoxicity	Disease	D006311
11474137_1	30	36	oxygen	Chemical	D010100
11474137_1	48	62	aminoglycoside	Chemical	D000617
11474137_1	123	137	aminoglycoside	Chemical	D000617
11474137_1	138	142	iron	Chemical	D007501
11474137_1	179	189	superoxide	Chemical	D013481

11474137_2|s|We therefore hypothesized that overexpression of Cu/Zn-superoxide dismutase (h-SOD1) should protect transgenic mice from ototoxicity.
11474137_2	121	132	ototoxicity	Disease	D006311
11474137_2	49	51	Cu	Chemical	D003300
11474137_2	52	54	Zn	Chemical	D015032
11474137_2	55	65	superoxide	Chemical	D013481

11474137_9|s|The protection by overexpression of superoxide dismutase supports the hypothesis that oxidant stress plays a significant role in aminoglycoside-induced ototoxicity.
11474137_9	152	163	ototoxicity	Disease	D006311
11474137_9	36	46	superoxide	Chemical	D013481
11474137_9	129	143	aminoglycoside	Chemical	D000617

11708428_0|s|Prednisone induces anxiety and glial cerebral changes in rats.
11708428_0	19	26	anxiety	Disease	D001008
11708428_0	0	10	Prednisone	Chemical	D011241
11708428_0	CID	D011241	D001008

11708428_1|s|OBJECTIVE: To assess whether prednisone (PDN) produces anxiety and/or cerebral glial changes in rats.
11708428_1	55	62	anxiety	Disease	D001008
11708428_1	29	39	prednisone	Chemical	D011241
11708428_1	41	44	PDN	Chemical	D011241
11708428_1	CID	D011241	D001008

11708428_8|s|RESULTS: Anxiety was documented in both groups of PDN treated rats compared with controls.
11708428_8	9	16	Anxiety	Disease	D001008
11708428_8	50	53	PDN	Chemical	D011241
11708428_8	CID	D011241	D001008

11708428_12|s|CONCLUSION: Subacute exposure to PDN induced anxiety and reactivity of microglia.
11708428_12	45	52	anxiety	Disease	D001008
11708428_12	33	36	PDN	Chemical	D011241
11708428_12	CID	D011241	D001008

11745287_0|s|Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.
11745287_0	83	120	squamous cell carcinoma of the cervix	Disease	D002294|D002583
11745287_0	18	29	carboplatin	Chemical	D016190
11745287_0	44	55	doxorubicin	Chemical	D004317

11745287_1|s|BACKGROUND: The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma.
11745287_1	143	161	cervical carcinoma	Disease	D002583
11745287_1	47	58	carboplatin	Chemical	D016190
11745287_1	73	84	doxorubicin	Chemical	D004317

11745287_2|s|METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile.
11745287_2	222	254	squamous cell cervical carcinoma	Disease	D002294|D002583
11745287_2	291	299	toxicity	Disease	D064420
11745287_2	28	39	carboplatin	Chemical	D016190
11745287_2	100	111	doxorubicin	Chemical	D004317
11745287_2	113	118	Doxil	Chemical	D004317

11745287_8|s|CONCLUSIONS: The combination of carboplatin and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma.
11745287_8	117	135	cervical carcinoma	Disease	D002583
11745287_8	32	43	carboplatin	Chemical	D016190
11745287_8	58	69	doxorubicin	Chemical	D004317

11799346_7|s|Cotrimoxazole, metronidazole, and erythromycin were involved in 15 reported manic episodes.
11799346_7	76	81	manic	Disease	D001714
11799346_7	0	13	Cotrimoxazole	Chemical	D015662
11799346_7	15	28	metronidazole	Chemical	D008795
11799346_7	34	46	erythromycin	Chemical	D004917
11799346_7	CID	D015662	D001714
11799346_7	CID	D008795	D001714
11799346_7	CID	D004917	D001714

11799346_8|s|Cases reported by the FDA showed clarithromycin and ciprofloxacin to be the most frequently associated with the development of mania.
11799346_8	127	132	mania	Disease	D001714
11799346_8	33	47	clarithromycin	Chemical	D017291
11799346_8	52	65	ciprofloxacin	Chemical	D002939
11799346_8	CID	D002939	D001714
11799346_8	CID	D017291	D001714

11835460_0|s|Levodopa-induced ocular dyskinesias in Parkinson's disease.
11835460_0	17	35	ocular dyskinesias	Disease	D015835
11835460_0	39	58	Parkinson's disease	Disease	D010300
11835460_0	0	8	Levodopa	Chemical	D007980
11835460_0	CID	D007980	D015835

11835460_1|s|Levodopa-induced ocular dyskinesias are very uncommon.
11835460_1	17	35	ocular dyskinesias	Disease	D015835
11835460_1	0	8	Levodopa	Chemical	D007980
11835460_1	CID	D007980	D015835

11835460_3|s|We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce ocular dyskinesias.
11835460_3	235	253	ocular dyskinesias	Disease	D015835
11835460_3	93	101	levodopa	Chemical	D007980
11835460_3	219	227	levodopa	Chemical	D007980
11835460_3	CID	D007980	D015835

11915580_0|s|A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea: an open, randomized, cross-over trial.
11915580_0	81	93	dysmenorrhea	Disease	D004412
11915580_0	16	35	glyceryl trinitrate	Chemical	D005996
11915580_0	41	51	diclofenac	Chemical	D004008

11915580_1|s|Primary dysmenorrhea is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial prostaglandins; non-steroidal anti-inflammatory drugs are the first choice for its treatment.
11915580_1	8	20	dysmenorrhea	Disease	D004412
11915580_1	124	138	prostaglandins	Chemical	D011453

11915580_3|s|The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary dysmenorrhea in comparison with diclofenac (DCF).
11915580_3	131	143	dysmenorrhea	Disease	D004412
11915580_3	62	81	glyceryl trinitrate	Chemical	D005996
11915580_3	83	86	GTN	Chemical	D005996
11915580_3	92	94	NO	Chemical	D009569
11915580_3	163	173	diclofenac	Chemical	D004008
11915580_3	175	178	DCF	Chemical	D004008

11915580_11|s|However, DCF continued to be effective in reducing pelvic pain for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12.8 +/- 17.9; DFC, -18.9 +/- 16.6 and after two hours: GTN, -23.7 +/- 20.5; DFC, -59.7 +/- 17.9, p = 0.0001).
11915580_11	51	62	pelvic pain	Disease	D017699
11915580_11	9	12	DCF	Chemical	D004008
11915580_11	86	89	GTN	Chemical	D005996
11915580_11	200	203	GTN	Chemical	D005996
11915580_11	262	265	GTN	Chemical	D005996

11915580_13|s|Headache was significantly increased by GTN but not by DCF.
11915580_13	0	8	Headache	Disease	D006261
11915580_13	40	43	GTN	Chemical	D005996
11915580_13	55	58	DCF	Chemical	D004008
11915580_13	CID	D005996	D006261

11915580_14|s|Eight patients stopped using GTN because headache--attributed to its use--became intolerable.
11915580_14	41	49	headache	Disease	D006261
11915580_14	29	32	GTN	Chemical	D005996
11915580_14	CID	D005996	D006261

11915580_15|s|These findings indicate that GTN has a reduced efficacy and tolerability by comparison with DCF in the treatment of primary dysmenorrhea.
11915580_15	124	136	dysmenorrhea	Disease	D004412
11915580_15	29	32	GTN	Chemical	D005996
11915580_15	92	95	DCF	Chemical	D004008

11936424_0|s|Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
11936424_0	90	107	glomerular injury	Disease	D007674
11936424_0	145	154	nephrosis	Disease	D009401
11936424_0	0	10	Temocapril	Chemical	C055603
11936424_0	39	50	angiotensin	Chemical	D000809
11936424_0	119	144	puromycin aminonucleoside	Chemical	D011692
11936424_0	CID	D011692	D009401

11936424_1|s|The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.
11936424_1	178	189	proteinuria	Disease	D011507
11936424_1	212	223	hypertrophy	Disease	D006984
11936424_1	238	256	glomerulosclerosis	Disease	D005921
11936424_1	310	319	nephrotic	Disease	D009404
11936424_1	84	94	temocapril	Chemical	C055603
11936424_1	123	134	angiotensin	Chemical	D000809
11936424_1	268	293	puromycin aminonucleoside	Chemical	D011692
11936424_1	295	298	PAN	Chemical	D011692
11936424_1	CID	D011692	D011507

11936424_2|s|Nephrosis was induced by injection of PAN (15mg/100g body weight) in male Sprague-Dawley (SD) rats.
11936424_2	0	9	Nephrosis	Disease	D009401
11936424_2	38	41	PAN	Chemical	D011692
11936424_2	CID	D011692	D009401

11936424_8|s|Temocapril did not attenuate proteinuria at 8 days, but it did markedly lower it from weeks 4 to 20.
11936424_8	29	40	proteinuria	Disease	D011507
11936424_8	0	10	Temocapril	Chemical	C055603

11936424_9|s|The glomerulosclerosis index (GSI) was 6.21 % at 4 weeks and respectively 25.35 % and 30.49 % at 14 and 20 weeks in the PAN group.
11936424_9	4	22	glomerulosclerosis	Disease	D005921
11936424_9	120	123	PAN	Chemical	D011692

11936424_12|s|It appears that temocapril was effective in retarding renal progression and protected renal function in PAN neprotic rats.
11936424_12	108	116	neprotic	Disease	D009401
11936424_12	16	26	temocapril	Chemical	C055603
11936424_12	104	107	PAN	Chemical	D011692
11936424_12	CID	D011692	D009401

11988250_0|s|Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants.
11988250_0	0	22	Pulmonary hypertension	Disease	D006976
11988250_0	29	38	ibuprofen	Chemical	D007052
11988250_0	CID	D007052	D006976

11988250_1|s|We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation.
11988250_1	32	42	hypoxaemia	Disease	D000860
11988250_1	140	164	patent ductus arteriosus	Disease	D004374
11988250_1	49	58	ibuprofen	Chemical	D007052
11988250_1	170	179	ibuprofen	Chemical	D007052
11988250_1	CID	D007052	D000860

11988250_3|s|Hypoxaemia resolved quickly on inhaled nitric oxide therapy.
11988250_3	0	10	Hypoxaemia	Disease	D000860
11988250_3	39	51	nitric oxide	Chemical	D009569

11988250_4|s|We suggest that investigators involved in similar trials pay close attention to pulmonary pressure if hypoxaemia occurs after prophylactic administration of ibuprofen.
11988250_4	102	112	hypoxaemia	Disease	D000860
11988250_4	157	166	ibuprofen	Chemical	D007052
11988250_4	CID	D007052	D000860

12051122_0|s|Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine: an over-representation of Asians?
12051122_0	0	12	Hyponatremia	Disease	D007010
12051122_0	17	64	syndrome of inappropriate anti-diuretic hormone	Disease	D007177
12051122_0	90	101	Vincristine	Chemical	D014750
12051122_0	CID	D014750	D007177
12051122_0	CID	D014750	D007010

12051122_1|s|PURPOSE: This retrospective study used a pharmaceutical company's global safety database to determine the reporting rate of hyponatremia and/or syndrome of inappropriate secretion of anti-diuretic hormone (SIADH) among vincristine-treated patients and to explore the possibility of at-risk population subgroups.
12051122_1	124	136	hyponatremia	Disease	D007010
12051122_1	144	204	syndrome of inappropriate secretion of anti-diuretic hormone	Disease	D007177
12051122_1	206	211	SIADH	Disease	D007177
12051122_1	219	230	vincristine	Chemical	D014750
12051122_1	CID	D014750	D007177
12051122_1	CID	D014750	D007010

12051122_2|s|METHOD: We searched the Eli Lilly and Company's computerized adverse event database for all reported cases of hyponatremia and/or SIADH as of 1 November 1999 that had been reported during the use of vincristine.
12051122_2	110	122	hyponatremia	Disease	D007010
12051122_2	130	135	SIADH	Disease	D007177
12051122_2	199	210	vincristine	Chemical	D014750
12051122_2	CID	D014750	D007177
12051122_2	CID	D014750	D007010

12051122_3|s|RESULTS: A total of 76 cases of hyponatremia and/or SIADH associated with vincristine use were identified.
12051122_3	32	44	hyponatremia	Disease	D007010
12051122_3	52	57	SIADH	Disease	D007177
12051122_3	74	85	vincristine	Chemical	D014750
12051122_3	CID	D014750	D007177
12051122_3	CID	D014750	D007010

12051122_8|s|CONCLUSION: Our data suggest that Asian patients may be at increased risk of hyponatremia and/or SIADH associated with vincristine use.
12051122_8	77	89	hyponatremia	Disease	D007010
12051122_8	97	102	SIADH	Disease	D007177
12051122_8	119	130	vincristine	Chemical	D014750
12051122_8	CID	D014750	D007177
12051122_8	CID	D014750	D007010

12051122_9|s|Although the overall reported rate of SIADH associated with vincristine is very low, physicians caring for Asian oncology patients should be aware of this potential serious but reversible adverse event.
12051122_9	38	43	SIADH	Disease	D007177
12051122_9	60	71	vincristine	Chemical	D014750
12051122_9	CID	D014750	D007177

12059909_0|s|Delayed toxicity of cyclophosphamide on the bladder of DBA/2 and C57BL/6 female mouse.
12059909_0	8	16	toxicity	Disease	D064420
12059909_0	20	36	cyclophosphamide	Chemical	D003520

12059909_3|s|Early CY toxicity caused a typical haemorrhagic cystitis in both strains that was completely repaired in about 7-10 days.
12059909_3	9	17	toxicity	Disease	D064420
12059909_3	35	47	haemorrhagic	Disease	D006470
12059909_3	48	56	cystitis	Disease	D003556
12059909_3	6	8	CY	Chemical	D003520
12059909_3	CID	D003520	D006470
12059909_3	CID	D003520	D003556

12059909_4|s|After 30 days of CY injection ulcerous and non-ulcerous forms of chronic cystitis appeared in 86% of DBA/2 mice but only in 4% of C57BL/6 mice.
12059909_4	73	81	cystitis	Disease	D003556
12059909_4	17	19	CY	Chemical	D003520
12059909_4	CID	D003520	D003556

12059909_10|s|These results indicate that delayed toxicity of CY in female DBA/2 mice causes a bladder pathology that is not observed in C57BL/6 mice.
12059909_10	36	44	toxicity	Disease	D064420
12059909_10	48	50	CY	Chemical	D003520

12119460_0|s|High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer.
12119460_0	114	128	gastric cancer	Disease	D013274
12119460_0	10	24	5-fluorouracil	Chemical	D005472
12119460_0	27	39	folinic acid	Chemical	D002955
12119460_0	73	84	mitomycin C	Chemical	D016685

12119460_2|s|BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.
12119460_2	158	172	gastric cancer	Disease	D013274
12119460_2	174	177	AGC	Disease	D013274
12119460_2	215	223	toxicity	Disease	D064420
12119460_2	47	61	5-fluorouracil	Chemical	D005472
12119460_2	63	67	5-FU	Chemical	D005472
12119460_2	73	85	folinic acid	Chemical	D002955
12119460_2	87	89	FA	Chemical	D002955

12119460_3|s|In a previous phase II study with 3-weekly bolus 5-FU, FA and mitomycin C (MMC) we found a low toxicity rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.
12119460_3	95	103	toxicity	Disease	D064420
12119460_3	49	53	5-FU	Chemical	D005472
12119460_3	55	57	FA	Chemical	D002955
12119460_3	62	73	mitomycin C	Chemical	D016685
12119460_3	75	78	MMC	Chemical	D016685

12119460_5|s|PATIENTS AND METHODS: From February, 1998 to September, 2000 we recruited 33 patients with AGC to receive weekly 24-hour 5-FU 2,600 mg/m(2) preceded by 2-hour FA 500 mg/m(2) for 6 weeks, followed by a 2-week rest period.
12119460_5	91	94	AGC	Disease	D013274
12119460_5	121	125	5-FU	Chemical	D005472
12119460_5	159	161	FA	Chemical	D002955

12119460_14|s|CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%).
12119460_14	93	96	AGC	Disease	D013274
12119460_14	23	27	5-FU	Chemical	D005472
12119460_14	28	30	FA	Chemical	D002955
12119460_14	31	34	MMC	Chemical	D016685

12119460_15|s|It may serve as an alternative to cisplatin-containing regimens; however, it has to be considered that possibly HUS may occur.
12119460_15	112	115	HUS	Disease	D006463
12119460_15	34	43	cisplatin	Chemical	D002945

12165618_0|s|Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir.
12165618_0	19	31	leukocyturia	Disease	-1
12165618_0	51	74	impaired renal function	Disease	D007674
12165618_0	78	122	human immunodeficiency virus type 1-infected	Disease	D015658
12165618_0	145	154	indinavir	Chemical	D019469
12165618_0	CID	D019469	D007674

12165618_3|s|DESIGN: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir.
12165618_3	57	71	nephrotoxicity	Disease	D007674
12165618_3	90	134	human immunodeficiency virus type 1-infected	Disease	D015658
12165618_3	39	48	indinavir	Chemical	D019469
12165618_3	157	166	indinavir	Chemical	D019469
12165618_3	CID	D019469	D007674

12165618_8|s|Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin/creatinine ratio and by microscopic hematuria.
12165618_8	19	31	leukocyturia	Disease	-1
12165618_8	136	145	hematuria	Disease	D006417
12165618_8	100	110	creatinine	Chemical	D003404

12165618_10|s|Children with persistent sterile leukocyturia more frequently had serum creatinine levels of 50% above normal than those children without persistent sterile leukocyturia.
12165618_10	33	45	leukocyturia	Disease	-1
12165618_10	157	169	leukocyturia	Disease	-1
12165618_10	72	82	creatinine	Chemical	D003404

12165618_12|s|A higher cumulative incidence of persistent leukocyturia was found in children with an area under the curve >19 mg/L x h or a peak serum level of indinavir >12 mg/L.
12165618_12	44	56	leukocyturia	Disease	-1
12165618_12	146	155	indinavir	Chemical	D019469

12165618_13|s|In 4 children, indinavir was discontinued because of nephrotoxicity.
12165618_13	53	67	nephrotoxicity	Disease	D007674
12165618_13	15	24	indinavir	Chemical	D019469
12165618_13	CID	D019469	D007674

12165618_14|s|Subsequently, the serum creatinine levels decreased, the urine albumin/creatinine ratios returned to zero, and the leukocyturia disappeared within 3 months.
12165618_14	115	127	leukocyturia	Disease	-1
12165618_14	24	34	creatinine	Chemical	D003404
12165618_14	71	81	creatinine	Chemical	D003404

12165618_15|s|CONCLUSIONS: Children treated with indinavir have a high cumulative incidence of persistent sterile leukocyturia.
12165618_15	100	112	leukocyturia	Disease	-1
12165618_15	35	44	indinavir	Chemical	D019469

12165618_16|s|Children with persistent sterile leukocyturia more frequently had an increase in serum creatinine levels of >50% above normal.
12165618_16	33	45	leukocyturia	Disease	-1
12165618_16	87	97	creatinine	Chemical	D003404

12165618_19|s|Indinavir-associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5.6 years, an area under the curve of indinavir >19 mg/L x h, and a C(max) >12 mg/L.
12165618_19	21	35	nephrotoxicity	Disease	D007674
12165618_19	131	143	leukocyturia	Disease	-1
12165618_19	0	9	Indinavir	Chemical	D019469
12165618_19	188	197	indinavir	Chemical	D019469
12165618_19	CID	D019469	D007674

12359538_0|s|Utility of troponin I in patients with cocaine-associated chest pain.
12359538_0	58	68	chest pain	Disease	D002637
12359538_0	39	46	cocaine	Chemical	D003042

12359538_1|s|Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with cocaine-associated chest pain.
12359538_1	83	102	myocardial necrosis	Disease	D009202
12359538_1	130	151	myocardial infarction	Disease	D009203
12359538_1	153	155	MI	Disease	D009203
12359538_1	203	213	chest pain	Disease	D002637
12359538_1	184	191	cocaine	Chemical	D003042
12359538_1	CID	D003042	D009203

12359538_3|s|OBJECTIVE: To assess outcomes based on troponin positivity in patients with cocaine chest pain admitted for exclusion of MI.
12359538_3	84	94	chest pain	Disease	D002637
12359538_3	121	123	MI	Disease	D009203
12359538_3	76	83	cocaine	Chemical	D003042
12359538_3	CID	D003042	D009203

12359538_4|s|METHODS: Outcomes were examined in patients admitted for possible MI after cocaine use.
12359538_4	66	68	MI	Disease	D009203
12359538_4	75	82	cocaine	Chemical	D003042
12359538_4	CID	D003042	D009203

12359538_12|s|Troponin appears to have an equivalent diagnostic accuracy compared with CK-MB for diagnosing necrosis in patients with cocaine-associated chest pain and suspected MI.
12359538_12	94	102	necrosis	Disease	D009336
12359538_12	139	149	chest pain	Disease	D002637
12359538_12	164	166	MI	Disease	D009203
12359538_12	120	127	cocaine	Chemical	D003042
12359538_12	CID	D003042	D009203

12372954_0|s|Acute interstitial nephritis due to nicergoline (Sermion).
12372954_0	6	28	interstitial nephritis	Disease	D009395
12372954_0	36	47	nicergoline	Chemical	D009530
12372954_0	49	56	Sermion	Chemical	D009530
12372954_0	CID	D009530	D009395

12372954_1|s|We report a case of acute interstitial nephritis (AIN) due to nicergoline (Sermion).
12372954_1	26	48	interstitial nephritis	Disease	D009395
12372954_1	50	53	AIN	Disease	D009395
12372954_1	62	73	nicergoline	Chemical	D009530
12372954_1	75	82	Sermion	Chemical	D009530
12372954_1	CID	D009530	D009395

12372954_3|s|Before admission, he had been taking nicergoline and bendazac lysine due to retinal vein occlusion at ophthalmologic department.
12372954_3	76	98	retinal vein occlusion	Disease	D012170
12372954_3	37	48	nicergoline	Chemical	D009530
12372954_3	53	68	bendazac lysine	Chemical	C036067

12372954_8|s|To our knowledge, this is the first report of nicergoline-associated AIN.
12372954_8	69	72	AIN	Disease	D009395
12372954_8	46	57	nicergoline	Chemical	D009530
12372954_8	CID	D009530	D009395

12452552_1|s|A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.
12452552_1	15	36	chronic renal failure	Disease	D007676
12452552_1	38	41	CRF	Disease	D007676
12452552_1	53	83	neuroleptic malignant syndrome	Disease	D009459
12452552_1	85	88	NMS	Disease	D009459
12452552_1	114	125	risperidone	Chemical	D018967
12452552_1	130	145	levomepromazine	Chemical	D008728
12452552_1	CID	D018967	D009459
12452552_1	CID	D008728	D009459

12487093_3|s|Adrenaline-induced hypertension was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s.
12487093_3	19	31	hypertension	Disease	D006973
12487093_3	0	10	Adrenaline	Chemical	D004837
12487093_3	87	107	triphenyltetrazolium	Chemical	C009591
12487093_3	109	112	TTC	Chemical	C009591
12487093_3	161	171	adrenaline	Chemical	D004837
12487093_3	CID	D004837	D006973

12498738_0|s|Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.
12498738_0	62	76	cardiomyopathy	Disease	D009202
12498738_0	0	10	Carvedilol	Chemical	C043211
12498738_0	28	39	doxorubicin	Chemical	D004317
12498738_0	CID	D004317	D009202

12498738_1|s|Several cytopathic mechanisms have been suggested to mediate the dose-limiting cumulative and irreversible cardiomyopathy caused by doxorubicin.
12498738_1	107	121	cardiomyopathy	Disease	D009202
12498738_1	132	143	doxorubicin	Chemical	D004317
12498738_1	CID	D004317	D009202

12498738_3|s|The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin toxicity.
12498738_3	286	294	toxicity	Disease	D064420
12498738_3	68	78	carvedilol	Chemical	C043211
12498738_3	274	285	doxorubicin	Chemical	D004317

12498738_11|s|It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.
12498738_11	190	215	mitochondrial dysfunction	Disease	D028361
12498738_11	220	234	cardiomyopathy	Disease	D009202
12498738_11	285	291	cancer	Disease	D009369
12498738_11	40	50	carvedilol	Chemical	C043211
12498738_11	262	273	doxorubicin	Chemical	D004317
12498738_11	CID	D004317	D009202

12523489_0|s|Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.
12523489_0	16	29	hyperactivity	Disease	D006948
12523489_0	105	118	hyperactivity	Disease	D006948
12523489_0	0	7	Cocaine	Chemical	D003042
12523489_0	52	61	adenosine	Chemical	D000241
12523489_0	85	96	amphetamine	Chemical	D000661

12523489_1|s|The influence of adenosine receptor agonists and antagonists on cocaine-and amphetamine-induced hyperactivity was examined in mice.
12523489_1	96	109	hyperactivity	Disease	D006948
12523489_1	17	26	adenosine	Chemical	D000241
12523489_1	64	71	cocaine	Chemical	D003042
12523489_1	76	87	amphetamine	Chemical	D000661

12523489_2|s|All adenosine receptor agonists significantly decreased the locomotor activity in mice, and the effects were dose-dependent.
12523489_2	46	78	decreased the locomotor activity	Disease	D004409
12523489_2	4	13	adenosine	Chemical	D000241

12523489_10|s|Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced hyperactivity.
12523489_10	73	86	hyperactivity	Disease	D006948
12523489_10	160	173	hyperactivity	Disease	D006948
12523489_10	15	24	adenosine	Chemical	D000241
12523489_10	53	64	amphetamine	Chemical	D000661
12523489_10	144	151	cocaine	Chemical	D003042

12523489_12|s|Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.
12523489_12	165	178	hyperactivity	Disease	D006948
12523489_12	282	295	hyperactivity	Disease	D006948
12523489_12	32	41	adenosine	Chemical	D000241
12523489_12	79	86	cocaine	Chemical	D003042
12523489_12	92	103	amphetamine	Chemical	D000661
12523489_12	149	156	cocaine	Chemical	D003042
12523489_12	201	210	adenosine	Chemical	D000241
12523489_12	262	273	amphetamine	Chemical	D000661

12535818_0|s|Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction.
12535818_0	27	42	bradyarrhythmia	Disease	D001919
12535818_0	98	117	atrial fibrillation	Disease	D001281
12535818_0	128	149	myocardial infarction	Disease	D009203
12535818_0	0	10	Amiodarone	Chemical	D000638
12535818_0	CID	D000638	D001919

12535818_1|s|OBJECTIVES: The aim of this study was to determine whether the use of amiodarone in patients with atrial fibrillation (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker.
12535818_1	98	117	atrial fibrillation	Disease	D001281
12535818_1	119	121	AF	Disease	D001281
12535818_1	145	160	bradyarrhythmia	Disease	D001919
12535818_1	70	80	amiodarone	Chemical	D000638
12535818_1	CID	D000638	D001919

12535818_2|s|BACKGROUND: Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ventricular arrhythmias.
12535818_2	30	45	bradyarrhythmia	Disease	D001919
12535818_2	173	196	ventricular arrhythmias	Disease	D001145
12535818_2	53	63	amiodarone	Chemical	D000638
12535818_2	CID	D000638	D001919

12535818_10|s|CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with AF and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker.
12535818_10	85	87	AF	Disease	D001281
12535818_10	103	105	MI	Disease	D009203
12535818_10	128	143	bradyarrhythmia	Disease	D001919
12535818_10	49	59	amiodarone	Chemical	D000638
12535818_10	CID	D000638	D001919

12559315_9|s|CONCLUSIONS: Indomethacin resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal mastocytosis.
12559315_9	74	95	interstitial cystitis	Disease	D018856
12559315_9	142	154	mastocytosis	Disease	D008415
12559315_9	13	25	Indomethacin	Chemical	D007213
12559315_9	CID	D007213	D008415
12559315_9	CID	D007213	D018856

12644816_0|s|An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.
12644816_0	77	92	prostate cancer	Disease	D011471
12644816_0	41	52	thalidomide	Chemical	D013792
12644816_0	56	64	androgen	Chemical	D000728

12644816_1|s|The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and haematological malignancies.
12644816_1	115	142	haematological malignancies	Disease	D019337
12644816_1	30	41	thalidomide	Chemical	D013792

12644816_3|s|We undertook an open-label study using thalidomide 100 mg once daily for up to 6 months in 20 men with androgen-independent prostate cancer.
12644816_3	124	139	prostate cancer	Disease	D011471
12644816_3	39	50	thalidomide	Chemical	D013792
12644816_3	103	111	androgen	Chemical	D000728

12644816_11|s|In the seven men who completed six months on thalidomide, subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing.
12644816_11	82	103	peripheral neuropathy	Disease	D010523
12644816_11	45	56	thalidomide	Chemical	D013792
12644816_11	CID	D013792	D010523

12644816_12|s|The findings indicate that thalidomide may be an option for patients who have failed other forms of therapy, provided close follow-up is maintained for development of peripheral neuropathy.
12644816_12	167	188	peripheral neuropathy	Disease	D010523
12644816_12	27	38	thalidomide	Chemical	D013792
12644816_12	CID	D013792	D010523

12677626_0|s|Central nervous system toxicity following the administration of levobupivacaine for lumbar plexus block: A report of two cases.
12677626_0	0	31	Central nervous system toxicity	Disease	D020258
12677626_0	64	79	levobupivacaine	Chemical	C476513

12677626_3|s|We describe 2 cases of grand mal seizures following accidental intravascular injection of levobupivacaine.
12677626_3	23	41	grand mal seizures	Disease	D004830
12677626_3	90	105	levobupivacaine	Chemical	C476513
12677626_3	CID	C476513	D004830

12677626_5|s|Immediately after the administration of levobupivacaine 0.5% with epinephrine 2.5 microgram/mL, the patients developed grand mal seizures, despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration.
12677626_5	119	137	grand mal seizures	Disease	D004830
12677626_5	40	55	levobupivacaine	Chemical	C476513
12677626_5	66	77	epinephrine	Chemical	D004837
12677626_5	214	225	epinephrine	Chemical	D004837
12677626_5	CID	C476513	D004830

12677626_6|s|The seizures were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient.
12677626_6	4	12	seizures	Disease	D012640
12677626_6	44	61	sodium thiopental	Chemical	D013874
12677626_6	77	92	succinylcholine	Chemical	D013390

12677626_9|s|CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.
12677626_9	55	71	cardiac toxicity	Disease	D066126
12677626_9	186	197	convulsions	Disease	D012640
12677626_9	22	37	levobupivacaine	Chemical	C476513
12677626_9	93	104	bupivacaine	Chemical	D002045
12677626_9	129	144	levobupivacaine	Chemical	C476513

12699527_1|s|Myotonia congenita (MC) is caused by a defect in the skeletal muscle chloride channel function, which may cause sustained membrane depolarisation.
12699527_1	0	18	Myotonia congenita	Disease	D009224
12699527_1	20	22	MC	Disease	D009224
12699527_1	112	145	sustained membrane depolarisation	Disease	-1
12699527_1	69	77	chloride	Chemical	D002712

12699527_2|s|We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of suxamethonium.
12699527_2	84	96	muscle spasm	Disease	D013035
12699527_2	174	187	suxamethonium	Chemical	D013390
12699527_2	CID	D013390	D013035

12752472_3|s|Here we sought to generate information with regard to the interictal period in animals with pilocarpine-induced epilepsy.
12752472_3	112	120	epilepsy	Disease	D004827
12752472_3	92	103	pilocarpine	Chemical	D010862
12752472_3	CID	D010862	D004827

12752472_7|s|RESULTS: The hyperventilation maneuver caused a decrease in spontaneous ventilation in pilocarpine-treated and control rats.
12752472_7	13	29	hyperventilation	Disease	D006985
12752472_7	87	98	pilocarpine	Chemical	D010862

12828076_0|s|Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose.
12828076_0	45	64	acute liver failure	Disease	D017114
12828076_0	84	92	overdose	Disease	D062787
12828076_0	72	83	paracetamol	Chemical	D000082
12828076_0	CID	D000082	D017114

12828076_6|s|Levels were significantly greater in patients with acute liver failure due to paracetamol overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01).
12828076_6	51	70	acute liver failure	Disease	D017114
12828076_6	90	98	overdose	Disease	D062787
12828076_6	179	188	hepatitis	Disease	D056486
12828076_6	78	89	paracetamol	Chemical	D000082
12828076_6	CID	D000082	D017114

12865514_3|s|METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and levodopa-induced dyskinesias underwent bilateral implantation of electrodes in the STN.
12865514_3	52	71	Parkinson's disease	Disease	D010300
12865514_3	129	141	bradykinesia	Disease	D018476
12865514_3	143	151	rigidity	Disease	D009127
12865514_3	174	185	dyskinesias	Disease	D004409
12865514_3	157	165	levodopa	Chemical	D007980
12865514_3	CID	D007980	D004409

12865514_13|s|The reduction in the levodopa dose is useful in controlling drug-induced dyskinesias.
12865514_13	60	84	drug-induced dyskinesias	Disease	D004409
12865514_13	21	29	levodopa	Chemical	D007980
12865514_13	CID	D007980	D004409

12912689_0|s|Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma.
12912689_0	68	82	retinoblastoma	Disease	D012175
12912689_0	39	50	carboplatin	Chemical	D016190

12912689_1|s|BACKGROUND: Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma.
12912689_1	90	98	toxicity	Disease	D064420
12912689_1	153	167	retinoblastoma	Disease	D012175
12912689_1	27	38	carboplatin	Chemical	D016190

12912689_2|s|OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.
12912689_2	50	74	abnormal ocular motility	Disease	D015835
12912689_2	109	120	carboplatin	Chemical	D016190
12912689_2	CID	D016190	D015835

12912689_3|s|METHODS: We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin.
12912689_3	18	42	abnormal ocular motility	Disease	D015835
12912689_3	75	89	retinoblastoma	Disease	D012175
12912689_3	116	127	carboplatin	Chemical	D016190
12912689_3	CID	D016190	D015835

12912689_6|s|RESULTS: Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy.
12912689_6	106	120	retinoblastoma	Disease	D012175
12912689_6	156	167	carboplatin	Chemical	D016190

12912689_9|s|CONCLUSIONS: Subtenon carboplatin chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult.
12912689_9	78	86	fibrosis	Disease	D005355
12912689_9	22	33	carboplatin	Chemical	D016190
12912689_9	CID	D016190	D005355

12912689_10|s|Subtenon carboplatin is not free of toxicity, and its use is best restricted to specific indications.
12912689_10	36	44	toxicity	Disease	D064420
12912689_10	9	20	carboplatin	Chemical	D016190

12948256_0|s|Ethambutol and optic neuropathy.
12948256_0	15	31	optic neuropathy	Disease	D009901
12948256_0	0	10	Ethambutol	Chemical	D004977
12948256_0	CID	D004977	D009901

12948256_1|s|PURPOSE: To demonstrate the association between ethambutol and optic neuropathy.
12948256_1	63	79	optic neuropathy	Disease	D009901
12948256_1	48	58	ethambutol	Chemical	D004977
12948256_1	CID	D004977	D009901

12948256_2|s|METHOD: Thirteen patients who developed optic neuropathy after being treated with ethambutol for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed.
12948256_2	40	56	optic neuropathy	Disease	D009901
12948256_2	97	135	tuberculosis of the lung or lymph node	Disease	D014397|D014388
12948256_2	82	92	ethambutol	Chemical	D004977
12948256_2	CID	D004977	D009901

12948256_4|s|RESULTS: All patients had optic neuropathy between 1 to 6 months (mean = 2.9 months) after starting ethambutol therapy at a dosage ranging from 13 to 20 mg/kg/day (mean = 17 mg/kg/day).
12948256_4	26	42	optic neuropathy	Disease	D009901
12948256_4	100	110	ethambutol	Chemical	D004977
12948256_4	CID	D004977	D009901

12948256_7|s|CONCLUSION: Early recognition of optic neuropathy should be considered in patients with ethambutol therapy.
12948256_7	33	49	optic neuropathy	Disease	D009901
12948256_7	88	98	ethambutol	Chemical	D004977
12948256_7	CID	D004977	D009901

12950111_0|s|Treatment of compensatory gustatory hyperhidrosis with topical glycopyrrolate.
12950111_0	26	49	gustatory hyperhidrosis	Disease	D013547
12950111_0	63	77	glycopyrrolate	Chemical	D006024

12950111_5|s|After applying topical glycopyrrolate, the subjective effect was excellent (no sweating after eating hot spicy food) in 10 patients (77%), and fair (clearly reduced sweating) in 3 patients (23%).
12950111_5	79	87	sweating	Disease	D013547
12950111_5	165	173	sweating	Disease	D013547
12950111_5	23	37	glycopyrrolate	Chemical	D006024

12950111_7|s|Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% glycopyrrolate).
12950111_7	34	43	dry mouth	Disease	D014987
12950111_7	50	61	sore throat	Disease	D010612
12950111_7	105	113	headache	Disease	D006261
12950111_7	80	94	glycopyrrolate	Chemical	D006024
12950111_7	133	147	glycopyrrolate	Chemical	D006024
12950111_7	CID	D006024	D006261
12950111_7	CID	D006024	D010612

12950111_8|s|The topical application of a glycopyrrolate pad appeared to be safe, efficacious, well tolerated, and a convenient method of treatment for moderate to severe symptoms of gustatory hyperhidrosis in post transthoracic endoscopic sympathectomy or sympathicotomy patients, with few side effects.
12950111_8	170	193	gustatory hyperhidrosis	Disease	D013547
12950111_8	29	43	glycopyrrolate	Chemical	D006024

14616590_9|s|Pain on injection (80 vs. 20%, p < 0.01) and thrombophlebitis (93.3 vs. 6.6%, p < 0.001) occurred more frequently with AM149 than with Disoprivan.
14616590_9	0	4	Pain	Disease	D010146
14616590_9	45	61	thrombophlebitis	Disease	D013924
14616590_9	135	145	Disoprivan	Chemical	D015742
14616590_9	CID	D015742	D013924
14616590_9	CID	D015742	D010146

14748761_2|s|In order to quantify the incidence of these cardiac events, we performed a meta-analysis of clinical trials comparing VNR with other chemotherapeutic agents in the treatment of various malignancies.
14748761_2	185	197	malignancies	Disease	D009369
14748761_2	118	121	VNR	Chemical	C030852

14748761_3|s|Randomized clinical trials comparing VNR with other drugs in the treatment of cancer were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002.
14748761_3	78	84	cancer	Disease	D009369
14748761_3	37	40	VNR	Chemical	C030852

14748761_8|s|The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].
14748761_8	72	83	cardiotoxic	Disease	D066126
14748761_8	12	15	VNR	Chemical	C030852
14748761_8	46	55	vindesine	Chemical	D014751
14748761_8	57	60	VDS	Chemical	D014751
14748761_8	91	103	fluorouracil	Chemical	D005472
14748761_8	105	119	anthracyclines	Chemical	D018943
14748761_8	121	132	gemcitabine	Chemical	C056507
14748761_8	134	137	GEM	Chemical	C056507
14748761_8	CID	C030852	D066126

15018178_1|s|We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by trimethoprim-sulfomethoxazole, resulting in cerebral anoxia leading to permanent damage.
15018178_1	97	113	hemolytic anemia	Disease	D000743
15018178_1	176	191	cerebral anoxia	Disease	D002534
15018178_1	132	161	trimethoprim-sulfomethoxazole	Chemical	D015662
15018178_1	CID	D015662	D000743

15094729_0|s|The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.
15094729_0	45	65	visual field defects	Disease	D014786
15094729_0	23	33	Vigabatrin	Chemical	D020888
15094729_0	CID	D020888	D014786

15094729_1|s|PURPOSE: To determine the natural history of visual field defects in a group of patients known to have Vigabatrin-associated changes who elected to continue the medication because of good seizure control.
15094729_1	45	65	visual field defects	Disease	D014786
15094729_1	188	195	seizure	Disease	D012640
15094729_1	103	113	Vigabatrin	Chemical	D020888
15094729_1	CID	D020888	D014786

15094729_8|s|CONCLUSION: Established visual field defects presumed to be due to Vigabatrin therapy did not usually progress in spite of continuing use of the medication.
15094729_8	24	44	visual field defects	Disease	D014786
15094729_8	67	77	Vigabatrin	Chemical	D020888
15094729_8	CID	D020888	D014786

15094729_9|s|These data give support to the hypothesis that the pathogenesis of Vigabatrin-associated visual field defects may be an idiosyncratic adverse drug reaction rather than dose-dependent toxicity.
15094729_9	89	109	visual field defects	Disease	D014786
15094729_9	183	191	toxicity	Disease	D064420
15094729_9	67	77	Vigabatrin	Chemical	D020888
15094729_9	CID	D020888	D014786

15096374_0|s|Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment.
15096374_0	25	35	dermatitis	Disease	D003872
15096374_0	56	86	facial inflammatory dermatoses	Disease	D005148
15096374_0	92	102	tacrolimus	Chemical	D016559

15096374_1|s|BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis.
15096374_1	209	216	rosacea	Disease	D012393
15096374_1	221	240	perioral dermatitis	Disease	D019557
15096374_1	12	22	Tacrolimus	Chemical	D016559
15096374_1	190	197	steroid	Chemical	D013256
15096374_1	CID	D016559	D012393

15096374_2|s|We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment.
15096374_2	25	35	dermatitis	Disease	D003872
15096374_2	72	82	tacrolimus	Chemical	D016559

15096374_3|s|OBSERVATIONS: Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments.
15096374_3	38	68	inflammatory facial dermatoses	Disease	D005148
15096374_3	87	97	tacrolimus	Chemical	D016559

15096374_8|s|CONCLUSIONS: Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with tacrolimus ointment is heterogeneous.
15096374_8	71	81	dermatitis	Disease	D003872
15096374_8	118	128	tacrolimus	Chemical	D016559

15229250_1|s|We visualize, for the first time, the profile of structural deficits in the human brain associated with chronic methamphetamine (MA) abuse.
15229250_1	49	87	structural deficits in the human brain	Disease	D001930
15229250_1	112	127	methamphetamine	Chemical	D008694
15229250_1	129	131	MA	Chemical	D008694
15229250_1	CID	D008694	D001930

15229250_2|s|Studies of human subjects who have used MA chronically have revealed deficits in dopaminergic and serotonergic systems and cerebral metabolic abnormalities.
15229250_2	132	155	metabolic abnormalities	Disease	D008659
15229250_2	40	42	MA	Chemical	D008694

15229250_3|s|Using magnetic resonance imaging (MRI) and new computational brain-mapping techniques, we determined the pattern of structural brain alterations associated with chronic MA abuse in human subjects and related these deficits to cognitive impairment.
15229250_3	226	246	cognitive impairment	Disease	D003072
15229250_3	169	171	MA	Chemical	D008694

15229250_4|s|We used high-resolution MRI and surface-based computational image analyses to map regional abnormalities in the cortex, hippocampus, white matter, and ventricles in 22 human subjects who used MA and 21 age-matched, healthy controls.
15229250_4	91	161	abnormalities in the cortex, hippocampus, white matter, and ventricles	Disease	D001930
15229250_4	192	194	MA	Chemical	D008694
15229250_4	CID	D008694	D001930

15229250_6|s|On average, MA abusers had 7.8% smaller hippocampal volumes than control subjects (p < 0.01; left, p = 0.01; right, p < 0.05) and significant white-matter hypertrophy (7.0%; p < 0.01).
15229250_6	155	166	hypertrophy	Disease	D006984
15229250_6	12	14	MA	Chemical	D008694

15229250_8|s|MRI-based maps suggest that chronic methamphetamine abuse causes a selective pattern of cerebral deterioration that contributes to impaired memory performance.
15229250_8	131	158	impaired memory performance	Disease	D008569
15229250_8	36	51	methamphetamine	Chemical	D008694
15229250_8	CID	D008694	D008569

15229250_11|s|These brain substrates may help account for the symptoms of MA abuse, providing therapeutic targets for drug-induced brain injury.
15229250_11	117	129	brain injury	Disease	D001930
15229250_11	60	62	MA	Chemical	D008694
15229250_11	CID	D008694	D001930

15265979_1|s|Amiodarone, an efficacious and widely used antiarrhythmic agent, has been reported to cause hepatotoxicity in some patients.
15265979_1	92	106	hepatotoxicity	Disease	D056486
15265979_1	0	10	Amiodarone	Chemical	D000638
15265979_1	CID	D000638	D056486

15265979_3|s|Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose.
15265979_3	19	31	hepatomegaly	Disease	D006529
15265979_3	0	10	Amiodarone	Chemical	D000638
15265979_3	115	128	triglycerides	Chemical	D014280
15265979_3	133	140	glucose	Chemical	D005947
15265979_3	CID	D000638	D006529

15265979_6|s|The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene.
15265979_6	51	63	hepatomegaly	Disease	D006529
15265979_6	136	146	amiodarone	Chemical	D000638
15265979_6	CID	D000638	D006529

15265979_7|s|Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body weight loss.
15265979_7	130	141	weight loss	Disease	D015431
15265979_7	64	74	amiodarone	Chemical	D000638

15265979_8|s|The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 hepatoma cells indicates that the effects of amiodarone on the function of this receptor were indirect.
15265979_8	118	126	hepatoma	Disease	D006528
15265979_8	17	27	amiodarone	Chemical	D000638
15265979_8	163	173	amiodarone	Chemical	D000638

15265979_10|s|These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against amiodarone-induced hepatotoxicity.
15265979_10	74	85	hepatotoxic	Disease	D056486
15265979_10	172	186	hepatotoxicity	Disease	D056486
15265979_10	97	107	amiodarone	Chemical	D000638
15265979_10	153	163	amiodarone	Chemical	D000638
15265979_10	CID	D000638	D056486

15276093_1|s|Niacin extended-release/lovastatin is a new combination product approved for treatment of primary hypercholesterolemia and mixed dyslipidemia.
15276093_1	98	118	hypercholesterolemia	Disease	D006937
15276093_1	129	141	dyslipidemia	Disease	D050171
15276093_1	0	34	Niacin extended-release/lovastatin	Chemical	C451780

15276093_5|s|Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about dyslipidemia and niacin extended-release/lovastatin.
15276093_5	145	157	dyslipidemia	Disease	D050171
15276093_5	162	196	niacin extended-release/lovastatin	Chemical	C451780

15276093_12|s|An increase of creatine phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced myopathy were observed.
15276093_12	136	144	myopathy	Disease	D009135
15276093_12	15	23	creatine	Chemical	D003401

15282950_0|s|Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol.
15282950_0	61	78	myocardial injury	Disease	D009202
15282950_0	21	39	Terminalia chebula	Chemical	D010936
15282950_0	90	103	isoproterenol	Chemical	D007545
15282950_0	CID	D007545	D009202

15282950_1|s|Cardioprotective effect of ethanolic extract of Terminalia chebula fruits (500 mg/kg body wt) was examined in isoproterenol (200 mg/kg body wt) induced myocardial damage in rats.
15282950_1	152	169	myocardial damage	Disease	D009202
15282950_1	27	73	ethanolic extract of Terminalia chebula fruits	Chemical	D010936
15282950_1	110	123	isoproterenol	Chemical	D007545
15282950_1	CID	D007545	D009202

15321332_0|s|A case of postoperative anxiety due to low dose droperidol used with patient-controlled analgesia.
15321332_0	24	31	anxiety	Disease	D001008
15321332_0	48	58	droperidol	Chemical	D004329
15321332_0	CID	D004329	D001008

15321332_4|s|The diagnosis of droperidol-induced psychological disturbance was not made straight away although on subsequent close questioning the patient gave a very clear history.
15321332_4	36	61	psychological disturbance	Disease	D001008
15321332_4	17	27	droperidol	Chemical	D004329
15321332_4	CID	D004329	D001008

15366550_3|s|The nursing staff, by reviewing the patient's health history with his family, discovered a history of polydipsia and long-standing lithium use.
15366550_3	102	112	polydipsia	Disease	D059606
15366550_3	131	138	lithium	Chemical	D008094

15366550_4|s|Lithium is implicated in drug-induced nephrogenic DI, and because the patient had not received lithium since being admitted to the hospital, his treatment changed to focus on nephrogenic DI.
15366550_4	38	52	nephrogenic DI	Disease	D018500
15366550_4	175	189	nephrogenic DI	Disease	D018500
15366550_4	0	7	Lithium	Chemical	D008094
15366550_4	95	102	lithium	Chemical	D008094
15366550_4	CID	D008094	D018500

15366550_5|s|By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his lithium-induced nephrogenic DI and developed neurogenic DI secondary to brain trauma.
15366550_5	212	226	nephrogenic DI	Disease	D018500
15366550_5	241	254	neurogenic DI	Disease	D018500
15366550_5	268	280	brain trauma	Disease	D001930
15366550_5	196	203	lithium	Chemical	D008094
15366550_5	CID	D008094	D018500

15482540_0|s|Factors contributing to ribavirin-induced anemia.
15482540_0	42	48	anemia	Disease	D000740
15482540_0	24	33	ribavirin	Chemical	D012254

15482540_1|s|BACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.
15482540_1	69	88	chronic hepatitis C	Disease	D019698
15482540_1	98	114	hemolytic anemia	Disease	D000743
15482540_1	20	30	Interferon	Chemical	D016898
15482540_1	35	44	ribavirin	Chemical	D012254
15482540_1	CID	D012254	D000743
15482540_1	CID	D016898	D000743

15482540_2|s|This study was conducted to identify the factors contributing to ribavirin-induced anemia.
15482540_2	83	89	anemia	Disease	D000740
15482540_2	65	74	ribavirin	Chemical	D012254

15482540_3|s|METHODS: Eighty-eight patients with chronic hepatitis C who received interferon-alpha-2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study.
15482540_3	36	55	chronic hepatitis C	Disease	D019698
15482540_3	69	88	interferon-alpha-2b	Chemical	D016898
15482540_3	169	178	ribavirin	Chemical	D012254

15482540_4|s|A hemoglobin concentration of <10 g/dL was defined as ribavirin-induced anemia.
15482540_4	72	78	anemia	Disease	D000740
15482540_4	54	63	ribavirin	Chemical	D012254

15482540_5|s|RESULTS: Ribavirin-induced anemia occurred in 18 (20.5%) patients during treatment.
15482540_5	27	33	anemia	Disease	D000740
15482540_5	9	18	Ribavirin	Chemical	D012254

15605432_0|s|Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury.
15605432_0	73	93	mitochondrial injury	Disease	D028361
15605432_0	46	56	adriamycin	Chemical	D004317
15605432_0	CID	D004317	D028361

15605432_1|s|The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.
15605432_1	158	172	cardiotoxicity	Disease	D066126
15605432_1	71	77	oxygen	Chemical	D010100
15605432_1	84	92	nitrogen	Chemical	D009584
15605432_1	133	143	adriamycin	Chemical	D004317
15605432_1	145	148	ADR	Chemical	D004317

15605432_6|s|Our data showed ADR induced 4HNE-protein adducts in mitochondria at the same time point as when mitochondrial injury initially appeared.
15605432_6	96	116	mitochondrial injury	Disease	D028361
15605432_6	16	19	ADR	Chemical	D004317
15605432_6	28	32	4HNE	Chemical	C027576
15605432_6	CID	D004317	D028361

15609701_0|s|Sotalol-induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia.
15609701_0	16	30	coronary spasm	Disease	D003329
15609701_0	49	71	dilated cardiomyopathy	Disease	D002311
15609701_0	98	121	ventricular tachycardia	Disease	D017180
15609701_0	0	7	Sotalol	Chemical	D013015
15609701_0	CID	D013015	D003329

15609701_2|s|After the administration of nifekalant hydrochloride, sustained VT was terminated.
15609701_2	64	66	VT	Disease	D017180
15609701_2	28	52	nifekalant hydrochloride	Chemical	C076259

15609701_3|s|An alternate class III agent, sotalol, was also effective for the prevention of VT.
15609701_3	80	82	VT	Disease	D017180
15609701_3	30	37	sotalol	Chemical	D013015

15609701_6|s|Coronary vasospasm may be induced by the non-selective beta-blocking properties of sotalol.
15609701_6	0	18	Coronary vasospasm	Disease	D003329
15609701_6	83	90	sotalol	Chemical	D013015
15609701_6	CID	D013015	D003329

15614572_4|s|METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.
15614572_4	94	111	oral stereotypies	Disease	D009062
15614572_4	116	125	catalepsy	Disease	D002375
15614572_4	41	50	trazodone	Chemical	D014196
15614572_4	54	68	dexamphetamine	Chemical	D003913
15614572_4	74	85	apomorphine	Chemical	D001058
15614572_4	137	148	haloperidol	Chemical	D006220
15614572_4	153	164	apomorphine	Chemical	D001058
15614572_4	188	199	ergometrine	Chemical	D004874
15614572_4	241	251	fluoxetine	Chemical	D005473
15614572_4	CID	D001058	D002375
15614572_4	CID	D006220	D002375

15614572_5|s|We also investigated whether trazodone induces catalepsy in rats.
15614572_5	47	56	catalepsy	Disease	D002375
15614572_5	29	38	trazodone	Chemical	D014196

15614572_6|s|RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.
15614572_6	55	64	catalepsy	Disease	D002375
15614572_6	167	176	catalepsy	Disease	D002375
15614572_6	9	18	Trazodone	Chemical	D014196
15614572_6	89	100	apomorphine	Chemical	D001058
15614572_6	134	145	apomorphine	Chemical	D001058
15614572_6	CID	D001058	D002375

15614572_7|s|However, pretreatment with 5, 10 and 20 mg/kg i.p. trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.
15614572_7	125	134	catalepsy	Disease	D002375
15614572_7	51	60	trazodone	Chemical	D014196
15614572_7	70	84	dexamphetamine	Chemical	D003913
15614572_7	113	124	haloperidol	Chemical	D006220
15614572_7	136	147	ergometrine	Chemical	D004874
15614572_7	173	183	fluoxetine	Chemical	D005473
15614572_7	CID	D006220	D002375

15614572_8|s|Trazodone at 30, 40 and 50 mg/kg i.p. induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies.
15614572_8	46	55	catalepsy	Disease	D002375
15614572_8	0	9	Trazodone	Chemical	D014196
15614572_8	72	83	apomorphine	Chemical	D001058
15614572_8	88	102	dexamphetamine	Chemical	D003913
15614572_8	CID	D001058	D002375

15614572_11|s|We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.
15614572_11	242	251	catalepsy	Disease	D002375
15614572_11	16	25	trazodone	Chemical	D014196
15614572_11	64	68	5-HT	Chemical	D012701
15614572_11	158	162	5-HT	Chemical	D012701
15614572_11	188	202	dexamphetamine	Chemical	D003913
15614572_11	230	241	haloperidol	Chemical	D006220
15614572_11	CID	D006220	D002375

15625689_2|s|The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without levodopa-induced dyskinesia.
15625689_2	72	74	PD	Disease	D010300
15625689_2	118	128	dyskinesia	Disease	D004409
15625689_2	101	109	levodopa	Chemical	D007980
15625689_2	CID	D007980	D004409

15625689_10|s|In the current study, dyskinetic patients performed better in swallowing function, which could be explained on the basis of a greater levodopa dose.
15625689_10	22	32	dyskinetic	Disease	D004409
15625689_10	134	142	levodopa	Chemical	D007980
15625689_10	CID	D007980	D004409

15625689_11|s|Our results suggest a role for levodopa in the oral phase of deglutition and confirm that dysphagia is not a good predictor of deglutition alterations in PD.
15625689_11	90	99	dysphagia	Disease	D003680
15625689_11	154	156	PD	Disease	D010300
15625689_11	31	39	levodopa	Chemical	D007980

15627798_0|s|Inhibition of nuclear factor-kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin.
15627798_0	58	86	tubulointerstitial nephritis	Disease	D009395
15627798_0	98	108	gentamicin	Chemical	D005839
15627798_0	CID	D005839	D009395

15627798_1|s|BACKGROUND: Animals treated with gentamicin can show residual areas of interstitial fibrosis in the renal cortex.
15627798_1	84	92	fibrosis	Disease	D005355
15627798_1	33	43	gentamicin	Chemical	D005839

15627798_11|s|CONCLUSIONS: These data show that inhibition of NF-kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin.
15627798_11	80	108	tubulointerstitial nephritis	Disease	D009395
15627798_11	120	130	gentamicin	Chemical	D005839
15627798_11	CID	D005839	D009395

15630069_0|s|Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
15630069_0	36	49	schizophrenia	Disease	D012559
15630069_0	0	7	Glucose	Chemical	D005947
15630069_0	127	134	glucose	Chemical	D005947

15630069_1|s|BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.
15630069_1	45	62	diabetes mellitus	Disease	D003920
15630069_1	98	111	schizophrenia	Disease	D012559
15630069_1	293	301	diabetes	Disease	D003920
15630069_1	230	237	glucose	Chemical	D005947

15630069_3|s|DESIGN: A cross-sectional design in stable, treated patients with schizophrenia evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis.
15630069_3	66	79	schizophrenia	Disease	D012559
15630069_3	129	136	glucose	Chemical	D005947

15630069_6|s|Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
15630069_6	34	47	schizophrenia	Disease	D012559
15630069_6	51	75	schizoaffective disorder	Disease	D011618
15630069_6	128	137	clozapine	Chemical	D003024
15630069_6	139	149	olanzapine	Chemical	C076029
15630069_6	154	165	risperidone	Chemical	D018967

15630069_7|s|MAIN OUTCOME MEASURES: Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and glucose effectiveness.
15630069_7	80	99	insulin sensitivity	Disease	D007333
15630069_7	139	157	insulin resistance	Disease	D007333
15630069_7	38	45	glucose	Chemical	D005947
15630069_7	163	170	glucose	Chemical	D005947

15630069_10|s|There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
15630069_10	38	57	insulin sensitivity	Disease	D007333
15630069_10	212	230	insulin resistance	Disease	D007333
15630069_10	102	111	clozapine	Chemical	D003024
15630069_10	112	122	olanzapine	Chemical	C076029
15630069_10	123	134	risperidone	Chemical	D018967
15630069_10	164	173	clozapine	Chemical	D003024
15630069_10	178	188	olanzapine	Chemical	C076029
15630069_10	276	287	risperidone	Chemical	D018967
15630069_10	289	298	clozapine	Chemical	D003024
15630069_10	302	313	risperidone	Chemical	D018967
15630069_10	338	348	olanzapine	Chemical	C076029
15630069_10	352	363	risperidone	Chemical	D018967
15630069_10	CID	C076029	D007333
15630069_10	CID	D003024	D007333

15630069_11|s|The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02).
15630069_11	36	54	insulin resistance	Disease	D007333
15630069_11	121	130	clozapine	Chemical	D003024
15630069_11	131	141	olanzapine	Chemical	C076029
15630069_11	142	153	risperidone	Chemical	D018967
15630069_11	156	165	clozapine	Chemical	D003024
15630069_11	169	180	risperidone	Chemical	D018967
15630069_11	206	216	olanzapine	Chemical	C076029
15630069_11	220	231	risperidone	Chemical	D018967
15630069_11	CID	C076029	D007333
15630069_11	CID	D003024	D007333

15630069_13|s|CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.
15630069_13	90	108	insulin resistance	Disease	D007333
15630069_13	27	36	clozapine	Chemical	D003024
15630069_13	42	52	olanzapine	Chemical	C076029
15630069_13	127	134	glucose	Chemical	D005947
15630069_13	163	174	risperidone	Chemical	D018967
15630069_13	CID	C076029	D007333
15630069_13	CID	D003024	D007333

15630069_14|s|Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences.
15630069_14	62	80	insulin resistance	Disease	D007333
15630069_14	85	88	its	Disease	D007333
15630069_14	16	25	clozapine	Chemical	D003024
15630069_14	30	40	olanzapine	Chemical	C076029
15630069_14	CID	C076029	D007333
15630069_14	CID	D003024	D007333

15815446_0|s|Focal cerebral ischemia in rats: effect of phenylephrine-induced hypertension during reperfusion.
15815446_0	6	23	cerebral ischemia	Disease	D002545
15815446_0	65	77	hypertension	Disease	D006973
15815446_0	43	56	phenylephrine	Chemical	D010656
15815446_0	CID	D010656	D006973

15815446_1|s|After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of phenylephrine-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined.
15815446_1	27	59	middle cerebral artery occlusion	Disease	D020244
15815446_1	77	89	hypertensive	Disease	D006973
15815446_1	132	144	hypertension	Disease	D006973
15815446_1	148	169	ischemic brain injury	Disease	D001930
15815446_1	110	123	phenylephrine	Chemical	D010656
15815446_1	CID	D010656	D006973

15815446_3|s|Part A, for eight rats in each group brain injury was evaluated by staining tissue using 2,3,5-triphenyltetrazolium chloride and edema was evaluated by microgravimetry.
15815446_3	37	49	brain injury	Disease	D001930
15815446_3	129	134	edema	Disease	D004487
15815446_3	89	124	2,3,5-triphenyltetrazolium chloride	Chemical	C009591

15815446_7|s|Evans Blue (mug g-1 of brain tissue) was greater in the 90/HTN group (24.4 +/- 6.0) versus the control group (12.3 +/- 4.1), which was in turn greater than the 15/HTN group (7.3 +/- 3.2).
15815446_7	59	62	HTN	Disease	D006973
15815446_7	163	166	HTN	Disease	D006973
15815446_7	0	10	Evans Blue	Chemical	D005070

15817013_0|s|People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.
15817013_0	23	42	atrial fibrillation	Disease	D001281
15817013_0	74	84	hemorrhage	Disease	D006470
15817013_0	89	95	stroke	Disease	D020521
15817013_0	46	54	warfarin	Chemical	D014859
15817013_0	CID	D014859	D006470

15817013_1|s|OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.
15817013_1	48	58	hemorrhage	Disease	D006470
15817013_1	63	69	stroke	Disease	D020521
15817013_1	103	122	atrial fibrillation	Disease	D001281
15817013_1	140	148	warfarin	Chemical	D014859
15817013_1	CID	D014859	D006470

15817013_4|s|PARTICIPANTS: Two hundred thirty-five patients aged 76 and older admitted to a major healthcare network between July 1, 2001, and June 30, 2002, with atrial fibrillation on warfarin were enrolled.
15817013_4	150	169	atrial fibrillation	Disease	D001281
15817013_4	173	181	warfarin	Chemical	D014859

15817013_5|s|MEASUREMENTS: Information regarding major bleeding episodes, strokes, and warfarin use was obtained from patients, relatives, primary physicians, and medical records.
15817013_5	42	50	bleeding	Disease	D006470
15817013_5	61	68	strokes	Disease	D020521
15817013_5	74	82	warfarin	Chemical	D014859
15817013_5	CID	D014859	D006470

15817013_9|s|The annual stroke rate after initiation of warfarin was 2.6%.
15817013_9	11	17	stroke	Disease	D020521
15817013_9	43	51	warfarin	Chemical	D014859

15817013_10|s|CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.
15817013_10	30	40	hemorrhage	Disease	D006470
15817013_10	145	151	stroke	Disease	D020521
15817013_10	160	168	warfarin	Chemical	D014859
15817013_10	206	214	warfarin	Chemical	D014859
15817013_10	CID	D014859	D006470

15859361_0|s|Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
15859361_0	45	59	skin reactions	Disease	D003875
15859361_0	10	19	celecoxib	Chemical	C105934
15859361_0	63	76	acetaminophen	Chemical	D000082
15859361_0	78	89	paracetamol	Chemical	D000082
15859361_0	95	105	nimesulide	Chemical	C012655
15859361_0	CID	D000082	D003875
15859361_0	CID	C012655	D003875

15859361_5|s|OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.
15859361_5	105	124	cutaneous reactions	Disease	D003875
15859361_5	44	46	CE	Chemical	C105934
15859361_5	128	129	P	Chemical	D000082
15859361_5	134	135	N	Chemical	C012655
15859361_5	CID	D000082	D003875
15859361_5	CID	C012655	D003875

15859361_6|s|METHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs.
15859361_6	36	52	hypersensitivity	Disease	D004342
15859361_6	56	57	P	Chemical	D000082
15859361_6	62	63	N	Chemical	C012655

15859361_7|s|The diagnosis of P and N-induced skin reactions was based in vivo challenge.
15859361_7	33	47	skin reactions	Disease	D003875
15859361_7	17	18	P	Chemical	D000082
15859361_7	23	24	N	Chemical	C012655
15859361_7	CID	D000082	D003875
15859361_7	CID	C012655	D003875

15859361_15|s|CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.
15859361_15	21	37	hypersensitivity	Disease	D004342
15859361_15	50	52	CE	Chemical	C105934
15859361_15	76	77	P	Chemical	D000082
15859361_15	82	83	N	Chemical	C012655

15882284_1|s|BACKGROUND: Studies on the association between the long-term use of aspirin and other analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs) and end-stage renal disease (ESRD) have given conflicting results.
15882284_1	150	173	end-stage renal disease	Disease	D007676
15882284_1	175	179	ESRD	Disease	D007676
15882284_1	68	75	aspirin	Chemical	D001241
15882284_1	CID	D001241	D007676

15882284_10|s|The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2.35 (1.17-4.72)].
15882284_10	12	16	ESRD	Disease	D007676
15882284_10	168	179	nephropathy	Disease	D007674
15882284_10	33	40	aspirin	Chemical	D001241
15882284_10	CID	D001241	D007676

15882284_12|s|However, the chronic use of aspirin may increase the risk of ESRD.
15882284_12	61	65	ESRD	Disease	D007676
15882284_12	28	35	aspirin	Chemical	D001241
15882284_12	CID	D001241	D007676

15953230_0|s|Two cases of amisulpride overdose: a cause for prolonged QT syndrome.
15953230_0	25	33	overdose	Disease	D062787
15953230_0	47	68	prolonged QT syndrome	Disease	D008133
15953230_0	13	24	amisulpride	Chemical	C012052
15953230_0	CID	C012052	D008133

15953230_1|s|Two cases of deliberate self-poisoning with 5 g and 3.6 g of amisulpride, respectively, are reported.
15953230_1	29	38	poisoning	Disease	D011041
15953230_1	61	72	amisulpride	Chemical	C012052

15953230_3|s|The QT prolongation appeared to respond to administration of i.v. calcium gluconate.
15953230_3	4	19	QT prolongation	Disease	D008133
15953230_3	66	83	calcium gluconate	Chemical	D002125

15987266_0|s|Growth-associated protein 43 expression in hippocampal molecular layer of chronic epileptic rats treated with cycloheximide.
15987266_0	82	91	epileptic	Disease	D004827
15987266_0	110	123	cycloheximide	Chemical	D003513

15987266_2|s|To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.
15987266_2	218	236	status epilepticus	Disease	D013226
15987266_2	248	259	pilocarpine	Chemical	D010862
15987266_2	261	265	Pilo	Chemical	D010862
15987266_2	300	313	cycloheximide	Chemical	D003513
15987266_2	315	318	CHX	Chemical	D003513
15987266_2	CID	D010862	D013226

15991002_4|s|OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.
15991002_4	70	77	anxiety	Disease	D001008
15991002_4	58	66	nicotine	Chemical	D009538
15991002_4	89	97	caffeine	Chemical	D002110
15991002_4	127	145	pentylenetetrazole	Chemical	D010433
15991002_4	CID	D010433	D001008
15991002_4	CID	D002110	D001008

15991002_10|s|Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced anxiety.
15991002_10	92	99	anxiety	Disease	D001008
15991002_10	0	8	Nicotine	Chemical	D009538
15991002_10	47	55	caffeine	Chemical	D002110
15991002_10	65	83	pentylenetetrazole	Chemical	D010433
15991002_10	CID	D010433	D001008
15991002_10	CID	D002110	D001008

15991002_12|s|CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on caffeine-induced anxiety is specific to caffeine, instead of a non-specific anxiolytic effect.
15991002_12	94	101	anxiety	Disease	D001008
15991002_12	65	73	nicotine	Chemical	D009538
15991002_12	77	85	caffeine	Chemical	D002110
15991002_12	117	125	caffeine	Chemical	D002110
15991002_12	CID	D002110	D001008

16034922_13|s|Long-term oestrogen-only HT also significantly increased the risk of stroke and gallbladder disease.
16034922_13	69	75	stroke	Disease	D020521
16034922_13	80	99	gallbladder disease	Disease	D005705
16034922_13	10	19	oestrogen	Chemical	D004967
16034922_13	CID	D004967	D005705
16034922_13	CID	D004967	D020521

16083708_9|s|Factors associated with the development of fulminant hepatic failure were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma bilirubin value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001).
16083708_9	43	68	fulminant hepatic failure	Disease	D017114
16083708_9	211	220	bilirubin	Chemical	D001663

16083708_11|s|Amoxicillin-clavulanate stands out as the most common drug related to DILI.
16083708_11	70	74	DILI	Disease	D056486
16083708_11	0	23	Amoxicillin-clavulanate	Chemical	D019980
16083708_11	CID	D019980	D056486

16092435_0|s|Morphological evaluation of the effect of d-ribose on adriamycin-evoked cardiotoxicity in rats.
16092435_0	72	86	cardiotoxicity	Disease	D066126
16092435_0	42	50	d-ribose	Chemical	D012266
16092435_0	54	64	adriamycin	Chemical	D004317

16092435_1|s|The influence of d-ribose on adriamycin-induced myocardiopathy in rats was studied.
16092435_1	48	62	myocardiopathy	Disease	D009202
16092435_1	17	25	d-ribose	Chemical	D012266
16092435_1	29	39	adriamycin	Chemical	D004317
16092435_1	CID	D004317	D009202

16092435_2|s|Adriamycin in the cumulative dose of 25 mg/kg evoked fully developed cardiac toxicity.
16092435_2	69	85	cardiac toxicity	Disease	D066126
16092435_2	0	10	Adriamycin	Chemical	D004317

16092435_3|s|D-ribose in the multiple doses of 200 mg/kg did not influence ADR cardiotoxicity.
16092435_3	66	80	cardiotoxicity	Disease	D066126
16092435_3	0	8	D-ribose	Chemical	D012266
16092435_3	62	65	ADR	Chemical	D004317

16112787_0|s|In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine.
16112787_0	96	110	nephrotoxicity	Disease	D007674
16112787_0	77	87	vancomycin	Chemical	D014640
16112787_0	126	136	erdosteine	Chemical	C048498
16112787_0	CID	D014640	D007674

16112787_1|s|The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.
16112787_1	293	309	renal impairment	Disease	D007674
16112787_1	39	49	vancomycin	Chemical	D014640
16112787_1	51	54	VCM	Chemical	D014640
16112787_1	118	124	oxygen	Chemical	D010100
16112787_1	170	180	erdosteine	Chemical	C048498
16112787_1	281	284	VCM	Chemical	D014640
16112787_1	CID	D014640	D007674

16112787_5|s|VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.
16112787_5	149	169	renal tubular injury	Disease	D007674
16112787_5	0	3	VCM	Chemical	D014640
16112787_5	65	80	malondialdehyde	Chemical	D008315
16112787_5	82	85	MDA	Chemical	D008315
16112787_5	195	205	superoxide	Chemical	D013481
16112787_5	CID	D014640	D007674

16112787_7|s|Erdosteine showed histopathological protection against VCM-induced nephrotoxicity.
16112787_7	67	81	nephrotoxicity	Disease	D007674
16112787_7	0	10	Erdosteine	Chemical	C048498
16112787_7	55	58	VCM	Chemical	D014640
16112787_7	CID	D014640	D007674

16112787_8|s|There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups.
16112787_8	96	103	atrophy	Disease	D001284
16112787_8	105	117	desquamation	Disease	-1
16112787_8	123	131	necrosis	Disease	D009336
16112787_8	135	138	VCM	Chemical	D014640
16112787_8	191	201	erdosteine	Chemical	C048498

16112787_10|s|It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.
16112787_10	89	103	nephrotoxicity	Disease	D007674
16112787_10	183	196	kidney damage	Disease	D007674
16112787_10	77	80	VCM	Chemical	D014640
16112787_10	148	158	erdosteine	Chemical	C048498
16112787_10	171	174	VCM	Chemical	D014640
16112787_10	CID	D014640	D007674

16309808_0|s|Does domperidone potentiate mirtazapine-associated restless legs syndrome?
16309808_0	51	73	restless legs syndrome	Disease	D012148
16309808_0	5	16	domperidone	Chemical	D004294
16309808_0	28	39	mirtazapine	Chemical	C035133
16309808_0	CID	C035133	D012148

16309808_2|s|For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.
16309808_2	29	32	RLS	Disease	D012148
16309808_2	170	173	RLS	Disease	D012148
16309808_2	65	73	levodopa	Chemical	D007980
16309808_2	78	86	dopamine	Chemical	D004298
16309808_2	113	121	dopamine	Chemical	D004298

16309808_3|s|To our knowledge, there is no previous report regarding whether domperidone, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of RLS.
16309808_3	164	167	RLS	Disease	D012148
16309808_3	64	75	domperidone	Chemical	D004294
16309808_3	90	98	dopamine	Chemical	D004298

16309808_4|s|Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications.
16309808_4	112	115	RLS	Disease	D012148
16309808_4	0	11	Mirtazapine	Chemical	C035133
16309808_4	CID	C035133	D012148

16309808_5|s|The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.
16309808_5	58	80	postprandial dyspepsia	Disease	D004415
16309808_5	95	98	RLS	Disease	D012148
16309808_5	105	116	mirtazapine	Chemical	C035133
16309808_5	139	150	domperidone	Chemical	D004294
16309808_5	CID	C035133	D012148

16309808_6|s|Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.
16309808_6	40	43	RLS	Disease	D012148
16309808_6	101	104	RLS	Disease	D012148
16309808_6	80	91	mirtazapine	Chemical	C035133
16309808_6	162	173	mirtazapine	Chemical	C035133
16309808_6	CID	C035133	D012148

16309808_7|s|Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.
16309808_7	80	83	RLS	Disease	D012148
16309808_7	177	180	RLS	Disease	D012148
16309808_7	48	59	mirtazapine	Chemical	C035133
16309808_7	140	150	domperione	Chemical	D004294
16309808_7	154	165	mirtazapine	Chemical	C035133
16309808_7	CID	C035133	D012148

16309808_8|s|However, physicians should be aware of the possibility that mirtazapine can be associated with RLS in some individuals, especially those receiving concomitant dopamine D2 receptor antagonists.
16309808_8	95	98	RLS	Disease	D012148
16309808_8	60	71	mirtazapine	Chemical	C035133
16309808_8	159	167	dopamine	Chemical	D004298
16309808_8	CID	C035133	D012148

16323982_2|s|MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.
16323982_2	248	263	prostate cancer	Disease	D011471
16323982_2	83	95	cholesterols	Chemical	D002784
16323982_2	97	98	C	Chemical	D002784
16323982_2	101	114	triglycerides	Chemical	D014280
16323982_2	116	118	TG	Chemical	D014280
16323982_2	323	342	cyproterone acetate	Chemical	D017373
16323982_2	344	347	CPA	Chemical	D017373

16323982_4|s|After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease.
16323982_4	108	130	coronary heart disease	Disease	D003327
16323982_4	31	34	CPA	Chemical	D017373

16323982_5|s|CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.
16323982_5	23	48	coronary arteriosclerosis	Disease	D003324
16323982_5	223	247	hyperglyceridemic effect	Disease	D050171
16323982_5	104	107	CPA	Chemical	D017373
16323982_5	151	162	cholesterol	Chemical	D002784
16323982_5	258	266	estrogen	Chemical	D004967
16323982_5	CID	D017373	D050171
16323982_5	CID	D017373	D003324

16369751_0|s|5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
16369751_0	15	29	cardiotoxicity	Disease	D066126
16369751_0	0	14	5-Fluorouracil	Chemical	D005472
16369751_0	41	66	alpha-fluoro-beta-alanine	Chemical	C032348

16369751_1|s|Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.
16369751_1	0	14	Cardiotoxicity	Disease	D066126
16369751_1	91	103	malignancies	Disease	D009369
16369751_1	55	69	5-fluorouracil	Chemical	D005472
16369751_1	71	75	5-FU	Chemical	D005472

16369751_2|s|We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.
16369751_2	65	79	cardiotoxicity	Disease	D066126
16369751_2	52	56	5-FU	Chemical	D005472
16369751_2	111	136	alpha-fluoro-beta-alanine	Chemical	C032348
16369751_2	138	142	FBAL	Chemical	C032348

16369751_4|s|After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.
16369751_4	108	123	precordial pain	Disease	D002637
16369751_4	129	154	right bundle branch block	Disease	D002037
16369751_4	75	79	5-FU	Chemical	D005472
16369751_4	196	200	FBAL	Chemical	C032348
16369751_4	CID	D005472	D002637
16369751_4	CID	D005472	D002037

16369751_5|s|Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU.
16369751_5	9	24	precordial pain	Disease	D002637
16369751_5	117	121	5-FU	Chemical	D005472
16369751_5	CID	D005472	D002637

16369751_6|s|As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.
16369751_6	7	22	precordial pain	Disease	D002637
16369751_6	87	101	cardiotoxicity	Disease	D066126
16369751_6	74	78	5-FU	Chemical	D005472
16369751_6	125	129	5-FU	Chemical	D005472
16369751_6	CID	D005472	D002637

16369751_11|s|The experience of this case, together with a review of the literature, suggests that FBAL is related to 5-FU-induced cardiotoxicity.
16369751_11	117	131	cardiotoxicity	Disease	D066126
16369751_11	85	89	FBAL	Chemical	C032348
16369751_11	104	108	5-FU	Chemical	D005472

16369751_12|s|S-1 may be administered safely to patients with 5-FU-induced cardiotoxicity.
16369751_12	61	75	cardiotoxicity	Disease	D066126
16369751_12	48	52	5-FU	Chemical	D005472

16565833_0|s|The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
16565833_0	128	142	cardiotoxicity	Disease	D066126
16565833_0	43	50	monoHER	Chemical	C522803
16565833_0	55	66	doxorubicin	Chemical	D004317
16565833_0	108	119	doxorubicin	Chemical	D004317

16565833_1|s|PURPOSE: Despite its well-known cardiotoxicity, the anthracyclin doxorubicin (DOX) continues to be an effective and widely used chemotherapeutic agent.
16565833_1	32	46	cardiotoxicity	Disease	D066126
16565833_1	65	76	doxorubicin	Chemical	D004317
16565833_1	78	81	DOX	Chemical	D004317

16565833_2|s|DOX-induced cardiac damage presumably results from the formation of free radicals by DOX.
16565833_2	12	26	cardiac damage	Disease	D006331
16565833_2	0	3	DOX	Chemical	D004317
16565833_2	85	88	DOX	Chemical	D004317

16565833_4|s|The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.
16565833_4	107	121	cardiotoxicity	Disease	D066126
16565833_4	18	27	flavonoid	Chemical	D005419
16565833_4	28	52	monohydroxyethylrutoside	Chemical	C522803
16565833_4	54	61	monoHER	Chemical	C522803
16565833_4	95	98	DOX	Chemical	D004317
16565833_4	157	161	iron	Chemical	D007501

16565833_10|s|Microscopic evaluation revealed that treatment with DOX alone induced significant cardiac damage in comparison to the saline control group (P<0.001).
16565833_10	82	96	cardiac damage	Disease	D006331
16565833_10	52	55	DOX	Chemical	D004317

16723784_0|s|Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.
16723784_0	74	105	atrial fibrillation and flutter	Disease	D001281|D001282
16723784_0	46	54	bepridil	Chemical	D015764

16723784_1|s|BACKGROUND: Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL).
16723784_1	90	109	atrial fibrillation	Disease	D001281
16723784_1	111	113	AF	Disease	D001281
16723784_1	119	133	atrial flutter	Disease	D001282
16723784_1	135	138	AFL	Disease	D001282
16723784_1	12	34	Bepridil hydrochloride	Chemical	D015764
16723784_1	36	39	Bpd	Chemical	D015764

16723784_4|s|Bpd was administered to 459 patients (361 males, 63+/-12 years old) comprising 378 AF and 81 AFL cases.
16723784_4	83	85	AF	Disease	D001281
16723784_4	93	96	AFL	Disease	D001282
16723784_4	0	3	Bpd	Chemical	D015764

16731636_0|s|Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen.
16731636_0	31	50	cardiac hypertrophy	Disease	D006332
16731636_0	9	22	isoproterenol	Chemical	D007545
16731636_0	CID	D007545	D006332

16731636_5|s|LV hypertrophy induced by Iso treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs. 0.24 +/- 0.004, respectively).
16731636_5	0	14	LV hypertrophy	Disease	D006332
16731636_5	26	29	Iso	Chemical	D007545
16731636_5	CID	D007545	D006332

16801510_0|s|Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.
16801510_0	13	29	long QT syndrome	Disease	D008133
16801510_0	64	73	methadone	Chemical	D008691
16801510_0	CID	D008691	D008133

16801510_3|s|In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.
16801510_3	43	67	QT interval prolongation	Disease	D008133
16801510_3	73	82	methadone	Chemical	D008691
16801510_3	CID	D008691	D008133

16801510_6|s|In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.
16801510_6	135	150	QT prolongation	Disease	D008133
16801510_6	15	24	methadone	Chemical	D008691
16801510_6	CID	D008691	D008133

16801510_8|s|Six patients (3.6%) in the methadone group presented torsades de pointes.
16801510_8	53	72	torsades de pointes	Disease	D016171
16801510_8	27	36	methadone	Chemical	D008691

16801510_10|s|Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.
16801510_10	145	156	hypokalemia	Disease	D007008
16801510_10	84	93	methadone	Chemical	D008691

16801510_11|s|CONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding.
16801510_11	13	37	QT interval prolongation	Disease	D008133
16801510_11	41	50	methadone	Chemical	D008691
16801510_11	CID	D008691	D008133

16801510_12|s|Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation.
16801510_12	111	126	QT prolongation	Disease	D008133
16801510_12	0	9	Methadone	Chemical	D008691
16801510_12	61	70	potassium	Chemical	D011188
16801510_12	CID	D008691	D008133

16801510_13|s|Long QT syndrome can occur with low doses of methadone.
16801510_13	0	16	Long QT syndrome	Disease	D008133
16801510_13	45	54	methadone	Chemical	D008691
16801510_13	CID	D008691	D008133

16810074_0|s|Mechanisms of hypertension induced by nitric oxide (NO) deficiency: focus on venous function.
16810074_0	14	26	hypertension	Disease	D006973
16810074_0	38	50	nitric oxide	Chemical	D009569
16810074_0	52	54	NO	Chemical	D009569
16810074_0	CID	D009569	D006973

16810074_1|s|Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of arterial dysfunction.
16810074_1	54	66	hypertension	Disease	D006973
16810074_1	84	104	arterial dysfunction	Disease	D018754
16810074_1	33	45	nitric oxide	Chemical	D009569
16810074_1	47	49	NO	Chemical	D009569
16810074_1	CID	D009569	D006973

16810074_2|s|Experimental hypertension created by the removal of NO, however, involves mechanisms in addition to decreased arterial vasodilator activity.
16810074_2	13	25	hypertension	Disease	D006973
16810074_2	52	54	NO	Chemical	D009569
16810074_2	CID	D009569	D006973

16810074_4|s|We hypothesized that increased venous smooth muscle (venomotor) tone plays a role in Nomega-nitro-L-arginine (LNNA) hypertension through these mechanisms.
16810074_4	116	128	hypertension	Disease	D006973
16810074_4	85	108	Nomega-nitro-L-arginine	Chemical	D019335
16810074_4	110	114	LNNA	Chemical	D019335

16810074_10|s|Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in LNNA hypertension at 1 or 2 weeks after LNNA.
16810074_10	98	110	hypertension	Disease	D006973
16810074_10	93	97	LNNA	Chemical	D019335
16810074_10	133	137	LNNA	Chemical	D019335

16810074_12|s|Similarly, ganglionic blockade with hexamethonium caused a significantly greater fall in LNNA hypertensive rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg).
16810074_12	94	106	hypertensive	Disease	D006973
16810074_12	36	49	hexamethonium	Chemical	D018738
16810074_12	89	93	LNNA	Chemical	D019335

16810074_14|s|These data suggest that while NO deficiency increases oxidative stress and sympathetic activity in both arterial and venous vessels, the impact on veins does not make a major contribution to this form of hypertension.
16810074_14	204	216	hypertension	Disease	D006973
16810074_14	30	32	NO	Chemical	D009569
16810074_14	CID	D009569	D006973

16867246_0|s|Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.
16867246_0	61	84	extrapyramidal syndrome	Disease	D001480
16867246_0	96	109	schizophrenic	Disease	D012559
16867246_0	38	52	chlorpromazine	Chemical	D002746
16867246_0	CID	D002746	D001480

16867246_3|s|In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.
16867246_3	73	76	EPS	Disease	D001480
16867246_3	80	93	schizophrenic	Disease	D012559
16867246_3	50	64	chlorpromazine	Chemical	D002746
16867246_3	CID	D002746	D001480

16867246_4|s|METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.
16867246_4	155	168	schizophrenic	Disease	D012559
16867246_4	189	192	EPS	Disease	D001480
16867246_4	208	211	EPS	Disease	D001480
16867246_4	263	277	chlorpromazine	Chemical	D002746
16867246_4	CID	D002746	D001480

16867246_8|s|CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia.
16867246_8	232	245	schizophrenia	Disease	D012559
16867246_8	182	196	chlorpromazine	Chemical	D002746

16876986_0|s|Physical training decreases susceptibility to subsequent pilocarpine-induced seizures in the rat.
16876986_0	77	85	seizures	Disease	D012640
16876986_0	57	68	pilocarpine	Chemical	D010862
16876986_0	CID	D010862	D012640

16876986_4|s|Thereafter, seizures were induced by pilocarpine injections in trained and non-trained control groups.
16876986_4	12	20	seizures	Disease	D012640
16876986_4	37	48	pilocarpine	Chemical	D010862
16876986_4	CID	D010862	D012640

16880771_2|s|Administration of the dopamine precursor levodopa enhances learning in healthy subjects and stroke patients.
16880771_2	92	98	stroke	Disease	D020521
16880771_2	22	30	dopamine	Chemical	D004298
16880771_2	41	49	levodopa	Chemical	D007980

16880771_7|s|The dopamine agonist significantly impaired novel word learning compared to placebo.
16880771_7	35	63	impaired novel word learning	Disease	D007859
16880771_7	4	12	dopamine	Chemical	D004298

16880771_12|s|Thus, phasic signaling seems to be the critical mechanism by which dopamine enhances associative learning in healthy subjects and stroke patients.
16880771_12	130	136	stroke	Disease	D020521
16880771_12	67	75	dopamine	Chemical	D004298

16906379_0|s|Minocycline-induced vasculitis fulfilling the criteria of polyarteritis nodosa.
16906379_0	20	30	vasculitis	Disease	D014657
16906379_0	58	78	polyarteritis nodosa	Disease	D010488
16906379_0	0	11	Minocycline	Chemical	D008911
16906379_0	CID	D008911	D010488

16906379_1|s|A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).
16906379_1	54	77	palmoplantar pustulosis	Disease	D011565
16906379_1	88	93	fever	Disease	D005334
16906379_1	95	103	myalgias	Disease	D063806
16906379_1	105	119	polyneuropathy	Disease	D011115
16906379_1	125	140	testicular pain	Disease	D013733
16906379_1	38	49	minocycline	Chemical	D008911

16906379_5|s|To our knowledge, this is the second case of minocycline-induced vasculitis satisfying the criteria.
16906379_5	65	75	vasculitis	Disease	D014657
16906379_5	45	56	minocycline	Chemical	D008911

16911931_0|s|Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation.
16911931_0	14	25	hepatitis B	Disease	D006509
16911931_0	84	95	hepatitis B	Disease	D006509
16911931_0	56	66	lamivudine	Chemical	D019259

16911931_1|s|BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients.
16911931_1	21	32	hepatitis B	Disease	D006509
16911931_1	107	118	hepatitis B	Disease	D006509
16911931_1	60	70	lamivudine	Chemical	D019259
16911931_1	190	195	HBsAg	Chemical	D006514

16920333_0|s|Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.
16920333_0	64	72	seizures	Disease	D012640
16920333_0	25	48	eslicarbazepine acetate	Chemical	C416835
16920333_0	50	59	BIA 2-093	Chemical	C416835
16920333_0	102	112	picrotoxin	Chemical	D010852
16920333_0	CID	D010852	D012640

16920333_2|s|We have studied the effects of oral treatment with eslicarbazepine acetate on a whole-animal model in which partial seizures can be elicited repeatedly on different days without changes in threshold or seizure patterns.
16920333_2	116	124	seizures	Disease	D012640
16920333_2	202	209	seizure	Disease	D012640
16920333_2	51	74	eslicarbazepine acetate	Chemical	C416835

16920333_3|s|In the animals treated with threshold doses of picrotoxin, the average number of seizures was 2.3+/-1.2, and average seizure duration was 39.5+/-8.4s.
16920333_3	81	89	seizures	Disease	D012640
16920333_3	117	124	seizure	Disease	D012640
16920333_3	47	57	picrotoxin	Chemical	D010852
16920333_3	CID	D010852	D012640

16920333_4|s|Pre-treatment with a dose of 30 mg/kg 2h before picrotoxin microperfusion prevented seizures in the 75% of the rats.
16920333_4	84	92	seizures	Disease	D012640
16920333_4	48	58	picrotoxin	Chemical	D010852
16920333_4	CID	D010852	D012640

17028363_0|s|Acute renal failure associated with prolonged intake of slimming pills containing anthraquinones.
17028363_0	0	19	Acute renal failure	Disease	D058186
17028363_0	82	96	anthraquinones	Chemical	D000880

17028363_2|s|Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of aristolochic acids.
17028363_2	0	11	Nephropathy	Disease	D007674
17028363_2	22	35	Chinese herbs	Chemical	D004365
17028363_2	95	113	aristolochic acids	Chemical	D034341

17028363_3|s|We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb).
17028363_3	44	63	acute renal failure	Disease	D058186
17028363_3	105	119	Chinese herbal	Chemical	D004365
17028363_3	149	162	anthraquinone	Chemical	D000880
17028363_3	CID	D004365	D058186

17028363_4|s|The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac.
17028363_4	4	16	renal injury	Disease	D058186
17028363_4	110	120	diclofenac	Chemical	D004008
17028363_4	CID	D004008	D058186

17028363_7|s|Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure.
17028363_7	95	107	renal injury	Disease	D058186
17028363_7	167	178	nephropathy	Disease	D007674
17028363_7	241	254	renal failure	Disease	D051437
17028363_7	53	66	anthraquinone	Chemical	D000880

17035713_0|s|Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
17035713_0	92	103	nephropathy	Disease	D007674
17035713_0	0	18	Chloroacetaldehyde	Chemical	C004656
17035713_0	24	34	sulfhydryl	Chemical	-1
17035713_0	65	70	thiol	Chemical	D013438
17035713_0	81	91	ifosfamide	Chemical	D007069
17035713_0	CID	D007069	D007674

17035713_1|s|Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
17035713_1	113	125	renal damage	Disease	D007674
17035713_1	141	146	tumor	Disease	D009369
17035713_1	0	18	Chloroacetaldehyde	Chemical	C004656
17035713_1	20	23	CAA	Chemical	C004656
17035713_1	65	75	ifosfamide	Chemical	D007069
17035713_1	77	80	IFO	Chemical	D007069
17035713_1	160	163	IFO	Chemical	D007069
17035713_1	CID	D007069	D007674

17035713_4|s|Toxicity of CAA was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity.
17035713_4	0	8	Toxicity	Disease	D064420
17035713_4	12	15	CAA	Chemical	C004656
17035713_4	77	88	trypan blue	Chemical	D014343

17035713_6|s|CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in necrosis markers.
17035713_6	107	115	necrosis	Disease	D009336
17035713_6	0	3	CAA	Chemical	C004656
17035713_6	81	87	thiols	Chemical	D013438

17035713_11|s|Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.
17035713_11	106	114	necrosis	Disease	D009336
17035713_11	44	47	CAA	Chemical	C004656
17035713_11	53	58	thiol	Chemical	D013438
17035713_11	99	102	CAA	Chemical	C004656
17035713_11	124	129	thiol	Chemical	D013438
17035713_11	144	152	cysteine	Chemical	D003545

17035713_12|s|Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its toxicity on hRPTEC.
17035713_12	86	94	toxicity	Disease	D064420
17035713_12	6	9	CAA	Chemical	C004656
17035713_12	64	70	thiols	Chemical	D013438

17035713_14|s|Therefore, urinary acidification could be an option to prevent IFO nephropathy in patients.
17035713_14	67	78	nephropathy	Disease	D007674
17035713_14	63	66	IFO	Chemical	D007069
17035713_14	CID	D007069	D007674

17042797_0|s|Stereological methods reveal the robust size and stability of ectopic hilar granule cells after pilocarpine-induced status epilepticus in the adult rat.
17042797_0	116	134	status epilepticus	Disease	D013226
17042797_0	96	107	pilocarpine	Chemical	D010862
17042797_0	CID	D010862	D013226

17042797_4|s|To quantify this population, the total number of ectopic hilar granule cells was estimated using unbiased stereology at different times after pilocarpine-induced status epilepticus.
17042797_4	162	180	status epilepticus	Disease	D013226
17042797_4	142	153	pilocarpine	Chemical	D010862
17042797_4	CID	D010862	D013226

17042797_9|s|The results provide new insight into the potential role of ectopic hilar granule cells in the pilocarpine model of temporal lobe epilepsy.
17042797_9	115	137	temporal lobe epilepsy	Disease	D004833
17042797_9	94	105	pilocarpine	Chemical	D010862
17042797_9	CID	D010862	D004833

17069550_0|s|A prospective, open-label trial of galantamine in autistic disorder.
17069550_0	50	67	autistic disorder	Disease	D001321
17069550_0	35	46	galantamine	Chemical	D005702

17069550_2|s|The purpose of this study was to assess the use of galantamine, an acetylcholinesterase inhibitor and nicotinic receptor modulator, in the treatment of interfering behaviors in children with autism.
17069550_2	191	197	autism	Disease	D001321
17069550_2	51	62	galantamine	Chemical	D005702

17069550_3|s|METHODS: Thirteen medication-free children with autism (mean age, 8.8 +/- 3.5 years) participated in a 12-week, open-label trial of galantamine.
17069550_3	48	54	autism	Disease	D001321
17069550_3	132	143	galantamine	Chemical	D005702

17069550_8|s|Overall, galantamine was well-tolerated, with no significant adverse effects apart from headaches in one patient.
17069550_8	88	97	headaches	Disease	D006261
17069550_8	9	20	galantamine	Chemical	D005702
17069550_8	CID	D005702	D006261

17069550_9|s|CONCLUSION: In this open trial, galantamine was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly aggression, behavioral dyscontrol, and inattention.
17069550_9	153	159	autism	Disease	D001321
17069550_9	174	184	aggression	Disease	D001523
17069550_9	186	207	behavioral dyscontrol	Disease	D002653
17069550_9	213	224	inattention	Disease	D019958
17069550_9	32	43	galantamine	Chemical	D005702

17151160_0|s|Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
17151160_0	90	103	schizophrenia	Disease	D012559
17151160_0	25	35	olanzapine	Chemical	C076029
17151160_0	43	54	risperidone	Chemical	D018967

17151160_1|s|OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders.
17151160_1	124	137	schizophrenia	Disease	D012559
17151160_1	63	73	olanzapine	Chemical	C076029
17151160_1	81	92	risperidone	Chemical	D018967

17151160_2|s|METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).
17151160_2	98	111	schizophrenia	Disease	D012559
17151160_2	119	144	schizophreniform disorder	Disease	D011618
17151160_2	155	179	schizoaffective disorder	Disease	D011618
17151160_2	226	236	olanzapine	Chemical	C076029
17151160_2	256	267	risperidone	Chemical	D018967

17151160_6|s|Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with olanzapine.
17151160_6	0	22	Extrapyramidal symptom	Disease	D001480
17151160_6	70	81	risperidone	Chemical	D018967
17151160_6	112	122	olanzapine	Chemical	C076029
17151160_6	CID	D018967	D001480
17151160_6	CID	C076029	D001480

17151160_7|s|Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.
17151160_7	19	30	weight gain	Disease	D015430
17151160_7	45	55	olanzapine	Chemical	C076029
17151160_7	66	77	risperidone	Chemical	D018967
17151160_7	178	188	olanzapine	Chemical	C076029
17151160_7	224	235	risperidone	Chemical	D018967
17151160_7	CID	C076029	D015430
17151160_7	CID	D018967	D015430

17151160_11|s|Both medications caused substantial rapid weight gain, but weight gain was greater with olanzapine.
17151160_11	42	53	weight gain	Disease	D015430
17151160_11	59	70	weight gain	Disease	D015430
17151160_11	88	98	olanzapine	Chemical	C076029
17151160_11	CID	C076029	D015430

17159032_0|s|Early paracentral visual field loss in patients taking hydroxychloroquine.
17159032_0	18	35	visual field loss	Disease	D014786
17159032_0	55	73	hydroxychloroquine	Chemical	D006886
17159032_0	CID	D006886	D014786

17159032_6|s|Thirty-five patients (13.4%) had visual field abnormalities, which were attributed to hydroxychloroquine treatment in 4 patients (1.5%).
17159032_6	33	59	visual field abnormalities	Disease	D014786
17159032_6	86	104	hydroxychloroquine	Chemical	D006886
17159032_6	CID	D006886	D014786

17223814_0|s|Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel.
17223814_0	15	37	atrioventricular block	Disease	D054537
17223814_0	71	81	epirubicin	Chemical	D015251
17223814_0	86	96	paclitaxel	Chemical	D017239
17223814_0	CID	D017239	D054537
17223814_0	CID	D015251	D054537

17255138_2|s|OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).
17255138_2	24	51	acute myocardial infarction	Disease	D009203
17255138_2	53	56	AMI	Disease	D009203
17255138_2	63	79	COX-2 inhibitors	Chemical	D052246
17255138_2	160	197	non-steroidal anti-inflammatory drugs	Chemical	D000894
17255138_2	CID	D052246	D009203
17255138_2	CID	D000894	D009203

17255138_3|s|We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.
17255138_3	53	56	AMI	Disease	D009203
17255138_3	61	72	GI bleeding	Disease	D006471
17255138_3	102	118	COX-2 inhibitors	Chemical	D052246
17255138_3	134	147	acetaminophen	Chemical	D000082
17255138_3	CID	D052246	D009203

17255138_8|s|Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
17255138_8	104	107	AMI	Disease	D009203
17255138_8	19	26	aspirin	Chemical	D001241
17255138_8	118	131	acetaminophen	Chemical	D000082
17255138_8	141	148	aspirin	Chemical	D001241
17255138_8	162	171	rofecoxib	Chemical	C116926
17255138_8	191	200	celecoxib	Chemical	C105934
17255138_8	220	228	naproxen	Chemical	D009288
17255138_8	248	258	diclofenac	Chemical	D004008
17255138_8	281	290	ibuprofen	Chemical	D007052
17255138_8	CID	D009288	D009203
17255138_8	CID	C116926	D009203

17255138_10|s|CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.
17255138_10	86	89	AMI	Disease	D009203
17255138_10	90	101	GI bleeding	Disease	D006471
17255138_10	31	38	aspirin	Chemical	D001241
17255138_10	40	48	naproxen	Chemical	D009288
17255138_10	CID	D009288	D009203
17255138_10	CID	D009288	D006471

17255138_11|s|The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.
17255138_11	4	7	AMI	Disease	D009203
17255138_11	11	19	toxicity	Disease	D064420
17255138_11	23	32	celecoxib	Chemical	C105934
17255138_11	56	69	acetaminophen	Chemical	D000082
17255138_11	108	117	rofecoxib	Chemical	C116926
17255138_11	CID	C116926	D009203

17297207_0|s|Quinine-induced arrhythmia in a patient with severe malaria.
17297207_0	16	26	arrhythmia	Disease	D001145
17297207_0	45	59	severe malaria	Disease	D016778
17297207_0	0	7	Quinine	Chemical	D011803

17297207_1|s|It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.
17297207_1	41	55	severe malaria	Disease	D016778
17297207_1	69	77	jaundice	Disease	D007565
17297207_1	97	107	arrhythmia	Disease	D001145
17297207_1	109	142	premature ventricular contraction	Disease	D018879
17297207_1	158	165	quinine	Chemical	D011803
17297207_1	CID	D011803	D018879

17297207_4|s|On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
17297207_4	216	230	severe malaria	Disease	D016778
17297207_4	236	244	jaundice	Disease	D007565
17297207_4	80	89	bilirubin	Chemical	D001663
17297207_4	113	122	bilirubin	Chemical	D001663
17297207_4	148	157	bilirubin	Chemical	D001663
17297207_4	170	179	potassium	Chemical	D011188
17297207_4	253	260	quinine	Chemical	D011803
17297207_4	273	281	dextrose	Chemical	D005947

17297207_6|s|After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.
17297207_6	52	63	palpitation	Disease	-1
17297207_6	111	144	premature ventricular contraction	Disease	D018879
17297207_6	146	149	PVC	Disease	D018879
17297207_6	191	207	sinoatrial block	Disease	D012848
17297207_6	18	25	quinine	Chemical	D011803
17297207_6	CID	D011803	D018879

17297207_9|s|Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L.
17297207_9	60	63	PVC	Disease	D018879
17297207_9	127	136	potassium	Chemical	D011188

17297207_11|s|Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.
17297207_11	62	72	arrhythmic	Disease	D001145
17297207_11	104	114	arrhythmic	Disease	D001145
17297207_11	138	149	arrhythmias	Disease	D001145
17297207_11	168	178	arrhythmia	Disease	D001145
17297207_11	196	199	PVC	Disease	D018879
17297207_11	0	7	Quinine	Chemical	D011803
17297207_11	14	23	quinidine	Chemical	D011802
17297207_11	92	94	it	Chemical	D011803
17297207_11	CID	D011803	D018879

17297207_12|s|Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
17297207_12	105	115	arrhythmic	Disease	D001145
17297207_12	162	176	heart diseases	Disease	D006331
17297207_12	194	214	electrolyte disorder	Disease	D014883
17297207_12	216	227	hypokalemia	Disease	D007008
17297207_12	260	268	vomiting	Disease	D014839
17297207_12	276	284	diarrhea	Disease	D003967
17297207_12	288	295	malaria	Disease	D008288
17297207_12	29	36	quinine	Chemical	D011803

17346443_0|s|Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.
17346443_0	22	42	lichenoid dermatitis	Disease	D017512
17346443_0	76	90	Wilson disease	Disease	D006527
17346443_0	126	133	anxiety	Disease	D001008
17346443_0	0	13	Penicillamine	Chemical	D010396
17346443_0	58	70	zinc acetate	Chemical	D019345
17346443_0	CID	D010396	D017512

17346443_1|s|Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders.
17346443_1	0	16	Wilson's disease	Disease	D006527
17346443_1	121	129	toxicity	Disease	D064420
17346443_1	161	206	hepatic, neurologic and psychiatric disorders	Disease	D056486|D009422|D001523
17346443_1	63	69	copper	Chemical	D003300
17346443_1	97	103	copper	Chemical	D003300

17346443_3|s|During the follow-up of our patient, penicillamine was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects.
17346443_3	93	113	lichenoid dermatitis	Disease	D017512
17346443_3	37	50	penicillamine	Chemical	D010396
17346443_3	119	131	zinc acetate	Chemical	D019345
17346443_3	CID	D010396	D017512

17346443_4|s|In our case the therapy with zinc acetate represented an effective treatment for a Wilson's disease patient in which penicillamine-related side effects appeared.
17346443_4	83	99	Wilson's disease	Disease	D006527
17346443_4	29	41	zinc acetate	Chemical	D019345
17346443_4	117	130	penicillamine	Chemical	D010396

17346443_5|s|The safety of the zinc acetate allowed us to avoid other potentially toxic chelating drugs; this observation is in line with the growing evidence on the efficacy of the drug in the treatment of Wilson's disease.
17346443_5	194	210	Wilson's disease	Disease	D006527
17346443_5	18	30	zinc acetate	Chemical	D019345

17346443_6|s|Since most of Wilson's disease penicillamine-treated patients do not seem to develop this skin lesion, it could be conceivable that a specific genetic factor is involved in drug response.
17346443_6	14	30	Wilson's disease	Disease	D006527
17346443_6	90	101	skin lesion	Disease	D012871
17346443_6	31	44	penicillamine	Chemical	D010396

17351238_0|s|A dramatic drop in blood pressure following prehospital GTN administration.
17351238_0	11	33	drop in blood pressure	Disease	D007022
17351238_0	56	59	GTN	Chemical	D005996
17351238_0	CID	D005996	D007022

17351238_4|s|Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by atropine sulphate and a fluid challenge.
17351238_4	63	85	drop in blood pressure	Disease	D007022
17351238_4	26	29	GTN	Chemical	D005996
17351238_4	124	141	atropine sulphate	Chemical	D001285
17351238_4	CID	D005996	D007022

17356399_0|s|Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.
17356399_0	0	20	Acute encephalopathy	Disease	D020803
17356399_0	25	43	cerebral vasospasm	Disease	D020301
17356399_0	149	177	acute lymphoblastic leukemia	Disease	D054198
17356399_0	84	100	PEG-asparaginase	Chemical	C042705
17356399_0	117	127	cytarabine	Chemical	D003561
17356399_0	CID	D003561	D020301
17356399_0	CID	C042705	D020301

17356399_2|s|The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.
17356399_2	22	42	acute encephalopathy	Disease	D020803
17356399_2	76	83	aphasia	Disease	D001037
17356399_2	85	97	incontinence	Disease	D014549
17356399_2	99	120	visual hallucinations	Disease	D006212
17356399_2	138	146	weakness	Disease	D018908
17356399_2	160	178	cerebral vasospasm	Disease	D020301
17356399_2	253	263	cytarabine	Chemical	D003561
17356399_2	CID	D003561	D020301
17356399_2	CID	D003561	D001037
17356399_2	CID	D003561	D006212
17356399_2	CID	D003561	D014549
17356399_2	CID	D003561	D018908

17379047_0|s|Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
17379047_0	195	207	hypertensive	Disease	D006973
17379047_0	14	23	valsartan	Chemical	C081489
17379047_0	24	43	hydrochlorothiazide	Chemical	D006852

17379047_3|s|OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.
17379047_3	172	194	essential hypertension	Disease	C562386
17379047_3	68	77	valsartan	Chemical	C081489
17379047_3	79	82	VAL	Chemical	C081489
17379047_3	87	106	hydrochlorothiazide	Chemical	D006852
17379047_3	108	112	HCTZ	Chemical	D006852

17379047_5|s|Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.
17379047_5	14	36	essential hypertension	Disease	C562386
17379047_5	148	151	VAL	Chemical	C081489
17379047_5	167	171	HCTZ	Chemical	D006852
17379047_5	187	190	VAL	Chemical	C081489
17379047_5	191	195	HCTZ	Chemical	D006852

17379047_17|s|The incidence of hypokalemia was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).
17379047_17	17	28	hypokalemia	Disease	D007008
17379047_17	44	47	VAL	Chemical	C081489
17379047_17	48	52	HCTZ	Chemical	D006852
17379047_17	88	92	HCTZ	Chemical	D006852
17379047_17	CID	D006852	D007008

17379047_20|s|CONCLUSIONS: In this study population, combination therapies with VAL/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less hypokalemia than HCTZ alone.
17379047_20	217	228	hypokalemia	Disease	D007008
17379047_20	66	69	VAL	Chemical	C081489
17379047_20	70	74	HCTZ	Chemical	D006852
17379047_20	234	238	HCTZ	Chemical	D006852
17379047_20	CID	D006852	D007008

17384765_0|s|Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure.
17384765_0	114	134	cognitive impairment	Disease	D003072
17384765_0	0	8	Succimer	Chemical	D004113
17384765_0	75	79	lead	Chemical	D007854
17384765_0	153	157	lead	Chemical	D007854
17384765_0	CID	D004113	D003072

17384765_3|s|OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of Pb poisoning.
17384765_3	202	214	Pb poisoning	Disease	D007855
17384765_3	110	112	Pb	Chemical	D007854
17384765_3	141	149	succimer	Chemical	D004113

17384765_4|s|RESULTS: Pb exposure produced lasting impairments in learning, attention, inhibitory control, and arousal regulation, paralleling the areas of dysfunction seen in Pb-exposed children.
17384765_4	38	116	impairments in learning, attention, inhibitory control, and arousal regulation	Disease	D007859|D019958
17384765_4	9	11	Pb	Chemical	D007854
17384765_4	163	165	Pb	Chemical	D007854
17384765_4	CID	D007854	D007859
17384765_4	CID	D007854	D019958

17384765_6|s|In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen.
17384765_6	100	135	cognitive and affective dysfunction	Disease	D003072|D019964
17384765_6	13	21	succimer	Chemical	D004113
17384765_6	66	68	Pb	Chemical	D007854
17384765_6	191	193	Pb	Chemical	D007854
17384765_6	CID	D004113	D003072

17384765_7|s|CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate cognitive deficits due to Pb exposure.
17384765_7	119	137	cognitive deficits	Disease	D003072
17384765_7	145	147	Pb	Chemical	D007854

17445520_0|s|Caffeine challenge test in panic disorder and depression with panic attacks.
17445520_0	27	41	panic disorder	Disease	D016584
17445520_0	46	56	depression	Disease	D003866
17445520_0	62	75	panic attacks	Disease	D016584
17445520_0	0	8	Caffeine	Chemical	D002110
17445520_0	CID	D002110	D016584

17445520_1|s|Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
17445520_1	40	54	panic disorder	Disease	D016584
17445520_1	56	58	PD	Disease	D016584
17445520_1	78	94	major depression	Disease	D003865
17445520_1	100	113	panic attacks	Disease	D016584
17445520_1	115	118	MDP	Disease	D003865|D016584
17445520_1	158	174	Mental Disorders	Disease	D001523
17445520_1	246	259	panic attacks	Disease	D016584
17445520_1	271	279	caffeine	Chemical	D002110
17445520_1	CID	D002110	D016584

17445520_4|s|In a randomized double-blind experiment performed in 2 occasions 7 days apart, 480 mg caffeine and a caffeine-free (placebo) solution were administered in a coffee form and anxiety scales were applied before and after each test.
17445520_4	173	180	anxiety	Disease	D001008
17445520_4	86	94	caffeine	Chemical	D002110
17445520_4	101	109	caffeine	Chemical	D002110

17445520_5|s|A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).
17445520_5	43	45	PD	Disease	D016584
17445520_5	79	82	MDP	Disease	D003865|D016584
17445520_5	115	117	MD	Disease	D003865
17445520_5	161	173	panic attack	Disease	D016584
17445520_5	191	199	caffeine	Chemical	D002110
17445520_5	CID	D002110	D016584

17445520_6|s|The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.
17445520_6	18	20	PD	Disease	D016584
17445520_6	25	28	MDP	Disease	D003865|D016584
17445520_6	85	87	MD	Disease	D003865
17445520_6	52	60	caffeine	Chemical	D002110
17445520_6	CID	D002110	D016584

17445520_7|s|No panic attack was observed after the caffeine-free solution intake.
17445520_7	3	15	panic attack	Disease	D016584
17445520_7	39	47	caffeine	Chemical	D002110
17445520_7	CID	D002110	D016584

17445520_9|s|Our data suggest that there is an association between panic attacks, no matter if associated with PD or MDP, and hyperreactivity to an oral caffeine challenge test.
17445520_9	54	67	panic attacks	Disease	D016584
17445520_9	98	100	PD	Disease	D016584
17445520_9	104	107	MDP	Disease	D003865|D016584
17445520_9	140	148	caffeine	Chemical	D002110
17445520_9	CID	D002110	D016584

17484470_7|s|Acute heart failure was induced by propranolol and volume loading after weaning from cardiopulmonary bypass; an absence of MR was confirmed by echocardiography.
17484470_7	6	19	heart failure	Disease	D006333
17484470_7	123	125	MR	Disease	D008944
17484470_7	35	46	propranolol	Chemical	D011433
17484470_7	CID	D011433	D006333

17496739_0|s|Piperacillin/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.
17496739_0	32	39	seizure	Disease	D012640
17496739_0	0	23	Piperacillin/tazobactam	Chemical	C085143

17496739_1|s|Despite popular use of piperacillin, the dire neurotoxicity associated with piperacillin still goes unrecognized, leading to a delay in appropriate management.
17496739_1	46	59	neurotoxicity	Disease	D020258
17496739_1	23	35	piperacillin	Chemical	D010878
17496739_1	76	88	piperacillin	Chemical	D010878

17496739_2|s|We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.
17496739_2	35	58	end-stage renal disease	Disease	D007676
17496739_2	149	155	tremor	Disease	D014202
17496739_2	194	203	confusion	Disease	D003221
17496739_2	235	255	tonic-clonic seizure	Disease	D004830
17496739_2	257	261	GTCS	Disease	D004830
17496739_2	332	346	bronchiectasis	Disease	D001987
17496739_2	352	371	secondary infection	Disease	D060085
17496739_2	280	303	piperacillin/tazobactam	Chemical	C085143
17496739_2	CID	C085143	D003221
17496739_2	CID	C085143	D004830
17496739_2	CID	C085143	D014202

17496739_3|s|The laboratory data revealed normal plasma electrolyte and ammonia levels but leukocytosis.
17496739_3	78	90	leukocytosis	Disease	D007964
17496739_3	59	66	ammonia	Chemical	D000641

17496739_6|s|Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of piperacillin/tazobactam.
17496739_6	49	53	GTCS	Disease	D004830
17496739_6	95	118	piperacillin/tazobactam	Chemical	C085143
17496739_6	CID	C085143	D004830

17496739_9|s|Piperacillin-induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations.
17496739_9	21	35	encephalopathy	Disease	D001927
17496739_9	64	70	uremic	Disease	D006463
17496739_9	0	12	Piperacillin	Chemical	D010878

17496739_10|s|CAPD is inefficient in removing piperacillin, whereas hemodialysis can rapidly terminate the piperacillin-induced encephalopathy.
17496739_10	114	128	encephalopathy	Disease	D001927
17496739_10	32	44	piperacillin	Chemical	D010878
17496739_10	93	105	piperacillin	Chemical	D010878

17572393_0|s|Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia.
17572393_0	107	125	cortical dysplasia	Disease	D054220
17572393_0	27	36	melatonin	Chemical	D008550
17572393_0	94	98	BCNU	Chemical	D002330
17572393_0	CID	D002330	D054220

17572393_2|s|This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.
17572393_2	252	270	cortical dysplasia	Disease	D054220
17572393_2	112	122	carmustine	Chemical	D002330
17572393_2	124	160	1,3-bis (2-chloroethyl)-1-nitrosoure	Chemical	D002330
17572393_2	163	167	BCNU	Chemical	D002330
17572393_2	213	222	melatonin	Chemical	D008550
17572393_2	239	243	BCNU	Chemical	D002330
17572393_2	CID	D002330	D054220

17572393_6|s|Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in BCNU-exposed cortical dysplasia group.
17572393_6	182	200	cortical dysplasia	Disease	D054220
17572393_6	169	173	BCNU	Chemical	D002330
17572393_6	CID	D002330	D054220

17828434_4|s|This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine-induced seizures model.
17828434_4	145	153	seizures	Disease	D012640
17828434_4	22	25	MIP	Chemical	C002647
17828434_4	91	98	lithium	Chemical	D008094
17828434_4	106	114	inositol	Chemical	D007294
17828434_4	125	136	pilocarpine	Chemical	D010862
17828434_4	CID	D010862	D012640

17879100_4|s|He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation.
17879100_4	63	68	fever	Disease	D005334
17879100_4	14	21	aspirin	Chemical	D001241
17879100_4	49	58	ibuprofen	Chemical	D007052

17879217_0|s|Rifampicin-associated segmental necrotizing glomerulonephritis in staphylococcal endocarditis.
17879217_0	44	62	glomerulonephritis	Disease	D005921
17879217_0	66	93	staphylococcal endocarditis	Disease	D013203|D004696
17879217_0	0	10	Rifampicin	Chemical	D012293
17879217_0	CID	D012293	D005921

17879217_1|s|Segmental necrotising glomerulonephritis has been reported as complication of rifampicin therapy in patients receiving treatment for tuberculosis.
17879217_1	22	40	glomerulonephritis	Disease	D005921
17879217_1	133	145	tuberculosis	Disease	D014376
17879217_1	78	88	rifampicin	Chemical	D012293
17879217_1	CID	D012293	D005921

17879217_2|s|Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of rifampicin for Staphylococcal infections.
17879217_2	25	35	infections	Disease	D007239
17879217_2	44	66	infective endocarditis	Disease	D004696
17879217_2	68	70	IE	Disease	D004696
17879217_2	124	149	Staphylococcal infections	Disease	D013203
17879217_2	109	119	rifampicin	Chemical	D012293

17879217_3|s|We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.
17879217_3	37	54	Staphylococcal IE	Disease	D013203|D004696
17879217_3	69	88	acute renal failure	Disease	D058186
17879217_3	126	144	glomerulonephritis	Disease	D005921
17879217_3	170	180	rifampicin	Chemical	D012293
17879217_3	239	249	rifampicin	Chemical	D012293
17879217_3	CID	D012293	D058186
17879217_3	CID	D012293	D005921

17954033_0|s|Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection.
17954033_0	73	108	chronic hepatitis B virus infection	Disease	D019694
17954033_0	30	40	lamivudine	Chemical	D019259

17954033_1|s|BACKGROUND: Lamivudine is used for the treatment of chronic hepatitis B patients.
17954033_1	52	71	chronic hepatitis B	Disease	D019694
17954033_1	12	22	Lamivudine	Chemical	D019259

17954033_2|s|Recent studies show that the YMDD motif mutants (resistant hepatitis B virus) occur as natural genome variability in lamivudine-untreated chronic hepatitis B patients.
17954033_2	59	70	hepatitis B	Disease	D006509
17954033_2	138	157	chronic hepatitis B	Disease	D019694
17954033_2	117	127	lamivudine	Chemical	D019259

17954033_3|s|In this study we aimed to determine the rate of YMDD motif mutants in lamivudine-untreated chronic hepatitis B patients in Iran.
17954033_3	91	110	chronic hepatitis B	Disease	D019694
17954033_3	70	80	lamivudine	Chemical	D019259

17954033_4|s|PATIENTS AND METHODS: A total of 77 chronic hepatitis B patients who had not been treated with lamivudine were included in the study.
17954033_4	36	55	chronic hepatitis B	Disease	D019694
17954033_4	95	105	lamivudine	Chemical	D019259

17954033_12|s|CONCLUSION: Although the natural occurrence of YMDD motif mutants in lamivudine-untreated patients with chronic hepatitis B has been reported, these mutants were not detected in Iranian lamivudine-untreated chronic hepatitis B patients.
17954033_12	104	123	chronic hepatitis B	Disease	D019694
17954033_12	207	226	chronic hepatitis B	Disease	D019694
17954033_12	69	79	lamivudine	Chemical	D019259
17954033_12	186	196	lamivudine	Chemical	D019259

18025637_0|s|Branch retinal vein occlusion and fluoxetine.
18025637_0	7	29	retinal vein occlusion	Disease	D012170
18025637_0	34	44	fluoxetine	Chemical	D005473
18025637_0	CID	D005473	D012170

18025637_1|s|A case of branch retinal vein occlusion associated with fluoxetine-induced secondary hypertension is described.
18025637_1	17	39	retinal vein occlusion	Disease	D012170
18025637_1	85	97	hypertension	Disease	D006973
18025637_1	56	66	fluoxetine	Chemical	D005473
18025637_1	CID	D005473	D012170
18025637_1	CID	D005473	D006973

18025637_2|s|Although an infrequent complication of selective serotonin reuptake inhibitor therapy, it is important that ophthalmologists are aware that these agents can cause hypertension because this class of drugs is widely prescribed.
18025637_2	163	175	hypertension	Disease	D006973
18025637_2	49	58	serotonin	Chemical	D012701

18165598_0|s|The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.
18165598_0	118	122	pain	Disease	D010146
18165598_0	137	141	pain	Disease	D010146
18165598_0	28	39	bupivacaine	Chemical	D002045
18165598_0	44	53	lidocaine	Chemical	D008012
18165598_0	57	73	prostaglandin E2	Chemical	D015232

18165598_2|s|In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
18165598_2	177	195	postoperative pain	Disease	D010149
18165598_2	65	76	bupivacaine	Chemical	D002045
18165598_2	86	102	prostaglandin E2	Chemical	D015232
18165598_2	104	108	PGE2	Chemical	D015232
18165598_2	CID	D002045	D010149

18165598_6|s|RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h.
18165598_6	69	73	pain	Disease	D010146
18165598_6	13	24	bupivacaine	Chemical	D002045
18165598_6	25	34	rofecoxib	Chemical	C116926

18165598_7|s|However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
18165598_7	67	71	pain	Disease	D010146
18165598_7	13	24	bupivacaine	Chemical	D002045
18165598_7	84	88	PGE2	Chemical	D015232

18165598_10|s|CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.
18165598_10	91	104	tissue injury	Disease	D017695
18165598_10	158	162	pain	Disease	D010146
18165598_10	40	51	bupivacaine	Chemical	D002045
18165598_10	138	142	PGE2	Chemical	D015232

18189308_0|s|p75NTR expression in rat urinary bladder sensory neurons and spinal cord with cyclophosphamide-induced cystitis.
18189308_0	103	111	cystitis	Disease	D003556
18189308_0	78	94	cyclophosphamide	Chemical	D003520
18189308_0	CID	D003520	D003556

18189308_2|s|Previous studies have examined the expression and regulation of tyrosine kinase receptors (Trks) in micturition reflexes with urinary bladder inflammation.
18189308_2	126	154	urinary bladder inflammation	Disease	D003556
18189308_2	64	72	tyrosine	Chemical	D014443

18189308_3|s|The present studies examine the expression and regulation of another receptor known to bind NGF, p75(NTR), after various durations of bladder inflammation induced by cyclophosphamide (CYP).
18189308_3	134	154	bladder inflammation	Disease	D003556
18189308_3	166	182	cyclophosphamide	Chemical	D003520
18189308_3	184	187	CYP	Chemical	D003520
18189308_3	CID	D003520	D003556

18189308_4|s|CYP-induced cystitis increased (P < or = 0.001) p75(NTR) expression in the superficial lateral and medial dorsal horn in L1-L2 and L6-S1 spinal segments.
18189308_4	12	20	cystitis	Disease	D003556
18189308_4	0	3	CYP	Chemical	D003520
18189308_4	CID	D003520	D003556

18189308_5|s|The number of p75(NTR)-immunoreactive (-IR) cells in the lumbosacral dorsal root ganglia (DRG) also increased (P < or = 0.05) with CYP-induced cystitis (acute, intermediate, and chronic).
18189308_5	143	151	cystitis	Disease	D003556
18189308_5	131	134	CYP	Chemical	D003520
18189308_5	CID	D003520	D003556

18189308_6|s|Quantitative, real-time polymerase chain reaction also demonstrated significant increases (P < or = 0.01) in p75(NTR) mRNA in DRG with intermediate and chronic CYP-induced cystitis.
18189308_6	172	180	cystitis	Disease	D003556
18189308_6	160	163	CYP	Chemical	D003520
18189308_6	CID	D003520	D003556

18340638_2|s|The side effects of azathioprine include anemia, which has been attributed to bone marrow suppression.
18340638_2	41	47	anemia	Disease	D000740
18340638_2	20	32	azathioprine	Chemical	D001379
18340638_2	CID	D001379	D000740

18340638_3|s|Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.
18340638_3	15	21	anemia	Disease	D000740
18340638_3	131	149	phosphatidylserine	Chemical	D010718
18340638_3	151	153	PS	Chemical	D010718

18340638_9|s|CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to azathioprine-induced anemia.
18340638_9	121	127	anemia	Disease	D000740
18340638_9	13	25	Azathioprine	Chemical	D001379
18340638_9	100	112	azathioprine	Chemical	D001379
18340638_9	CID	D001379	D000740

18399341_9|s|Four (10.8%) patients in the conventional group and 1 (2.7%) in the unilateral group, P= 0.17 required epinephrine infusion to treat hypotension.
18399341_9	133	144	hypotension	Disease	D007022
18399341_9	103	114	epinephrine	Chemical	D004837

18422462_4|s|Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
18422462_4	23	29	anemia	Disease	D000740
18422462_4	112	121	hepatitis	Disease	D056486
18422462_4	132	140	jaundice	Disease	D007565
18422462_4	146	153	alanine	Chemical	D000409

18422462_6|s|Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).
18422462_6	102	106	rash	Disease	D005076
18422462_6	139	160	peripheral neuropathy	Disease	D010523
18422462_6	45	48	NVP	Chemical	D019829
18422462_6	111	114	d4T	Chemical	D018119
18422462_6	CID	D018119	D010523
18422462_6	CID	D019829	D005076

18450790_0|s|Thalidomide and sensory neurotoxicity: a neurophysiological study.
18450790_0	16	37	sensory neurotoxicity	Disease	D010523
18450790_0	0	11	Thalidomide	Chemical	D013792
18450790_0	CID	D013792	D010523

18450790_1|s|BACKGROUND: Recent studies confirmed a high incidence of sensory axonal neuropathy in patients treated with different doses of thalidomide.
18450790_1	57	82	sensory axonal neuropathy	Disease	D010523
18450790_1	127	138	thalidomide	Chemical	D013792
18450790_1	CID	D013792	D010523

18450790_2|s|The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.
18450790_2	128	157	cutaneous lupus erythematosus	Disease	D008178
18450790_2	159	162	CLE	Disease	D008178
18450790_2	228	238	neurotoxic	Disease	D020258
18450790_2	177	188	thalidomide	Chemical	D013792
18450790_2	252	263	thalidomide	Chemical	D013792

18450790_3|s|PATIENTS AND METHODS: Clinical and electrophysiological data in 12 female patients with CLE during treatment with thalidomide and up to 47 months after discontinuation of treatment were analysed.
18450790_3	88	91	CLE	Disease	D008178
18450790_3	114	125	thalidomide	Chemical	D013792

18450790_12|s|This electrophysiological parameter provides information about subclinical neurotoxic potential of thalidomide but is not helpful in predicting the appearance of sensory symptoms.
18450790_12	75	85	neurotoxic	Disease	D020258
18450790_12	99	110	thalidomide	Chemical	D013792

18801087_0|s|Amiodarone-related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease: Diagnostic pitfall and new findings.
18801087_0	19	33	pulmonary mass	Disease	D055370
18801087_0	45	74	membranous glomerulonephritis	Disease	D015433
18801087_0	93	115	valvular heart disease	Disease	D006349
18801087_0	0	10	Amiodarone	Chemical	D000638
18801087_0	CID	D000638	D055370
18801087_0	CID	D000638	D015433

18801087_1|s|Amiodarone is an anti-arrhythmic drug for life-threatening tachycardia, but various adverse effects have been reported.
18801087_1	22	32	arrhythmic	Disease	D001145
18801087_1	59	70	tachycardia	Disease	D013610
18801087_1	0	10	Amiodarone	Chemical	D000638

18801087_2|s|Reported herein is an autopsy case of valvular heart disease, in a patient who developed a lung mass (1.5 cm in diameter) and proteinuria (2.76 g/day) after treatment with amiodarone for a long time.
18801087_2	38	60	valvular heart disease	Disease	D006349
18801087_2	91	100	lung mass	Disease	D055370
18801087_2	126	137	proteinuria	Disease	D011507
18801087_2	172	182	amiodarone	Chemical	D000638
18801087_2	CID	D000638	D055370

18801087_3|s|The lung mass was highly suspected to be lung cancer on CT and positron emission tomography, but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra-alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies, indicating that it was an amiodarone-related lesion.
18801087_3	4	13	lung mass	Disease	D055370
18801087_3	41	52	lung cancer	Disease	D008175
18801087_3	310	320	amiodarone	Chemical	D000638
18801087_3	CID	D000638	D055370

18801087_7|s|The present case highlights the possibility that differential diagnosis between an amiodarone-related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment.
18801087_7	102	118	pulmonary lesion	Disease	D055370
18801087_7	125	133	neoplasm	Disease	D009369
18801087_7	190	219	membranous glomerulonephritis	Disease	D015433
18801087_7	83	93	amiodarone	Chemical	D000638
18801087_7	262	272	amiodarone	Chemical	D000638
18801087_7	CID	D000638	D055370
18801087_7	CID	D000638	D015433

18945509_0|s|Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
18945509_0	8	31	coronary artery disease	Disease	D003324
18945509_0	97	112	type 2 diabetes	Disease	D003924
18945509_0	56	69	sulphonylurea	Chemical	-1

18945509_1|s|AIMS: This study sought to assess the risk of developing coronary artery disease (CAD) associated with initial treatment of type 2 diabetes with different sulphonylureas.
18945509_1	57	80	coronary artery disease	Disease	D003324
18945509_1	82	85	CAD	Disease	D003324
18945509_1	124	139	type 2 diabetes	Disease	D003924
18945509_1	155	169	sulphonylureas	Chemical	-1

18945509_5|s|The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.
18945509_5	25	28	CAD	Disease	D003324
18945509_5	118	131	glibenclamide	Chemical	D005905
18945509_5	164	173	glipizide	Chemical	D005913
18945509_5	239	248	metformin	Chemical	D008687
18945509_5	CID	D005905	D003324

18945509_7|s|CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
18945509_7	37	52	type 2 diabetes	Disease	D003924
18945509_7	122	125	CAD	Disease	D003324
18945509_7	58	71	glibenclamide	Chemical	D005905
18945509_7	75	84	glipizide	Chemical	D005913
18945509_7	143	153	gliclazide	Chemical	D005907
18945509_7	157	168	glimepiride	Chemical	C057619
18945509_7	CID	D005905	D003324

18987260_0|s|Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.
18987260_0	34	45	nephropathy	Disease	D007674
18987260_0	63	75	hypertensive	Disease	D006973
18987260_0	23	33	adriamycin	Chemical	D004317
18987260_0	92	100	losartan	Chemical	D019808

18987260_1|s|BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
18987260_1	168	181	renal disease	Disease	D007674
18987260_1	211	223	hypertensive	Disease	D006973
18987260_1	257	268	nephropathy	Disease	D007674
18987260_1	84	98	angiotensin II	Chemical	D000804
18987260_1	124	132	losartan	Chemical	D019808
18987260_1	240	250	adriamycin	Chemical	D004317
18987260_1	252	255	ADR	Chemical	D004317

18987260_9|s|RESULTS: Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria.
18987260_9	125	143	glomerulosclerosis	Disease	D005921
18987260_9	167	178	proteinuria	Disease	D011507
18987260_9	20	28	losartan	Chemical	D019808

18987260_10|s|Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.
18987260_10	62	80	glomerulosclerosis	Disease	D005921
18987260_10	128	135	atrophy	Disease	D001284
18987260_10	140	161	interstitial fibrosis	Disease	D005355
18987260_10	185	196	proteinuria	Disease	D011507
18987260_10	201	222	chronic renal failure	Disease	D007676
18987260_10	25	33	losartan	Chemical	D019808

18987260_11|s|Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.
18987260_11	17	24	uraemia	Disease	D014511
18987260_11	70	81	nephropathy	Disease	D007674
18987260_11	0	8	Losartan	Chemical	D019808
18987260_11	39	43	urea	Chemical	D014508
18987260_11	66	69	ADR	Chemical	D004317
18987260_11	CID	D004317	D014511

18987260_12|s|Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.
18987260_12	68	75	atrophy	Disease	D001284
18987260_12	107	115	fibrosis	Disease	D005355
18987260_12	123	134	nephropathy	Disease	D007674
18987260_12	37	45	losartan	Chemical	D019808
18987260_12	119	122	ADR	Chemical	D004317

18987260_13|s|CONCLUSION: Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.
18987260_13	68	102	focal segmental glomerulosclerosis	Disease	D005923
18987260_13	106	129	end-stage renal disease	Disease	D007676
18987260_13	12	20	Losartan	Chemical	D019808
18987260_13	56	59	ADR	Chemical	D004317
18987260_13	CID	D004317	D005923

19108278_0|s|The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias.1.
19108278_0	85	104	cardiac arrhythmias	Disease	D001145
19108278_0	52	63	propranolol	Chemical	D011433

19108278_8|s|Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.
19108278_8	74	93	cardiac arrhythmias	Disease	D001145
19108278_8	16	27	propranolol	Chemical	D011433
19108278_8	55	65	adrenaline	Chemical	D004837
19108278_8	121	130	halothane	Chemical	D006221
19108278_8	157	168	propranolol	Chemical	D011433
19108278_8	211	222	propranolol	Chemical	D011433
19108278_8	CID	D006221	D001145
19108278_8	CID	D004837	D001145

19108278_10|s|Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline.7.
19108278_10	12	23	arrhythmias	Disease	D001145
19108278_10	85	95	adrenaline	Chemical	D004837
19108278_10	CID	D004837	D001145

19108278_11|s|Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs.
19108278_11	59	82	ventricular tachycardia	Disease	D017180
19108278_11	16	27	propranolol	Chemical	D011433
19108278_11	93	100	ouabain	Chemical	D010042
19108278_11	CID	D010042	D017180

19139825_0|s|Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.
19139825_0	59	71	glioblastoma	Disease	D005909
19139825_0	0	9	Topotecan	Chemical	D019772

19139825_2|s|Topotecan is an attractive option as it exhibits growth inhibition of human glioma as well as brain penetration.
19139825_2	76	82	glioma	Disease	D005910
19139825_2	0	9	Topotecan	Chemical	D019772

19139825_3|s|The present study assessed the combination of radiotherapy (60 Gy/30 fractions/40 days) and topotecan (0.9 mg/m(2)/day on days 1-5 on weeks 1, 3 and 5) in 50 adults with histologically proven and untreated GBM.
19139825_3	206	209	GBM	Disease	D005909
19139825_3	92	101	topotecan	Chemical	D019772

19154241_0|s|Long-term lithium therapy leading to hyperparathyroidism: a case report.
19154241_0	37	56	hyperparathyroidism	Disease	D006961
19154241_0	10	17	lithium	Chemical	D008094
19154241_0	CID	D008094	D006961

19154241_2|s|We examined the case of a lithium-treated patient who had recurrent hypercalcemia to better understand the disease process.
19154241_2	68	81	hypercalcemia	Disease	D006934
19154241_2	26	33	lithium	Chemical	D008094
19154241_2	CID	D008094	D006934

19154241_3|s|CONCLUSION: Primary hyperparathyroidism is a rare but potentially life-threatening side effect of long-term lithium therapy.
19154241_3	12	39	Primary hyperparathyroidism	Disease	D049950
19154241_3	108	115	lithium	Chemical	D008094

19154241_5|s|PRACTICAL IMPLICATIONS: As much as 15% of lithium-treated patients become hypercalcemic.
19154241_5	74	87	hypercalcemic	Disease	D006934
19154241_5	42	49	lithium	Chemical	D008094
19154241_5	CID	D008094	D006934

19178808_1|s|BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of intraoperative bleeding as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by propofol-remifentanil total i.v. anesthesia (TIVA).
19178808_1	113	121	bleeding	Disease	D006470
19178808_1	327	338	hypotension	Disease	D007022
19178808_1	361	369	propofol	Chemical	D015742
19178808_1	370	382	remifentanil	Chemical	C071741
19178808_1	CID	D015742	D007022
19178808_1	CID	C071741	D007022

19178808_2|s|METHODS: Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol-remifentanil-TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT.
19178808_2	119	130	hypotension	Disease	D007022
19178808_2	152	160	propofol	Chemical	D015742
19178808_2	161	173	remifentanil	Chemical	C071741
19178808_2	CID	D015742	D007022
19178808_2	CID	C071741	D007022

19178808_4|s|RESULTS: Controlled hypotension was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of remifentanil.
19178808_4	20	31	hypotension	Disease	D007022
19178808_4	111	123	remifentanil	Chemical	C071741
19178808_4	157	169	remifentanil	Chemical	C071741
19178808_4	CID	C071741	D007022

19178808_5|s|CONCLUSION: In summary, our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS.
19178808_5	98	109	hypotension	Disease	D007022
19178808_5	246	257	hypotension	Disease	D007022
19178808_5	276	288	remifentanil	Chemical	C071741
19178808_5	CID	C071741	D007022

19184102_0|s|Nonalcoholic fatty liver disease during valproate therapy.
19184102_0	0	32	Nonalcoholic fatty liver disease	Disease	D065626
19184102_0	40	49	valproate	Chemical	D014635
19184102_0	CID	D014635	D065626

19184102_1|s|Valproic acid (VPA) is effective for the treatment of many types of epilepsy, but its use can be associated with an increase in body weight.
19184102_1	68	76	epilepsy	Disease	D004827
19184102_1	0	13	Valproic acid	Chemical	D014635
19184102_1	15	18	VPA	Chemical	D014635

19184102_2|s|We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during VPA treatment.
19184102_2	20	52	nonalcoholic fatty liver disease	Disease	D065626
19184102_2	54	59	NAFLD	Disease	D065626
19184102_2	94	101	obesity	Disease	D009765
19184102_2	109	112	VPA	Chemical	D014635
19184102_2	CID	D014635	D009765
19184102_2	CID	D014635	D065626

19184102_4|s|After the withdrawal of VPA therapy, our patient showed a significant weight loss, a decrease of body mass index, and normalization of metabolic and endocrine parameters; moreover, ultrasound measurements showed a complete normalization.
19184102_4	70	81	weight loss	Disease	D015431
19184102_4	24	27	VPA	Chemical	D014635

19184102_5|s|The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.
19184102_5	31	38	obesity	Disease	D009765
19184102_5	40	56	hyperinsulinemia	Disease	D006946
19184102_5	58	76	insulin resistance	Disease	D007333
19184102_5	157	162	NAFLD	Disease	D065626
19184102_5	107	110	VPA	Chemical	D014635
19184102_5	201	204	VPA	Chemical	D014635
19184102_5	CID	D014635	D009765
19184102_5	CID	D014635	D006946
19184102_5	CID	D014635	D065626
19184102_5	CID	D014635	D007333

19263707_0|s|Carbimazole induced ANCA positive vasculitis.
19263707_0	20	44	ANCA positive vasculitis	Disease	D056648
19263707_0	0	11	Carbimazole	Chemical	D002231
19263707_0	CID	D002231	D056648

19263707_1|s|Anti-thyroid drugs, like carbimazole and propylthiouracil (PTU) are commonly prescribed for the treatment of hyperthyroidism.
19263707_1	109	124	hyperthyroidism	Disease	D006980
19263707_1	0	18	Anti-thyroid drugs	Chemical	D013956
19263707_1	25	36	carbimazole	Chemical	D002231
19263707_1	41	57	propylthiouracil	Chemical	D011441
19263707_1	59	62	PTU	Chemical	D011441

19263707_3|s|Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications.
19263707_3	0	65	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis	Disease	D056648
19263707_3	118	140	antithyroidmedications	Chemical	D013956
19263707_3	CID	D013956	D056648

19263707_4|s|We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis.
19263707_4	25	40	Graves' disease	Disease	D006111
19263707_4	89	99	vasculitis	Disease	D014657
19263707_4	69	80	carbimazole	Chemical	D002231

19263707_8|s|To the best of our knowledge this is the first ANCA positive carbimazole induced vasculitis case reported from India.
19263707_8	81	91	vasculitis	Disease	D014657
19263707_8	61	72	carbimazole	Chemical	D002231

19293073_4|s|Preventive Services Task Force (USPSTF) strongly recommended that clinicians discuss aspirin with adults who are at increased risk for coronary heart disease.
19293073_4	135	157	coronary heart disease	Disease	D003327
19293073_4	85	92	aspirin	Chemical	D001241

19293073_5|s|PURPOSE: To determine the benefits and harms of taking aspirin for the primary prevention of myocardial infarctions, strokes, and death.
19293073_5	93	115	myocardial infarctions	Disease	D009203
19293073_5	117	124	strokes	Disease	D020521
19293073_5	55	62	aspirin	Chemical	D001241
19293073_5	CID	D001241	D020521

19293073_7|s|STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?
19293073_7	188	210	cardiovascular disease	Disease	D002318
19293073_7	212	215	CVD	Disease	D002318
19293073_7	311	318	strokes	Disease	D020521
19293073_7	356	362	stroke	Disease	D020521
19293073_7	411	414	CVD	Disease	D002318
19293073_7	135	142	aspirin	Chemical	D001241
19293073_7	271	278	aspirin	Chemical	D001241
19293073_7	CID	D001241	D020521

19293073_8|s|Does aspirin increase gastrointestinal bleeding or hemorrhagic strokes?
19293073_8	22	47	gastrointestinal bleeding	Disease	D006471
19293073_8	51	70	hemorrhagic strokes	Disease	D020300|D020521
19293073_8	5	12	aspirin	Chemical	D001241
19293073_8	CID	D001241	D020521
19293073_8	CID	D001241	D020300
19293073_8	CID	D001241	D006471

19293073_10|s|DATA SYNTHESIS: New evidence from 1 good-quality RCT, 1 good-quality meta-analysis, and 2 fair-quality subanalyses of RCTs demonstrates that aspirin use reduces the number of CVD events in patients without known CVD.
19293073_10	175	178	CVD	Disease	D002318
19293073_10	212	215	CVD	Disease	D002318
19293073_10	141	148	aspirin	Chemical	D001241

19293073_12|s|Aspirin does not seem to affect CVD mortality or all-cause mortality in either men or women.
19293073_12	32	35	CVD	Disease	D002318
19293073_12	0	7	Aspirin	Chemical	D001241

19293073_13|s|The use of aspirin for primary prevention increases the risk for major bleeding events, primarily gastrointestinal bleeding events, in both men and women.
19293073_13	71	79	bleeding	Disease	D006470
19293073_13	98	123	gastrointestinal bleeding	Disease	D006471
19293073_13	11	18	aspirin	Chemical	D001241
19293073_13	CID	D001241	D006471

19293073_14|s|Men have an increased risk for hemorrhagic strokes with aspirin use.
19293073_14	31	50	hemorrhagic strokes	Disease	D020300|D020521
19293073_14	56	63	aspirin	Chemical	D001241
19293073_14	CID	D001241	D020521
19293073_14	CID	D001241	D020300

19293073_16|s|LIMITATIONS: New evidence on aspirin for the primary prevention of CVD is limited.
19293073_16	67	70	CVD	Disease	D002318
19293073_16	29	36	aspirin	Chemical	D001241

19293073_19|s|CONCLUSION: Aspirin reduces the risk for myocardial infarction in men and strokes in women.
19293073_19	41	62	myocardial infarction	Disease	D009203
19293073_19	74	81	strokes	Disease	D020521
19293073_19	12	19	Aspirin	Chemical	D001241
19293073_19	CID	D001241	D020521

19293073_20|s|Aspirin use increases the risk for serious bleeding events.
19293073_20	43	51	bleeding	Disease	D006470
19293073_20	0	7	Aspirin	Chemical	D001241

19338378_0|s|Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
19338378_0	113	129	thrombocytopenia	Disease	D013921
19338378_0	75	85	argatroban	Chemical	C031942
19338378_0	97	104	heparin	Chemical	D006493

19338378_1|s|Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).
19338378_1	104	114	thrombosis	Disease	D013927
19338378_1	134	150	thrombocytopenia	Disease	D013921
19338378_1	152	155	HIT	Disease	D013921
19338378_1	193	196	HIT	Disease	D013921
19338378_1	0	10	Argatroban	Chemical	C031942
19338378_1	118	125	heparin	Chemical	D006493

19338378_2|s|The objective of this review is to summarize practical considerations of argatroban therapy in HIT.
19338378_2	95	98	HIT	Disease	D013921
19338378_2	73	83	argatroban	Chemical	C031942

19338378_3|s|The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds).
19338378_3	42	45	HIT	Disease	D013921
19338378_3	91	109	hepatic impairment	Disease	D008107
19338378_3	23	33	argatroban	Chemical	C031942

19338378_7|s|For PCI, argatroban has not been investigated in hepatically impaired patients; dose adjustment is unnecessary for adult age, sex, race/ethnicity or obesity, and lesser doses may be adequate with concurrent glycoprotein IIb/IIIa inhibition.
19338378_7	149	156	obesity	Disease	D009765
19338378_7	9	19	argatroban	Chemical	C031942

19338378_9|s|Major bleeding with argatroban is 0-10% in the non-interventional setting and 0-5.8% periprocedurally.
19338378_9	6	14	bleeding	Disease	D006470
19338378_9	20	30	argatroban	Chemical	C031942
19338378_9	CID	C031942	D006470

19338378_11|s|Improved familiarity of healthcare professionals with argatroban therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer thromboses) or its treatment (e.g. fewer argatroban medication errors).
19338378_11	76	79	HIT	Disease	D013921
19338378_11	179	182	HIT	Disease	D013921
19338378_11	54	64	argatroban	Chemical	C031942
19338378_11	236	246	argatroban	Chemical	C031942

19392810_0|s|Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy.
19392810_0	0	14	Rhabdomyolysis	Disease	D012206
19392810_0	25	40	ischemic stroke	Disease	D002544
19392810_0	46	52	heroin	Chemical	D003932
19392810_0	74	83	methadone	Chemical	D008691
19392810_0	CID	D003932	D012206
19392810_0	CID	D008691	D012206

19392810_4|s|RESULTS: A 33-year-old man presented with rhabdomyolysis and cerebral ischemic stroke after intravenous heroin.
19392810_4	42	56	rhabdomyolysis	Disease	D012206
19392810_4	70	85	ischemic stroke	Disease	D002544
19392810_4	104	110	heroin	Chemical	D003932
19392810_4	CID	D003932	D012206

19392810_11|s|CONCLUSION: Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke.
19392810_11	81	95	rhabdomyolysis	Disease	D012206
19392810_11	100	115	ischemic stroke	Disease	D002544
19392810_11	24	33	methadone	Chemical	D008691
19392810_11	38	44	heroin	Chemical	D003932
19392810_11	CID	D003932	D012206
19392810_11	CID	D008691	D012206

19392810_13|s|Hypotheses of heroin-related rhabdomyolysis and stroke in heroin abusers are discussed.
19392810_13	29	43	rhabdomyolysis	Disease	D012206
19392810_13	48	54	stroke	Disease	D020521
19392810_13	14	20	heroin	Chemical	D003932
19392810_13	58	64	heroin	Chemical	D003932
19392810_13	CID	D003932	D012206
19392810_13	CID	D003932	D020521

19419794_0|s|Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.
19419794_0	79	90	dyskinesias	Disease	D004409
19419794_0	27	44	6-hydroxydopamine	Chemical	D016627

19419794_5|s|Treatment with L-DOPA+benserazide (12 weeks) resulted in less severe dyskinesias in CB1 KO than in WT mice.
19419794_5	69	80	dyskinesias	Disease	D004409
19419794_5	15	33	L-DOPA+benserazide	Chemical	C005177

19419794_6|s|The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion, and reduced L-DOPA-induced dyskinesias.
19419794_6	149	160	dyskinesias	Disease	D004409
19419794_6	111	113	DA	Chemical	D004298
19419794_6	134	140	L-DOPA	Chemical	D007980
19419794_6	CID	D007980	D004409

19419794_7|s|These results suggest that activation of CB1 receptors offers neuroprotection against dopaminergic lesion and the development of L-DOPA-induced dyskinesias.
19419794_7	144	155	dyskinesias	Disease	D004409
19419794_7	129	135	L-DOPA	Chemical	D007980
19419794_7	CID	D007980	D004409

19447152_0|s|Animal model of mania induced by ouabain: Evidence of oxidative stress in submitochondrial particles of the rat brain.
19447152_0	16	21	mania	Disease	D001714
19447152_0	33	40	ouabain	Chemical	D010042
19447152_0	CID	D010042	D001714

19447152_1|s|The intracerebroventricular (ICV) administration of ouabain (a Na(+)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania.
19447152_1	151	164	bipolar mania	Disease	D001714
19447152_1	52	59	ouabain	Chemical	D010042
19447152_1	63	65	Na	Chemical	D012964
19447152_1	69	70	K	Chemical	D011188
19447152_1	CID	D010042	D001714

19447152_6|s|Our findings demonstrated that ouabain at 10(-2) and 10(-3)M induced hyperlocomotion in rats, and this response remained up to 7 days following a single ICV injection.
19447152_6	69	84	hyperlocomotion	Disease	D009069
19447152_6	31	38	ouabain	Chemical	D010042

19447152_8|s|In conclusion, ouabain-induced mania-like behavior may provide a useful animal model to test the hypothesis of the involvement of oxidative stress in bipolar disorder.
19447152_8	31	36	mania	Disease	D001714
19447152_8	150	166	bipolar disorder	Disease	D001714
19447152_8	15	22	ouabain	Chemical	D010042
19447152_8	CID	D010042	D001714

19515070_4|s|Systemic anticoagulation is unsafe and regional citrate anticoagulation in the absence of a functional liver carries the risk of citrate toxicity.
19515070_4	137	145	toxicity	Disease	D064420
19515070_4	48	55	citrate	Chemical	D019343
19515070_4	129	136	citrate	Chemical	D019343

19515070_6|s|We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.
19515070_6	68	91	fulminant liver failure	Disease	D017114
19515070_6	108	111	AKI	Disease	D058186
19515070_6	46	59	acetaminophen	Chemical	D000082
19515070_6	207	214	citrate	Chemical	D019343
19515070_6	CID	D000082	D017114
19515070_6	CID	D000082	D058186

19515070_7|s|The patient tolerated the procedure well without any signs of citrate toxicity and maintained adequate anticoagulation for patency of the dialysis circuit.
19515070_7	70	78	toxicity	Disease	D064420
19515070_7	62	69	citrate	Chemical	D019343

19515070_8|s|Citrate dialysate is a safe alternative for intradialytic support of liver transplantation in fulminant liver failure.
19515070_8	94	117	fulminant liver failure	Disease	D017114
19515070_8	0	7	Citrate	Chemical	D019343

19531695_0|s|Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.
19531695_0	0	8	Delirium	Disease	D003693
19531695_0	33	43	flecainide	Chemical	D005424
19531695_0	119	129	paroxetine	Chemical	D017374
19531695_0	CID	D005424	D003693
19531695_0	CID	D017374	D003693

19531695_1|s|OBJECTIVE: To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with paroxetine.
19531695_1	52	60	delirium	Disease	D003693
19531695_1	33	43	flecainide	Chemical	D005424
19531695_1	117	127	paroxetine	Chemical	D017374
19531695_1	CID	D005424	D003693
19531695_1	CID	D017374	D003693

19531695_4|s|Flecainide had been started 2 weeks prior for atrial fibrillation.
19531695_4	46	65	atrial fibrillation	Disease	D001281
19531695_4	0	10	Flecainide	Chemical	D005424

19531695_9|s|DISCUSSION: Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients.
19531695_9	105	113	delirium	Disease	D003693
19531695_9	12	22	Flecainide	Chemical	D005424
19531695_9	79	85	sodium	Chemical	D012964
19531695_9	CID	D005424	D003693

19531695_10|s|A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.
19531695_10	223	231	delirium	Disease	D003693
19531695_10	107	117	flecainide	Chemical	D005424
19531695_10	143	153	paroxetine	Chemical	D017374
19531695_10	204	214	flecainide	Chemical	D005424
19531695_10	CID	D005424	D003693
19531695_10	CID	D017374	D003693

19531695_11|s|According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine.
19531695_11	95	103	delirium	Disease	D003693
19531695_11	44	54	flecainide	Chemical	D005424
19531695_11	211	221	flecainide	Chemical	D005424
19531695_11	226	236	paroxetine	Chemical	D017374
19531695_11	CID	D005424	D003693
19531695_11	CID	D017374	D003693

19531695_12|s|CONCLUSIONS: Supratherapeutic flecainide plasma concentrations may cause delirium.
19531695_12	73	81	delirium	Disease	D003693
19531695_12	30	40	flecainide	Chemical	D005424
19531695_12	CID	D005424	D003693

19531695_13|s|Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors.
19531695_13	8	16	toxicity	Disease	D064420
19531695_13	32	42	flecainide	Chemical	D005424
19531695_13	62	72	paroxetine	Chemical	D017374
19531695_13	109	119	flecainide	Chemical	D005424

19549709_0|s|Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.
19549709_0	58	63	NSCLC	Disease	D002289
19549709_0	12	22	everolimus	Chemical	C107135
19549709_0	24	30	RAD001	Chemical	C107135

19549709_2|s|RAD001, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC.
19549709_2	101	106	NSCLC	Disease	D002289
19549709_2	0	6	RAD001	Chemical	C107135
19549709_2	53	62	rapamycin	Chemical	D020123

19549709_3|s|METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.
19549709_3	26	31	NSCLC	Disease	D002289
19549709_3	278	286	toxicity	Disease	D064420
19549709_3	93	101	platinum	Chemical	D010984
19549709_3	178	186	tyrosine	Chemical	D014443
19549709_3	227	233	RAD001	Chemical	C107135

19549709_13|s|CONCLUSIONS: RAD001 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC.
19549709_13	97	102	NSCLC	Disease	D002289
19549709_13	13	19	RAD001	Chemical	C107135

19549709_14|s|Evaluation of RAD001 plus standard therapy for metastatic NSCLC continues.
19549709_14	58	63	NSCLC	Disease	D002289
19549709_14	14	20	RAD001	Chemical	C107135

19553912_0|s|Posttransplant anemia: the role of sirolimus.
19553912_0	15	21	anemia	Disease	D000740
19553912_0	35	44	sirolimus	Chemical	D020123
19553912_0	CID	D020123	D000740

19553912_4|s|Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia.
19553912_4	118	124	anemia	Disease	D000740
19553912_4	0	9	Sirolimus	Chemical	D020123
19553912_4	33	42	rapamycin	Chemical	D020123
19553912_4	CID	D020123	D000740

19553912_5|s|This review considers anemia associated with sirolimus, including its presentation, mechanisms, and management.
19553912_5	22	28	anemia	Disease	D000740
19553912_5	45	54	sirolimus	Chemical	D020123
19553912_5	CID	D020123	D000740

19655282_0|s|Coronary computerized tomography angiography for rapid discharge of low-risk patients with cocaine-associated chest pain.
19655282_0	110	120	chest pain	Disease	D002637
19655282_0	91	98	cocaine	Chemical	D003042
19655282_0	CID	D003042	D002637

19655282_1|s|BACKGROUND: Most patients presenting to emergency departments (EDs) with cocaine-associated chest pain are admitted for at least 12 hours and receive a "rule out acute coronary syndrome" protocol, often with noninvasive testing prior to discharge.
19655282_1	92	102	chest pain	Disease	D002637
19655282_1	162	185	acute coronary syndrome	Disease	D054058
19655282_1	73	80	cocaine	Chemical	D003042
19655282_1	CID	D003042	D002637

19655282_3|s|It is unclear whether a coronary CTA strategy would be efficacious in cocaine-associated chest pain, as coronary vasospasm may account for some of the ischemia.
19655282_3	89	99	chest pain	Disease	D002637
19655282_3	104	122	coronary vasospasm	Disease	D003329
19655282_3	151	159	ischemia	Disease	D007511
19655282_3	70	77	cocaine	Chemical	D003042
19655282_3	CID	D003042	D002637

19655282_4|s|We studied whether a negative coronary CTA in patients with cocaine-associated chest pain could identify a subset safe for discharge.
19655282_4	79	89	chest pain	Disease	D002637
19655282_4	60	67	cocaine	Chemical	D003042
19655282_4	CID	D003042	D002637

19655282_9|s|RESULTS: A total of 59 patients with cocaine-associated chest pain were evaluated.
19655282_9	56	66	chest pain	Disease	D002637
19655282_9	37	44	cocaine	Chemical	D003042
19655282_9	CID	D003042	D002637

19655282_16|s|CONCLUSIONS: Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.
19655282_16	41	60	myocardial ischemia	Disease	D017202
19655282_16	137	147	chest pain	Disease	D002637
19655282_16	155	163	ischemic	Disease	D007511
19655282_16	22	29	cocaine	Chemical	D003042
19655282_16	118	125	cocaine	Chemical	D003042
19655282_16	CID	D003042	D002637
19655282_16	CID	D003042	D017202

19728177_2|s|METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema.
19728177_2	131	134	FHF	Disease	D017114
19728177_2	168	182	cerebral edema	Disease	D001929
19728177_2	140	153	acetaminophen	Chemical	D000082
19728177_2	CID	D000082	D017114
19728177_2	CID	D000082	D001929

19728177_3|s|RESULTS: Our patient was admitted to the MICU after being found unresponsive with presumed toxicity from acetaminophen which was ingested over a 2-day period.
19728177_3	91	99	toxicity	Disease	D064420
19728177_3	105	118	acetaminophen	Chemical	D000082

19728177_5|s|Initial evaluation confirmed FHF from acetaminophen and cerebral edema.
19728177_5	29	32	FHF	Disease	D017114
19728177_5	56	70	cerebral edema	Disease	D001929
19728177_5	38	51	acetaminophen	Chemical	D000082
19728177_5	CID	D000082	D017114
19728177_5	CID	D000082	D001929

19728177_11|s|CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.
19728177_11	29	32	FHF	Disease	D017114
19728177_11	37	51	cerebral edema	Disease	D001929
19728177_11	71	79	overdose	Disease	D062787
19728177_11	103	114	hypothermia	Disease	D007035
19728177_11	57	70	acetaminophen	Chemical	D000082
19728177_11	CID	D000082	D017114
19728177_11	CID	D000082	D001929

19815465_0|s|Binasal visual field defects are not specific to vigabatrin.
19815465_0	0	28	Binasal visual field defects	Disease	D014786
19815465_0	49	59	vigabatrin	Chemical	D020888
19815465_0	CID	D020888	D014786

19815465_1|s|This study investigated the visual defects associated with the antiepileptic drug vigabatrin (VGB).
19815465_1	28	42	visual defects	Disease	D014786
19815465_1	82	92	vigabatrin	Chemical	D020888
19815465_1	94	97	VGB	Chemical	D020888
19815465_1	CID	D020888	D014786

19815465_2|s|Two hundred four people with epilepsy were grouped on the basis of antiepileptic drug therapy (current, previous, or no exposure to VGB).
19815465_2	29	37	epilepsy	Disease	D004827
19815465_2	132	135	VGB	Chemical	D020888

19815465_8|s|Assessment by conventional static perimetry may neither be sufficiently sensitive nor specific to reliably identify retinal toxicity associated with VGB.
19815465_8	116	132	retinal toxicity	Disease	D012164
19815465_8	149	152	VGB	Chemical	D020888
19815465_8	CID	D020888	D012164

19841052_0|s|Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs.
19841052_0	46	59	HIV infection	Disease	D015658
19841052_0	11	24	crack cocaine	Chemical	D016578

19841052_1|s|BACKGROUND: Little is known about the possible role that smoking crack cocaine has on the incidence of HIV infection.
19841052_1	103	116	HIV infection	Disease	D015658
19841052_1	65	78	crack cocaine	Chemical	D016578

19841052_2|s|Given the increasing use of crack cocaine, we sought to examine whether use of this illicit drug has become a risk factor for HIV infection.
19841052_2	126	139	HIV infection	Disease	D015658
19841052_2	28	41	crack cocaine	Chemical	D016578

19841052_4|s|To determine whether the risk of HIV seroconversion among daily smokers of crack cocaine changed over time, we used Cox proportional hazards regression and divided the study into 3 periods: May 1, 1996-Nov. 30, 1999 (period 1), Dec. 1, 1999-Nov. 30, 2002 (period 2), and Dec. 1, 2002-Dec. 30, 2005 (period 3).
19841052_4	33	51	HIV seroconversion	Disease	D006679
19841052_4	75	88	crack cocaine	Chemical	D016578
19841052_4	CID	D016578	D006679

19841052_8|s|After adjusting for potential confounders, we found that the risk of HIV seroconversion among participants who were daily smokers of crack cocaine increased over time (period 1: hazard ratio [HR] 1.03, 95% confidence interval [CI] 0.57-1.85; period 2: HR 1.68, 95% CI 1.01-2.80; and period 3: HR 2.74, 95% CI 1.06-7.11).
19841052_8	69	87	HIV seroconversion	Disease	D006679
19841052_8	133	146	crack cocaine	Chemical	D016578
19841052_8	CID	D016578	D006679

19841052_9|s|INTERPRETATION: Smoking of crack cocaine was found to be an independent risk factor for HIV seroconversion among people who were injection drug users.
19841052_9	88	106	HIV seroconversion	Disease	D006679
19841052_9	27	40	crack cocaine	Chemical	D016578
19841052_9	CID	D016578	D006679

19914299_0|s|Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil.
19914299_0	24	39	memory deficits	Disease	D008569
19914299_0	0	10	Fluoxetine	Chemical	D005473
19914299_0	73	87	5-fluorouracil	Chemical	D005472
19914299_0	CID	D005472	D008569

19920070_0|s|Liver-specific ablation of integrin-linked kinase in mice results in enhanced and prolonged cell proliferation and hepatomegaly after phenobarbital administration.
19920070_0	115	127	hepatomegaly	Disease	D006529
19920070_0	134	147	phenobarbital	Chemical	D010634
19920070_0	CID	D010634	D006529

19967075_0|s|Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced Nephropathy.
19967075_0	84	95	Nephropathy	Disease	D007674
19967075_0	24	26	Na	Chemical	D012964
19967075_0	27	28	K	Chemical	D011188
19967075_0	65	75	Gentamicin	Chemical	D005839
19967075_0	CID	D005839	D007674

19967075_1|s|The present study was aimed to determine whether there is an altered regulation of tubular transporters in gentamicin-induced nephropathy.
19967075_1	126	137	nephropathy	Disease	D007674
19967075_1	107	117	gentamicin	Chemical	D005839
19967075_1	CID	D005839	D007674

19967075_9|s|Gentamicin-induced nephropathy may at least in part be causally related with a decreased expression of Na(+)/K(+)-ATPase, NHE3, NBC1, AQP1 and OAT.
19967075_9	19	30	nephropathy	Disease	D007674
19967075_9	0	10	Gentamicin	Chemical	D005839
19967075_9	103	105	Na	Chemical	D012964
19967075_9	109	110	K	Chemical	D011188
19967075_9	CID	D005839	D007674

20024739_0|s|Longitudinal association of alcohol use with HIV disease progression and psychological health of women with HIV.
20024739_0	45	56	HIV disease	Disease	D015658
20024739_0	28	35	alcohol	Chemical	D000431

20024739_1|s|We evaluated the association of alcohol consumption and depression, and their effects on HIV disease progression among women with HIV.
20024739_1	56	66	depression	Disease	D003866
20024739_1	89	100	HIV disease	Disease	D015658
20024739_1	32	39	alcohol	Chemical	D000431
20024739_1	CID	D000431	D003866

20024739_3|s|The participants had physical examination, medical record extraction, and venipuncture, CD4+T-cell counts determination, measurement of depression symptoms (using the self-report Center for Epidemiological Studies-Depression Scale), and alcohol use assessment at enrollment, and semiannually until March 2000.
20024739_3	136	146	depression	Disease	D003866
20024739_3	214	224	Depression	Disease	D003866
20024739_3	237	244	alcohol	Chemical	D000431
20024739_3	CID	D000431	D003866

20024739_7|s|The association between alcohol consumption and depression was significant (p<0.001).
20024739_7	48	58	depression	Disease	D003866
20024739_7	24	31	alcohol	Chemical	D000431
20024739_7	CID	D000431	D003866

20024739_9|s|Our findings suggest that alcohol consumption has a direct association with depression.
20024739_9	76	86	depression	Disease	D003866
20024739_9	26	33	alcohol	Chemical	D000431
20024739_9	CID	D000431	D003866

20034406_0|s|Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus.
20034406_0	100	118	status epilepticus	Disease	D013226
20034406_0	80	91	pilocarpine	Chemical	D010862
20034406_0	CID	D010862	D013226

20034406_3|s|In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by pilocarpine injection.
20034406_3	62	80	status epilepticus	Disease	D013226
20034406_3	82	84	SE	Disease	D013226
20034406_3	97	108	pilocarpine	Chemical	D010862
20034406_3	CID	D010862	D013226

20034406_4|s|METHODS: SE was induced by pilocarpine injection.
20034406_4	9	11	SE	Disease	D013226
20034406_4	27	38	pilocarpine	Chemical	D010862
20034406_4	CID	D010862	D013226

20034406_16|s|CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after pilocarpine-induced SE.
20034406_16	107	109	SE	Disease	D013226
20034406_16	87	98	pilocarpine	Chemical	D010862
20034406_16	CID	D010862	D013226

20046642_3|s|The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal cognitive dysfunction in rats.
20046642_3	103	124	cognitive dysfunction	Disease	D003072
20046642_3	49	51	MT	Chemical	D008668
20046642_3	65	75	carmustine	Chemical	D002330
20046642_3	77	81	BCNU	Chemical	D002330
20046642_3	CID	D002330	D003072

20046642_8|s|The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
20046642_8	64	111	deterioration of learning and short-term memory	Disease	D007859|D008569
20046642_8	32	36	BCNU	Chemical	D002330
20046642_8	202	213	glutathione	Chemical	D005978
20046642_8	250	261	glutathione	Chemical	D005978
20046642_8	263	266	GSH	Chemical	D005978
20046642_8	CID	D002330	D008569
20046642_8	CID	D002330	D007859

20046642_9|s|Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
20046642_9	42	47	tumor	Disease	D009369
20046642_9	48	56	necrosis	Disease	D009336
20046642_9	6	10	BCNU	Chemical	D002330
20046642_9	94	96	MT	Chemical	D008668
20046642_9	101	116	malondialdehyde	Chemical	D008315
20046642_9	118	121	MDA	Chemical	D008315

20046642_12|s|In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.
20046642_12	59	67	toxicity	Disease	D064420
20046642_12	15	17	MT	Chemical	D008668
20046642_12	34	38	BCNU	Chemical	D002330
20046642_12	102	105	GSH	Chemical	D005978
20046642_12	167	170	MDA	Chemical	D008315

20129423_0|s|Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.
20129423_0	28	50	fulminant eosinophilic	Disease	D004802
20129423_0	52	68	hypersensitivity	Disease	D004342
20129423_0	70	81	myocarditis	Disease	D009205
20129423_0	167	188	drug hypersensitivity	Disease	D004342
20129423_0	6	19	carbamazepine	Chemical	D002220
20129423_0	CID	D002220	D009205
20129423_0	CID	D002220	D004802
20129423_0	CID	D002220	D004342

20129423_2|s|A frequently fatal, although exceptionally rare side effect of carbamazepine is necrotizing eosinophilic (hypersensitivity) myocarditis.
20129423_2	106	122	hypersensitivity	Disease	D004342
20129423_2	124	135	myocarditis	Disease	D009205
20129423_2	63	76	carbamazepine	Chemical	D002220
20129423_2	CID	D002220	D009205
20129423_2	CID	D002220	D004342

20129423_3|s|We report a case of hypersensitivity myocarditis secondary to administration of carbamazepine.
20129423_3	20	36	hypersensitivity	Disease	D004342
20129423_3	37	48	myocarditis	Disease	D009205
20129423_3	80	93	carbamazepine	Chemical	D002220
20129423_3	CID	D002220	D009205
20129423_3	CID	D002220	D004342

20129423_7|s|To best of our knowledge this is the second case of fatal carbamazepine induced myocarditis reported in English literature.
20129423_7	80	91	myocarditis	Disease	D009205
20129423_7	58	71	carbamazepine	Chemical	D002220
20129423_7	CID	D002220	D009205

20169779_0|s|Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.
20169779_0	57	76	Parkinson's disease	Disease	D010302
20169779_0	34	38	MPTP	Chemical	D015632

20169779_3|s|The levodopa-treated MPTP-lesioned marmoset was used as a model of neuropsychiatric symptoms in PD patients.
20169779_3	67	92	neuropsychiatric symptoms	Disease	D001523
20169779_3	96	98	PD	Disease	D010302
20169779_3	4	12	levodopa	Chemical	D007980
20169779_3	21	25	MPTP	Chemical	D015632

20169779_4|s|Here we compare the time course of levodopa-induced motor fluctuations and neuropsychiatric-like behaviors to determine the relationship between duration of treatment and onset of symptoms.
20169779_4	75	106	neuropsychiatric-like behaviors	Disease	D001523
20169779_4	35	43	levodopa	Chemical	D007980

20169779_5|s|METHODS: Marmosets were administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (2.0 mg/kg s.c.) for five days, resulting in stable parkinsonism.
20169779_5	134	146	parkinsonism	Disease	D010302
20169779_5	37	81	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	Chemical	D015632

20169779_7|s|Animals were evaluated for parkinsonian disability, dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day.
20169779_7	27	50	parkinsonian disability	Disease	D020734
20169779_7	52	62	dyskinesia	Disease	D004409
20169779_7	100	131	neuropsychiatric-like behaviors	Disease	D001523
20169779_7	151	159	levodopa	Chemical	D007980
20169779_7	CID	D007980	D004409

20169779_9|s|As anticipated, animals exhibited a progressive increase in levodopa-induced motor fluctuations, dyskinesia and wearing-off, that correlated with the duration of levodopa therapy.
20169779_9	97	107	dyskinesia	Disease	D004409
20169779_9	60	68	levodopa	Chemical	D007980
20169779_9	162	170	levodopa	Chemical	D007980
20169779_9	CID	D007980	D004409

20169779_10|s|In contrast, levodopa-induced neuropsychiatric-like behaviors were present on Day 1 of levodopa treatment and their severity did not correlate with duration of treatment.
20169779_10	30	61	neuropsychiatric-like behaviors	Disease	D001523
20169779_10	13	21	levodopa	Chemical	D007980
20169779_10	87	95	levodopa	Chemical	D007980

20169779_11|s|CONCLUSIONS: The data suggest that neuropsychiatric disorders in PD are more likely an interaction between levodopa and the disease state than a consequence of sensitisation to repeated dopaminergic therapy.
20169779_11	35	61	neuropsychiatric disorders	Disease	D001523
20169779_11	65	67	PD	Disease	D010302
20169779_11	107	115	levodopa	Chemical	D007980

20192893_0|s|Contrast medium nephrotoxicity after renal artery and coronary angioplasty.
20192893_0	16	30	nephrotoxicity	Disease	D007674
20192893_0	0	15	Contrast medium	Chemical	D003287
20192893_0	CID	D003287	D007674

20192893_1|s|BACKGROUND: Renal dysfunction induced by iodinated contrast medium (CM) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty (PTRA).
20192893_1	12	29	Renal dysfunction	Disease	D007674
20192893_1	51	66	contrast medium	Chemical	D003287
20192893_1	68	70	CM	Chemical	D003287
20192893_1	CID	D003287	D007674

20192893_2|s|PURPOSE: To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI).
20192893_2	42	53	nephrotoxic	Disease	D007674
20192893_2	64	66	CM	Chemical	D003287
20192893_2	CID	D003287	D007674

20192893_8|s|CONCLUSION: In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients.
20192893_8	98	110	renal damage	Disease	D007674
20192893_8	122	124	CM	Chemical	D003287
20192893_8	CID	D003287	D007674

20192893_9|s|The effectiveness of PTRA on renal function seems to be barely influenced by CM toxicity.
20192893_9	80	88	toxicity	Disease	D064420
20192893_9	77	79	CM	Chemical	D003287

20408947_0|s|Medical and psychiatric outcomes for patients transplanted for acetaminophen-induced acute liver failure: a case-control study.
20408947_0	85	104	acute liver failure	Disease	D017114
20408947_0	63	76	acetaminophen	Chemical	D000082
20408947_0	CID	D000082	D017114

20408947_1|s|BACKGROUND: Acetaminophen-induced hepatotoxicity is the most common cause of acute liver failure (ALF) in the UK.
20408947_1	34	48	hepatotoxicity	Disease	D056486
20408947_1	77	96	acute liver failure	Disease	D017114
20408947_1	98	101	ALF	Disease	D017114
20408947_1	12	25	Acetaminophen	Chemical	D000082
20408947_1	CID	D000082	D056486
20408947_1	CID	D000082	D017114

20408947_3|s|AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).
20408947_3	245	248	ALF	Disease	D017114
20408947_3	344	347	ALF	Disease	D017114
20408947_3	375	396	chronic liver disease	Disease	D008107
20408947_3	398	401	CLD	Disease	D008107
20408947_3	223	236	acetaminophen	Chemical	D000082
20408947_3	322	335	acetaminophen	Chemical	D000082
20408947_3	CID	D000082	D017114

20408947_4|s|RESULTS: Acetaminophen-induced ALF patients undergoing LT had a greater severity of pre-LT illness reflected by higher Acute Physiology and Chronic Health Evaluation II scores and requirement for organ support compared with the other two groups.
20408947_4	31	34	ALF	Disease	D017114
20408947_4	9	22	Acetaminophen	Chemical	D000082
20408947_4	CID	D000082	D017114

20408947_5|s|Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.
20408947_5	35	38	ALF	Disease	D017114
20408947_5	120	123	ALF	Disease	D017114
20408947_5	130	133	CLD	Disease	D008107
20408947_5	13	26	acetaminophen	Chemical	D000082
20408947_5	98	111	acetaminophen	Chemical	D000082
20408947_5	CID	D000082	D017114

20408947_6|s|During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).
20408947_6	175	178	ALF	Disease	D017114
20408947_6	230	233	ALF	Disease	D017114
20408947_6	244	247	CLD	Disease	D008107
20408947_6	153	166	acetaminophen	Chemical	D000082
20408947_6	208	221	acetaminophen	Chemical	D000082
20408947_6	CID	D000082	D017114

20408947_7|s|Two acetaminophen-induced ALF patients reattempted suicide post-LT (one died 8 years post-LT).
20408947_7	26	29	ALF	Disease	D017114
20408947_7	4	17	acetaminophen	Chemical	D000082
20408947_7	CID	D000082	D017114

20408947_8|s|CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.
20408947_8	139	142	ALF	Disease	D017114
20408947_8	211	214	ALF	Disease	D017114
20408947_8	234	237	CLD	Disease	D008107
20408947_8	117	130	acetaminophen	Chemical	D000082
20408947_8	189	202	acetaminophen	Chemical	D000082
20408947_8	CID	D000082	D017114

20447294_0|s|Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
20447294_0	115	131	neuropathic pain	Disease	D009437
20447294_0	27	35	morphine	Chemical	D009020
20447294_0	48	54	sodium	Chemical	D012964
20447294_0	72	79	CNSB002	Chemical	C401121

20447294_1|s|OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain.
20447294_1	206	222	neuropathic pain	Disease	D009437
20447294_1	64	71	CNSB002	Chemical	C401121
20447294_1	75	81	sodium	Chemical	D012964
20447294_1	163	171	morphine	Chemical	D009020

20447294_2|s|DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
20447294_2	229	233	pain	Disease	D010146
20447294_2	266	278	inflammation	Disease	D007249
20447294_2	312	331	diabetic neuropathy	Disease	D003929
20447294_2	54	62	morphine	Chemical	D009020
20447294_2	67	74	CNSB002	Chemical	C401121
20447294_2	242	253	carrageenan	Chemical	D002351
20447294_2	283	297	streptozotocin	Chemical	D013311
20447294_2	299	302	STZ	Chemical	D013311
20447294_2	CID	D013311	D003929
20447294_2	CID	D002351	D007249

20447294_4|s|The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
20447294_4	46	58	hyperalgesia	Disease	D006930
20447294_4	176	186	neuropathy	Disease	D009422
20447294_4	106	117	carrageenan	Chemical	D002351
20447294_4	164	167	STZ	Chemical	D013311
20447294_4	197	204	CNSB002	Chemical	C401121
20447294_4	209	217	morphine	Chemical	D009020
20447294_4	CID	D013311	D006930
20447294_4	CID	D002351	D006930

20447294_6|s|The ED50 values for morphine when given in combination with CNSB002 (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the neuropathy model (mg/kg; mean, SEM).
20447294_6	183	193	neuropathy	Disease	D009422
20447294_6	20	28	morphine	Chemical	D009020
20447294_6	60	67	CNSB002	Chemical	C401121
20447294_6	142	153	carrageenan	Chemical	D002351

20447294_7|s|The antinociception after morphine (3.2 mg/kg) was increased by co-administration with CNSB002 from 28.0 and 31.7% to 114.6 and 56.9% reversal of hyperalgesia in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone).
20447294_7	146	158	hyperalgesia	Disease	D006930
20447294_7	183	194	neuropathic	Disease	D009422
20447294_7	26	34	morphine	Chemical	D009020
20447294_7	87	94	CNSB002	Chemical	C401121

20495512_0|s|Heparin-induced thrombocytopenia: a practical review.
20495512_0	16	32	thrombocytopenia	Disease	D013921
20495512_0	0	7	Heparin	Chemical	D006493
20495512_0	CID	D006493	D013921

20495512_1|s|Heparin-induced thrombocytopenia (HIT) remains under-recognized despite its potentially devastating outcomes.
20495512_1	16	32	thrombocytopenia	Disease	D013921
20495512_1	34	37	HIT	Disease	D013921
20495512_1	0	7	Heparin	Chemical	D006493
20495512_1	CID	D006493	D013921

20495512_5|s|HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after heparin exposure.
20495512_5	0	3	HIT	Disease	D013921
20495512_5	58	68	thrombosis	Disease	D013927
20495512_5	92	102	thrombosis	Disease	D013927
20495512_5	116	123	heparin	Chemical	D006493
20495512_5	CID	D006493	D013921
20495512_5	CID	D006493	D013927

20495512_7|s|The treatment of HIT mandates an immediate cessation of all heparin exposure and the institution of an antithrombotic therapy, most commonly using a direct thrombin inhibitor.
20495512_7	17	20	HIT	Disease	D013921
20495512_7	60	67	heparin	Chemical	D006493
20495512_7	149	174	direct thrombin inhibitor	Chemical	D000991
20495512_7	CID	D006493	D013921

20495512_10|s|Direct thrombin inhibitors are appropriate, evidence-based alternatives to heparin in patients with a history of HIT, who need to undergo percutaneous coronary intervention.
20495512_10	113	116	HIT	Disease	D013921
20495512_10	0	26	Direct thrombin inhibitors	Chemical	D000991
20495512_10	75	82	heparin	Chemical	D006493
20495512_10	CID	D006493	D013921

20495512_11|s|As heparin remains one of the most frequently used medications today with potential for HIT with every heparin exposure, a close vigilance of platelet counts must be practiced whenever heparin is initiated.
20495512_11	88	91	HIT	Disease	D013921
20495512_11	3	10	heparin	Chemical	D006493
20495512_11	103	110	heparin	Chemical	D006493
20495512_11	185	192	heparin	Chemical	D006493
20495512_11	CID	D006493	D013921

20513036_0|s|Abductor paralysis after botox injection for adductor spasmodic dysphonia.
20513036_0	9	18	paralysis	Disease	D010243
20513036_0	45	73	adductor spasmodic dysphonia	Disease	D014826
20513036_0	25	30	botox	Chemical	C542870
20513036_0	CID	C542870	D014826

20513036_1|s|OBJECTIVES/HYPOTHESIS: Botulinum toxin (Botox) injections into the thyroarytenoid muscles are the current standard of care for adductor spasmodic dysphonia (ADSD).
20513036_1	127	155	adductor spasmodic dysphonia	Disease	D014826
20513036_1	157	161	ADSD	Disease	D014826
20513036_1	40	45	Botox	Chemical	C542870
20513036_1	CID	C542870	D014826

20513036_3|s|Here we report multiple cases of bilateral abductor paralysis following Botox injections for ADSD, a complication previously unreported.
20513036_3	52	61	paralysis	Disease	D010243
20513036_3	93	97	ADSD	Disease	D014826
20513036_3	72	77	Botox	Chemical	C542870
20513036_3	CID	C542870	D014826

20513036_5|s|METHODS: Patients that received Botox injections for spasmodic dysphonia between January 2000 and October 2009 were evaluated.
20513036_5	53	72	spasmodic dysphonia	Disease	D055154
20513036_5	32	37	Botox	Chemical	C542870

20513036_8|s|For patients with bilateral abductor paralysis, age, sex, paralytic Botox dose, prior Botox dose, and course following paralysis were noted.
20513036_8	37	46	paralysis	Disease	D010243
20513036_8	119	128	paralysis	Disease	D010243
20513036_8	68	73	Botox	Chemical	C542870
20513036_8	86	91	Botox	Chemical	C542870

20513036_9|s|RESULTS: From a database of 452 patients receiving Botox, 352 patients had been diagnosed with ADSD.
20513036_9	95	99	ADSD	Disease	D014826
20513036_9	51	56	Botox	Chemical	C542870
20513036_9	CID	C542870	D014826

20513036_14|s|The incidence of abductor paralysis after Botox injection for ADSD was 0.34%.
20513036_14	26	35	paralysis	Disease	D010243
20513036_14	62	66	ADSD	Disease	D014826
20513036_14	42	47	Botox	Chemical	C542870
20513036_14	CID	C542870	D014826

20513036_15|s|CONCLUSIONS: Bilateral abductor paralysis is a rare complication of Botox injections for ADSD, causing difficulty with breathing upon exertion.
20513036_15	32	41	paralysis	Disease	D010243
20513036_15	89	93	ADSD	Disease	D014826
20513036_15	68	73	Botox	Chemical	C542870
20513036_15	CID	C542870	D014826

20513036_16|s|The likely mechanism of paralysis is diffusion of Botox around the muscular process of the arytenoid to the posterior cricoarytenoid muscles.
20513036_16	24	33	paralysis	Disease	D010243
20513036_16	50	55	Botox	Chemical	C542870

20566328_0|s|Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.
20566328_0	0	24	Mitochondrial impairment	Disease	D028361
20566328_0	56	75	cardiac dysfunction	Disease	D006331
20566328_0	40	47	cocaine	Chemical	D003042
20566328_0	116	121	MitoQ	Chemical	C476756
20566328_0	CID	D003042	D006331

20566328_1|s|The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction.
20566328_1	123	142	cardiac dysfunction	Disease	D006331
20566328_1	107	114	cocaine	Chemical	D003042
20566328_1	CID	D003042	D006331

20566328_6|s|This uncoupling effect on oxidative phosphorylation was not detectable after short-term exposure to cocaine, suggesting that these mitochondrial abnormalities were a late rather than a primary event in the pathological response to cocaine.
20566328_6	131	158	mitochondrial abnormalities	Disease	D028361
20566328_6	100	107	cocaine	Chemical	D003042
20566328_6	231	238	cocaine	Chemical	D003042

20566328_7|s|MitoQ, a mitochondrial-targeted antioxidant, was shown to completely prevent these mitochondrial abnormalities as well as cardiac dysfunction characterized here by a diastolic dysfunction studied with a conductance catheter to obtain pressure-volume data.
20566328_7	83	110	mitochondrial abnormalities	Disease	D028361
20566328_7	122	141	cardiac dysfunction	Disease	D006331
20566328_7	166	187	diastolic dysfunction	Disease	-1
20566328_7	0	5	MitoQ	Chemical	C476756

20566328_8|s|Taken together, these results extend previous studies and demonstrate that cocaine-induced cardiac dysfunction may be due to a mitochondrial defect.
20566328_8	91	110	cardiac dysfunction	Disease	D006331
20566328_8	127	147	mitochondrial defect	Disease	D028361
20566328_8	75	82	cocaine	Chemical	D003042
20566328_8	CID	D003042	D006331

20589632_0|s|Trimethoprim-induced immune hemolytic anemia in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction.
20589632_0	28	44	hemolytic anemia	Disease	D000743
20589632_0	0	12	Trimethoprim	Chemical	D014295
20589632_0	CID	D014295	D000743

20682692_0|s|Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy.
20682692_0	123	143	diabetic nephropathy	Disease	D003928
20682692_0	100	114	streptozotocin	Chemical	D013311
20682692_0	CID	D013311	D003928

20682692_1|s|OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy).
20682692_1	119	134	type 1 diabetes	Disease	D003922
20682692_1	190	201	nephropathy	Disease	D007674
20682692_1	280	300	diabetic nephropathy	Disease	D003928
20682692_1	302	322	diabetic nephropathy	Disease	D003928
20682692_1	83	94	angiotensin	Chemical	D000804

20682692_2|s|We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (STZ)-induced diabetes.
20682692_2	140	148	fibrosis	Disease	D005355
20682692_2	225	233	diabetes	Disease	D003920
20682692_2	196	210	streptozotocin	Chemical	D013311
20682692_2	212	215	STZ	Chemical	D013311

20682692_6|s|Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 (SIS3) were performed in MMECs and in STZ-induced diabetic nephropathy in Tie2-Cre;Loxp-EGFP mice.
20682692_6	130	150	diabetic nephropathy	Disease	D003928
20682692_6	118	121	STZ	Chemical	D013311
20682692_6	CID	D013311	D003928

20682692_8|s|Immunoprecipitation/Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in STZ-induced diabetic nephropathy.
20682692_8	131	151	diabetic nephropathy	Disease	D003928
20682692_8	119	122	STZ	Chemical	D013311
20682692_8	CID	D013311	D003928

20828385_0|s|Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
20828385_0	69	89	mantle cell lymphoma	Disease	D020522
20828385_0	42	54	temsirolimus	Chemical	C401859

20828385_3|s|However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
20828385_3	71	74	MCL	Disease	D020522
20828385_3	177	180	MCL	Disease	D020522
20828385_3	189	194	tumor	Disease	D009369
20828385_3	88	100	temsirolimus	Chemical	C401859
20828385_3	223	235	temsirolimus	Chemical	C401859

20828385_5|s|Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells.
20828385_5	66	71	tumor	Disease	D009369
20828385_5	175	180	tumor	Disease	D009369
20828385_5	43	55	temsirolimus	Chemical	C401859

20828385_6|s|Apart from this cytostatic effect, temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and of VEGF expression.
20828385_6	94	99	tumor	Disease	D009369
20828385_6	35	47	temsirolimus	Chemical	C401859

20828385_7|s|Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-necrotic tissue repair, were found after 6-month temsirolimus therapy.
20828385_7	77	85	necrotic	Disease	D009336
20828385_7	126	138	temsirolimus	Chemical	C401859
20828385_7	CID	C401859	D009336

20828385_8|s|Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.
20828385_8	27	32	tumor	Disease	D009369
20828385_8	134	139	tumor	Disease	D009369
20828385_8	214	217	MCL	Disease	D020522
20828385_8	6	18	temsirolimus	Chemical	C401859
20828385_8	118	130	temsirolimus	Chemical	C401859

20859899_0|s|Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
20859899_0	0	7	Syncope	Disease	D013575
20859899_0	18	30	hyperkalemia	Disease	D006947
20859899_0	73	84	angiotensin	Chemical	D000809
20859899_0	117	131	spironolactone	Chemical	D013148
20859899_0	CID	D013148	D006947

20859899_3|s|The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.
20859899_3	13	25	hyperkalemia	Disease	D006947
20859899_3	64	78	spiranolactone	Chemical	D013148
20859899_3	83	94	aldosterone	Chemical	D000450
20859899_3	146	154	ramipril	Chemical	D017257
20859899_3	CID	D013148	D006947
20859899_3	CID	D017257	D006947

20859899_5|s|Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild renal disturbance.
20859899_5	49	61	hyperkalemia	Disease	D006947
20859899_5	171	188	renal disturbance	Disease	D007674
20859899_5	128	137	potassium	Chemical	D011188

20927253_0|s|Diffuse skeletal pain after administration of alendronate.
20927253_0	17	21	pain	Disease	D010146
20927253_0	46	57	alendronate	Chemical	D019386
20927253_0	CID	D019386	D010146

20927253_1|s|BACKGROUND: Osteoporosis is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption.
20927253_1	12	24	Osteoporosis	Disease	D010024
20927253_1	87	102	bisphosphonates	Chemical	D004164

20927253_2|s|Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women.
20927253_2	84	96	osteoporosis	Disease	D010024
20927253_2	0	11	Alendronate	Chemical	D019386
20927253_2	15	28	biphosphonate	Chemical	-1

20927253_5|s|We presented a patient admitted to our out-patient clinic with diffuse skeletal pain after three consecutive administration of alendronate.
20927253_5	80	84	pain	Disease	D010146
20927253_5	127	138	alendronate	Chemical	D019386
20927253_5	CID	D019386	D010146

20927253_6|s|CONCLUSION: We conclude that patients with osteoporosis can report pain, and bisphosphonate-related pain should also be considered before ascribing this complaint to osteoporosis.
20927253_6	43	55	osteoporosis	Disease	D010024
20927253_6	67	71	pain	Disease	D010146
20927253_6	100	104	pain	Disease	D010146
20927253_6	166	178	osteoporosis	Disease	D010024
20927253_6	77	91	bisphosphonate	Chemical	D004164

20959502_0|s|Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.
20959502_0	91	101	meningitis	Disease	D008581
20959502_0	45	55	daptomycin	Chemical	D017576

20959502_1|s|OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.
20959502_1	82	92	bacteremia	Disease	D016470
20959502_1	113	123	meningitis	Disease	D008581
20959502_1	31	42	methicillin	Chemical	D008712
20959502_1	147	157	daptomycin	Chemical	D017576

20959502_6|s|On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission).
20959502_6	32	51	acute renal failure	Disease	D058186
20959502_6	59	69	creatinine	Chemical	D003404

20959502_9|s|Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16.
20959502_9	84	94	meningitis	Disease	D008581
20959502_9	0	9	Nafcillin	Chemical	D009254
20959502_9	31	41	daptomycin	Chemical	D017576

20959502_13|s|DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.
20959502_13	98	120	interstitial nephritis	Disease	D009395
20959502_13	135	145	bacteremia	Disease	D016470
20959502_13	12	22	Daptomycin	Chemical	D017576
20959502_13	74	83	nafcillin	Chemical	D009254
20959502_13	CID	D009254	D009395

20959502_15|s|CONCLUSIONS: High-dose daptomycin may be an alternative option for MSSA bacteremia with or without a CNS source in patients who have failed or cannot tolerate standard therapy.
20959502_15	72	82	bacteremia	Disease	D016470
20959502_15	23	33	daptomycin	Chemical	D017576

21195121_0|s|The role of nitric oxide in convulsions induced by lindane in rats.
21195121_0	28	39	convulsions	Disease	D012640
21195121_0	12	24	nitric oxide	Chemical	D009569
21195121_0	51	58	lindane	Chemical	D001556
21195121_0	CID	D001556	D012640

21195121_2|s|It evokes convulsions mainly trough the blockage of GABA(A) receptors.
21195121_2	10	21	convulsions	Disease	D012640
21195121_2	52	56	GABA	Chemical	D005680

21195121_3|s|Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.
21195121_3	207	215	epilepsy	Disease	D004827
21195121_3	0	12	Nitric oxide	Chemical	D009569
21195121_3	14	16	NO	Chemical	D009569
21195121_3	113	123	L-arginine	Chemical	D001120
21195121_3	138	140	NO	Chemical	D009569
21195121_3	162	168	L-NAME	Chemical	D019331

21195121_4|s|The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane-induced epilepsy in male Wistar albino rats.
21195121_4	125	133	epilepsy	Disease	D004827
21195121_4	61	63	NO	Chemical	D009569
21195121_4	109	116	lindane	Chemical	D001556

21195121_5|s|The administration of L-arginine (600, 800 and 1000 mg/kg, i.p.) in dose-dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose (4 mg/kg, i.p.).
21195121_5	114	124	convulsion	Disease	D012640
21195121_5	184	194	convulsion	Disease	D012640
21195121_5	22	32	L-arginine	Chemical	D001120
21195121_5	213	220	lindane	Chemical	D001556
21195121_5	CID	D001556	D012640

21195121_6|s|On the contrary, pretreatment with L-NAME (500, 700 and 900 mg/kg, i.p.) decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i.p.).
21195121_6	83	93	convulsion	Disease	D012640
21195121_6	147	157	convulsion	Disease	D012640
21195121_6	185	195	convulsive	Disease	D012640
21195121_6	35	41	L-NAME	Chemical	D019331
21195121_6	204	211	lindane	Chemical	D001556
21195121_6	CID	D001556	D012640

21195121_8|s|These results support the conclusion that NO plays a role of endogenous convulsant in rat model of lindane seizures.
21195121_8	107	115	seizures	Disease	D012640
21195121_8	42	44	NO	Chemical	D009569
21195121_8	99	106	lindane	Chemical	D001556
21195121_8	CID	D001556	D012640

24055495_0|s|Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.
24055495_0	44	62	cognitive deficits	Disease	D003072
24055495_0	15	24	galactose	Chemical	D005690
24055495_0	122	136	streptozotocin	Chemical	D013311
24055495_0	CID	D013311	D003072
24055495_0	CID	D005690	D003072

24055495_1|s|Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.
24055495_1	50	58	dementia	Disease	D003704
24055495_1	71	90	Alzheimer's disease	Disease	D000544
24055495_1	191	198	glucose	Chemical	D005947
24055495_1	213	220	glucose	Chemical	D005947
24055495_1	253	260	glucose	Chemical	D005947
24055495_1	CID	D005947	D000544

24055495_3|s|Exclusively parenteral daily injections of galactose induce memory deterioration in rodents and are used to generate animal aging model, but the effects of oral galactose treatment on cognitive functions have never been tested.
24055495_3	60	80	memory deterioration	Disease	D008569
24055495_3	43	52	galactose	Chemical	D005690
24055495_3	161	170	galactose	Chemical	D005690

24055495_4|s|We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.
24055495_4	97	115	cognitive deficits	Disease	D003072
24055495_4	58	67	galactose	Chemical	D005690
24055495_4	119	133	streptozotocin	Chemical	D013311
24055495_4	143	146	STZ	Chemical	D013311
24055495_4	CID	D013311	D003072
24055495_4	CID	D005690	D003072

24055495_5|s|One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced cognitive deficits.
24055495_5	152	170	cognitive deficits	Disease	D003072
24055495_5	18	27	galactose	Chemical	D005690
24055495_5	70	73	STZ	Chemical	D013311
24055495_5	136	139	STZ	Chemical	D013311
24055495_5	CID	D013311	D003072
24055495_5	CID	D005690	D003072

24055495_9|s|Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD.
24055495_9	137	155	cognitive deficits	Disease	D003072
24055495_9	172	194	glucose hypometabolism	Disease	D018149
24055495_9	198	200	AD	Disease	D000544
24055495_9	5	14	galactose	Chemical	D005690
24055495_9	CID	D005690	D003072

